
 
 
 
 
 
 
 
 
 
   Područje izuma  Field of invention 
 
 
   Izum je iz područja farmakologije.  The invention is from the field of pharmacology. 
 
 
   Ovaj izum djelomično se odnosi na molekule nukleinske kiseline koje kodiraju nove Drosophila melanogaster G protein vezane receptore (DmGPCR- ovi), nove polipeptide, analize za screening spojeva koji se vežu za DmGPCR i/ili moduliraju aktivnost DmGPCR, metode za vezanje DmGPCR, reagense kao što su antitijela na DmGPCR, vodeće sekvencije i sonde za detektiranje nukleotidnih sekvencija koje kodiraju DmGPCR, pribore koji uključuju antitijela, vodeće sekvencije i sonde ovog izuma, smjese koje sadrže DmGPCR-ovi-ove, DmGPCR vezujuće partnere i DmGPCR modulatore, te metode za kontroliranje populacije insekata korištenjem DmGPCR vezujućeg partnera ili modulatora.  This invention relates in part to nucleic acid molecules encoding novel Drosophila melanogaster G protein-coupled receptors (DmGPCRs), novel polypeptides, assays for screening compounds that bind to DmGPCR and/or modulate DmGPCR activity, methods for DmGPCR binding, reagents such as which are antibodies to DmGPCR, leader sequences and probes for detecting nucleotide sequences encoding DmGPCR, kits including antibodies, leader sequences and probes of the present invention, mixtures containing DmGPCRs, DmGPCR binding partners and DmGPCR modulators, and methods for controlling insect populations using DmGPCR binding partners or modulators. 
 
 
   Stanje tehnike  State of the art 
 
 
   Ljudi i drugi živi oblici sastoje se od živih stanica. Među mehanizmima putem kojih stanice organizma komuniciraju međusobno i dobivaju informacije te se stimuliraju iz njihove okoline su reeptorske molekule stanične membrane s ekspresijom na površini stanice. Mnogo takvih receptora je identificirano, karakterizirano i ponekad klasificirano u glavne receptorske superfamilije temeljem strukturnih motive i svojstava prijenosa signala. Takve familije obuhvaćaju (ali nisu ograničene na) ligand-usmjerene ionske kanalne receptore, naponski ovisne ionske kanalne reeptore, receptor tirozin kinaze, receptor protein tirozin fosfataze i G protein-vezane receptore. Receptori su prva suštinski bitna veza za prevođenje izvanstaničnog signala u stanični fiziološki odgovor.  Humans and other living forms are made up of living cells. Among the mechanisms through which the cells of the organism communicate with each other and receive information and are stimulated from their environment are receptor molecules of the cell membrane with expression on the cell surface. Many such receptors have been identified, characterized, and sometimes classified into major receptor superfamilies based on structural motifs and signal transduction properties. Such families include (but are not limited to) ligand-gated ion channel receptors, voltage-gated ion channel receptors, receptor tyrosine kinases, receptor protein tyrosine phosphatases, and G protein-coupled receptors. Receptors are the first essential link for the translation of an extracellular signal into a cellular physiological response. 
 
 
   G protein-vezani receptori (npr. GPCR-ovi) čine veliku superfamiliju staničnih površinskih receptora koji su karakterizirani amino-terminalnom izvanstaničnom domenom, karboksi-terminalnom unutarstaničnom domenom i uzvojitom strukturom koja prolazi kroz staničnu membranu sedam puta. Dakle, takvi receptori se ponekad nazivaju sedam transmembranskih (7TM) receptora. Ovih sedam transmembranskih domena definira tri izvanstanične petlje i tri unutarstanične petlje, uz amino- i karboksi-terminalne domene. Izvanstanični dijelovi receptora imaju ulogu u prepoznavanju i vezanju jednog ili više izvanstaničnih vezujućih partnera (npr. liganada), pri čemu unutarstanični dijelovi imaju ulogu u prepoznavanju i komuniciranju s uzvodnim (downstream) efektorskim molekulama.  G protein-coupled receptors (eg, GPCRs) form a large superfamily of cell surface receptors that are characterized by an amino-terminal extracellular domain, a carboxy-terminal intracellular domain, and a coiled-coil structure that crosses the cell membrane seven times. Thus, such receptors are sometimes called seven transmembrane (7TM) receptors. These seven transmembrane domains define three extracellular loops and three intracellular loops, in addition to amino- and carboxy-terminal domains. The extracellular parts of the receptor have a role in recognizing and binding one or more extracellular binding partners (eg ligands), while the intracellular parts have a role in recognizing and communicating with upstream (downstream) effector molecules. 
 
 
   GPCR-ovi vežu cijeli niz liganada uključujući kalcijeve ione, hormone, kemokine, neuropeptide, neurotransmitere, nukleotide, lipide, odorante i čak fotone. Ne iznenađuje, GPCR-ovi su značajni u normalnoj (i ponekad aberantnoj) funkciji mnogih staničnih tipova. Vidi općenito Strosberg, Eur. J. Biochem., 1991,196,1-10; Bohm et al, Biochem J., 1997, 322, 1-18. Kada se specifični ligand veže za svoj odgovarajući receptor, ligand tipično stimulira receptor da aktivira specifični heterotrimerni guanin nukleotid-vezujući regulatorski protein (G protein) koji je vezan za unutarstanični dio ili područje receptora. G protein, opet, prenosi signal do efektorske molekule unutar stanice bilo stimuliranjem ili inhibiranjem aktivnosti efektorske molekule. Ove efektorske molekule obuhvaćaju adenilat ciklazu, fosfolipaze i ionske kanale. Adenilat ciklaza i fosfolipaze su enzimi koji su uključeni u proizvodnji sekundarne glasničke molekule cAMP, inozitol trifosfata i diaciglicerola. To se postiže nizom aktova kojima izvanstanični stimulirajući ligand daje unutarstanične promjene putem G protein-vezanog receptora. Svaki takav receptor ima svoju karakterističnu primarnu strukturu, oblik ekspresije, ligand vezujući profil i unutarstanični efektorski sustav.  GPCRs bind a whole range of ligands including calcium ions, hormones, chemokines, neuropeptides, neurotransmitters, nucleotides, lipids, odorants and even photons. Not surprisingly, GPCRs are important in the normal (and sometimes aberrant) function of many cell types. See generally Strosberg, Eur. J. Biochem., 1991,196,1-10; Bohm et al, Biochem J., 1997, 322, 1-18. When a specific ligand binds to its respective receptor, the ligand typically stimulates the receptor to activate a specific heterotrimeric guanine nucleotide-binding regulatory protein (G protein) that is bound to the intracellular portion or region of the receptor. The G protein, in turn, transmits the signal to the effector molecule within the cell by either stimulating or inhibiting the activity of the effector molecule. These effector molecules include adenylate cyclase, phospholipases and ion channels. Adenylate cyclase and phospholipase are enzymes involved in the production of the secondary messenger molecule cAMP, inositol triphosphate and diacylglycerol. This is achieved through a series of actions by which an extracellular stimulating ligand produces intracellular changes via a G protein-coupled receptor. Each such receptor has its own characteristic primary structure, form of expression, ligand binding profile and intracellular effector system. 
 
 
   Zbog vitalne uloge G protein-vezanih receptora u komunikaciji između stanica i njihove okoline, ti receptori su privlačne mete za reguliranje, primjerice aktiviranjem ili antagoniziranjem takvih receptora. Za receptore koji imaju poznati ligand, identificiranje agonista ili antagonista može se vršiti specifično da se pojača ili inhibira djelovanje liganda. Primjerice, neki G protein-vezani receptori imaju ulogu u patogenezi bolesti (npr. neki kemokinski receptori koji djeluju kao HIV koreceptori mogu imati određenu ulogu u patogenezi AIDS-a) i privlačen su mete za terapijsku intervenciju čak i ako nedostaje znanje o prirodnom ligandu receptora. Drugi receptori su privlačne mete za terapijsku intervenciju zbog načina njihove ekspresije u tkivima ili staničnim tipovima koji su sami privlačne mete za terapijsku intervenciju. Primjeri ove posljednje kategorije receptora obuhvaćaju receptore s ekspresijom u imunološkim stanicama, koji mogu biti cilj bilo zbog toga da se inhibiraju autoimunološki odgovori ili da se pojačaju imunološki odgovori za borbu s patogenima ili karcinomom, te receptorima s ekspresijom u mozgu ili drugim neurološkim organima ili tkivima, što su vjerojatne mete u tretiranju shizofrenije, depresije, bipolarne bolesti ili drugih neuroloških poremećaja. Ova posljednja kategorija receptora je također korisna kao obilježivač u identificiranju i/ili pročišćavanju (npr. pomoću fluorescencijom aktiviranog staničnog sortiranja) staničnih podtipova koji vrše ekspresiju receptora.  Due to the vital role of G protein-coupled receptors in communication between cells and their environment, these receptors are attractive targets for regulation, for example by activating or antagonizing such receptors. For receptors that have a known ligand, identifying agonists or antagonists can be done specifically to enhance or inhibit the action of the ligand. For example, some G protein-coupled receptors play a role in the pathogenesis of disease (eg, some chemokine receptors that act as HIV coreceptors may have a role in the pathogenesis of AIDS) and are attractive targets for therapeutic intervention even if knowledge of the receptor's natural ligand is lacking. . Other receptors are attractive targets for therapeutic intervention due to the way they are expressed in tissues or cell types that are themselves attractive targets for therapeutic intervention. Examples of this latter category of receptors include receptors expressed in immune cells, which can be targeted either to inhibit autoimmune responses or to enhance immune responses to fight pathogens or cancer, and receptors expressed in the brain or other neurological organs or tissues. , which are likely targets in the treatment of schizophrenia, depression, bipolar disease or other neurological disorders. This latter category of receptors is also useful as a marker in identifying and/or purifying (eg, by fluorescence-activated cell sorting) cell subtypes that express the receptor. 
 
 
   Insekti su poznati kao glavni štetnici u zemljoradnji i u kućnom domaćem okruženju. Insekti su također paraziti na domaćim životinjama i ljudima, pa ih u takvim slučajevima nazivamo ektoparazitima, povećanjem morbiditeta i mortaliteta. Insekti također služe kao vektori za prijenos virusnih i parazitnih bolesti na biljke, životinje i ljude. Dakle, postoji stalna i prinudna potreba da se otkriju nove metode za kontroliranje populacije insekata te za odbijanje i/ili uništavanje patogenih vrsta. Jedan način da se kontrolira populacija insekata je da se insekti usmrte ili paraliziraju upotrebom kemijskih tvari, koje se nazivaju insekticidima, koje su selektivno otrovne za insekte i potencijalno za druge beskralježnjake. Trenutačno, insekticidi su vrlo vrijedni u kontroli insekata koji su štetni za produkte zemljoradnje, uključujući usjeve. Insekticidi se također rabe u humanom kućnom okruženju, za kontrolu kućnih i vrtnih štetočinja te insekata koji su štetni ili razdražljivi za ljude, kao što su insekti koji bodu i ujedaju, muhe i žohari. Insekticidi imaju enormnu vrijednost za tretiranje i prevenciju bolesnih stanja koja su izazvana ektoparazitima, uključujući mušice, uši, krpelji i grinje, u kućnih ljubimaca i domaćih životinja. Međutim, kemikalije koje se trenutačno rabe kao insekticidi nisu optimalne. Neke su pokazale svoju toksičnost za sisavce, dok se u nekih ciljanih vrsta pojavila otpornost prema njima. Prema tome, postoji potreba za novim selektivnim insekticidima koji imaju nov mehanizam djelovanja.  Insects are known as the main pests in agriculture and in the domestic domestic environment. Insects are also parasites on domestic animals and humans, so in such cases we call them ectoparasites, increasing morbidity and mortality. Insects also serve as vectors for the transmission of viral and parasitic diseases to plants, animals and humans. Thus, there is a constant and compelling need to discover new methods for controlling insect populations and for repelling and/or destroying pathogenic species. One way to control insect populations is to kill or paralyze the insects using chemicals, called insecticides, that are selectively toxic to insects and potentially other invertebrates. Currently, insecticides are very valuable in controlling insects that are harmful to agricultural products, including crops. Insecticides are also used in the humane home environment to control household and garden pests and insects that are harmful or irritating to humans, such as stinging and biting insects, flies and cockroaches. Insecticides are of enormous value for the treatment and prevention of disease conditions caused by ectoparasites, including flies, lice, ticks and mites, in pets and domestic animals. However, the chemicals currently used as insecticides are not optimal. Some have shown their toxicity to mammals, while some target species have developed resistance to them. Therefore, there is a need for new selective insecticides that have a new mechanism of action. 
 
 
   Poznati su primjeri insektnih GPCR-ova koji sadrže neuropeptidne ligande (vidi npr. Li, et al., EMBO Journal, 1991, 10, 3221-3229; Li, et al., J. Biol. Chem., 1992, 267, 9-12; Monnier, et al., J. Biol. Chem., 1992, 267, 1298-1302; Vanden Broeck, et al., Int. Rev. Cytology, 1996, 164, 189-268; Guerrero, Peptides, 1997, 18, 1-5; Hauser, et al., J. Biol. Chem., 1997, 272, 1002-1010; Birgul et al., EMBO J., 1999, 18, 5892-5900; Torfs et al., J. Neurochem., 2000, 74, 2182-2189; i Hauser et al., Biochem. Biophys. Res. Comm., 1998, 249, 822-828; Larsen, et al., Biochem. Biophys. Res. Comm., 2001, 286, 895-901; Lenz, et al., Biochem. Biophys. Res. Comm., 2001, 286, 1117-1122; Kubiak et al., Biochem. Biophys. Res. Comm., 2002, 291, 313-320; Staubli et al., Proc. Natl. Acad. Sci. USA, 2002, 9, 3446-3451; Garczynski et al., Peptides, 2002, 23, 773-780; Holmes et al., Insect Molecular Biology, 2000, (5), 457-465; Cazzamali et al., Proc. Natl. Acad. Sci. USA, 2002, 99, 12073-12078; Cazzamali et al., Biochem. Biophys. Res. Comm., 2002, 298, 31-36; Radford et.al., J. Biol. Chem. 2002, 277, 38810-38817; Park et al., Proc. Natl. Acad. Sci. USA, 2002, 99, 11423-11428; Kreienkamp et al., J. Biol. Chem, 10.1074/jbc.M206931200 (publicirano online 6. kolovoza 2002.) i Mertens, et al., Biochem. Biophys. Res. Comm., 2002, 297, 1140-1148. Novije srodne patentne prijave: Ebens, Allen James, Jr.; Torpey, Justin; Keegan, Kevin Patrick, Nucleic acids and and polypeptides of Drosophila melanogaster G protein-coupled receptor and their use as pesticidal and pharmaceutical targets. PCT međunarodna prijava (2001), 43 str. CODEN: PIXXD2 WO 0170981 A2 20010927 CAN 135:268323 AN 2001:713564 CAPLUS. Kravchik, Anibal. Drosophila G protein-coupled receptors, genomic DNA and cDNA molecule encoding GPCR proteins and their uses as insecticidal targets. PCT međunarodna prijava (2001), 392 str. CODEN: PIXXD2 WO 0170980 A2 20010927 CAN 135:269068 AN 2001:713563 CAPLUS.  Examples of insect GPCRs containing neuropeptide ligands are known (see, e.g., Li, et al., EMBO Journal, 1991, 10, 3221-3229; Li, et al., J. Biol. Chem., 1992, 267, 9 -12; Monnier, et al., J. Biol. Chem., 1992, 267, 1298-1302; Vanden Broeck, et al., Int. Rev. Cytology, 1996, 164, 189-268; Guerrero, Peptides, 1997 , 18, 1-5; Hauser, et al., J. Biol. Chem., 1997, 272, 1002-1010; Birgul et al., EMBO J., 1999, 18, 5892-5900; Torfs et al., J. Neurochem., 2000, 74, 2182-2189; and Hauser et al., Biochem. Biophys. Res. Comm., 1998, 249, 822-828; Larsen, et al., Biochem. Biophys. Res. Comm. , 2001, 286, 895-901; Lenz, et al., Biochem. Biophys. Res. Comm., 2001, 286, 1117-1122; Kubiak et al., Biochem. Biophys. Res. Comm., 2002, 291, 313-320; Staubli et al., Proc. Natl. Acad. Sci. USA, 2002, 9, 3446-3451; Garczynski et al., Peptides, 2002, 23, 773-780; Holmes et al., Insect Molecular Biology , 2000, (5), 457-465; Cazzamali et al., Proc. Natl. Acad. Sci. USA, 2002, 99, 12073-12078; Cazzamali et al. , Biochem. Biophys. Crisp. Comm., 2002, 298, 31-36; Radford et al., J. Biol. Chem. 2002, 277, 38810-38817; Park et al., Proc. Natl. Acad. Sci. USA, 2002, 99, 11423-11428; Kreienkamp et al., J. Biol. Chem, 10.1074/jbc.M206931200 (published online August 6, 2002) and Mertens, et al., Biochem. Biophys. Crisp. Comm., 2002, 297, 1140-1148. More recent related patent applications: Ebens, Allen James, Jr.; Torpey, Justin; Keegan, Kevin Patrick, Nucleic acids and polypeptides of Drosophila melanogaster G protein-coupled receptor and their use as pesticidal and pharmaceutical targets. PCT International Application (2001), 43 p. CODEN: PIXXD2 WO 0170981 A2 20010927 CAN 135:268323 AN 2001:713564 CAPLUS. Kravchik, Anibal. Drosophila G protein-coupled receptors, genomic DNA and cDNA molecules encoding GPCR proteins and their uses as insecticidal targets. PCT International Application (2001), 392 p. CODEN: PIXXD2 WO 0170980 A2 20010927 CAN 135:269068 AN 2001:713563 CAPLUS. 
 
 
   Velika familija općenito dužine 4-12 aminokiselina tipično se nalaze u životinjama beskralježnjacima (npr. insekti) i ta klasa neuropeptida poznata je ako FMRFamid-srodni peptidi (npr. FaRP-ovi). Prototipični FMRFamidni (FMRFa) peptidi tako su nazvani zbog „FMRF“ koncenzusne aminokiselinske sekvencije na njihovu C-terminalu, koja se sastoji općenito od (F,Y)(M,V,I,L)R(F,Y)NH2. Kao neuropeptidi, ove su molekule uključene u vitalnim biološkim procesima koji zahtijevaju kontroliranu neuromuskularnu aktivnost. Mada se za neke neurotrasmitere i neuromodulatore (uključujući neuropeptide) pokazalo da funkcioniraju kao ligandi za receptore, do sada nisu identificirani FaRP neuropeptidi kao ligand za GPCR.  A large family generally 4-12 amino acids in length are typically found in invertebrates (eg, insects) and this class of neuropeptides is known as FMRFamide-related peptides (eg, FaRPs). The prototypic FMRFamide (FMRFa) peptides are so named because of the “FMRF” consensus amino acid sequence at their C-terminus, which generally consists of (F,Y)(M,V,I,L)R(F,Y)NH2. As neuropeptides, these molecules are involved in vital biological processes that require controlled neuromuscular activity. Although some neurotransmitters and neuromodulators (including neuropeptides) have been shown to function as ligands for receptors, no FaRP neuropeptides have been identified as ligands for GPCRs. 
 
 
   Drosophila peptidi sadrže konzervirani FXGXR-amidni motiv i strukturno su srodni životinjskim tahikinima te su, prema tome, povezani drotahikinini (Siviter et al., J. Biol. Chem., 2000, 275(30), 23273-23280). Drotahikinini imaju jake stimulirajuće učinke na kontrakcije utrobe životinje (id.).  Drosophila peptides contain a conserved FXGXR-amide motif and are structurally related to animal tachykins and are therefore related drotachykinins (Siviter et al., J. Biol. Chem., 2000, 275(30), 23273-23280). Drotachykinins have strong stimulating effects on the contractions of the animal's womb (id.). 
 
 
   Leukokinini su skupina raširenih insektnih hormona koji stimuliraju pokretljivost utrobe i brzinu sekrecije tekućine iz tubula. U tubulama, njihovo glavno djelovanje je povećanje permeabilnoti klorida vezanjem receptora na bazolateralnoj membrani. Leukokinin djeluje povećanjem unutarstaničnog kalcija samo u zvjezdastim stanicama (O’Donnell et al., Am. J. Physiol., 1998, 43, R1039-R1049).  Leukokinins are a group of widespread insect hormones that stimulate gut motility and the rate of fluid secretion from the tubules. In tubules, their main action is to increase chloride permeability by binding to receptors on the basolateral membrane. Leukokinin acts by increasing intracellular calcium only in stellate cells (O'Donnell et al., Am. J. Physiol., 1998, 43, R1039-R1049). 
 
 
   Alatostatini su značajna skupina insektnih neurohormona koji kontroliraju diverzne funkcije uključujući sintezu mladenačkih hormona za koje je poznato da imaju središnju ulogu u preobrazbi i reprodukciji u različitim vrstama insekata. Prvi Drosophila alatostatin, Ser-Arg-Pro-Tyr-Ser-Phe-Gly-Leu-NH2 (tj. drostatin-3) (sekv. br. 165), izdvojen je iz ekstrakta Drosophila glave (Birgul et al., EMBO J., 1999, 18, 5892-5900). U novije vrijeme, kloniran je Drosophila alatostatin preprophormonski gen koji kodira četiri Drosophila alatostatina: Val-Glu-Arg-Tyr-Ala-Phe-Gly-Leu-NH2 (drostatin-1) (sekv. br. 163), Leu-Pro-Val-Tyr-Asn-Phe-Gly-Leu-NH2 (drostatin-2) (sekv. br. 164), Ser-Arg-Pro-Tyr-Ser-Phe-Gly-Leu-NH2 (drostatin-3) (sekv. br. 165) i Thr-Thr-Arg-Pro-Gln-Pro-Phe-Asn-Phe-Gly-Leu-NH2 (drostatin-4) (sekv. br. 166) (Lenz et al., Biochem. Biophys. Res. Comm., 2000, 273, 1126-1131). Prvi Drosophila alatostatinski receptor klonirao je Birgul sa suradnicima i pokazalo se da je funkcionalno aktiviran pomoću drostatin-3 putem Gi/Go puteva (Birgul et al., EMBO J., 1999, 18, 5892-5900). Drugi potencijalni Drosophila alatostatinski receptor (tj. DARII) nedavno je kloniran (Lenz et al., Biochem. Biophys. Res. Comm., 2000, 273, 571-577). DARII receptor cDNA (pristupni br. AF253526) kodira za protein koji je jako srodan s prvim that Drosophila alatostatinskim receptorom. Nedavno, functionalno aktiviranje DARII pomoću alatostatina smo pokazali mi (Larsen, et al., Biochem. Biophys. Res. Comm., 2001, 286, 895-901) i drugi (Lenz, et al., Biochem. Biophys. Res. Comm., 2001, 286, 1117-1122). Nedavno, kloniran je Drosophila alatostatin tip C preprophormonski gen koji kodira Drosophila alatostatin-C: Gln-Val-Arg-Tyr-Ghi-Cys-Tyr-Phe-Asn-Pro-Ile-Ser-Cys-Phe-OH (Williamson et al., Biochem. Biophys. Res. Comm., 2001, 282, 124-130). Zreli peptid trebao bi imati pGlu na N-terminalu, koji nastaje kao rezultat N-terminalne Gln ciklizacije da se dobije: pGlu-Val-Axg-Tyr-Gln-Cys-Tyr-Phe-Asn-Pro-Ile-Ser-Cys-Phe-OH (sekv. br. 183) i disulfidni most između Cys6 i Cys13, slično kao za Manduca sexta tip C alatostatina, pGlu-Val-Arg-Phe-Gln-Cys-Tyr-Phe-Asn-Pro-Ile-Ser-Cys-Phe-OH (sekv. br. 182), koji se razlikuje samo na položaju 4 (Phe4 vs. Tyr4) (Kramer et al., Proc. Natl. Acad. Sci. USA, 1991, 88, 9458-9462). Nichols i suradnici pokazali su snažno i produženo inhibiranje mišićne kontrakcije Drosophila alatostatina-C i nazvali su ga ‘flatline’ (FLT) peptidom (Nichols et al., Peptides, 2002, 23, 787-794). Sukladno našim spoznajama, do sada nisu identificirani receptori za alatostatin tip-C.  Allatostatins are a significant group of insect neurohormones that control diverse functions including the synthesis of juvenile hormones known to play a central role in metamorphosis and reproduction in various insect species. The first Drosophila allatostatin, Ser-Arg-Pro-Tyr-Ser-Phe-Gly-Leu-NH2 (ie, drostatin-3) (SEQ ID NO: 165), was isolated from Drosophila head extract (Birgul et al., EMBO J ., 1999, 18, 5892-5900). Recently, the Drosophila allatostatin preprohormone gene was cloned, encoding four Drosophila allatostatins: Val-Glu-Arg-Tyr-Ala-Phe-Gly-Leu-NH2 (drostatin-1) (SEQ ID NO: 163), Leu-Pro- Val-Tyr-Asn-Phe-Gly-Leu-NH2 (drostatin-2) (SEQ ID NO: 164), Ser-Arg-Pro-Tyr-Ser-Phe-Gly-Leu-NH2 (drostatin-3) (SEQ ID NO: . no. 165) and Thr-Thr-Arg-Pro-Gln-Pro-Phe-Asn-Phe-Gly-Leu-NH2 (drostatin-4) (seq. no. 166) (Lenz et al., Biochem. Biophys Res. Comm., 2000, 273, 1126-1131). The first Drosophila allatostatin receptor was cloned by Birgul et al. and shown to be functionally activated by drostatin-3 via Gi/Go pathways (Birgul et al., EMBO J., 1999, 18, 5892-5900). Another potential Drosophila allatostatin receptor (ie, DARII) has recently been cloned (Lenz et al., Biochem. Biophys. Res. Comm., 2000, 273, 571-577). The DARII receptor cDNA (accession no. AF253526) encodes a protein that is closely related to the first Drosophila allatostatin receptor. Recently, functional activation of DARII by allatostatin has been demonstrated by us (Larsen, et al., Biochem. Biophys. Res. Comm., 2001, 286, 895-901) and others (Lenz, et al., Biochem. Biophys. Res. Comm. ., 2001, 286, 1117-1122). Recently, the Drosophila alatostatin type C preprohormone gene encoding Drosophila alatostatin-C: Gln-Val-Arg-Tyr-Ghi-Cys-Tyr-Phe-Asn-Pro-Ile-Ser-Cys-Phe-OH was cloned (Williamson et al ., Biochem. Biophys. Res. Comm., 2001, 282, 124-130). The mature peptide should have pGlu at the N-terminus, which results from N-terminal Gln cyclization to give: pGlu-Val-Axg-Tyr-Gln-Cys-Tyr-Phe-Asn-Pro-Ile-Ser-Cys- Phe-OH (SEQ ID NO: 183) and a disulfide bridge between Cys6 and Cys13, similar to Manduca sexta type C allatostatin, pGlu-Val-Arg-Phe-Gln-Cys-Tyr-Phe-Asn-Pro-Ile-Ser -Cys-Phe-OH (SEQ ID NO: 182), which differs only at position 4 (Phe4 vs. Tyr4) (Kramer et al., Proc. Natl. Acad. Sci. USA, 1991, 88, 9458-9462 ). Nichols et al. showed a strong and prolonged inhibition of Drosophila allatostatin-C muscle contraction and named it the 'flatline' (FLT) peptide (Nichols et al., Peptides, 2002, 23, 787-794). To our knowledge, no receptors for allatostatin type-C have been identified so far. 
 
 
   Sulfakinini su familija insektnih Tyr-sulfatiranih neuropeptida. Oni pokazuju sekvencijsku i funkcionalnu (miotropni učinci, stimuliranje otpuštanja digestivnog enzima) sličnost s gastrin peptidima kralježnjaka i kolecistokininom. Gen koji kodira dva sulfakinina (također nazvani drosulfakinini), DSKI [Phe-Asp-Asp-Tyr(SO3H)-Gly-His-Met-Arg-Phe-amid] (sekv. br. 160) i DSKII [Gly-Gly-Asp-Asp-Gln-Phe-Asp-Asp-Tyr(SO3H)-Gly-His-Met-Arg-Phe-amid] (sekv. br. 161), identificiran je u Drosophila melanogaster (Nichols, Mol. Cell Neuroscience, 1992, 3, 342-347; Nichols et al., J. Biol. Chem., 1988, 263, 12167-12170). C-terminalna heptapeptidna sekvencija, Asp-Tyr(SO3H)-Gly-His-Met-Arg-Phe-amid (sekv. br. 162), identična je u svim sulfakininima koji su dosad identificirani u insektima koji su široko odijeljeni u evolucijskom smislu. Održavanje heptapeptidne sekvencije, uključujući prisutnost sulfatirane Tyr rezidue, u vrlo divergentnoj insektnoj taksi vjerojatno odražava značaj miotropne „aktivne jezgre“ (Nachman & Holman, u: Insect Neuropeptides: Chemistry, Biology and Action, Menn, Kelly & Massler, Eds., American Chemical Society, Washington, D.C., 1991, str. 194-214). Nedavno, identificirali smo Drosophila usamljeni (orphan) receptor (DmGPCR9) kao drosulfakininski receptor (nazvan DSK-R1) i povezali ga s njegovim aktivirajućim peptidom, Met5→Leu modifciiranim drosulfakininom-1, Asp-Tyr(SO3H)-Gly-His-Leu-Arg-Phe-amid (sekv. br. 157) (Kubiak et al., Biochem. Biophys. Res. Comm., 2002, 291, 313-320). Novi neusamljeni Drosophila GPCR-ovi uključuju receptore za PRXamidne peptide, CCAP, korazonin i AKH (Park et al., Proc. Natl. Acad. Sci. USA, 2002, 99, 11423-11428; Cazzamali et al., Biochem. Biophys. Res. Comm., 2002, 298, 31-36); leukokinin (Radford et.al, J. Biol. Chem. 2002, 277, 38810-38817); drostatin-C (Kreienkamp et al., J. Biol. Chem, 10.1074/jbc.M206931200 (publicirano online 6. kolovoza 2002.); FMRFamid (Cazzamali et al., Proc. Natl. Acad. Sci. USA, 2002, 39, 12073-12078); te neuoropeptid F (Mertens, et al., Biochem. Biophys. Res. Comm., 2002, 297, 1140-1148).  Sulfakinins are a family of insect Tyr-sulfated neuropeptides. They show sequence and functional (myotropic effects, stimulation of digestive enzyme release) similarity to vertebrate gastrin peptides and cholecystokinin. The gene encoding two sulfakinins (also called drosulfakinins), DSKI [Phe-Asp-Asp-Tyr(SO3H)-Gly-His-Met-Arg-Phe-amide] (SEQ ID NO: 160) and DSKII [Gly-Gly- Asp-Asp-Gln-Phe-Asp-Asp-Tyr(SO3H)-Gly-His-Met-Arg-Phe-amide] (SEQ ID NO: 161), was identified in Drosophila melanogaster (Nichols, Mol. Cell Neuroscience, 1992, 3, 342-347; Nichols et al., J. Biol. Chem., 1988, 263, 12167-12170). The C-terminal heptapeptide sequence, Asp-Tyr(SO3H)-Gly-His-Met-Arg-Phe-amide (SEQ ID NO: 162), is identical in all sulfakinins identified so far in widely separated insects in evolutionary terms . The maintenance of a heptapeptide sequence, including the presence of a sulfated Tyr residue, in highly divergent insect taxa likely reflects the importance of a myotropic "active core" (Nachman & Holman, in: Insect Neuropeptides: Chemistry, Biology and Action, Menn, Kelly & Massler, Eds., American Chemical Society, Washington, D.C., 1991, pp. 194-214). Recently, we identified the Drosophila orphan receptor (DmGPCR9) as a drosulfakinin receptor (named DSK-R1) and linked it to its activating peptide, Met5→Leu modified drosulfakinin-1, Asp-Tyr(SO3H)-Gly-His-Leu -Arg-Phe-amide (SEQ ID NO: 157) (Kubiak et al., Biochem. Biophys. Res. Comm., 2002, 291, 313-320). Novel non-isolated Drosophila GPCRs include receptors for PRXamide peptides, CCAP, corazonin, and AKH (Park et al., Proc. Natl. Acad. Sci. USA, 2002, 99, 11423-11428; Cazzamali et al., Biochem. Biophys. Res. Comm., 2002, 298, 31-36); leucokinin (Radford et. al, J. Biol. Chem. 2002, 277, 38810-38817); drostatin-C (Kreienkamp et al., J. Biol. Chem, 10.1074/jbc.M206931200 (published online August 6, 2002); FMRFamide (Cazzamali et al., Proc. Natl. Acad. Sci. USA, 2002, 39 , 12073-12078); and neuropeptide F (Mertens, et al., Biochem. Biophys. Res. Comm., 2002, 297, 1140-1148). 
 
 
   Sažetak izuma  Summary of the invention 
 
 
   U ovom izumu obuhvaćeno je iznenađujuće otkriće novih polipeptida u Drosophila melanogaster, koji su ovdje nazvani DmGPCR-ovi (Drosophila melanogaster G protein-vezani receptori), te pokazuju različiti stupanj homologije u odnosu na ostale neuropeptidne GPCR-ove. Ovim izumom dobivaju se geni koji kodiraju dosad nepoznate G protein-vezane receptore, DmGPCR polipeptidi koji su kodirani genima, antitijela za polipeptide, pribori koji koriste polinukleotide i polipeptide te metode dobivanja i korištenja sve navedenog. DmGPCR-ovi mogu imati ulogu kao ključne komponente, primjerice u reguliranju neuropeptidnog vezanja i/ili signaliziranja. DmGPCR-ovi su dakle korisni u potrazi za novim sredstvima koji mogu modificirati i/ili kontrolirati vezanje i/ili signaliziranje pomoću neuropeptida i drugih sredstava. Niže su opisani ovi i drugi aspekti ovog izuma.  This invention covers the surprising discovery of new polypeptides in Drosophila melanogaster, which are here called DmGPCRs (Drosophila melanogaster G protein-coupled receptors), and which show a different degree of homology in relation to other neuropeptide GPCRs. This invention provides genes that encode hitherto unknown G protein-coupled receptors, DmGPCR polypeptides that are encoded by genes, antibodies for polypeptides, accessories that use polynucleotides and polypeptides, and methods of obtaining and using all of the above. DmGPCRs can play a role as key components, for example in regulating neuropeptide binding and/or signaling. DmGPCRs are therefore useful in the search for new agents that can modify and/or control binding and/or signaling by neuropeptides and other agents. These and other aspects of the present invention are described below. 
 
 
   U nekim realizacijama, izumom se dobivaju pročišćeni i izolirani DmGPCR polipeptidi koji sadrže aminokiselinsku sekvenciju koja se nalazi u bilo kojoj od sekvencija br. 2, 4, 6, 8,10, 12, 14, 16, 18, 20, 22 ili 24 ili njen fragment koji sadrži epitop specifičan za DmGPCR. Pod „epitop specifičan za“ podrazumijeva se dio DmGPCR receptora koji je prepoznat od antitijela koje je specifično za DmGPCR, kao što je u detaljima definirano niže. Jedan realizacija ovog izuma obuhvaća pročišćene i izdvojene polipeptide koji sadrže potpune aminokiselinske sekvencije koje su u aminokiselinskim sekvencijama br.: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 ili 24, što je navedeni u tablici 4 dolje. Ove aminokiselinske sekvencije su izvedene iz polinukleotidnih sekvencija koje kodiraju DmGPCR (sekv. br. 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21 ili 23, navedeni u tablici 4 niže). Pojam „DmGPCR“ kako se ovdje rabi u jednini označuje sekvenciju od deset aminokiselina koja je prikazana niže, koja je kodirana odgovarajućim polinukleotidnim sekvencijama.  In some embodiments, the invention provides purified and isolated DmGPCR polypeptides containing the amino acid sequence found in any of the sequences no. 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 or 24 or a fragment thereof containing an epitope specific for DmGPCR. By "epitope specific for" is meant a part of a DmGPCR receptor that is recognized by an antibody that is specific for a DmGPCR, as defined in detail below. One embodiment of the present invention includes purified and isolated polypeptides containing complete amino acid sequences that are in amino acid sequence nos: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 or 24, as set forth in table 4 below. These amino acid sequences are derived from the polynucleotide sequences encoding DmGPCR (SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21 or 23, listed in Table 4 below). The term "DmGPCR" as used herein in the singular refers to the ten amino acid sequence shown below, which is encoded by the corresponding polynucleotide sequences. 
 
 
   Premda su definirane sekvencije konkretne Drosophila sekvencije, ovaj izum obuhvaća unutar svoga dosega alelne inačice, oblike DmGPCR kralježnjaka i beskralježnjaka.  Although specific Drosophila sequences are defined, this invention includes within its scope allelic versions, vertebrate and invertebrate forms of DmGPCR. 
 
 
   U nekim realizacijama, ovaj izum definira pročišćene i izdvojene polinukleotide (npr. cDNA, genomsku DNA, sintetsku DNA, RNA ili njihove kombinacije, i jednostruko i dvostruko uvijene) koji sadrže nukleotidnu sekvenciju koja kodira aminokiselinsku sekvenciju polipeptida ovog izuma. Takvi polinukleotidi korisni su za rekombinantnu ekspresiju receptora i također za detektiranje ekspresije receptora u stanicama (npr. korištenjem ‘Northern’ hibridiziranja i in situ hibridizacijskih analiza). Takvi polinukleotidi su korisni u oblikovanju protivsmislenih i drugih molekula za supresiju ili regulaciju ekspresije DmGPCR u uzgojenoj stanici, tkivu ili životinji. Specifično izuzeti iz definicije polinukleotida ovog izuma su potpuno izdvojeni, nerekombinantni nativni kromosomi stanica domaćina. Polinukleotidi ovog izuma mogu imati sekvenciju bilo koje sekvencije sljedećeg skupa: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21 ili 23, što odgovara prirodnim DmGPCR sekvencijama. Valja uočiti da postoje brojne druge polinukleotidne sekvencije koje također kodiraju DmGPCR sa sekvencijom iz sljedećeg skupa: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 ili 24 zbog dobro poznate degeneracije univerzalnog genetskog koda.  In some embodiments, the present invention defines purified and isolated polynucleotides (eg, cDNA, genomic DNA, synthetic DNA, RNA, or combinations thereof, both single and double stranded) comprising a nucleotide sequence encoding the amino acid sequence of a polypeptide of the present invention. Such polynucleotides are useful for recombinant expression of receptors and also for detecting receptor expression in cells (eg, using 'Northern' hybridization and in situ hybridization assays). Such polynucleotides are useful in designing antisense and other molecules to suppress or regulate DmGPCR expression in a cultured cell, tissue or animal. Specifically excluded from the definition of polynucleotides of the present invention are fully isolated, non-recombinant native chromosomes of host cells. The polynucleotides of the present invention may have the sequence of any of the following set of sequences: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21 or 23, corresponding to native DmGPCR sequences. It should be noted that there are numerous other polynucleotide sequences that also encode a DmGPCR with a sequence from the following set: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 or 24 due to the well-known degeneracy of the universal genetic code. 
 
 
   Izum također definira pročišćene i izdvojene polinukleotide koji sadrže nukleotidnu sekvenciju koja kodira polipeptid sisavaca, pri čemu polinukleotid hibridizira prema polinukleotidu sa bilo kojom sekvencijom iz sljedećeg skupa: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21 ili 23 ili nekodirajućoj niti koja je komplementarna, u sljedećim vjetima hibridiziranja:  The invention also defines purified and isolated polynucleotides comprising a nucleotide sequence encoding a mammalian polypeptide, wherein the polynucleotide hybridizes to a polynucleotide with any sequence from the following set: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21 or 23 or to a non-coding strand that is complementary, in the following hybridization sequences: 
 
 
   hibridiziranje 16 sati na 42°C u otopini za hibridiziranje koja sadrži 50% formamid, 1% SDS, 1 M NaCl, 10% dekstran sulfat; i  hybridization for 16 hours at 42°C in a hybridization solution containing 50% formamide, 1% SDS, 1 M NaCl, 10% dextran sulfate; and 
 
 
   ispiranje 2 puta po 30 minuta na 60°C u otopini za ispiranje koja sadrži 0,1% SSC, 1% SDS.  washing 2 times for 30 minutes at 60°C in a washing solution containing 0.1% SSC, 1% SDS. 
 
 
   Uvjeti hibridiziranja trebali bi biti takvi da se hibridiziranje zbiva samo s genima u prisutnosti molekula drugih nukleinskih kiselina. U utvrđenim uvjetima hibridiziranja hibridiziraju samo sekvencije vrlo komplementarnih nukleinskih kiselina.  Hybridization conditions should be such that hybridization occurs only with genes in the presence of other nucleic acid molecules. Under the established hybridization conditions, only highly complementary nucleic acid sequences hybridize. 
 
 
   Takvi uvjeti mogu spriječiti hibridiziranje nukleinske kiseline koja ima 1 ili 2 pogreške od 20 kontinuiranih nukleotida.  Such conditions can prevent nucleic acid having 1 or 2 errors out of 20 contiguous nucleotides from hybridizing. 
 
 
   U nekim realizacijama, ovaj izum definira vektore koji sadrže polinukleotid ovog izuma. Takvi vektori korisni su, npr. za pojačavanje polinukleotida u stanicama domaćina da se stvori njegova korisna količina. U nekim realizacijama, vektor je ekspresijski vektor pri čemu je polinukleotid ovog izuma operativno povezan za polinukleotid koji sadrži ekspresijsku kontrolnu sekvenciju. Takvi vektori korisni su za rekombinantnu proizvodnju polipeptida ovog izuma.  In some embodiments, the present invention defines vectors comprising a polynucleotide of the present invention. Such vectors are useful, eg, for amplifying a polynucleotide in host cells to generate a useful amount thereof. In some embodiments, the vector is an expression vector wherein a polynucleotide of the present invention is operably linked to a polynucleotide comprising an expression control sequence. Such vectors are useful for recombinant production of the polypeptides of the present invention. 
 
 
   U nekim realizacijama, ovaj izum definira stanice domaćina koje su transformirane ili transficirane (postojano ili prolazno) s polinukleotidima ovog izuma ili vektorima ovog izuma. Kao što je prije navedeno, takve stanice domaćina korisne su za pojačavanje polinukleotida i također za ekspresiju DmGPCR polipeptida ili njegova fragmenta koji je kodiran pomoću polinukleotida.  In some embodiments, the present invention defines host cells that have been transformed or transfected (permanently or transiently) with polynucleotides of the present invention or vectors of the present invention. As previously noted, such host cells are useful for amplifying the polynucleotide and also for expressing the DmGPCR polypeptide or fragment thereof encoded by the polynucleotide. 
 
 
   U sljedećoj realizaciji, izumom su definirane metode za dobivanje DmGPCR polipeptida (ili njegova fragmenta) što obuhvaća stupnjeve rasta stanice domaćina ovog izuma u hranjivom mediju te izdvajanje polipeptida ili njegove inačice iz stanice ili iz medija. Budući da je DmGPCR sedam transmembranski receptor, uočava se da za neke primjene, kao što su određene analize aktivnosti, izdvajanje može uključivati izdvajanje staničnih membrana koje sadrže ugrađeni polipeptid, dok za druge primjene može biti poželjno potpunije izdvajanje.  In the next embodiment, the invention defines methods for obtaining a DmGPCR polypeptide (or its fragment), which includes growth stages of the host cell of this invention in a nutrient medium and extracting the polypeptide or its version from the cell or from the medium. Since DmGPCR is a seven transmembrane receptor, it is appreciated that for some applications, such as certain activity assays, isolation may involve separation of cell membranes containing the embedded polypeptide, while for other applications more complete isolation may be desirable. 
 
 
   Uočljivo je da su izvanstanični epitopi osobito korisni za generiranje i screening antitijela i drugih vezujućih spojeva koji se vežu za receptore kao što je DmGPCR. Prema tome, u sljedećoj realizaciji, ovaj izum definira pročišćen i izdvojen polipeptid koji sadrži bar jednu izvanstaničnu domenu (npr. N-terminalnu izvanstaničnu domenu ili jednu od triju izvanstaničnih petlji) DmGPCR-a kao što je N-terminalna izvanstanična domena DmGPCR-a. Također su obuhvaćeni ovim izumom pročišćeni polipeptidi koji sadrže transmembranske domene DmGPCR-a, izvanstaničnu petlju koja povezuje transmembranske domene DmGPCR-a, unutarstaničnu petlju koja povezuje transmembranske domene DmGPCR-a, C-terminalno citoplazmatsko područje DmGPCR i njihove fuzije. Takvi fragmenti mogu biti kontinuirani dijelovi nativnog receptora. Međutim, valja uočiti da poznavanje gena DmGPCR-a i proteinskih sekvencija koje je ovdje definirano omogućuje rekombiniranje različitih domena koje nisu kontinuirane u nativnom proteinu.  It can be seen that extracellular epitopes are particularly useful for the generation and screening of antibodies and other binding compounds that bind to receptors such as DmGPCR. Accordingly, in a further embodiment, the present invention defines a purified and isolated polypeptide comprising at least one extracellular domain (eg, the N-terminal extracellular domain or one of the three extracellular loops) of a DmGPCR such as the N-terminal extracellular domain of a DmGPCR. Also covered by this invention are purified polypeptides containing the transmembrane domains of DmGPCR, the extracellular loop connecting the transmembrane domains of DmGPCR, the intracellular loop connecting the transmembrane domains of DmGPCR, the C-terminal cytoplasmic region of DmGPCR and their fusions. Such fragments may be continuous parts of the native receptor. However, it should be noted that the knowledge of the DmGPCR gene and protein sequences defined here allows the recombination of different domains that are not continuous in the native protein. 
 
 
   U daljnjoj realizaciji, ovaj izum definira antitijela specifična za DmGPCR ovog izuma. Specifičnost antitijela opisana je s više pojedinosti niže. Međutim, valja naglasiti da se antitijela koja mogu biti generirana iz polipeptida koji su prije opisni u literaturi i koji mogu slučajno interferirati (unakrsna reakcija, “cross-reaction”) s DmGPCR-om (npr. zbog slučajnog postojanja sličnog epitopa u oba polipeptida) smatraju interferencijski reaktivnim („cross-reactive“) antitijelima. Takva antitijela nisu antitijela koja se “specifična” za DmGPCR. Određivanje je li neko antitijelo specifično DmGPCR ili je interferencijski reaktivno s drugim poznatim receptorom može se izvršiti pomoću nekoliko analiza, kao što su ‘Western blotting’ analize, što je dobro poznato u tehnici. Za identificiranje stanica koje vrše ekspresiju DmGPCR i također za moduliranje DmGPCR-ligand vezujuće aktivnosti, mogu se rabiti antitijela koja se specifično vežu za izvanstanični epitop DmGPCR-a.  In a further embodiment, the present invention defines antibodies specific for the DmGPCR of the present invention. Antibody specificity is described in more detail below. However, it should be emphasized that antibodies that can be generated from polypeptides previously described in the literature and that can accidentally interfere ("cross-reaction") with DmGPCR (e.g. due to the accidental existence of a similar epitope in both polypeptides) are considered interference-reactive ("cross-reactive") antibodies. Such antibodies are not antibodies that are "specific" for DmGPCR. Determining whether an antibody is DmGPCR specific or cross-reactive with another known receptor can be performed using several assays, such as Western blotting assays, which are well known in the art. To identify cells expressing DmGPCR and also to modulate DmGPCR-ligand binding activity, antibodies that specifically bind to the extracellular epitope of DmGPCR can be used. 
 
 
   U jednoj inačici, ovaj izum definira monoklonska antitijela. Hibridomi koji proizvode takva antitijela također su obuhvaćeni kao aspekti ovog izuma.  In one embodiment, the present invention defines monoclonal antibodies. Hybridomas producing such antibodies are also encompassed as aspects of the present invention. 
 
 
   U sljedećoj inačici, ovaj izum definira smjesu bez stanica koja sadrži poliklonska antitijela, pri čemu bar jedno od antitijela je antitijelo ovog izuma koje je specifično za DmGPCR. Antiserumi koji su izdvojeni iz životinje su primjer smjese, kao što je i smjesa koja sadrži frakciju antitijela antiseruma koja je resuspendirana u vodi ili u drugom razrjeđivaču, ekscipijentu ili nosaču.  In another embodiment, the present invention defines a cell-free mixture comprising polyclonal antibodies, wherein at least one of the antibodies is an antibody of the present invention that is specific for DmGPCR. Antisera that have been isolated from an animal are an example of a mixture, as is a mixture containing an antibody fraction of an antiserum that has been resuspended in water or in another diluent, excipient, or carrier. 
 
 
   U sljedećoj srodnoj realizaciji, ovaj izum definira anti-idiotipska antitijela za antitijelo koje je specifično za DmGPCR.  In another related embodiment, the present invention defines anti-idiotypic antibodies for an antibody that is specific for a DmGPCR. 
 
 
   Dobro je poznato da antitijela sadrže relativno malene antigen vezujuće domene koje se mogu izdvojiti kemijski ili pomoću rekombinantnih tehnika. Takve domene same su korisne su DmGPCR vezujuće molekule i također mogu biti sjedinjene s toksinima ili drugim polipeptidima. Dakle, u sljedećoj realizaciji, izum definira polipeptid koji sadrži fragment DmGPCR-specifičnog antitijela, pri čemu se fragment i polipeptid vežu za DmGPCR. Kao primjer koji ne ograničuje, ovaj izum definira polipeptide koji su jednolančasta antitijela, CDR-usađena antitijela i humanizirana antitijela.  It is well known that antibodies contain relatively small antigen-binding domains that can be isolated chemically or by recombinant techniques. Such domains alone are useful DmGPCR binding molecules and can also be fused to toxins or other polypeptides. Thus, in the following embodiment, the invention defines a polypeptide containing a fragment of a DmGPCR-specific antibody, wherein the fragment and the polypeptide bind to the DmGPCR. By way of non-limiting example, the present invention defines polypeptides that are single-chain antibodies, CDR-grafted antibodies, and humanized antibodies. 
 
 
   Također su unutar dosega ovog izuma smjese koje sadrže polipeptide, polinukleotide ili antitijela ovog izuma koji su formulirani npr. s farmaceutski prihvatljivim nosačem.  Also within the scope of this invention are mixtures containing polypeptides, polynucleotides or antibodies of this invention that are formulated, for example, with a pharmaceutically acceptable carrier. 
 
 
   Izum također definira metode za korištenje antitijela ovog izuma. Primjerice, izumom su definirane metode za moduliranje ligandnog vezanja DmGPCR-a što uključuje stupanj dovođenja u dodir DmGPCR s antitijelom specifičnim za DmGPCR, u uvjetima pri čemu antitijelo veže receptor.  The invention also defines methods for using the antibodies of the invention. For example, the invention defines methods for modulating ligand binding of DmGPCR, which includes the step of bringing the DmGPCR into contact with an antibody specific for DmGPCR, under conditions where the antibody binds the receptor. 
 
 
   Izumom su definirane metode izazivanja imunološkog odgovora u subjekta prema polipeptidu koji sadrži sekvenciju iz skupa koji se sastoji od sekvencija s br. 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 i 24 ili homologa ili fragmenta. Metode obuhvaćaju primjenu subjektu određene količine polipeptida koja je dovoljna da se izazove imunološki odgovor.  The invention defines methods of inducing an immune response in a subject to a polypeptide containing a sequence from the set consisting of sequences with no. 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 and 24 or homologs or fragments thereof. The methods comprise administering to the subject an amount of the polypeptide sufficient to elicit an immune response. 
 
 
   Izum također definira analize da se identificiraju spojevi koji vežu DmGPCR. Jedna takva analiza uključuje sljedeće stupnjeve: (a) dovođenje u dodir smjese koja sadrži DmGPCR sa spojem za kojega se očekuje da veže DmGPCR; i (b) mjerenje vezanja između spoja i DmGPCR. U jednoj inačici, smjesa sadrži stanice s ekspresijom DmGPCR na svojoj površini. U sljedećoj inačici, koriste se izdvojeni DmGPCR ili stanične membrane koje sadrže DmGPCR. Vezanje se može mjeriti izravno, npr. pomoću obilježenog spoja ili se može mjeriti posredno pomoću nekoliko tehnika, uključujući mjerenje unutarstaničnog signaliziranja DmGPCR-a koje je izazvano pomoću spoja (ili mjerenje promjena u razini signaliziranja DmGPCR-a).  The invention also defines assays to identify compounds that bind DmGPCR. One such assay involves the following steps: (a) contacting a mixture containing a DmGPCR with a compound expected to bind the DmGPCR; and (b) measuring binding between the compound and DmGPCR. In one embodiment, the mixture contains cells with DmGPCR expression on its surface. In a further variant, isolated DmGPCRs or cell membranes containing DmGPCRs are used. Binding can be measured directly, eg, using a labeled compound, or can be measured indirectly using several techniques, including measuring compound-induced intracellular DmGPCR signaling (or measuring changes in the level of DmGPCR signaling). 
 
 
   Izum također definira metode vezanja DmGPCR s vezujućim partnerom. Metode uključuju sljedeće stupnjeve: (a) dovođenje u dodir smjese koja sadrži DmGPCR s vezujućim partnerom i (b) omogućavanje da vezujući partner veže DmGPCR. Primjerice, DmGPCR može biti DmGPCR1 (sekv. br. 1), DmGPCR5 (sekv. br. 9), DmGPCR7 (sekv. br. 17) ili DmGPCR8 (sekv. br. 19). Vezujući partner može biti, primjerice, drotahikinin, leukokinin ili alatostatin-C. Drotahikinin (DTK) može biti, primjerice, DTK-1 (sekv. br. 169), Met8-DTK-2 (sekv. br. 170), DTK-2 (sekv. br. 171), DTK-3 (sekv. br. 172), DTK-4 (sekv. br. 173) i DTK-5 (sekv. br. 174). Leukokinin (LK) može biti, primjerice, LK-I (sekv. br. 175), LK-V (sekv. br. 176), LK-VI (sekv. br. 177) i LK-VIII (sekv. br. 178), kulekinin (sekv. br. 179), mekušac leukokinin-slični peptid, limnokinin (PSFHSWSa) (sekv. br. 180) i Drosophila leukokinin-slični peptidi DLK-1 (NSVVLGKKQRFHSWGa) (sekv. br. 181), DLK-2 (pGlu-RFHSWGa) (sekv. br. 182) i DLK-2 (QRFHSWGa) (sekv. br. 183). Alatostatin (AST) može biti, primjerice, AST-C (sekv. br. 184) ili DST-C (sekv. br. 185). Drugi vezujući partneri obuhvaćaju, bez ograničenja, sekv. br. 186 i sekv. br. 187.  The invention also defines methods of binding a DmGPCR to a binding partner. The methods include the following steps: (a) contacting the mixture containing the DmGPCR with the binding partner and (b) allowing the binding partner to bind the DmGPCR. For example, the DmGPCR can be DmGPCR1 (SEQ ID NO: 1), DmGPCR5 (SEQ ID NO: 9), DmGPCR7 (SEQ ID NO: 17) or DmGPCR8 (SEQ ID NO: 19). The binding partner can be, for example, drotachikinin, leucokinin or alatostatin-C. Drotachykinin (DTK) can be, for example, DTK-1 (SEQ ID NO: 169), Met8-DTK-2 (SEQ ID NO: 170), DTK-2 (SEQ ID NO: 171), DTK-3 (SEQ ID NO: 171). no. 172), DTK-4 (seq. no. 173) and DTK-5 (seq. no. 174). Leukokinin (LK) can be, for example, LK-I (SEQ ID NO: 175), LK-V (SEQ ID NO: 176), LK-VI (SEQ ID NO: 177) and LK-VIII (SEQ ID NO: 177). 178), culekinin (SEQ ID NO: 179), mollusc leucokinin-like peptide, limnokinin (PSFHSWSSa) (SEQ ID NO: 180) and Drosophila leucokinin-like peptides DLK-1 (NSVVLGKKQRFHSWGa) (SEQ ID NO: 181), DLK -2 (pGlu-RFHSWGa) (SEQ ID NO: 182) and DLK-2 (QRFHSWGa) (SEQ ID NO: 183). Allatostatin (AST) can be, for example, AST-C (SEQ ID NO: 184) or DST-C (SEQ ID NO: 185). Other binding partners include, without limitation, seq. no. 186 et seq. no. 187. 
 
 
   Izum također definira metode za identificiranje modulatora vezanja između DmGPCR i DmGPCR vezujućeg partnera, što obuhvaća sljedeće stupnjeve: (a) dovođenje u dodir DmGPCR vezujućeg partnera i smjese koja sadrži DmGPCR u prisutnosti i u odsutnosti potencijalnog modulatorskog spoja; (b) detektiranje vezanja između vezujućeg partnera i DmGPCR; i (c) identificiranje modulatorskog spoja ili modulatorskog spoja u svjetlu smanjenog ili povećanog vezanja između vezujućeg partnera i DmGPCR u prisutnosti potencijalnog modulatora, u usporedbi s vezanjem u odsutnosti potencijalnog modulatora. Primjerice, DmGPCR može biti DmGPCR5 (sekv. br. 9), DmGPCR7 (sekv. br. 17) ili DmGPCR8 (sekv. br. 19). Vezujući partner može biti, primjerice, drotahikinin, leukokinin ili alatostatin. Drotahikinin (DTK) može biti, primjerice, DTK-1 (sekv. br. 169), Met8-DTK-2 (sekv. br. 170), DTK-2 (sekv. br. 171), DTK-3 (sekv. br. 172), DTK-4 (sekv. br. 173) i DTK-5 (sekv. br. 174). Leukokinin (LK) može biti, primjerice, LK-I (sekv. br. 175), LK-V (sekv. br. 176), LK-VI (sekv. br. 177) i LK-VIII (sekv. br. 178), kulekinin (sekv. br. 179), mekušac leukokinin-slični peptid, limnokinin (PSFHSWSa) (sekv. br. 180) i Drosophila leukokinin-slični peptidi DLK-1 (NSVVLGKKQRFHSWGa) (sekv. br. 181), DLK-2 (pGlu-RFHSWGa) (sekv. br. 182) i DLK-2A (QRFHSWGa) (sekv. br. 183). Alatostatin (AST) može biti, primjerice, AST-C (sekv. br. 184) ili DST-C (sekv. br. 185). U jednoj inačici, smjesa sadrži stanice koje vrše ekspresiju DmGPCR nas svojoj površini. U drugoj inačici, koriste se izdvojeni DmGPCR ili stanične membrane koje sadrže DmGPCR. Vezanje se može mjeriti izravno, npr. korištenjem obilježenog spoja ili se može mjeriti posredno pomoću nekoliko tehnika, uključujući mjerenje unutarstaničnog signaliziranja DmGPCR-a što je izazvano pomoću spoja (ili mjerenje promjena razine signaliziranja DmGPCR-a). Primjerice, funkcija se može mjeriti pomoću analize agonistom izazvanog vezanja [35S]GTPγS, pomoću cAMP analize (induciranje ili inhibiranje proizvodnje cAMP) ili mjerenjem unutarstanične razine kalcija pomoću analize fluorimetrijskog čitača ploče (FLIPR).  The invention also defines methods for identifying binding modulators between a DmGPCR and a DmGPCR binding partner, comprising the following steps: (a) contacting the DmGPCR binding partner and a mixture containing the DmGPCR in the presence and absence of a potential modulatory compound; (b) detecting binding between the binding partner and the DmGPCR; and (c) identifying the modulatory compound or modulatory compound in light of decreased or increased binding between the binding partner and the DmGPCR in the presence of the potential modulator, compared to binding in the absence of the potential modulator. For example, the DmGPCR can be DmGPCR5 (SEQ ID NO: 9), DmGPCR7 (SEQ ID NO: 17) or DmGPCR8 (SEQ ID NO: 19). The binding partner can be, for example, drotachikinin, leucokinin or allatostatin. Drotachykinin (DTK) can be, for example, DTK-1 (SEQ ID NO: 169), Met8-DTK-2 (SEQ ID NO: 170), DTK-2 (SEQ ID NO: 171), DTK-3 (SEQ ID NO: 171). no. 172), DTK-4 (seq. no. 173) and DTK-5 (seq. no. 174). Leukokinin (LK) can be, for example, LK-I (SEQ ID NO: 175), LK-V (SEQ ID NO: 176), LK-VI (SEQ ID NO: 177) and LK-VIII (SEQ ID NO: 177). 178), culekinin (SEQ ID NO: 179), mollusc leucokinin-like peptide, limnokinin (PSFHSWSSa) (SEQ ID NO: 180) and Drosophila leucokinin-like peptides DLK-1 (NSVVLGKKQRFHSWGa) (SEQ ID NO: 181), DLK -2 (pGlu-RFHSWGa) (SEQ ID NO: 182) and DLK-2A (QRFHSWGa) (SEQ ID NO: 183). Allatostatin (AST) can be, for example, AST-C (SEQ ID NO: 184) or DST-C (SEQ ID NO: 185). In one embodiment, the mixture contains cells that express DmGPCR on their surface. In another variant, isolated DmGPCRs or cell membranes containing DmGPCRs are used. Binding can be measured directly, eg, using a labeled compound, or can be measured indirectly using several techniques, including measuring intracellular DmGPCR signaling induced by the compound (or measuring changes in the level of DmGPCR signaling). For example, function can be measured using an agonist-induced [35S]GTPγS binding assay, using a cAMP assay (inducing or inhibiting cAMP production), or measuring intracellular calcium levels using a fluorimetric plate reader (FLIPR) assay. 
 
 
   DmGPCR vezujući partneri koji stimuliraju aktivnost DmGPCR korisni su kao agonisti za pojačanje ili produljenje signaliziranja DmGPCR i na taj način interferiraju sa signalnim putovima normalno aktiviranog receptora. DmGPCR vezujući partneri koji blokiraju ligand-upravljano signaliziranje DmGPCR korisni su kao DmGPCR antagonisti u interferenciji s normalnim DmGPCR signaliziranjem te ometaju receptor-upravljane učinke. Nadalje, DmGPCR modulatori, kao i DmGPCR polinukleotidi i polipeptidi, korisni su u dijagnostičkim analizama za stanja u kojima je DmGPCR aktivnost povećana ili oštećena.  DmGPCR binding partners that stimulate DmGPCR activity are useful as agonists to enhance or prolong DmGPCR signaling and thereby interfere with signaling pathways of the normally activated receptor. DmGPCR binding partners that block ligand-directed DmGPCR signaling are useful as DmGPCR antagonists in interfering with normal DmGPCR signaling and interfering with receptor-directed effects. Furthermore, DmGPCR modulators, as well as DmGPCR polynucleotides and polypeptides, are useful in diagnostic assays for conditions in which DmGPCR activity is increased or impaired. 
 
 
   U sljedećem aspektu, izumom su definirane metode poremećaja ili bolesti koji su izazvani ektoparazitom primjenom subjektu kojemu je to potrebno tvari koja modulira aktivnost ili ekspresiju polipeptida ektoparazita koji je odabran iz skupa kojega sačinjavaju sekvencije s br. 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 ili 24.  In the next aspect, the invention defines methods of disorders or diseases that are caused by an ectoparasite by administering to a subject in need of it a substance that modulates the activity or expression of an ectoparasite polypeptide selected from the group consisting of sequences with no. 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 or 24. 
 
 
   Tvari koje su korisne za tretiranje poremećaja ili bolesti koji su izazvani ektoparazitom mogu pokazati pozitivne rezultate u jednoj ili više in vitro analiza na aktivnost koja odgovara tretmanu konkretnog poremećaja ili bolesti. Tvari koje moduliraju aktivnost polipeptida uključuju, ali nisu ograničene na protivsmislene oligonukleotide, agoniste i antagonisti te antitijela.  Substances useful for treating a disorder or disease caused by an ectoparasite may show positive results in one or more in vitro assays for activity corresponding to the treatment of a particular disorder or disease. Agents that modulate polypeptide activity include, but are not limited to, antisense oligonucleotides, agonists and antagonists, and antibodies. 
 
 
   U sljedećem aspektu, ovaj izum oblikuje metode za detektiranje polipeptida u uzorku kao dijagnostičko pomagalo za bolesti i poremećaje koji su izazvani ektoparazitima, pri čemu metode uključuju sljedeće stupnjeve: (a) dovođenje u dodir uzorka sa sondom nukleinske kiseline koja hibridizira u hibridizacijskim uvjetima analize ciljano područje nukleinske kiseline koja kodira polipeptid koji je odabran iz skupa kojega sačinjavaju sekvencije s br. 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 ili 24, a navedena sonda sadrži sekvenciju nukleinske kiseline koja kodira polipeptid, njegove fragmenta i/ili komplemente sekvencija i fragmente; i (b) detektiranje prisutnosti ili određene količine hibrida sonda:ciljano područje kao indikacije stanja.  In a further aspect, the present invention provides methods for detecting polypeptides in a sample as a diagnostic aid for diseases and disorders caused by ectoparasites, the methods comprising the following steps: (a) contacting the sample with a nucleic acid probe that hybridizes under hybridization assay conditions targeted a nucleic acid region encoding a polypeptide selected from the group consisting of sequences with no. 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 or 24, and said probe contains a nucleic acid sequence encoding a polypeptide, its fragments and/or sequence complements and fragments; and (b) detecting the presence or amount of the probe:target hybrid as an indication of the condition. 
 
 
   Testni uzorci koji su odgovarajući za metode sondiranja nukleinske kiseline ovog izuma obuhvaćaju primjerice stanice ili ekstrakte stanica nukleinskih kiselina ili biološke tekućine. Uzorci koji se rabe u gore opisanim metodama će varirati sukladno formatu analiza, metodi detektiranja i prirodi tkiva, stanica ili ekstrakata koji se analiziraju. Metode priređivanja ekstrakata stanica nukleinskih kiselina dobro su poznate u tehnici i mogu se lako prilagoditi da se dobiju uzorci koji su sukladno s korištenom metodom.  Test samples suitable for the nucleic acid probing methods of the present invention include, for example, cells or nucleic acid cell extracts or biological fluids. The samples used in the methods described above will vary according to the analysis format, the detection method and the nature of the tissues, cells or extracts being analyzed. Methods for preparing nucleic acid cell extracts are well known in the art and can be readily adapted to obtain samples consistent with the method used. 
 
 
   U nekim realizacijama ovaj izum definira homologe, kao što su homolozi sisavaca, DmGCPR-ova. Homolozi DmGPCR-a sisavaca mogu biti s ekspresijom u tkivima uključujući ali bez ograničenja tkiva živčanog sustava, gušterače (te konkretno gušteračinog otočnog tkiva), hipofize, skeletnog mišića, adipoznog tkiva, jetre, probavnog (GI)-sustava i štitnjače.  In some embodiments, the present invention defines homologues, such as mammalian homologues, of DmGCPRs. Mammalian DmGPCR homologues may be expressed in tissues including but not limited to tissues of the nervous system, pancreas (and specifically pancreatic islet tissue), pituitary gland, skeletal muscle, adipose tissue, liver, digestive (GI)-system and thyroid. 
 
 
   U nekim realizacijama, ovaj izum definira metode identificiranja homologa DmGPCR-a sisavca što obuhvaća stupnjeve screening-a baze nukleinskih kiselina ili biblioteke nukleinskih kiselina sisavaca s molekulom nukleinske kiseline koja je odabrana iz skupa sekvencija s br. 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21 i 23 ili njenog dijela te određivanja je li dio baze podataka ili biblioteke homologan sa sekvencijom.  In some embodiments, the present invention provides methods of identifying homologues of a mammalian DmGPCR comprising the steps of screening a nucleic acid base or library of mammalian nucleic acids with a nucleic acid molecule selected from the set of sequences no. 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21 and 23 or part thereof and determining whether part of the database or library is homologous to the sequence. 
 
 
   Sljedećim aspektom izuma su definirane metode kontroliranja populacije insekata primjenom vezujućeg partnera ili modulatora DmGPCR polinukleotida ili polipeptida prema insektu da se modificira ekspresija ili aktivnost DmGPCR-a. Primjerice, insekt može biti odabran iz skupa kojega sačinjavaju muha, voćna muha, krpelj, buha, uši, grinje i žohar.  A further aspect of the invention defines methods of controlling insect populations by applying binding partners or modulators of DmGPCR polynucleotides or polypeptides to the insect to modify the expression or activity of DmGPCR. For example, an insect can be selected from the group consisting of a fly, a fruit fly, a tick, a flea, lice, mites, and a cockroach. 
 
 
   DmGPCR binding partner može biti drotahikinin (npr. DTK-1 (sekv. br. 169), Met8-DTK-2 (sekv. br. 170), DTK-2 (sekv. br. 171), DTK-3 (sekv. br. 172), DTK-4 (sekv. br. 173) i DTK-5 (sekv. br. 174)), leukokinin (npr. LK-I (sekv. br. 175), LK-V (sekv. br. 176), LK- VI (sekv. br. 177) i LK-VHI (sekv. br. 178), kulekinin (sekv. br. 179), mekušac leukokinin-slični peptid, limnokinin (PSFHSWSa) (sekv. br. 180), DLK-1 (sekv. br. 181), DLK-2 (sekv. br. 182) i DLK-2A (QRFHSWGa) (sekv. br. 183)) ili alatostatin (AST-C (sekv. br. 184 ili DST-C sekv. br. 185)). Drugi vezujući partneri uključuju, bez ograničenja, sekv. br. 186 i sekv. br. 187. DmGPCR modulator može biti anti- DmGPCR antitijelo ili DmGPCR protivsmisleni polinukleotid.  DmGPCR binding partner can be drotachikinin (e.g. DTK-1 (SEQ ID NO: 169), Met8-DTK-2 (SEQ ID NO: 170), DTK-2 (SEQ ID NO: 171), DTK-3 (SEQ ID NO: 171). No. 172), DTK-4 (SEQ ID NO: 173) and DTK-5 (SEQ ID NO: 174)), leucokinin (e.g. LK-I (SEQ ID NO: 175), LK-V (SEQ ID NO: 175) . 176), LK-VI (SEQ ID NO: 177) and LK-VHI (SEQ ID NO: 178), Kulekinin (SEQ ID NO: 179), molluscan leucokinin-like peptide, limnokinin (PSFHSWSa) (SEQ ID NO: 179). 180), DLK-1 (SEQ ID NO: 181), DLK-2 (SEQ ID NO: 182) and DLK-2A (QRFHSWGa) (SEQ ID NO: 183)) or allatostatin (AST-C (SEQ ID NO: 183)). 184 or DST-C seq. no. 185)). Other binding partners include, without limitation, seq. no. 186 et seq. no. 187. The DmGPCR modulator can be an anti-DmGPCR antibody or a DmGPCR antisense polynucleotide. 
 
 
   Sljedećim aspektom izuma su definirane metode prevencije ili tretiranja bolesti ili stanja koje je izazvano ektoparazitom u subjekta-domaćina primjenom subjektu vezujućeg partnera ili modulatora DmGPCR-ova polinukleotida ili polipeptida da se modificira ekspresija ili aktivnost DmGPCR-a.  A further aspect of the invention defines methods of preventing or treating a disease or condition caused by an ectoparasite in a subject-host by applying to the subject a binding partner or modulator of DmGPCR polynucleotides or polypeptides to modify the expression or activity of DmGPCR. 
 
 
   Daljnja svojstva i inačice ovog izuma bit će očigledni onima koji poznaju ovo područje tehnike iz cjeline ove prijave, uključujući detaljni opis i sva takva svojstva koja se smatraju aspektima ovog izuma. Slično, svojstva ovog izuma koja su ovdje opisana mogu se rekombinirati u dodatne realizacije koje se smatraju aspektima ovog izuma, bez obzira smatra li se kombinacija svojstava koja je specifično navedena prije aspektom ili realizacijom ovog izuma. Također, samo takva ograničenja koja su ovdje opisana kao kritična treba promatrati kao takva. Inačice ovog izuma koje nemaju ograničenja u ovom opisu koja se smatraju kritičnima potpadaju pod aspekte ovog izuma.  Further features and variations of the present invention will be apparent to those skilled in the art from the entirety of this application, including the detailed description and all such features which are considered aspects of the present invention. Similarly, the features of this invention described herein may be recombined into additional embodiments that are considered aspects of this invention, regardless of whether the combination of features specifically recited above is considered an aspect or embodiment of this invention. Also, only such limitations described here as critical should be considered as such. Variations of the present invention which are not limited in this description and which are considered critical fall within the aspects of the present invention. 
 
 
   Detaljni opis poželjnih realizacija izuma  Detailed description of preferred embodiments of the invention 
 
 
   Ovaj izum definira, između ostalog, izdvojene ili pročišćene polinukleotide koji kodiraju D. melanogaster G protein vezani receptor (DmGPCR) ili njegov dio, vektore koji sadrže ove polinukleotida, stanice domaćina koje su transformirane ovim vektorima, procese dobivanja DmGPCR, metode korištenja gore navedenih polinukleotida i vektora, izdvojene i pročišćene DmGPCR, metode za screening spojeva koji moduliraju DmGPCR aktivnost i metode identificiranja homologa DmGPCR-a sisavaca, kralježnjaka i beskralježnjaka.  This invention defines, among other things, isolated or purified polynucleotides encoding the D. melanogaster G protein-coupled receptor (DmGPCR) or its part, vectors containing these polynucleotides, host cells transformed with these vectors, processes for obtaining DmGPCR, methods of using the aforementioned polynucleotides and vectors, isolated and purified DmGPCR, methods for screening compounds that modulate DmGPCR activity and methods for identifying DmGPCR homologues of mammals, vertebrates and invertebrates. 
 
 
   U ovom dokumentu postoje različite definicije. Većina izraza koji se rabe ima značenje koje im pridjeljuju osobe koje poznaju ovo područje tehnike. Izrazi koji su specifično deifnirani bilo niž i drugdje u ovom dokumentu imaju značenje koje je definirano u kontekstu ovog izuma kao cjeline i tipično s epodrazumijeva od strane onih koji poznaju ovo područje tehnike.  There are different definitions in this document. Most of the terms used have a meaning assigned to them by persons familiar with the art. Terms specifically defined either below or elsewhere in this document have the meaning as defined in the context of this invention as a whole and typically understood by those skilled in the art. 
 
 
   Podrazumijeva se da ako je navedena skupina sekvencija, njihove kombinacije i potkombinacije također se specifično podrazumijevaju. Primjerice, kada u opisu piše „sekvencije s rednim br. 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21 ili 23“, podrazumijeva se da ovaj izum uključuje kombinacije i potkombinacije, ali bez ograničenja, kombinacije sekvencija 1 and 3; 1 i 5; 1, 3 i 5; itd.  It is understood that if a group of sequences is specified, combinations and subcombinations thereof are also specifically intended. For example, when the description says "sequences with serial no. 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21 or 23", it is understood that this invention includes combinations and subcombinations, but without limitation, combinations of sequences 1 and 3; 1 and 5; 1, 3 and 5; etc. 
 
 
   „Sintetiziran“ kako se rabi ovdje i u tehnici, odnosi se na polinukleotide koji su dobiveni čisto kemijski, za razliku od enzimskih metoda. „Potpuno“ sintetizirane DNA sekvencije su prema tome dobivene isključivo kemijskim sredstvima i „djelomično“ sintetizirane DNA obuhvaćaju one u kojih je samo dio rezultirajuće DNA dobiven kemijskim načinom.  "Synthesized" as used herein and in the art refers to polynucleotides that have been obtained purely chemically, as opposed to by enzymatic methods. "Fully" synthesized DNA sequences are thus obtained exclusively by chemical means and "partially" synthesized DNA includes those in which only part of the resulting DNA was obtained by chemical means. 
 
 
   Pojmom „područje“ označuje se fizički kontinuirani dio primarne strukture biomolekule. U slučaju proteina, područje se definira kao kontinuirani dio aminokiselinske sekvencije toga proteina.  The term "region" refers to a physically continuous part of the primary structure of a biomolecule. In the case of a protein, a region is defined as a continuous part of the amino acid sequence of that protein. 
 
 
   Pojam „domena“ koristi se ovdje da označi strukturni dio biomolekule koji doprinosi poznatoj ili suspektnoj funkciji biomolekule. Domene mogu biti koekstenzivne s njenim dijelovima ili područjima. Domene mogu također sadržavati dio molekule koji se razlikuje od konkretnog područja, uz cjelinu ili dio toga područja. Primjeri domena GPCR proteina uključuju, ali nisu ograničeni na izvanstanične (tj. N-terminal), transmembranske i citoplazmatske (tj. C-terminal) domene, koje su koekstenzivne sa slično nazvanim područjima GPCR-ova, svakog od sedam transmembranskih segmenata GPCR-a. Svaki od segmenata petlje (i izvanstaničnih i unutarstaničnih petlji) povezuje susjedne transmembranske segmente.  The term "domain" is used herein to denote a structural part of a biomolecule that contributes to a known or suspected function of the biomolecule. Domains can be coextensive with its parts or areas. Domains can also contain a part of the molecule that differs from the specific region, in addition to all or part of that region. Examples of GPCR protein domains include, but are not limited to, extracellular (ie, N-terminal), transmembrane, and cytoplasmic (ie, C-terminal) domains, which are coextensive with similarly named regions of GPCRs, of each of the seven transmembrane segments of GPCRs . Each of the loop segments (both extracellular and intracellular loops) connects adjacent transmembrane segments. 
 
 
   Kako se ovdje rabi, pojam „aktivnost“ odnosi se na cijeli niz mjerljivih indeksa koji ukazuju ili dokazuju vezanje, bilo izravno ili posredno; uz djelovanje na odgovor, tj. postoji mjerljivi učinak kao odgovor na neko izlaganje ili stimuliranje, uključujući, primjerice, afinitet spoja za izravno vezanje polipeptida ili polinukleotida ovog izuma, ili, primjerice, mjerenje količine ‘uzvodnih’ ili ‘nizvodnih’ proteina ili drugih funkcija nakon neko stimulansa ili događaja.  As used herein, the term "activity" refers to a whole range of measurable indices that indicate or prove binding, either directly or indirectly; with a response effect, i.e., there is a measurable effect in response to some exposure or stimulation, including, for example, the affinity of a compound to directly bind a polypeptide or polynucleotide of this invention, or, for example, measuring the amount of 'upstream' or 'downstream' proteins or other functions after some stimulus or event. 
 
 
   Kako se ovdje rabi, pojam „antitijelo“ namijenjen je da označuje cjelovita, intaktna antitijela i Fab, Fab’, F(ab’)2, Fv i druge fragmente. Cjelovita, intaktna antitijela uključuju monoklonska antitijela kao što su mišja monoklonska antitijela, kimerna antitijela, humana antitijela i humanizirana antitijela.  As used herein, the term "antibody" is intended to refer to complete, intact antibodies and Fab, Fab', F(ab')2, Fv and other fragments. Complete, intact antibodies include monoclonal antibodies such as murine monoclonal antibodies, chimeric antibodies, human antibodies, and humanized antibodies. 
 
 
   Kako se ovdje rabi, pojam „vezanje“ označuje fizičku ili kemijsku interakciju između dviju proteina ili spojeva ili povezanih proteina ili spojeva ili njihove kombinacije. Vezanje obuhvaća ionske, neionske, van der Waalsove, hidrofobne interakcije itd. Fizička interakcija, vezanje, može biti izravno ili posredno. Posredno vezanje može biti putem ili zbog učinaka drugog proteina ili spoja. Izravno vezanje odnosi se na interakcije koje se ne zbivaju putem ili zbog djelovanja drugog proteina ili spoja već se zbiva bez stvarnih kemijskih intermedijera.  As used herein, the term "binding" refers to a physical or chemical interaction between two proteins or compounds or associated proteins or compounds or a combination thereof. Bonding includes ionic, non-ionic, van der Waals, hydrophobic interactions, etc. Physical interaction, bonding, can be direct or indirect. Indirect binding may be through or due to the effects of another protein or compound. Direct binding refers to interactions that do not occur through or due to the action of another protein or compound, but occur without actual chemical intermediates. 
 
 
   Kako se ovdje rabi, pojam „spoj“ označuje neku identificirajuću molekulu, uključujući, ali bez ograničenja, malenu molekulu, peptid, protein, ugljikohidrat, nukleotid ili nukleinsku kiselinu i takav spoj može biti prirodni ili umjetni.  As used herein, the term "compound" refers to an identifying molecule, including, but not limited to, a small molecule, peptide, protein, carbohydrate, nucleotide, or nucleic acid, and such compound may be natural or artificial. 
 
 
   Kako se ovdje rabi, pojam „komplementarni“ odnosi se na Watson-Crick sparivanje baza između nukleotidnih jedinica molekule nukleinske kiseline.  As used herein, the term "complementary" refers to Watson-Crick base pairing between nucleotide units of a nucleic acid molecule. 
 
 
   Kako se ovdje rabi, pojam „dovođenje u dodir“ označuje međusobno povezivanje, bilo izravno ili posredno, spoja u fizičkoj blizini prema polipeptidu ili polinukleotidu ovog izuma. Polipeptid ili polinukleotid može biti u bilo kojem broju pufera, soli, otopina itd. Dovođenje u dodir uključuje, primjerice, stavljanje spoja u posudu, mikrotitarsku sploču, tikvicu sa staničnom kulturom ili mikroploču, kao što je genski čip ili slično, gdje se nalazi molekula nukleinske kiseline ili polipeptid koji kodira GPCR ili njegov fragment.  As used herein, the term "contacting" refers to the mutual linking, either directly or indirectly, of a compound in physical proximity to a polypeptide or polynucleotide of the present invention. The polypeptide or polynucleotide may be in any number of buffers, salts, solutions, etc. Contacting includes, for example, placing the compound in a dish, microtiter plate, cell culture flask, or microplate, such as a gene chip or the like, where the molecule is located. nucleic acids or a polypeptide encoding a GPCR or a fragment thereof. 
 
 
   Kako se ovdje rabi, fraza „homologna nukleotidna sekvencija“ ili „homologna aminokiselinska sekvencija,“ ili njene inačice, odnosi se na sekvencije koje su karakterizirane homologijom na nukleotidnoj razini ili aminokiselinskoj razini, do bar specificiranog postotka. Homologne nukleotidne sekvencije uključuju one sekvencije koje kodiraju za izoforme proteina. Takve izoforme mogu imati ekspresiju u različitim tkivima istog organizma kao rezultat, primjerice, alternativni splicing RNA. Alternativno, izoforme mogu biti kodirane pomoću različitih gena. Homologne nukleotidne sekvencije uključuju nukleotidne sekvencije koje kodiraju protein specija koje nisu insekti uključujući, ali bez ograničenja, sisavce. Homologne nukleotidne sekvencije također uključuju, ali nisu ograničene na prirodne alelne inačice i mutacije nukleotidne sekvencije koja je ovdje definirana. Homologna nukleotidna sekvencija ne uključuje, međutim, nukleotidnu sekvenciju koja kodira druge poznate GPCR-ove. Homologne aminokiselinske sekvencije uključuju one aminokiselinske sekvencije koje kodiraju konzervativne aminokiselinske supstitucije, kao i polipeptide koji imaju aktivnost neuropeptidnog vezanja i/ili signaliziranja. Homologna aminokiselinska sekvencija ne uključuje, međutim, aminokiselinsku sekvenciju koja kodira druge poznate GPCR-ove. Udio homologije može se odrediti pomoću, primjerice, Gap programa (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, Madison, WI), korištenjem podrazumijevanih postavki, koje rabe algoritam Smiths i Watermana (Adv. Appl. Math., 1981, 2, 482-489, što je ovdje uključeno kao referenca u cijelosti).  As used herein, the phrase "homologous nucleotide sequence" or "homologous amino acid sequence," or variations thereof, refers to sequences that are characterized by homology at the nucleotide level or amino acid level, up to at least a specified percentage. Homologous nucleotide sequences include those sequences that code for protein isoforms. Such isoforms can be expressed in different tissues of the same organism as a result of, for example, alternative RNA splicing. Alternatively, the isoforms may be encoded by different genes. Homologous nucleotide sequences include protein-encoding nucleotide sequences of non-insect species including, but not limited to, mammals. Homologous nucleotide sequences also include, but are not limited to, naturally occurring allelic variants and mutations of a nucleotide sequence as defined herein. A homologous nucleotide sequence does not include, however, a nucleotide sequence encoding other known GPCRs. Homologous amino acid sequences include those amino acid sequences that encode conservative amino acid substitutions, as well as polypeptides that have neuropeptide binding and/or signaling activity. The homologous amino acid sequence does not include, however, the amino acid sequence encoding other known GPCRs. The proportion of homology can be determined using, for example, the Gap program (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, Madison, WI), using default settings, which use the algorithm of Smiths and Waterman (Adv. Appl. Math., 1981, 2, 482-489, which is incorporated herein by reference in its entirety). 
 
 
   Kako se ovdje rabi, pojam „izdvojena“ molekula nukleinske kiseline odnosi se na molekulu nukleinske kiseline (DNA ili RNA) koja je uklonjena iz svoje prirodne okoline. Primjeri izdvojenih molekula nukleinske kiseline uključuju, ali nisu ograničeni na rekombinantne DNA molekule koje su sadržane u vektorskoj, rekombinantnoj DNA molekuli koja je zadržana u heterolognoj stanici domaćina, djelomično ili potpuno pročišćene molekule nukleinskih kiselina te sintetske DNA ili RNA molekule.  As used herein, the term "isolated" nucleic acid molecule refers to a nucleic acid molecule (DNA or RNA) that has been removed from its natural environment. Examples of isolated nucleic acid molecules include, but are not limited to, recombinant DNA molecules contained in a vector, recombinant DNA molecules retained in a heterologous host cell, partially or fully purified nucleic acid molecules, and synthetic DNA or RNA molecules. 
 
 
   Kako se ovdje rabe, pojmovi „regulira“, „modulira“ ili „modificira“ označuju povećanje ili smanjenje količine, kakvoće ili učinka određene aktivnosti ili proteina.  As used herein, the terms "regulate," "modulate," or "modify" refer to increasing or decreasing the amount, quality, or effect of a particular activity or protein. 
 
 
   Kako se ovdje rabi, pojam „pojačana aktivnost“ označuje povećanu aktivnost. Pojam „oštećena aktivnost“ označuje smanjenu aktivnost.  As used herein, the term "enhanced activity" refers to increased activity. The term "impaired activity" means reduced activity. 
 
 
   Kako se ovdje rabi, pojam „oligonukleotid“ odnosi se na niz povezanih nukleotidnih rezidua koje imaju dovoljan broj baza da se koriste u polimeraznoj lančanoj reakciji (PCR). Ova kratka sekvencija temelji se (izvedena je) na genomskoj ili cDNA sekvenciji te se koristi da se pojača, potvrdi ili pokaže prisutnost identične, slične ili komplementarne DNA ili RNA u konkretnoj stanici ili tkivu. Oligonukleotidi sadrže dio sekvencije DNA koja ima bar oko 10 nukleotida i bar do oko 50 nukleotida, poželjno oko 15 do 30 nukleotida. Oni se kemijski sintetiziraju i mogu se koristiti kao sonde.  As used herein, the term "oligonucleotide" refers to a series of linked nucleotide residues having a sufficient number of bases to be used in polymerase chain reaction (PCR). This short sequence is based on (derived from) a genomic or cDNA sequence and is used to amplify, confirm or demonstrate the presence of identical, similar or complementary DNA or RNA in a particular cell or tissue. Oligonucleotides contain a part of the DNA sequence that has at least about 10 nucleotides and at least up to about 50 nucleotides, preferably about 15 to 30 nucleotides. They are chemically synthesized and can be used as probes. 
 
 
   Kako se ovdje rabi, pojam „sonda“ odnosi se na sekvenciju nukleinskih kiselina promjenjive duljine, poželjno između bar oko 10 i do oko 6000 nukleotida, ovisno o upotrebi. Oni se rabe u detektiranju identičnih, sličnih ili komplemenatrnih sekvencija nukleinskih kiselina. Sonde veće duljine obično se dobivaju iz prirodnog ili rekombinantnog izvora, visoko su specifične i mnogo sporije hibridiziraju nego oligomeri. One mogu biti jednostruko ili dvostruko uvijene i pažljivo obilježene da bi imale specifičnost u PCR, hidridizacijsko membranskim ili ELISA tehnologijama.  As used herein, the term "probe" refers to a nucleic acid sequence of variable length, preferably between at least about 10 and up to about 6000 nucleotides, depending on the use. They are used to detect identical, similar or complementary sequences of nucleic acids. Probes of longer length are usually derived from natural or recombinant sources, are highly specific, and hybridize much more slowly than oligomers. They can be single or double stranded and carefully labeled to have specificity in PCR, hydraidization membrane or ELISA technologies. 
 
 
   „Dio“ ili „fragment“ kada se odnosi na polinukleotid uključuje polinukleotidnu sekvenciju koja ima bar 14, 16, 18, 20, 25, 50 ili 75 konzekutivnih nukleotida referentnog polinukleotida iz kojega je izveden fragment ili dio. „Dio“ ili „fragment“ kada se odnosi na polipeptid odnosi se na polipeptid koji ima bar 5, 10, 15, 20, 25, 30, 35 ili 40 konzekutivnih aminokiselina referentnog polipeptida iz kojega se izvodi fragment.  "Part" or "fragment" when referring to a polynucleotide includes a polynucleotide sequence having at least 14, 16, 18, 20, 25, 50 or 75 consecutive nucleotides of the reference polynucleotide from which the fragment or part is derived. "Part" or "fragment" when referring to a polypeptide refers to a polypeptide having at least 5, 10, 15, 20, 25, 30, 35 or 40 consecutive amino acids of the reference polypeptide from which the fragment is derived. 
 
 
   Pojam „prevencija“ odnosi se na smanjenje mogućnosti da organizam iskaže ili razvije nenormalno stanje.  The term "prevention" refers to the reduction of the possibility of the organism expressing or developing an abnormal condition. 
 
 
   Fraza „kontroliranje populacije insekata“ ili ili njene inačice odnosi se na povećanje ili smanjenje broja insekata u populaciji. Primjerice, metode kontroliranja populacije insekata uključuju metode povećanja broja blagotvornih insekata u danoj populaciji insekata te metode smanjenja broja štetnih insekata u danoj populaciji insekata.  The phrase "insect population control" or its variants refers to increasing or decreasing the number of insects in a population. For example, methods of controlling insect populations include methods of increasing the number of beneficial insects in a given insect population and methods of reducing the number of harmful insects in a given insect population. 
 
 
   Pojam „tretiranje“ odnosi se na postojanje terapijskog učinka i bar djelomično izbjegavanje ili ublažavanje nenormalnog stanja u organizmu.  The term "treatment" refers to the existence of a therapeutic effect and at least partial avoidance or mitigation of an abnormal state in the body. 
 
 
   Pojam „subjekt“ kako se ovdje rabi odnosi se na insekte, kralježnjake, beskralježnjake i sisavce.  The term "subject" as used herein refers to insects, vertebrates, invertebrates and mammals. 
 
 
   Pojam „terapijski učinak“ odnosi se na inhibiranje ili aktiviranje čimbenika koji izazivaju ili doprinose nenormalnom ili normalnom stanju. Terapijski učinak otklanja do neke mjere jedan ili više simptoma nenormalnog ili normalnog stanja. Terapijski učinak može se odnositi na jedno ili više sljedećeg: (a) povećanje proliferacije, rasta i/ili diferenciranja stanica; (b) inhibiranje (tj. usporavanje ili zaustavljanje) stanične smrti; (c) inhibiranje degeneracije; (d) otklanjanje do neke mjere jednog ili više simptoma koji su povezani sa stanjem; i (e) pojačavanje funkcije zahvaćene populacije stanica. Spojevi koji se pokazuju učinkovitima prema nenormalnim ili normalnim stanjima mogu se identificirati kao što je ovdje opisano.  The term "therapeutic effect" refers to the inhibition or activation of factors that cause or contribute to an abnormal or normal condition. The therapeutic effect removes to some extent one or more symptoms of an abnormal or normal condition. The therapeutic effect may relate to one or more of the following: (a) increasing cell proliferation, growth and/or differentiation; (b) inhibiting (ie, slowing or stopping) cell death; (c) inhibiting degeneration; (d) alleviating to some extent one or more symptoms associated with the condition; and (e) enhancing the function of the affected cell population. Compounds shown to be effective against abnormal or normal conditions can be identified as described herein. 
 
 
   Stanje organizma koje treba tretirati može biti nenormalno ili normalno. Pojam „nenormalno stanje“ odnosi se na funkciju u stanicama ili tkivima organizma koje odstupa od njihove normalne funkcije u tom organizmu. Primjerice, nenormalno stanje može se odnositi na staničnu proliferaciju, stanično diferenciranje, stanično signaliziranje ili stanično preživljavanje.  The condition of the organism to be treated can be abnormal or normal. The term "abnormal condition" refers to a function in the cells or tissues of an organism that deviates from their normal function in that organism. For example, the abnormal condition may relate to cell proliferation, cell differentiation, cell signaling, or cell survival. 
 
 
   Fraza „normalno stanje“ odnosi se na normalnu funkciju u stanicama ili tkivu organizma. Primjerice, normalno stanje može se odnositi na staničnu proliferaciju, stanično diferenciranje, stanično signaliziranje ili stanično preživljavanje.  The phrase "normal state" refers to normal function in the cells or tissue of an organism. For example, a normal state may refer to cell proliferation, cell differentiation, cell signaling, or cell survival. 
 
 
   Pojam „primjena“ odnosi se na metodu ugradnje spoja u stanice ili tkiva organizma. Stanje se može spriječiti, tretirati ili izazvati kada stanice ili tkiva organizma postoje unutar organizma ili izvan organizma. Stanice koje postoje izvan organizma mogu se održavati ili uzgajati u posudama sa staničnom kulturom. Za stanice s utočištem unutar organizma, u tehnici postoje brojne tehnike da se primijene spojevi, uključujući (ali bez ograničenja) oralnu, parenteralnu, dermalnu, injekcijsku ili aerosolnu primjenu. Za stanice izvan organizma, postoje brojne tehnike za primjenu spojeva, uključujući (ali bez ograničenja) tehnike staničnog mikroiniciranja, tehnike transformiranja i tehnike nosača.  The term "administration" refers to the method of incorporating the compound into the cells or tissues of the organism. A condition can be prevented, treated or caused when cells or tissues of an organism exist inside or outside the organism. Cells that exist outside the body can be maintained or grown in cell culture dishes. For cells harboring within the organism, there are numerous techniques in the art to administer the compounds, including (but not limited to) oral, parenteral, dermal, injectable, or aerosol administration. For cells outside the organism, there are numerous techniques for administering the compounds, including (but not limited to) cellular microinitiation techniques, transformation techniques, and carrier techniques. 
 
 
   Stanje se može također spriječiti, tretirati ili izazvati primjenom spoja skupini stanica koje moraju modificirati puteve prijenosa signala organizma koji je subjekt. Učinak primjene spoja na funkciju organizma se zatim može pratiti. Subjekt može primjerice biti sisavac, kao što je miš, štakor, kunić, svinja, kućna životinja (kao što je pas ili mačka), domaća životinja (kao što je kokoš, svinja ili krava), koza, konj, majmun ili čovjek, crv ili insekt.  The condition can also be prevented, treated, or induced by administering the compound to a group of cells that must modify the signal transmission pathways of the subject organism. The effect of the application of the compound on the function of the organism can then be monitored. The subject can be, for example, a mammal, such as a mouse, rat, rabbit, pig, domestic animal (such as a dog or cat), a domestic animal (such as a chicken, pig or cow), a goat, a horse, a monkey or a human, a worm or an insect. 
 
 
   Pod „pojačavanjem“ podrazumijeva se povećanje broja DNA ili RNA u stanici u usporedbi s normalnim stanicama. „Pojačavanje“ kakvo jest odnosi se na RNA koja se može detektirati u prisutnosti RNA u stanicama, budući da u nekih normalnih stanica nema bazalne ekspresije RNA. U drugim normalnim stanicama, postoji bazalna razina ekspresije, prema tome u tim slučajevima pojačavanje je detektiranje od bar 1-2-puta i poželjno više, u usporedbi s bazalnom razinom.  "Amplification" means an increase in the number of DNA or RNA in a cell compared to normal cells. "Amplification" as such refers to RNA that can be detected in the presence of RNA in cells, since there is no basal expression of RNA in some normal cells. In other normal cells, there is a basal level of expression, thus in these cases the amplification is detectable at least 1-2-fold and preferably more, compared to the basal level. 
 
 
   Kako se ovdje rabi, fraza „strogi uvjeti hibridiziranja “ ili „strogi uvjeti“ odnosi se na stanja u kojima će svaka sonda, primjer ili oligonukleotid hibridizirati prema svojoj ciljanoj sekvenciji, ali ne s ostalim sekvencijama. Strogi uvjeti su sekvencijski ovisni i bit će različiti u različitim okolnostima. Dulje sekvencije hibridiziraju specifično pri višim temperaturama. Općenito, strogi uvjeti odabrani su da budu oko 5ºC niži nego što je temperatura tališta (Tm) za specifičnu sekvenciju pri definiranoj ionskoj jakosti i pH. Tm je temperatura (uz definiranu ionsku jakost, pH i koncentraciju nukleinske kiseline) pri kojoj 50% sondi koje su komplementarne prema ciljanoj sekvenciji hibridizira prema ciljanoj sekvenciji u ravnoteži. Budući da su ciljane sekvencije obično u suvišku, pri Tm, 50% sondi je zauzeto u ravnoteži. Tipično, strogi uvjeti su oni u kojima je koncentracija soli manja od oko 1,0 M natrijeva iona, tipično oko 0,01 do 1,0 M natrijeva iona (ili drugih soli) pri pH 7,0 do 8,3 i temperaturi koja je bar oko 30ºC za kratke sonde, primere i oligonukleotide (npr. 10 do 50 nukleotida) i bar oko 60ºC za dulje sonde, primere ili oligonukleotide. Strogi uvjeti mogu se postići dodatkom sredstva za destabiliziranje, kao što je formamid.  As used herein, the phrase "stringent hybridization conditions" or "stringent conditions" refers to conditions in which each probe, primer, or oligonucleotide will hybridize to its target sequence, but not to other sequences. The strict conditions are sequence dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures. Generally, the stringency conditions are chosen to be about 5ºC lower than the melting temperature (Tm) for a specific sequence at a defined ionic strength and pH. Tm is the temperature (with defined ionic strength, pH and nucleic acid concentration) at which 50% of probes complementary to the target sequence hybridize to the target sequence at equilibrium. Since the target sequences are usually in excess, at Tm, 50% of the probes are occupied at equilibrium. Typically, stringent conditions are those in which the salt concentration is less than about 1.0 M sodium ion, typically about 0.01 to 1.0 M sodium ion (or other salts) at pH 7.0 to 8.3 and a temperature that is at least around 30ºC for short probes, primers and oligonucleotides (eg 10 to 50 nucleotides) and at least around 60ºC for longer probes, primers or oligonucleotides. Stringent conditions can be achieved by adding a destabilizing agent, such as formamide. 
 
 
   Aminokiselinske sekvencije nalaze se u smjeru od amino prema karboksi, s lijeva na desno. Amino i karboksilne skupine ne nalaze se u sekvenciji. Nukleotidne sekvencije nalaze se samo u jednoj uzvojnici, u smjeru od 5’ prema 3’, s lijeva na desno. Nukleotidi i aminokiseline predstavljeni su na način kao što preporučuje IUPAC-IUB Biochemical Nomenclature Commission ili (za aminokiseline) pomoću koda s tri slova.  Amino acid sequences are arranged from amino to carboxy, from left to right. Amino and carboxyl groups are not in sequence. Nucleotide sequences are found in only one helix, in the direction from 5' to 3', from left to right. Nucleotides and amino acids are represented as recommended by the IUPAC-IUB Biochemical Nomenclature Commission or (for amino acids) using a three-letter code. 
 
 
   Polinukleotidi  Polynucleotides 
 
 
   Genomska DNA ovog izuma sadrži protein-kodirajuće područje za polipeptid ovog izuma i također je određeno da uključuje njegove alelne inačice. Široko je usvojeno da se, za mnoge gene, DNA transkribira u RNA transkripte koji podliježu jednom ili više cijepanja pri čemu se introni (nekodirajuća područja) uklanjaju ili „izbacuju“. RNA transkripti koje se mogu ispreplesti alternativnim mehanizmima i prema tome predmet su uklanjanja različitih RNA sekvencija ali još uvijek kodiraju DmGPCR polipeptid, u tehnici se označuju kao „splice inačice“ koje su obuhvaćene ovim izumom. Splice inačice koje su obuhvaćene ovim izumom prema tome prema tome su kodirane pomoći identične genomske DNA sekvencije ali koja je iz odvojenih mRNA transkripata. Alelne inačice su modificirani oblici sekvencije gena divljeg tipa, modifikacije koja je rezultat rekombinacije tijekom kromosomske segregacije ili izlaganja uvjetima koji dovode do mutiranja gena. Alelne inačice, poput gena divljeg tipa, su prirodne sekvencije (za razliku od inačica koje se ne nalaze u prirodi i rezultat su in vitro manipuliranja).  The genomic DNA of the present invention contains the protein-coding region for the polypeptide of the present invention and is also determined to include allelic variants thereof. It is widely accepted that, for many genes, DNA is transcribed into RNA transcripts that undergo one or more cleavages in which introns (non-coding regions) are removed or "knocked out". RNA transcripts that can be spliced by alternative mechanisms and are therefore subject to the removal of different RNA sequences but still encode the DmGPCR polypeptide, are referred to in the art as "splice versions" that are covered by this invention. The splice variants encompassed by the present invention are therefore encoded by an identical genomic DNA sequence but from separate mRNA transcripts. Allelic variants are modified forms of the wild-type gene sequence, a modification resulting from recombination during chromosomal segregation or exposure to conditions that cause the gene to mutate. Allelic variants, like wild-type genes, are naturally occurring sequences (as opposed to variants that are not found in nature and are the result of in vitro manipulation). 
 
 
   Ovaj izum također obuhvaća cDNA koja se dobiva reverznom transkripcijom RNA polinukleotida koji kodira DmGPCR (standardno slijedi sinteza druge uzvojnice komplementarne uzvojnice da se dobije dvostruko uvijena DNA).  The present invention also encompasses cDNA obtained by reverse transcription of an RNA polynucleotide encoding a DmGPCR (standardly followed by synthesis of the second helix of the complementary helix to obtain double-stranded DNA). 
 
 
   DNA sekvencija koja kodira DmGPCR polipeptid pripada bilo kojoj sekvenciji iz skupa sekvencija s br. 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21 ili 23. DNA ovog izuma može sadržavati dvostruko uvijenu molekulu zajedno s komplementarnom molekulom („nekodirajuća uzvojnica“ ili „komplement“) koja ima sekvenciju koja je nesumnjivo izvedena iz kodirajuće uzvojnice sukladno Watson-Crick pravilu sparivanja baza za DNA. Također su obuhvaćeni ovim izumom drugi polinukleotidi koji kodiraju bilo koji od konkretne DmGPCR polipeptide ovog izuma koji se razlikuju u sekvenciji od konkretnog polinukleotida koji je ovdje opisan zbog dobro poznate degeneracije univerzalnog genetskog koda.  The DNA sequence encoding the DmGPCR polypeptide belongs to any sequence from the set of sequences with no. 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21 or 23. The DNA of the present invention may comprise a double-stranded molecule together with a complementary molecule ("non-coding strand" or "complement") having a sequence that is undoubtedly derived from the coding coil according to the Watson-Crick base pairing rule for DNA. Also encompassed by the present invention are other polynucleotides encoding any of the particular DmGPCR polypeptides of the present invention that differ in sequence from the particular polynucleotide described herein due to the well-known degeneracy of the universal genetic code. 
 
 
   Ovaj izum nadalje obuhvaća specije, kao što su one sisavaca, homologe DmGPCR-a DNA. Specijski homolozi, koji se ponekad nazivaju „ortolozi,“ općenito dijele bar 35%, bar 40%, bar 45%, bar 50%, bar 60%, bar 65%, bar 70%, bar 75%, bar 80%, bar 85%, bar 90%, bar 95%, bar 98% ili bar 99% homologije s DNA ovog izuma. Općenito, postotoak sekvencije “homologije” u odnosu na polinukleotide ovog izuma može se izračunati kao postotak nukleotidnih baza u kandidatskoj sekvenciji koje su identične nukleotidima u DmGPCR sekvenciji koja se nalazi u određenoj polinukleotidnoj sekvenciji, nakon usklađivanja sekvencija i uvođenja praznina, ako je neophodno, da se postigne maksimalni postotak sekvencijske identičnosti.  The present invention further encompasses species, such as mammalian, DmGPCR DNA homologues. Species homologs, sometimes called "orthologs," generally share at least 35%, at least 40%, at least 45%, at least 50%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98% or at least 99% homology with the DNA of this invention. In general, the percentage of sequence "homology" to the polynucleotides of this invention can be calculated as the percentage of nucleotide bases in a candidate sequence that are identical to nucleotides in a DmGPCR sequence found in a particular polynucleotide sequence, after aligning the sequences and introducing gaps, if necessary, to the maximum percentage of sequence identity is achieved. 
 
 
   Sljedeći aspekt ovog izuma je korištenje nukleotidne sekvencije DmGPCR-a koja je ovdje opisana za identificiranje homologa DmGPCR-a, u drugim životinjama, uključujući sisavce, kralježnjake i beskralježnjake. Bilo koje nukleotidne sekvencije koje su ovdje opisane ili bilo koji njihov dio, mogu se primjerice koristiti kao sonde za screening baze podataka ili biblioteke nukleinskih kisleina, kao što su primjerice genomske ili cDNA biblioteke, da se identificiraju homolozi, korištenjem screening postupaka koji su dobro poznati onima koji poznaju ovo područje.  A further aspect of the present invention is the use of the DmGPCR nucleotide sequence described herein to identify DmGPCR homologues in other animals, including mammals, vertebrates and invertebrates. Any of the nucleotide sequences described herein, or any portion thereof, can, for example, be used as probes to screen databases or libraries of nucleic acids, such as genomic or cDNA libraries, to identify homologues, using screening procedures well known in the art. to those who know this area. 
 
 
   Informacije o polinukleotidnoj sekvenciji koje se dobivaju ovim izumom omogućuju ekspresiju u širokom opsegu kodiranog polipeptida pomoću tehnika koje su dobro poznate i rutinski se primjenjuju u tehnici. Polinukleotidi ovog izuma također omogućuju identificiranje i izdvajanje polinukleotida koji kodira srodne DmGPCR polipeptide, kao što su alelne inačice i specijski homolozi, pomoću dobro poznatih tehnika uključujući ‘Southern’ i/ili ‘Northern’ hibiridiziranje i polimeraznu lančanu reakciju (PCR). Primjeri srodnih polinukleotida uključuju genomske sekvencije, uključujući alelne inačice, kao i polinukleotide koji kodiraju polipeptidne homologe za DmGPCR i strukturno srodne polipeptide koji dijele jedna ili više bioloških, imunoloških i/ili fizičkih svojstava DmGPCR-a. Geni koji kodiraju proteine koji su homologni za DmGPCR također se mogu identificirati pomoću ‘Southern’ i/ili PCR analize i korisni su životinjskim modelima za GPCR poremećaje. Poznavanje sekvencija DNA DmGPCR-a također omogućuje upotrebom ‘Southern’ hibridiziranja ili polimeraza lančane reakcije (PCR) identificiranje genomskih DNA sekvencija koje kodiraju DmGPCR ekspresijske kontrolne regulacijske sekvencije kao što su promotori, operatori, pojačivači, represori i slično. Polinukleotidi ovog izuma su također korisni u analizama hibridiziranja da se odredi kapacitet stanica za ekspresiju DmGPCR. Polinukleotidi ovog izuma mogu također biti osnovica za dijagnostičke metode koje su korisne za identificiranje prisutnosti ektoparazitne ekspresije DmGPCR čemu podliježe stanje ili stanja bolesti, a ta informacija je korisna kao za dijagnozi tako i za odabiranje terapijske strategije.  The polynucleotide sequence information provided by the present invention enables broad-scale expression of the encoded polypeptide using techniques well known and routinely practiced in the art. The polynucleotides of the present invention also enable the identification and isolation of polynucleotides encoding related DmGPCR polypeptides, such as allelic variants and species homologues, using well-known techniques including 'Southern' and/or 'Northern' hybridization and polymerase chain reaction (PCR). Examples of related polynucleotides include genomic sequences, including allelic variants, as well as polynucleotides encoding polypeptide homologues for DmGPCRs and structurally related polypeptides that share one or more biological, immunological, and/or physical properties of DmGPCRs. Genes encoding proteins that are homologous to DmGPCRs can also be identified by Southern and/or PCR analysis and are useful in animal models for GPCR disorders. Knowing the DNA sequences of DmGPCR also enables the use of 'Southern' hybridization or polymerase chain reaction (PCR) to identify genomic DNA sequences that encode DmGPCR expression control regulatory sequences such as promoters, operators, enhancers, repressors and the like. Polynucleotides of the present invention are also useful in hybridization assays to determine the capacity of cells to express DmGPCR. The polynucleotides of this invention may also be the basis for diagnostic methods useful for identifying the presence of ectoparasitic DmGPCR expression underlying a disease state or states, and this information is useful both for diagnosis and for selecting a therapeutic strategy. 
 
 
   Ovdje dani opis polinukleotida pune duljine koji kodira DmGPCR polipeptid omogućuje dobivanje za onoga koji poznaje ovo područje tehnike svakog mogućeg formata polinukleotida pune duljine. Ovaj izum prema tome definira fragmente DmGPCR-a-koji kodiraju polinukleotide koji se sastoje od bar 14 i poželjno bar 16, 18, 20, 25, 50 ili 75 konzekutivnih nukleotida polinukleotida koji kodiraju DmGPCR. Fragment polinukleotida ovog izuma može sadržavati sekvencije koje su jedinstvene za DmGPCR-kodirajuću polinukleotidnu sekvenciju i prema tome hibridizira u vrlo strogim ili umjereno strogim uvjetima samo (tj. „specifično“) za polinukleotide koji kodiraju DmGPCR (ili njegove fragmente). Polinukleotidni fragmenti genomskih sekvencija ovog izuma ne sadrže samo sekvencije koje su jedinstvene za kodirajuće područje, već također obuhvaćaju fragmente sekvencija pune duljine izvedenih iz introna, regulacijskih područja i/ili drugih neprevedenih sekvencija. Sekvencije koje su jedinstvene za polinukleotide ovog izuma mogu se prepoznati pomoću uspoređivanja sekvencija prema drugim poznatim nukleotidima i mogu se identificirati pomoću programa za usklađivanje koji se rutinski koriste u tehnici, npr. oni koji postoje u javnoj bazi podataka o sekvencijama. Takve sekvencije mogu se također prepoznati pomoću ‘Southern’ analiza hibridiziranja da se odredi broj fragmenata genomske DNA za koju će hibridizirati polinukleotid. Polinukleotidi ovog izuma mogu se obilježiti na način koji omogućuje njihovo detektiranje, uključujući radioaktivno, fluorescentno i enzimsko obilježavanje.  The description given herein of a full-length polynucleotide encoding a DmGPCR polypeptide enables one skilled in the art to obtain any possible full-length polynucleotide format. The present invention therefore defines fragments of DmGPCR-encoding polynucleotides consisting of at least 14 and preferably at least 16, 18, 20, 25, 50 or 75 consecutive nucleotides of a DmGPCR-encoding polynucleotide. A polynucleotide fragment of the present invention may contain sequences that are unique to the DmGPCR-encoding polynucleotide sequence and thus hybridize under highly or moderately stringent conditions only (ie, "specific") to DmGPCR-encoding polynucleotides (or fragments thereof). Polynucleotide fragments of the genomic sequences of the present invention not only contain sequences that are unique to the coding region, but also include fragments of full-length sequences derived from introns, regulatory regions, and/or other untranslated sequences. Sequences that are unique to the polynucleotides of the present invention can be identified by sequence comparison to other known nucleotides and can be identified using alignment programs routinely used in the art, eg, those that exist in public sequence databases. Such sequences can also be identified using 'Southern' hybridization analyzes to determine the number of genomic DNA fragments to which the polynucleotide will hybridize. The polynucleotides of the present invention can be labeled in a manner that allows them to be detected, including radioactive, fluorescent, and enzymatic labeling. 
 
 
   Fragmentni polinukleotidi su osobito korisni kao sonde za detektiranje polinukleotida DmGPCR pune duljine ili fragmenta. Jedan ili više polinukleotida može biti sadržano u priborima koji se koriste za detektiranje prisutnosti polinukleotida koji kodira DmGPCR ili se mogu koristiti za detektiranje varijacija u polinukleotidnoj sekvenciji koja kodira DmGPCR.  Fragment polynucleotides are particularly useful as probes for detecting full-length or fragmented DmGPCR polynucleotides. One or more polynucleotides may be contained in kits used to detect the presence of a polynucleotide encoding a DmGPCR or may be used to detect variations in a polynucleotide sequence encoding a DmGPCR. 
 
 
   Ovaj izum također obuhvaća DNA koje kodiraju DmGPCR polipeptide koje hibridiziraju u umjereno strogim ili osobito strogim uvjetima prema nekodirajućoj zavojnici ili komplementu, polinukleoitida iz skupa sekvencija koji se sastoji od sekvencija s br. 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21 ili 23.  The present invention also encompasses DNAs encoding DmGPCR polypeptides that hybridize under moderately stringent or particularly stringent conditions to the noncoding helix or complement of a polynucleotide from a set of sequences consisting of sequences with no. 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21 or 23. 
 
 
   Primjeri osobito strogih uvjeta hibridiziranja su sljedeći: hibridiziranje na 42°C u otopini za hibridiziranje koja sadrži 50% formamid, 1% SDS, 1 M NaCl, 10% dekstran sulfat i ispiranje dva puta po 30 minuta na 60°C u otopini za ispiranje koja sadrži 0,1×SSC i 1% SDS. U tehnici se podrazumijeva da se uvjeti identične strogosti mogu postići variranjem temperature i pufera ili koncentracije soli kao što je opisano u: Ausubel et al. (Eds.), Protocols in Molecular Biology, John Wiley & Sons, 1994, str. 6.0.3-6.4.10. Modifikacije i uvjeti hibridiziranja mogu se iskustveno odrediti i točno izračunati temeljem duljine i postotoka guanozin/citozin (GC) sparivanja baza sonde. Uvjeti hibiridiziranja mogu se izračunati sukladno postupku koji je opisan u: Sambrook et al. (Eds.), Molecular Cloning: Laboratory Manual, Cold Spring Harbor Laboratory Press: Cold Spring Harbor, New York, 1989, str. 9.47-9.51.  Examples of particularly stringent hybridization conditions are as follows: hybridization at 42°C in hybridization solution containing 50% formamide, 1% SDS, 1 M NaCl, 10% dextran sulfate and washing twice for 30 minutes at 60°C in wash solution containing 0.1×SSC and 1% SDS. It is understood in the art that conditions of identical stringency can be achieved by varying the temperature and buffer or salt concentration as described in: Ausubel et al. (Eds.), Protocols in Molecular Biology, John Wiley & Sons, 1994, p. 6.0.3-6.4.10. Modifications and hybridization conditions can be empirically determined and accurately calculated based on the length and percentage of guanosine/cytosine (GC) pairing of probe bases. Hybridization conditions can be calculated according to the procedure described in: Sambrook et al. (Eds.), Molecular Cloning: Laboratory Manual, Cold Spring Harbor Laboratory Press: Cold Spring Harbor, New York, 1989, p. 9.47-9.51. 
 
 
   Poznavanjem informacije o nukleotidnoj sekvenciji ovog izuma, onaj tko poznaje ovo područje tehnike može identificirati i dobiti nukleotidne sekvencije koje kodiraju DmGPCR-ove iz različitih izvora (tj. različita tkiva ili različiti organizmi) na mnogo načina što je poznato onima koji poznaju ovo područje tehnike i što je primjerice opisano u: Sambrook et al., Molecular cloning: laboratory manual, Second Edition, Cold Spring Harbor Press, Cold Spring Harbor, NY, 1989, što je ovdje uključeno kao referenca u cijelosti.  Knowing the nucleotide sequence information of the present invention, one skilled in the art can identify and obtain nucleotide sequences encoding DmGPCRs from different sources (ie, different tissues or different organisms) in a variety of ways known to those skilled in the art and as described, for example, in: Sambrook et al., Molecular cloning: laboratory manual, Second Edition, Cold Spring Harbor Press, Cold Spring Harbor, NY, 1989, which is incorporated herein by reference in its entirety. 
 
 
   Primjerice, DNA koji kodira DmGPCR može se dobiti screeningom mRNA, cDNA ili genomske DNA s oligonukleotidnom sondom koja je nastala iz informacije DmGPCR genske sekvencije koja je ovdje definirana. Sonde mogu biti obilježene s detektirajućom skupinom, kao što je fluorescentna skupina, radioaktivni atom ili kemiluminescentna skupina sukladno s postupcima koji su poznati onima koji poznaju ovo područje tehnike i koriste se u standardnim analizama hibridizacije, što su primjerice opisali Samrook i suradnici.  For example, DNA encoding a DmGPCR can be obtained by screening mRNA, cDNA, or genomic DNA with an oligonucleotide probe generated from the DmGPCR gene sequence information defined herein. Probes can be labeled with a detectable group, such as a fluorescent group, a radioactive atom, or a chemiluminescent group according to procedures known to those skilled in the art and used in standard hybridization assays, as described for example by Samrook et al. 
 
 
   Molekula nukleinske kiseline koja sadrži bilo koju od prije opisanih nukleotidnih sekvencija DmGPCR-a može se alternativno sintetizirati upotrebom postupka polimeraza lančane reakcije (PCR), pri čemu su oligonukleotidni primeri proizvedeni iz nukleotidne sekvencije koja je ovdje definirana. Vidi američki patent br. 4,683,195 koji pripada Mullis-u i suradnicima te 4,683,202 koji pripada Mullis-u. PCR reakcija definira metodu za selektivno povećanje koncentracije konkretne sekvencije nukleinske kiseline čak i kada ta sekvencija nije prethodno pročišćena i prisutna je samo u jednom primjerku u konkretnom uzorku. Metoda se može koristiti za pojačavanje bilo jednostruko ili dvostruko uvijene DNA. Suština metode obuhvaća korištenje dviju oligonukleotidnih sondi da služe kao primeri za šablonski ovisno, polimeraza-upravljano repliciranje željene molekule nukleinske kiseline.  A nucleic acid molecule comprising any of the previously described DmGPCR nucleotide sequences can alternatively be synthesized using the polymerase chain reaction (PCR) method, wherein oligonucleotide primers are produced from the nucleotide sequence defined herein. See US Pat. No. 4,683,195 belonging to Mullis and associates and 4,683,202 belonging to Mullis. The PCR reaction defines a method for selectively increasing the concentration of a particular nucleic acid sequence even when that sequence has not been previously purified and is present in only one copy in a particular sample. The method can be used to amplify either single or double stranded DNA. The essence of the method involves the use of two oligonucleotide probes to serve as primers for template-dependent, polymerase-directed replication of the desired nucleic acid molecule. 
 
 
   Cijeli niz alternativnih kloniranja i in vitro metodologija pojačavanja je poznato onima koji se bave ovim područjem tehnike. Primjeri ovih tehnika mogu se naći primjerice u: Berger et al., Guide to Molecular Cloning Techniques, Methods in Enzymology 152 Academic Press, Inc., San Diego, CA (Berger), što je ovdje uključeno kao referenca u cijelosti.  A variety of alternative cloning and in vitro amplification methodologies are known to those skilled in the art. Examples of these techniques can be found, for example, in: Berger et al., Guide to Molecular Cloning Techniques, Methods in Enzymology 152 Academic Press, Inc., San Diego, CA (Berger), which is incorporated herein by reference in its entirety. 
 
 
   Molekule nukleinskih kiselina ovog izuma i fragmenti koji su izvedeni iz njih korisni su za screening restrikcijskih fragmenata dugih polimorfizama (RFLP-ova) i za genetsko mapiranje.  The nucleic acid molecules of the present invention and fragments derived therefrom are useful for screening of restriction fragment length polymorphisms (RFLPs) and for genetic mapping. 
 
 
   Metode automatskog sekvenciranja mogu se koristiti da se dobije ili provjeri nukleotidna sekvencija DmGPCR-a. DmGPCR nukleotidne sekvencije ovog izuma vjeruje se da su 100% točne. Međutim, kao što je poznato u tehnici, nukleotidne sekvencije koje su dobivene automatskim metodama mogu sadržavati neke pogreške. Nukleotidne sekvencije koje su automatski određene tipično su bar oko 90%, tipičnije bar oko 95% do bar oko 99,9% identične sa stvarnom nukleotidnom sekvencijom dane molekule nukleinske kiseline. Točna sekvencija može se točnije odrediti korištenjem ručnih metoda sekvenciranja, koje su dobro poznate u tehnici. Pogreška u sekvenciji koja rezultira ubacivanjem ili brisanjem jednog ili više nukleotida može rezultirati pomakom okvira u translaciji tako da će se predviđena aminokiselinska sekvencija razlikovati od one koja bi bila predviđena prema stvarnoj nukleotidnoj sekvenciji molekule nukleinske kiseline, počevši od točke mutiranja.  Automated sequencing methods can be used to obtain or verify the nucleotide sequence of a DmGPCR. The dmGPCR nucleotide sequences of the present invention are believed to be 100% correct. However, as known in the art, nucleotide sequences obtained by automated methods may contain some errors. Nucleotide sequences that are automatically determined are typically at least about 90%, more typically at least about 95% to at least about 99.9% identical to the actual nucleotide sequence of a given nucleic acid molecule. The exact sequence can be more accurately determined using manual sequencing methods, which are well known in the art. An error in the sequence resulting in the insertion or deletion of one or more nucleotides can result in a translational frameshift such that the predicted amino acid sequence will differ from that which would be predicted from the actual nucleotide sequence of the nucleic acid molecule, starting from the point of mutation. 
 
 
   Ekspresijski konstrukti i vektori  Expression constructs and vectors 
 
 
   Autonomno replicirajući rekombinantni ekspresijski konstrukti kao što su plazmidni i virusni DNA vektori koji sadrže polinukleotide ovog izuma su također definirani. Vektori se ovdje koriste bilo za pojačanje DNA ili RNA koja kodira DmGPCR i/ili za ekspresiju DNA koja kodira DmGPCR. Vektori ovog izuma uključuju, ali nisu ograničeni na plazmide, fage, kozmide, episome, virusne čestice, viruse i integratabilne DNA fragmente (tj. fragmente koji se mogu integrirati u genom domaćina pomoću homologne rekombinacije). Virusne čestice mogu uključivati, ali nisu ograničeni na adenoviruse, bakuloviruse, parvoviruse, herpesviruse, poksviruse, adeno-pridružene viruse, Smeliki Forest viruse, vaccinia viruse i retroviruse. Primjeri ekspresijskih vektora uključuju, ali nisu ograničeni na pcDNA3 (Invitrogen) i pSVL (Pharmacia Biotech). Drugi ekspresijski vektori uključuju, ali nisu ograničeni na pSPORT vektore, pGEM vektore (Promega), pPROEXvektore (LTI, Bethesda, MD), Bluescript vektore (Stratagene), pQE vektore (Qiagen), pSE420 (Invitrogen) i pYES2 (Invitrogen).  Autonomously replicating recombinant expression constructs such as plasmid and viral DNA vectors containing the polynucleotides of the invention are also defined. Vectors are used herein either to amplify DNA or RNA encoding DmGPCR and/or to express DNA encoding DmGPCR. Vectors of the invention include, but are not limited to, plasmids, phages, cosmids, episomes, viral particles, viruses, and integrable DNA fragments (ie, fragments that can be integrated into the host genome by homologous recombination). Viral particles may include, but are not limited to, adenoviruses, baculoviruses, parvoviruses, herpesviruses, poxviruses, adeno-associated viruses, Smeliki Forest viruses, vaccinia viruses, and retroviruses. Examples of expression vectors include, but are not limited to, pcDNA3 (Invitrogen) and pSVL (Pharmacia Biotech). Other expression vectors include, but are not limited to, pSPORT vectors, pGEM vectors (Promega), pPROEXvectors (LTI, Bethesda, MD), Bluescript vectors (Stratagene), pQE vectors (Qiagen), pSE420 (Invitrogen), and pYES2 (Invitrogen). 
 
 
   Ekspresijski konstrukti pri čemu su DmGPCR-kodirajući polinukleotidi operativno povezani su za endogeni ili egzogeni ekspresijski kontrolni DNA sekvencijski i transkripcijski terminator su također ovdje definirani. Ekspresijske kontrolne DNA sekvencije općenito uključuju promotore, pojačivače, operatore i regulacijska elementna mjesta i tipično su odabrane temeljem ekspresijskih sustava u kojima se koristi ekspresijski konstrukt. Promotorske i pojačivačke sekvencije općenito su odabrane glede sposobnosti povećanja ekspresije gena, dok su operatorske sekvencije općenito odabrane glede sposobnosti reguliranja ekspresije gena. Ekspresijski konstrukti ovog izuma mogu također uključivati sekvencije koje kodiraju jedan ili više selektibilnih obilježivača koji dozvoljavaju identificiranje stanice domaćina koja nosu konstrukt. Ekspresijski konstrukti mogu također uključivati sekvencije koje olakšavaju i/ili unaprjeđuju homolognu rekombinaciju u stanici domaćina. Konstrukti ovog izuma mogu također uključivati sekvencije koje su neophodne za repliciranje u stanici domaćina.  Expression constructs wherein the DmGPCR-encoding polynucleotides are operably linked to an endogenous or exogenous expression control DNA sequence and a transcriptional terminator are also defined herein. Expression control DNA sequences generally include promoters, enhancers, operators and regulatory element sites and are typically selected based on the expression systems in which the expression construct is used. Promoter and enhancer sequences are generally selected for their ability to increase gene expression, while operator sequences are generally selected for their ability to regulate gene expression. Expression constructs of the present invention may also include sequences encoding one or more selectable markers that allow identification of the host cell carrying the construct. Expression constructs may also include sequences that facilitate and/or enhance homologous recombination in the host cell. Constructs of the present invention may also include sequences that are necessary for replication in the host cell. 
 
 
   Ekspresijski konstrukti mogu se rabiti za proizvodnju kodiranog proteina, ali se također mogu koristiti jednostavno za pojačavanje DmGPCR-kodirajuće polinukleotidne sekvencije. U nekim realizacijama, vektor je ekspresijski vektor pri čemu je polinukleotid ovog izuma operativno vezan za polinukleotid koji sadrži ekspresijsku kontrolnu sekvenciju. Neki ekspresijski vektori su replicirajući DNA konstrukti u kojima je DNA sekvencija koja kodira DmGPCR operativno vezana ili povezana s odgovarajućom kontrolnom sekvencijom koja može potaknuti ekspresiju DmGPCR-a u prikladnom domaćinu. DNA područja su operativno vezana ili povezana kada su među njima postoji funkcionalna srodnost. Primjerice, promotor je operativno vezan ili povezan s kodirajućom sekvencijom ako ona kontrolira transkripciju sekvencije. Pojačivački vektori ne zahtijevaju ekspresijske kontrolne domene već im je potrebna samo sposobnost da repliciraju u domaćina, što je obično preneseno izvorom repliciranja i odabirom gena da se olakša prepoznavanje transformanta. Potreba za kontrolnim sekvencijama u ekspresijskom vektoru će varirati ovisno o odabranom domaćinu i odabranoj metodi transformiranja. Općenito, kontrolne sekvencije uključuju transkripcijski promotor, proizvoljnu operatorsku sekvenciju za kontrolnu transkripciju, sekvenciju koja kodira ribosomsko vezanje odgovarajuću mRNA i sekvencije koje kontroliraju terminaciju transkripcije i prevođenja.  The expression constructs can be used to produce the encoded protein, but can also be used simply to amplify the DmGPCR-encoding polynucleotide sequence. In some embodiments, the vector is an expression vector wherein a polynucleotide of the present invention is operably linked to a polynucleotide containing an expression control sequence. Some expression vectors are replicative DNA constructs in which the DNA sequence encoding the DmGPCR is operably linked or linked to a suitable control sequence capable of driving expression of the DmGPCR in a suitable host. DNA regions are operatively linked or connected when there is a functional affinity between them. For example, a promoter is operably linked or linked to a coding sequence if it controls the transcription of the sequence. Enhancer vectors do not require expression control domains but only need the ability to replicate in the host, which is usually imparted by the source of replication and gene selection to facilitate transformant recognition. The need for control sequences in the expression vector will vary depending on the host chosen and the transformation method chosen. In general, control sequences include a transcriptional promoter, an arbitrary operator sequence for controlling transcription, a sequence that encodes ribosomal binding of the corresponding mRNA, and sequences that control the termination of transcription and translation. 
 
 
   Vektori mogu sadržavati promotor koji je prepoznat od organizma domaćina. Promotorske sekvencije ovog izuma mogu biti prokariotske, eukariotske ili virusne. Primjeri pogodnih prokariotskih sekvencija uključuju PR i PL promotore lambda bakteriofaga (The bacteriophage Lambda, Hershey, A.D., Ed., Cold Spring Harbor Press, Cold Spring Harbor, NY, 1973, što je ovdje uključeno kao referenca u cijelosti; Lambda II, Hendrix, R.W., Ed., Cold Spring Harbor Press, Cold Spring Harbor, NY, 1980, što je ovdje uključeno kao referenca u cijelosti); the trp, recA, promotore toplinskog šoka i lacZ promotore E. coli i SV40 rani promotor (Benoist et al., Nature, 1981,290, 304-310, što je ovdje uključeno kao referenca u cijelosti). Daljnji promotori uključuju, ali nisu ograničeni na tumorski virus mišje dojke, dugo terminalno ponavljanje humanog imunodeficijentnog virusa (HW), maloney virus, trenutačni citomegalovirusni rani promotor, Epstein Barr virus, Rous sarkom virus, humani aktin, human miozin, humani hemoglobin, humani mišićni kreatin i humani metalotionein.  Vectors may contain a promoter that is recognized by the host organism. The promoter sequences of the present invention may be prokaryotic, eukaryotic or viral. Examples of suitable prokaryotic sequences include the PR and PL promoters of bacteriophage lambda (The bacteriophage Lambda, Hershey, A.D., Ed., Cold Spring Harbor Press, Cold Spring Harbor, NY, 1973, which is incorporated herein by reference in its entirety; Lambda II, Hendrix, R.W., Ed., Cold Spring Harbor Press, Cold Spring Harbor, NY, 1980, which is hereby incorporated by reference in its entirety); the trp, recA, heat shock and lacZ promoters of E. coli and the SV40 early promoter (Benoist et al., Nature, 1981, 290, 304-310, which is incorporated herein by reference in its entirety). Further promoters include, but are not limited to, murine mammary tumor virus, human immunodeficiency virus (HW) long terminal repeat, Maloney virus, current cytomegalovirus early promoter, Epstein Barr virus, Rous sarcoma virus, human actin, human myosin, human hemoglobin, human muscle creatine and human metallothionein. 
 
 
   Dodatne regulacijske sekvencije mogu također biti uključene u vektorima ovog izuma. Primjeri pogodnih regulacijskih sekvencija uključuju, primjerice, Shine-Dalgarno sekvenciju replikaznog gena faga MS-2 i gen cII bakteriofaga lambda. Nakon Shine-Dalgarno sekvencije može neposredno slijediti DNA koja kodira DmGPCR, što rezultira ekspresijom zrelog DmGPCR proteina.  Additional regulatory sequences may also be included in the vectors of the present invention. Examples of suitable regulatory sequences include, for example, the Shine-Dalgarno sequence of the phage MS-2 replicase gene and the cII gene of bacteriophage lambda. The Shine-Dalgarno sequence can be immediately followed by the DNA encoding the DmGPCR, resulting in the expression of the mature DmGPCR protein. 
 
 
   Štoviše, pogodni ekspresijski vektori mogu uključivati odgovarajući obilježivač koji omogućuje screening transformirane stanice domaćina. Transformiranje odabranog domaćina vrši se pomoću bilo koje od različitih tehnika koje su dobro poznate onima koji poznaju ovo područje i opisao ih je primjerice Sambrook s autorima, supra.  Moreover, suitable expression vectors may include a suitable marker that allows screening of the transformed host cell. Transformation of the selected host is performed using any of a variety of techniques well known to those skilled in the art and described, for example, by Sambrook et al., supra. 
 
 
   Izvor replikacije može se također postići bilo konstrukcijom vektora tako da se uključi egzogeni izvor ili pomoću mehanizma kromosomske replikacije stanice domaćina. Ako je vektor integriran u kromosom stanice domaćina, ovo posljednje može biti dovoljno. Alternativno, umjesto da koristi vektore koji sadrže virusne izvore replikacije, onaj tko poznaje ovo područje može transformirati stanica sisavca pomoću metode kotransformiranja s odgovarajućim obilježivačem i DmGPCR DNA. Primjer pogodnog obilježivača je dihidrofolat reduktaza (DHFR) ili timidin kinaza (npr. američki patent br. 4,399,216).  The source of replication can also be achieved either by constructing the vector to include an exogenous source or by the chromosomal replication machinery of the host cell. If the vector is integrated into the chromosome of the host cell, the latter may be sufficient. Alternatively, instead of using vectors containing viral sources of replication, one skilled in the art can transform mammalian cells using the cotransformation method with the appropriate marker and DmGPCR DNA. An example of a suitable label is dihydrofolate reductase (DHFR) or thymidine kinase (eg, US Patent No. 4,399,216). 
 
 
   Nukleotidne sekvencije koje kodiraju DmGPCR mogu biti rekombinirane s vektorskom DNA sukladno s konvencionalnim tehnikama, uključujući blunt ili staggered (tupe i stepenaste) završetke za ligaciju, razgradnju restrikcijskog enzima da se dobiju odgovarajući završeci, ispunjavanje kohezivnih završetaka na odgovarajući način, tretiranje alkalnom fosfatazom da se izbjegne neželjeno spajanje i ligacija s odgovarajućim ligazama. Tehnike za takvo manipuliranje opisane su u: Sambrook et al., supra i dobro su poznate u tehnici. Metode konstrukcije ekspresijskih vektora sisavaca opisane su u, primjerice, Okayama et al., Mol. Cell. Biol., 1983,3, 280; Cosman et al., Mol. Immunol. 1986,23,935; Cosman et al., Nature, 1984, 312, 768; EP-A-0367566 i WO 91/18982, a svaki je ovdje uključen kao referenca u cijelosti.  Nucleotide sequences encoding DmGPCRs can be recombined with vector DNA according to conventional techniques, including blunt or staggered end ligation, restriction enzyme digestion to obtain appropriate ends, filling in cohesive ends appropriately, treatment with alkaline phosphatase to avoids unwanted joining and ligation with appropriate ligases. Techniques for such manipulation are described in: Sambrook et al., supra and are well known in the art. Methods for the construction of mammalian expression vectors are described in, for example, Okayama et al., Mol. Cell. Biol., 1983, 3, 280; Cosman et al., Mol. Immunol. 1986, 23,935; Cosman et al., Nature, 1984, 312, 768; EP-A-0367566 and WO 91/18982, each of which is incorporated herein by reference in its entirety. 
 
 
   Stanice domaćina  Host cells 
 
 
   Sukladno sljedećem aspektu ovog izuma, definirane su stanice domaćina, uključujući prokariotske i eukariotske stanice, što obuhvaća polinukleotid ovog izuma (ili vektor ovog izuma) na način koji omogućuje ekspresiju kodiranog DmGPCR polipeptida. Polinukleotidi ovog izuma mogu biti uneseni u stanicu domaćina kao dio cirkularnog plazmida ili kao linearna DNA koja sadrži izdvojeno protein-kodirajuće područje ili virusni vektor. Metode za unošenje DNA u stanicu domaćima koje su dobro poznate i rutinski se rabe u uključuju transformiranje, transfekciju, electroporiranje, injiciranje u jezgu ili fuziju s nosačima kao što su liposomi, micele, ghost stanice domaćina i protoplasti. Ekspresijski sustavi ovog izuma uključuju bakterijske, kvaščeve, gljivične, biljne, insektne, beskralježničke, kralježničke sustave i stanične sustave sisavaca.  According to a further aspect of the present invention, host cells, including prokaryotic and eukaryotic cells, are defined which comprise a polynucleotide of the present invention (or a vector of the present invention) in a manner that enables expression of the encoded DmGPCR polypeptide. The polynucleotides of the present invention can be introduced into a host cell as part of a circular plasmid or as linear DNA containing an isolated protein-coding region or a viral vector. Methods for introducing DNA into a host cell that are well known and routinely used include transformation, transfection, electroporation, nuclear injection, or fusion with carriers such as liposomes, micelles, host ghost cells, and protoplasts. Expression systems of the present invention include bacterial, yeast, fungal, plant, insect, invertebrate, vertebrate and mammalian cell systems. 
 
 
   Ovaj izum definira stanice domaćina koje su transformirane ili transficirane (postojano ili prijelazno) s polinukleotidima ovog izuma ili vektorima ovog izuma. Kao što je prije navedeno, takve stanice domaćina korisne su za pojačavanje polinukleotida i također za ekspresiju DmGPCR polipeptida ili njegova fragmenta koji je kodiran polinukleotidom.  The present invention defines host cells that have been transformed or transfected (permanently or transiently) with polynucleotides of the present invention or vectors of the present invention. As previously noted, such host cells are useful for amplifying the polynucleotide and also for expressing the DmGPCR polypeptide or fragment thereof encoded by the polynucleotide. 
 
 
   Sukladno nekim aspektima ovog izuma, definirane su transformirane stanice domaćina koje imaju ekspresijski vektor koji sadrži bilo koju molekulu nukleinske kiseline što je prije opisano. Ekspresija nukleotidne sekvencije zbiva se kada se ekspresijski vektor unese u odgovarajuću stanicu domaćina. Pogodne stanice domaćina za ekspresiju polipeptida ovog izuma uključuju, ali nisu ograničene na prokariote, kvasce i eukariote. Ako se rabi prokariotska ekspresija, onda odgovarajuća stanica domaćina može biti neka prokariotska stanica koja može vršiti ekspresiju kloniranih sekvencija. Pogodne prokariotske stanice uključuju, ali bez ograničenja, bakterije roda Escherichia, Bacillus, Salmonella, Pseudomonas, Streptomyces i Staphylococcus.  In accordance with some aspects of the present invention, transformed host cells having an expression vector comprising any of the nucleic acid molecules described above are defined. Expression of the nucleotide sequence occurs when the expression vector is introduced into the appropriate host cell. Suitable host cells for expressing polypeptides of the present invention include, but are not limited to, prokaryotes, yeasts, and eukaryotes. If prokaryotic expression is used, then the appropriate host cell may be a prokaryotic cell capable of expressing the cloned sequences. Suitable prokaryotic cells include, but are not limited to, bacteria of the genera Escherichia, Bacillus, Salmonella, Pseudomonas, Streptomyces, and Staphylococcus. 
 
 
   Ako se koristi eukariotski ekspresijski vektor, onda bi odgovarajuća stanica domaćina trebala biti eukariotska stanica koja može vršiti ekspresiju klonirane sekvencije. Eukariotske stanice mogu biti stanice viših eukariota. Pogodne eukariotske stanice uključuju, ali nisu ograničene na kulture ne-humanih stanica tkiva dojke i kulture stanica humanog tkiva. Stanice domaćina mogu uključivati, ali nisu ograničene na stanice insekata, HeLa stanice, stanice jajnika kineskog zamorca (CHO stanice), stanice bubrega afričkog zelenog majmuma (COS cells), humane 293 stanice i mišje 3T3 fibroblaste. Rast takvih stanica u staničnoj kulturi može postati rutinski postupak (vidi npr. Tissue Culture, Academic Press, Kruse and Patterson, eds., 1973, što je ovdje uključeno kao referenca u cijelosti).  If a eukaryotic expression vector is used, then the appropriate host cell should be a eukaryotic cell capable of expressing the cloned sequence. Eukaryotic cells can be cells of higher eukaryotes. Suitable eukaryotic cells include, but are not limited to, non-human breast tissue cell cultures and human tissue cell cultures. Host cells may include, but are not limited to, insect cells, HeLa cells, Chinese guinea pig ovary cells (CHO cells), African green monkey kidney cells (COS cells), human 293 cells, and mouse 3T3 fibroblasts. Growth of such cells in cell culture may become a routine procedure (see, e.g., Tissue Culture, Academic Press, Kruse and Patterson, eds., 1973, which is incorporated herein by reference in its entirety). 
 
 
   Nadalje, kvaščev domaćin može se koristiti kao stanica domaćin. Primjeri kvaščevih stanica uključuju, ali nisu ograničeni na rodove Saccharomyces, Pichia i Kluveromyces. Primjeri kvaščenih domaćina su S. cerevisiae i P. pastoris. Kvaščevi vektori mogu sadržavati izvor replikacijske sekvencije iz 2T kvaščeva plazmida, autonomne replicirajuće sekvencije (ARS), promotorsko područje, sekvencije za poliadenilaciju, sekvencije za transkripcijsko terminiranje i selektibilni gen obilježivač. Ovdje su također uključeni ‘shuttle’ vektori za repliciranje u kvascu i E. coli.  Furthermore, a yeast host can be used as a host cell. Examples of yeast cells include, but are not limited to, the genera Saccharomyces, Pichia, and Kluveromyces. Examples of yeast hosts are S. cerevisiae and P. pastoris. Yeast vectors can contain a source of replication sequence from a 2T yeast plasmid, an autonomously replicating sequence (ARS), a promoter region, polyadenylation sequences, transcription termination sequences, and a selectable marker gene. Shuttle vectors for replication in yeast and E. coli are also included here. 
 
 
   Alternativno, insektne stanice mogu se koristiti kao stanice domaćina. U jednoj realizaciji, polipeptidi ovog izuma imaju ekspresiju korištenjem bakulovirusnog ekspresijskog sustava (vidi Luckow et al., Bio/Technology, 1988, 6, 47, Baculovirus Expression Vektors: Laboratory Manual, O’Rielly et al. (Eds.), W.H. Freeman and Company, New York, 1992 i američki patent br. 4,879,236, a svi su ovdje uključeni kao referenca u cijelosti). Nadalje, MAXBAC™ ekspresijski sustav cjelovitog bakulovirusa (Invitrogen) može se, primjerice, koristiti za proizvodnju u stanicama insekata.  Alternatively, insect cells can be used as host cells. In one embodiment, the polypeptides of the invention are expressed using a baculovirus expression system (see Luckow et al., Bio/Technology, 1988, 6, 47, Baculovirus Expression Vectors: Laboratory Manual, O'Rielly et al. (Eds.), W.H. Freeman and Company, New York, 1992 and US Patent No. 4,879,236, all of which are incorporated herein by reference in their entirety). Furthermore, the MAXBAC™ whole baculovirus expression system (Invitrogen) can be used, for example, for production in insect cells. 
 
 
   U sljedećoj srodnoj realizaciji, izumom su definirane metode za dobivanje DmGPCR polipeptida (ili njegova fragmenta) što uključuje stupnjeve rasta stanica domaćina ovog izuma u hranjivom mediju i izdvajanje polipeptida ili njegove inačice iz stanice ili iz medija. Budući da je DmGPCR sedam transmembranski receptor, razumljivo je da za neke primjene, kao što su određene analize aktivnosti, izdvajanje može uključivati izdvajanje staničnih membrane koje sadrže u njima ugrađeni polipeptid, dok za druge primjene može biti poželjno potpunije izdvajanje.  In the next related embodiment, the invention defines methods for obtaining a DmGPCR polypeptide (or its fragment) which includes growth stages of host cells of this invention in a nutrient medium and isolation of the polypeptide or its variant from the cell or from the medium. Since DmGPCR is a seven transmembrane receptor, it is understood that for some applications, such as certain activity assays, isolation may involve isolation of cell membranes containing embedded polypeptide, while for other applications more complete isolation may be desired. 
 
 
   Stanice domaćina ovog izuma su vrijedan izvor imunogena za razvoj antitijela koja su specifično imunoreaktivna s DmGPCR-om. Stanice domaćina ovog izuma su također korisne za metode masovne proizvodnje DmGPCR polipeptida pri čemu stanice se stanice razvijaju u odgovarajućem mediju kulture i željeni polipeptidni produkti izdvajaju se iz stanica ili iz medija u kojem rastu stanice, metodama pročišćavanja koje su poznate u tehnici, npr. standardnim kromatografskim metodama uključujući imunoafinitetnu kromatografiju, receptorsku afinitetnu kromatografiju, hidrofobnu interakcijsku kromatografiju, lektin afinitetnu kromatografiju, veličinsko ekskluzivno filtriranje, kationsku ili anionsku izmjenjivačku kromatografiju, visokotlačnu tekućinsku kromatografiju (HPLC), reverzno-faznu HPLC i slično. Druge metode pročišćavanje uključuju one metode u kojima se vrši ekspresija željenog proteina i pročišćavanje kao fuzijskog proteina koji ima specifični privjesak, oznaku ili kelirajuću speciju koja je prepoznata pomoću specifičnog vezujućeg partnera ili sredstva. Pročišćeni protein može se cijepati da se dobije željeni protein ili može ostati kao intaktni fuzijski protein. Cijepanje fuzijske komponente može proizvesti oblik željenog proteina koji ima dodatne aminokiselinske rezidue kao rezultat procesa cijepanja.  The host cells of the present invention are a valuable source of immunogens for the development of antibodies that are specifically immunoreactive with DmGPCR. The host cells of the present invention are also useful for methods of mass production of DmGPCR polypeptides, wherein the cells are grown in an appropriate culture medium and the desired polypeptide products are isolated from the cells or from the medium in which the cells grow, by purification methods known in the art, e.g., standard chromatographic methods including immunoaffinity chromatography, receptor affinity chromatography, hydrophobic interaction chromatography, lectin affinity chromatography, size exclusive filtration, cation or anion exchange chromatography, high pressure liquid chromatography (HPLC), reverse-phase HPLC and the like. Other purification methods include those methods in which the desired protein is expressed and purified as a fusion protein having a specific pendant, tag, or chelating species that is recognized by a specific binding partner or agent. The purified protein can be cleaved to produce the desired protein or it can remain as an intact fusion protein. Cleavage of the fusion component can produce a form of the desired protein that has additional amino acid residues as a result of the cleavage process. 
 
 
   Poznavanje DNA sekvencija DmGPCR-a omogućuje modificiranje stanica da se omogući ili poveća ekspresija endogenog DmGPCR. Stanice mogu biti modificirane (npr. homolognim rekombiniranjem) da se postigne povećana ekspresija zamjenom, djelomičnom ili potpunom, prirodnog DmGPCR promotora s cijelim ili djelomičnim heterolognim promotorom tako da stanice vrše ekspresiju DmGPCR na višim razinama. Heterologni promotor ubacuje se na takav način da se operativno veže za kodirajuće sekvencije endogenog DmGPCR (vidi npr. PCT međunarodnu publikaciju br. WO 94/12650, PCT međunarodnu publikaciju br. WO 92/20808 i PCT međunarodnu publikaciju br. WO 91/09955.) Također se podrazumijeva da se, uz heterolognu promotorsku DNA, pojačivački obilježivač DNA (npr. ada, dhfr i višefunkcionalni CAD gen koji kodira karbamoil fosfat sintazu, aspartat transkarbamilazu i dihodroorotazu) i/ili intronska DNA mogu ubaciti zajedno s heterolognom promotorskom DNA. Ako je povezano s DmGPCR kodirajućom sekvencijom, pojačavanje obilježivačke DNA standardnim metodama odabiranja rezultira kopojačavanjem kodirajućih sekvencija DmGPCR-a u stanicama.  Knowing the DNA sequences of DmGPCRs allows cells to be modified to enable or increase expression of endogenous DmGPCRs. Cells can be modified (eg, by homologous recombination) to achieve increased expression by replacing, in part or in whole, the native DmGPCR promoter with a whole or in part heterologous promoter so that the cells express the DmGPCR at higher levels. The heterologous promoter is inserted in such a way that it operably binds to the coding sequences of the endogenous DmGPCR (see, e.g., PCT International Publication No. WO 94/12650, PCT International Publication No. WO 92/20808 and PCT International Publication No. WO 91/09955. ) It is also understood that, in addition to the heterologous promoter DNA, enhancer marker DNA (eg, ada, dhfr and the multifunctional CAD gene encoding carbamoyl phosphate synthase, aspartate transcarbamylase and dihydroorotase) and/or intronic DNA can be inserted together with the heterologous promoter DNA. If associated with a DmGPCR coding sequence, amplification of the marker DNA by standard selection methods results in co-amplification of DmGPCR coding sequences in cells. 
 
 
   Izbačeni (knock-outs)  Knock-outs 
 
 
   Informacije o DNA sekvenciji koje daje ovaj izum također omogućuju razvoj (npr. homolognim rekombiniranjem ili „knock-out“ strategijama; vidi Capecchi, Science, 1989, 244, 1288-1292) subjekata koji ne mogu vršiti ekspresiju funkcionalnog DmGPCR ili koji vrše ekspresiju inačice DmGPCR-a. Takvi subjekti (poglavito uključujući insekte i crve) korisni su kao modeli za istraživanje in vivo aktivnosti DmGPCR-a i modulatora DmGPCR-a i također su korisni za daljnje rasvjetljavanje uloge DmGPCR-ova u insektima i crvima.  The DNA sequence information provided by this invention also enables the development (eg, by homologous recombination or knock-out strategies; see Capecchi, Science, 1989, 244, 1288-1292) of subjects that cannot express a functional DmGPCR or that express a variant of DmGPCR. Such subjects (especially including insects and worms) are useful as models for investigating the in vivo activity of DmGPCRs and DmGPCR modulators and are also useful for further elucidating the role of DmGPCRs in insects and worms. 
 
 
   Protivsmisleni  Contradictory 
 
 
   Također su postali dostupni ovim izumom protivsmisleni polinukleotidi koji prepoznaju i hibridiziraju polinukleotide koji kodiraju DmGPCR. Dobivaju se protivsmisleni polinukleotidi pune duljine i fragmenti. Fragment protivsmislene molekule ovog izuma uključuju one koji specifično prepoznaju i hibridiziraju DmGPCR ekspresijske kontrolne sekvencije ili DmGPCR RNA (kao što se određuje sekvencijskim uspoređivanjem DNA koja kodira DmGPCR prema DNA koja kodira druge poznate molekule). Identifikacijska sekvencija koja je jedinstvena za DmGPCR-kodirajuće polinukleotide može se izvesti upotrebom bilo koje javno dostupne sekvencijske baze i/ili upotrebnom komercijalno dostupnih programa za uspoređivanje sekvencija. Nakon identificiranja željenih sekvencija, može se izvršiti odvajanje pomoću restrikcijske razgradnje ili pojačavanja korištenjem neke od različitih tehnika polimeraza lančanih reakcija, koje su dobro poznate u tehnici. Protivsmisleni polinukleotidi su osobito značajni za reguliranje ekspresije DmGPCR-a pomoću onih stanica s ekspresijom DmGPCR mRNA.  Also made available by this invention are antisense polynucleotides that recognize and hybridize to polynucleotides encoding DmGPCR. Full-length antisense polynucleotides and fragments are obtained. Fragment antisense molecules of the present invention include those that specifically recognize and hybridize to DmGPCR expression control sequences or DmGPCR RNA (as determined by sequence comparison of DNA encoding DmGPCR to DNA encoding other known molecules). An identification sequence that is unique to DmGPCR-encoding polynucleotides can be derived using any publicly available sequence database and/or using commercially available sequence comparison programs. After identifying the desired sequences, separation can be performed by restriction digestion or amplification using any of the various polymerase chain reaction techniques well known in the art. Antisense polynucleotides are particularly important for regulating DmGPCR expression by those cells expressing DmGPCR mRNA. 
 
 
   Protivsmislene nukleinske kiseline (poželjno 10 do 20 bazičnih-par oligonukleotida) koji se mogu specifično vezati za kontrolne ekspresijske sekvencije DmGPCR ili DmGPCR RNA uvode se u stanice (npr. pomoću virusnog vektora ili koloidnog disperzijskog sustava kao što je liposom). Protivsmislena nukleinska kiselina veže se za DmGPCR ciljanu nukleotidnu sekvenciju u stanici i sprječava transkripciju i/ili prevođenje ciljane sekvencije. Fosforotioat ili metilfosfonatni protivsmisleni oligonukleotidi su speciično predviđeni za terapijsku upotrebu korištenjem ovog izuma. Protivsmisleni oligonukleotidi mogu biti nadalje modificirani pomoću poli-1-lizin, transferin polilizin ili kolesterol specijama na njihovu 5’ kraju. Supresija DmGPCR-a ekspresije bilo na razini transkripcije ili prevođenja korisna je za generiranje staničnih ili životinjskih modela da se istraži biološka uloga DmGPCR-ova.  Antisense nucleic acids (preferably 10 to 20 base-pair oligonucleotides) that can specifically bind to DmGPCR or DmGPCR RNA control expression sequences are introduced into cells (eg, using a viral vector or a colloidal dispersion system such as a liposome). The antisense nucleic acid binds to the DmGPCR target nucleotide sequence in the cell and prevents transcription and/or translation of the target sequence. Phosphorothioate or methylphosphonate antisense oligonucleotides are specifically contemplated for therapeutic use using the present invention. Antisense oligonucleotides can be further modified with poly-1-lysine, transferrin polylysine or cholesterol species at their 5' end. Suppression of DmGPCR expression either at the transcriptional or translational level is useful for generating cell or animal models to investigate the biological role of DmGPCRs. 
 
 
   Protivsmisleni oligonukleotidi ili fragmenti nukleotidnih sekvencija koji su odabrani iz skupa kojega sačinjavaju sekvencije s br. 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21 ili 23 ili sekvencije koje su njima komplementarne ili homologne, izvedeni iz nukleotidne sekvencije ovog izuma koji kodiraju DmGPCR korisni su za sondiranje genske ekspresije u različitim tkivima. Primjerice, tkivo može biti sondirano in situ s oligonukleotidnim sondama koje nose detektibilne skupine, pomoću standardnih tehnika autoradiografije. Protivsmisleni oligonukleotidi koji su usmjereni prema regulacijskim područjima nukleotidne sekvencije mogu biti odabrani iz skupa kojega sačinjavaju sekvencije s br. 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21 ili 23 ili odgovarajuće mRNA, uključujući, ali bez ograničenja, inicijacijski kodon, TATA kutiju, pojačivač sekvencija i slično.  Antisense oligonucleotides or fragments of nucleotide sequences that are selected from the set consisting of sequences with no. 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21 or 23 or sequences complementary or homologous thereto, derived from the nucleotide sequence of the present invention encoding DmGPCR are useful for probing gene expression in various tissues . For example, tissue can be probed in situ with oligonucleotide probes carrying detectable moieties, using standard autoradiography techniques. Antisense oligonucleotides that are directed towards the regulatory regions of the nucleotide sequence can be selected from the group consisting of sequences with no. 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21 or 23 or corresponding mRNAs, including but not limited to initiation codon, TATA box, enhancer sequences and the like. 
 
 
   Faktori transkripcije  Transcription factors 
 
 
   DmGPCR sekvencije ovog izuma olakšavaju oblikovanje faktora za moduliranje DmGPCR ekspresije u nativnim stanicama i subjektima i stanicama koje su transformirane ili transficirane s DmGPCR polinukleotidima. Primjerice, Cys2-His2 cink ‘finger’ proteini, koji vežu DNA putem svojih cink ‘finger’ domena, pokazalo se da su podložni strukturnim promjenama koje dovode do prepoznavanja različitih ciljanih sekvencija. Ovi umjetni cink ‘finger’ proteini prepoznaju specifična ciljana mjesta s visokim afinitetom i malenim konstantama disocijacije i mogu djelovati kao genski prekidači da se modulira ekspresija gena. Poznavanje konkretne DmGPCR ciljane sekvencije ovog izuma olakšava inženjering cink ‘finger’ proteina koji su specifični za ciljanu sekvenciju pomoću poznatih metoda kao što je kombinacija strukturno-zasnovanog modeliranja i screeninga biblioteke faga (Segal et al., Proc. Natl. Acad. Sci. USA, 1999, 96, 2758-2763; Liu et al., Proc. Natl. Acad. Sci. USA, 1997, 94, 5525-5530 (1997); Greisman et al., Science, 1997, 275, 657-661; Choo et al., J. Mol. Biol., 1997, 273, 525-532). Svaka cink ‘finger’ domena obično prepoznaje tri ili više parova baza. Budući da je sekvencija za prepoznavanje od 18 parova baza općenito dovoljne duljine da se smatra jedinstvenom u bilo kojem poznatom genomu, cink ‘finger’ protein koji se sastoji od 6 tandem ponavljanja cink ‘finger’-a trebalo bi očekivati da jamči specifičnost za konkretnu sekvenciju (Segal et al.). Umjetna cink ‘finger’ ponavljanja, koja su oblikovana temeljem DmGPCR sekvencija, sjedinjena su prema aktivacijskim ili represijskim domenama da se poboljša ili suprimira DmGPCR ekspresija (Liu et al.). Alternativno, cink ‘finger’ domene mogu se sjediniti u TATA kutija-vezujući faktor (TBP) s varirajućim duljinama veznog područja između cink ‘finger’ peptida i TBP da se stvore bilo transkripcijski aktivatori ili represori (Kim et al., Proc. Natl. Acad. Sci. USA, 1997, 94, 3616-3620). Takvi proteini i polinukleotidi koji ih kodiraju korisni su za moduliranje DmGPCR ekspresije in vivo. Novi transkripcijski faktor može se unijeti u ciljane stanice transfekcijom konstrukata koji vrše ekspresiju transkripcijskog faktora (genska terapija) ili uvođenjem proteina. Inženjering cink ‘finger’ proteina može također biti oblikovan da se povežu RNA sekvencije za upotrebu u terapeuticima kao alternative protivsmislenim ili katalitičkim RNA metodama (McColl et al., Proc. Natl. Acad. Sci. USA, 1997, 96, 9521-9526; Wu et al, Proc. Natl. Acad. Sci. USA, 1995, 92, 344-348). Ovaj izum podrazumijeva metode oblikovanja takvih transkripcijskih faktora temeljem genske sekvencije ovog izuma, kao i prilagođenih cink ‘finger’ proteina koji su korisni da se modulira DmGPCR ekspresija u stanicama (prirodnim ili transformiranim) gdje genetski komplement uključuje ove sekvencije.  The DmGPCR sequences of the present invention facilitate the design of factors to modulate DmGPCR expression in native cells and subjects and cells transformed or transfected with DmGPCR polynucleotides. For example, Cys2-His2 zinc 'finger' proteins, which bind DNA via their zinc 'finger' domains, have been shown to be subject to structural changes that lead to the recognition of different target sequences. These artificial zinc 'finger' proteins recognize specific target sites with high affinity and small dissociation constants and can act as gene switches to modulate gene expression. Knowledge of the specific DmGPCR target sequence of the present invention facilitates the engineering of zinc finger proteins that are specific for the target sequence using known methods such as a combination of structure-based modeling and phage library screening (Segal et al., Proc. Natl. Acad. Sci. USA , 1999, 96, 2758-2763; Liu et al., Proc. Natl. Acad. Sci. USA, 1997, 94, 5525-5530 (1997); Greisman et al., Science, 1997, 275, 657-661; Choo et al., J. Mol. Biol., 1997, 273, 525-532). Each zinc finger domain usually recognizes three or more base pairs. Since a recognition sequence of 18 base pairs is generally of sufficient length to be considered unique in any known genome, a zinc 'finger' protein consisting of 6 tandem zinc 'finger' repeats should be expected to guarantee specificity for a particular sequence (Segal et al.). Artificial zinc 'finger' repeats, which are designed based on DmGPCR sequences, are fused to activation or repression domains to enhance or suppress DmGPCR expression (Liu et al.). Alternatively, zinc 'finger' domains can be fused to a TATA box-binding factor (TBP) with varying lengths of the linker region between the zinc 'finger' peptide and TBP to create either transcriptional activators or repressors (Kim et al., Proc. Natl. Acad. Sci. USA, 1997, 94, 3616-3620). Such proteins and polynucleotides encoding them are useful for modulating DmGPCR expression in vivo. A new transcription factor can be introduced into target cells by transfection of constructs that express the transcription factor (gene therapy) or by introducing proteins. Engineered zinc 'finger' proteins can also be designed to bind RNA sequences for use in therapeutics as an alternative to antisense or catalytic RNA methods (McColl et al., Proc. Natl. Acad. Sci. USA, 1997, 96, 9521-9526; Wu et al, Proc. Natl. Acad. Sci. USA, 1995, 92, 344-348). The present invention encompasses methods of designing such transcription factors based on the gene sequence of the present invention, as well as custom zinc finger proteins useful to modulate DmGPCR expression in cells (native or transformed) where the genetic complement includes these sequences. 
 
 
   Polipeptidi  Polypeptides 
 
 
   Izum također definira pročišćene i izdvojene DmGPCR polipeptide koji su kodirani pomoću polinukleotida ovog izuma uključujući DmGPCR polipeptid koji sadrži aminokiselinsku sekvenciju koja se nalazi u sekvencijama s br. 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 ili 24.  The invention also defines purified and isolated DmGPCR polypeptides that are encoded by the polynucleotides of the present invention including a DmGPCR polypeptide comprising the amino acid sequence found in SEQ ID NOs. 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 or 24. 
 
 
   Uočava se da su izvanstanični epitopi osobito korisni za generiranje i screening antitijela i drugih vezujućih spojeva koji se vežu za receptore kao što je DmGPCR. Prema tome, u sljedećoj realizaciji, ovaj izum definira pročišćene i izdvojene polipeptide koji sadrže bar jednu izvanstaničnu domenu (npr. N-terminalnu izvanstaničnu domenu ili jednu od triju izvanstaničnih petlji) DmGPCR-a, kao što je N-terminalna izvanstanična domena DmGPCR-a. Također su obuhvaćeni dosegom ovog izuma pročišćeni i izdvojeni polipeptidi koji sadrže DmGPCR fragment koji je odabran iz skupa koji se sastoji od transmembranskih domena DmGPCR-a, izvanstanične petlje koja povezuje transmembranske domene DmGPCR-a, unutarstanične petlje koja povezuje transmembranske domene DmGPCR-a, C-terminalnog citplazmatskog područja DmGPCR-a i njihovih fuzija. Takvi fragmenti mogu biti kontinuirani dijelovi prirodnog receptora. Međutim, lako je uočiti da poznavanje DmGPCR-a gena i proteinskih sekvencija koje su ovdje definirane omogućuje rekombiniranje različitih domena koje nisu kontinuirane u nativnom proteinu. Korištenjem FORTRAN kompjuterskog program nazvanog „tmtrestall“ (Parodi et al., Comput. Appl. Biosci., 1994, 5, 527-535), pokazalo se da DmGPCR sadrži transmembranski-premoštenih domena.  Extracellular epitopes are found to be particularly useful for generating and screening antibodies and other binding compounds that bind to receptors such as DmGPCR. Accordingly, in a further embodiment, the present invention defines purified and isolated polypeptides comprising at least one extracellular domain (eg, the N-terminal extracellular domain or one of the three extracellular loops) of a DmGPCR, such as the N-terminal extracellular domain of a DmGPCR . Also included within the scope of this invention are purified and isolated polypeptides containing a DmGPCR fragment that is selected from the group consisting of transmembrane domains of DmGPCR, an extracellular loop that connects transmembrane domains of DmGPCR, an intracellular loop that connects transmembrane domains of DmGPCR, C -terminal cytoplasmic region of DmGPCR and their fusions. Such fragments may be continuous parts of the native receptor. However, it is easy to see that knowledge of the DmGPCR gene and protein sequences defined here allows the recombination of different domains that are not continuous in the native protein. Using a FORTRAN computer program called "tmtrestall" (Parodi et al., Comput. Appl. Biosci., 1994, 5, 527-535), DmGPCR was shown to contain transmembrane-spanning domains. 
 
 
   Ovaj izum također obuhvaća polipeptide koji imaju bar 99%, bar 95%, bar 90%, bar 85%, bar 80%, bar 75%, bar 70%, bar 65%, bar 60%, bar 55% ili bar 50% identičnosti i/ili homologije s referentnim polipeptidom ovog izuma. Postotak “identičnosti” aminokiselinske sekvencije u odnosu na referentni polipeptid ovog izuma je ovdje definiran kao postotak aminokiselinskih rezidua u kandidatskoj sekvenciji koji je identičan s reziduama u DmGPCR sekvenciji nakon usklađivanja obiju sekvencija i uvođenja praznina, ako je potrebno, da se postigne maksimalni postotak sekvencijske identičnosti i ne razmatraju bilo kakve konzervativne supstitucije kao dio sekvencijske identičnosti. Postotak sekvencijske “homologije” u odnosu na referentni polipeptid ovog izuma definiran je ovdje kao postotak aminokiselinskih rezidua u kandidatskoj sekvenciji koje su identične s reziduama u DmGPCR sekvenciji nakon usklađivanja sekvencija i uvođenja praznina, ako je potrebno, da se postigne maksimalni postotak sekvencijske identičnosti i da se također razmotre bilo koje konzervativne supstitucije kao dio sekvencijske identičnosti.  The present invention also encompasses polypeptides having at least 99%, at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 65%, at least 60%, at least 55% or at least 50% of identity and/or homology with the reference polypeptide of this invention. Percent amino acid sequence "identity" to a reference polypeptide of the present invention is defined herein as the percentage of amino acid residues in the candidate sequence that are identical to residues in the DmGPCR sequence after alignment of both sequences and introduction of gaps, if necessary, to achieve maximum percent sequence identity and do not consider any conservative substitutions as part of sequence identity. Percent sequence "homology" to a reference polypeptide of the present invention is defined herein as the percentage of amino acid residues in the candidate sequence that are identical to residues in the DmGPCR sequence after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity and to any conservative substitutions are also considered as part of the sequence identity. 
 
 
   U jednom aspektu, postotak homologije izračunava se kao postotak aminokiselinskih rezidua u manjoj od dvoju sekvencija koja se poklapa s identičnom aminokiselinskom reziduom u sekvenciji s kojom se uspoređuje, kada se četiri praznine duljine 100 aminokisleina mogu uvesti da se maksimira sukladnost (Dayhoff, u: Atlas of Protein Sequence and Structure, vol. 5, National Biochemical Research Foundation, Washington, D.C., 1972, p. 124, uključeno ovdje kao referenca).  In one aspect, the percentage of homology is calculated as the percentage of amino acid residues in the smaller of the two sequences that match the identical amino acid residue in the sequence being compared, when four gaps of 100 amino acids can be introduced to maximize concordance (Dayhoff, in: Atlas of Protein Sequence and Structure, vol. 5, National Biochemical Research Foundation, Washington, D.C., 1972, p. 124, incorporated herein by reference). 
 
 
   Polipeptidi ovog izuma mogu biti izdvojeni iz prirodnih izvora stanica ili mogu biti kemijski sintetizirani te mogu biti proizvedeni rekombinantnim postupcima koji uključuju stanice domaćima ovog izuma. Upotreba stanica domaćina sisavaca očekuje se da omogućuje takve post-translacijske modifikacije (npr. glikoziliranje, odbacivanje, lipidiranje i fosforiliranje) što se može pokazati potrebnim da se postigne optimalna biološka aktivnost na produktima rekombinantne ekspresije ovog izuma. Glikozilirani i neglikozilirani oblici DmGPCR polipeptida obuhvaćeni su ovim izumom.  The polypeptides of the present invention may be isolated from natural cell sources or may be chemically synthesized and may be produced by recombinant methods involving the host cells of the present invention. The use of mammalian host cells is expected to allow for such post-translational modifications (eg, glycosylation, shedding, lipidation, and phosphorylation) as may prove necessary to achieve optimal biological activity on the recombinant expression products of the present invention. Glycosylated and non-glycosylated forms of DmGPCR polypeptides are encompassed by this invention. 
 
 
   Ovaj izum također obuhvaća inačice (ili analoge) DmGPCR polipeptida. U jednom primjeru, definirane su inačice s umetanjem pri čemu jedna ili više aminokiselinskih rezidua dopunjuje DmGPCR aminokiselinsku sekvenciju. Umetanje može biti vezano za jedan ili oba kraja ili se može nalaziti unutar internih područja DmGPCR aminokiselinske sekvencije. Inačice s umetanjem s dodatnim reziduama na jednom ili oba kraja uključuju, primjerice, fuzisjke proteine i proteine uključujući aminokiselinske tagove ili oznake.  The present invention also encompasses variants (or analogs) of DmGPCR polypeptides. In one example, insertion variants are defined wherein one or more amino acid residues complement the DmGPCR amino acid sequence. The insertion may be attached to one or both ends or may be located within internal regions of the DmGPCR amino acid sequence. Insertion variants with additional residues at one or both ends include, for example, fusion proteins and proteins including amino acid tags or tags. 
 
 
   Inačice s umetanjem DmGPCR polipeptide pri čemu je jedna ili više aminokiselinskih rezidua dodano DmGPCR kiselinskoj sekvenciji ili njenom biološki aktivnom fragmentu.  Insertion variants of the DmGPCR polypeptide wherein one or more amino acid residues are added to the DmGPCR acid sequence or biologically active fragment thereof. 
 
 
   Varijantni produkti ovog izuma također uključuju zrele DmGPCR produkte, tj. DmGPCR produkte pri čemu su uklonjene vodeće ili signalne sekvencije, uz dodatne aminokiselinske rezidue. Dodatne aminoterminalne rezidue mogu biti izvedene iz drugog proteina ili mogu uključivati jednu ili više rezidua za koje se ne može identificirati da su izvedene iz specifičnih proteina. Također su obuhvaćeni DmGPCR produkti s dodatnim metioninom u položaju -1 (Met-1-DmGPCR), kao i inačice s dodatnim metioninom i lizinom u položajima -2 i -1 (Met-2-Lys-1-DmGPCR). Inačice DmGPCR-a s dodatnim Met, Met-Lys, Lys reziduama (ili općenito jednom ili više bazičnih rezidua) su osobito korisne za pojačanu proizvodnju rekombinantnog proteina u bakterijskoj stanici domaćina.  Variant products of the present invention also include mature DmGPCR products, i.e., DmGPCR products with leader or signal sequences removed, along with additional amino acid residues. Additional amino-terminal residues may be derived from another protein or may include one or more residues that cannot be identified as being derived from specific proteins. Also included are DmGPCR products with an additional methionine in position -1 (Met-1-DmGPCR), as well as versions with additional methionine and lysine in positions -2 and -1 (Met-2-Lys-1-DmGPCR). Versions of DmGPCRs with additional Met, Met-Lys, Lys residues (or generally one or more basic residues) are particularly useful for enhanced recombinant protein production in a bacterial host cell. 
 
 
   Ovaj izum također obuhvaća DmGPCR inačice koje imaju dodatne aminokiselinske rezidue koje su rezultat upotrebe specifičnih sustava ekspresije. Primjerice, upotreba komercijalno raspoloživih vektora koji vrše ekspresiju polipeptida kao dio glutation-S-transferaza (GST) fuzijskog produkta definira željeni polipeptid koji ima dodatne glicinske rezidue u položaju -1 nakon cijepanja GST komponente iz željenog polipeptida. Također su obuhvaćene inačice koje su rezultat ekspresije u drugim vektorskim sustavima.  The present invention also encompasses DmGPCR variants having additional amino acid residues resulting from the use of specific expression systems. For example, the use of commercially available vectors that express the polypeptide as part of a glutathione-S-transferase (GST) fusion product defines a desired polypeptide that has additional glycine residues in the -1 position after cleavage of the GST component from the desired polypeptide. Variants resulting from expression in other vector systems are also included. 
 
 
   Inačice s umetanjem također uključuju fuzijske proteine pri čemu su aminoterminal i/ili karboksilni terminal DmGPCR-a sjedinjeni s drugim polipeptidom.  Insertion variants also include fusion proteins wherein the amino terminus and/or carboxyl terminus of the DmGPCR is fused to another polypeptide. 
 
 
   U sljedećem aspektu, ovaj izum definira inačice brisanja pri čemu je jedna ili više aminokiselinskih rezidua u DmGPCR polipeptidu uklonjeno. Brisanje se može izvršiti na jednom ili na oba kraja DmGPCR polipeptida ili uz uklanjanje jedne ili više neterminalnih aminokiselinskih rezidua DmGPCR-a. Inačice brisanja, prema tome, uključuju sve fragmente DmGPCR polipeptida.  In a further aspect, the present invention defines deletion variants wherein one or more amino acid residues in the DmGPCR polypeptide have been removed. Deletion can be performed at one or both ends of the DmGPCR polypeptide or by removing one or more non-terminal amino acid residues of the DmGPCR. Deletion variants, therefore, include all fragments of the DmGPCR polypeptide. 
 
 
   Ovaj izum također obuhvaća polipeptidne fragmente sekvencija koje pripadaju skupu kojega sačinjavaju sekvencije s br. 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 ili 24 pri čemu fragmenti zadržavaju biološka (npr. ligandno vezanje i/ili unutarstanično signaliziranje) te imunološka svojstva DmGPCR polipeptida. Fragmenti koji sadrže bar 5, 10, 15, 20, 25, 30, 35 ili 40 konzekutivnih aminokiselina bilo kojeg polipeptida on onih koji su ovdje opisani, obuhvaćeni su ovim izumom. Polipeptidni fragmenti mogu pokazivati antigena svojstva koja su jedinstvena ili specifična za DmGPCR i njegove homologe alela i specija. Fragmenti ovog izuma koji imaju poželjna biološka i imunološka svojstva mogu se prirediti metodama koje su dobro poznate i rutinski se koriste u tehnici.  This invention also encompasses polypeptide fragments of sequences belonging to the set consisting of sequences with no. 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 or 24, whereby the fragments retain the biological (eg ligand binding and/or intracellular signaling) and immunological properties of the DmGPCR polypeptide. Fragments containing at least 5, 10, 15, 20, 25, 30, 35 or 40 consecutive amino acids of any of the polypeptides described herein are encompassed by this invention. Polypeptide fragments may exhibit antigenic properties that are unique or specific to the DmGPCR and its allele and species homologues. Fragments of the present invention having desirable biological and immunological properties can be prepared by methods well known and routinely used in the art. 
 
 
   U daljnjem aspektu, ovaj izum definira supstitucijske inačice DmGPCR polipeptida. Supstitucijske inačice uključuju one polipeptide pri čemu su jedna ili više aminokiselinskih rezidua DmGPCR polipeptida uklonjene i zamijenjene alternativnim reziduama. U jednom aspektu, supstitucije su konzervativne prirode. Međutim, ovaj izum uključuje supstitucije koje također nisu konzervativne. Konzervativne supstitucije za ovu namjenu mogu biti definirane kao što je navedeno u tablicama 1, 2 ili 3 niže.  In a further aspect, the present invention defines substitutional versions of DmGPCR polypeptides. Substitution variants include those polypeptides wherein one or more amino acid residues of the DmGPCR polypeptide have been removed and replaced with alternative residues. In one aspect, the substitutions are conservative in nature. However, this invention includes substitutions that are also not conservative. Conservative substitutions for this purpose may be defined as set forth in Tables 1, 2 or 3 below. 
 
 
   Varijantni polipeptidi uključuju one pri čemu su konzervativne supstitucije uvedene modificiranjem polinukleotida koji kodiraju polipeptide ovog izuma. Aminokiseline se mogu klasificirati sukladno fizičkim svojstvima i doprinosu sekundarnoj i tercijarnoj proteinskoj strukturi. Konzervativna supstitucija poznata je u tehnici kao supstitucija jedne aminokiseline drugom pri čemu one imaju slična svojstva. Primjeri konzervativnih supstitucija navedeni su u tablici 1 (iz WO 97/09433, str. 10, publicirano 13. ožujka 1997. (PCT/GB96/02197, podneseno 9/6/96)), neposredno niže.  Variant polypeptides include those wherein conservative substitutions have been introduced by modifying the polynucleotides encoding the polypeptides of the invention. Amino acids can be classified according to their physical properties and contribution to secondary and tertiary protein structure. Conservative substitution is known in the art as the substitution of one amino acid for another where they have similar properties. Examples of conservative substitutions are listed in Table 1 (from WO 97/09433, p. 10, published March 13, 1997 (PCT/GB96/02197, filed 9/6/96)), immediately below. 
 
 
   [image]  [image] 
 
 
   Alternativno, konzervativne aminokiseline mogu se grupoirati kao što je opisao Lehninger, (Biochemistry, Second Edition; Worth Publishers, Inc. NY, NY, 1975, str.71-77) kao što je navedeno u tablici 2, neposredno niže.  Alternatively, conservative amino acids may be grouped as described by Lehninger, (Biochemistry, Second Edition; Worth Publishers, Inc. NY, NY, 1975, pp. 71-77) as listed in Table 2, immediately below. 
 
 
   [image]  [image] 
 
 
   Kao sljedeća mogućnost, primjeri konzervativnih supstitucija navedeni su u tablici 3, niže.  As a further possibility, examples of conservative substitutions are listed in Table 3, below. 
 
 
   [image]  [image] 
 
 
   Valja imati na umu da je definicija polipeptida ovog izuma previđena da uključuje polipeptide koji posjeduju druge modifikacije osim ubacivanja, brisanja ili supstitucije aminokiselinskih rezidua. Kao primjer, modifikacije mogu biti kovalentne prirode i uključuju primjerice, kemijsko vezanje s polimerima, lipidima, drugim organskim i anorganskim specijama. Takvi derivati mogu se prirediti da se poveća cirkulirajuće vrijeme poluživota polipeptida ili mogu ili oblikovani da se poveća ciljani kapacitet polipeptida za poželjne stanice, tkiva ili organe. Slično, ovaj izum nadalje obuhvaća DmGPCR polipeptide koji su ili kovalentno modificirani uključujući jedan ili više u vodi topljivih polimernih dodataka kao što su polietilen glikol, polioksietilen glikol ili polipropilen glikol.  It should be noted that the definition of a polypeptide of the present invention is intended to include polypeptides possessing modifications other than insertions, deletions or substitutions of amino acid residues. As an example, modifications can be covalent in nature and include, for example, chemical bonding with polymers, lipids, other organic and inorganic species. Such derivatives may be engineered to increase the circulating half-life of the polypeptide or may or may be designed to increase the targeting capacity of the polypeptide to desired cells, tissues or organs. Similarly, the present invention further encompasses DmGPCR polypeptides that are either covalently modified by including one or more water-soluble polymeric additives such as polyethylene glycol, polyoxyethylene glycol, or polypropylene glycol. 
 
 
   Inačice koje pokazuju ligandna vezujuća svojstva nativnog DmGPCR i koje imaju ekspresiju na višim razinama, kao i inačice koje daju konstitutivno aktivne receptore su osobito korisne u analizama ovog izuma. Te inačice su također korisne u analizama ovog izuma i u definiranju staničnih, tkivnih i životinjskih modela za istraživanje aberantne aktivnosti DmGPCR.  Variants that exhibit the ligand binding properties of the native DmGPCR and are expressed at higher levels, as well as variants that provide constitutively active receptors, are particularly useful in the assays of this invention. These variants are also useful in assays of the present invention and in defining cell, tissue and animal models for investigating aberrant DmGPCR activity. 
 
 
   Antitijela  Antibodies 
 
 
   Također su ovim izumom obuhvaćena antitijela (npr. monoklonska i poliklonska antitijela, jednolančana antitijela, kimerna antitijela, bifunkcionalna/bispecifična antitijela, humanizirana antitijela, humana antitijela i komplementarna determinirajuća područja (CDR)-usađenih antitijela, uključujući spojeve koji sadrže CDR sekvencije koje specifično prepoznaju polipeptid ovog izuma) specifična za DmGPCR ili njegove fragmente. Fragmenti antitijela, uključujući Fab, Fab’, F(ab’)2 i Fv, također su definirani ovim izumom. Pojam „specifičan za,“ kada se rabi za opis antitijela ovog izuma, označuje da promjenjiva područja antitijela ovog izuma prepoznaju i vežu ekskluzivno DmGPCR polipeptide (tj. mogu razlikovati DmGPCR polipeptide od ostalih poznatih GPCR polipeptida temeljem mjerljivih razlika u vezujućem afinitetu, bez obzira na moguće postojanje lokalizirane sekvencijske identičnosti, homologije ili sličnosti između DmGPCR i takvog polipeptida). Podrazumijeva se da specifična antitijela mogu također biti u interakciji s drugim proteinima (primjerice, S. aureus protein ili druga antitijela u ELISA tehnikama) kroz interakcije sa sekvencijama izvan promjenjivog područja antitijela, i, konkretno, u nepromjenjivom području molekule. Screening analize za određivanje vezujuće specifičnosti antitijela ovog izuma dobro su poznate i rutinski se primjenjuju u tehnici. Za iscrpno razmatranje takvih analiza, vidi Harlow et al. (Eds.), Antitijela Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1988, poglavlje 6. Antitijela koja prepoznaju i vežu fragmente DmGPCR polipeptida ovog izuma također s epodrazumijevaju pod uvjetom da su antitijela specifična za DmGPCR polipeptide. Antitijela ovog izuma mogu se proizvesti korištenjem bilo koje metode koja je dobro poznata i rutinski se primjenjuje u tehnici.  Also encompassed by this invention are antibodies (eg, monoclonal and polyclonal antibodies, single chain antibodies, chimeric antibodies, bifunctional/bispecific antibodies, humanized antibodies, human antibodies, and complementarity determining region (CDR)-implanted antibodies, including compounds containing CDR sequences that specifically recognize polypeptide of this invention) specific for DmGPCR or fragments thereof. Antibody fragments, including Fab, Fab', F(ab')2 and Fv, are also defined by the present invention. The term "specific for," when used to describe the antibodies of the present invention, means that the variable regions of the antibodies of the present invention recognize and bind exclusively DmGPCR polypeptides (ie, can distinguish DmGPCR polypeptides from other known GPCR polypeptides based on measurable differences in binding affinity, regardless of possible existence of localized sequence identity, homology or similarity between DmGPCR and such polypeptide). It is understood that specific antibodies may also interact with other proteins (eg, S. aureus protein or other antibodies in ELISA techniques) through interactions with sequences outside the variable region of the antibody, and, specifically, in the constant region of the molecule. Screening assays to determine the binding specificity of antibodies of the present invention are well known and routinely used in the art. For an exhaustive discussion of such analyses, see Harlow et al. (Eds.), Antibody Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1988, Chapter 6. Antibodies that recognize and bind fragments of the DmGPCR polypeptides of the present invention are also contemplated provided that the antibodies are specific for DmGPCR polypeptides. Antibodies of the present invention can be produced using any method well known and routinely practiced in the art. 
 
 
   Ovaj izum definira antitijela koja su specifična za DmGPCR ovog izuma. Specifičnost antitijela opisana je detaljno niže. Međutim, valja naglasiti da se antitijela koja mogu nastati iz polipeptida koji su prethodno opisani u literaturi i koji mogu sličajno interferirati s DmGPCR-om (npr. zbog slučajnog postojanja sličnog epitopa u oba polipeptida) smatraju se “interferencijskim” (cross-reactive) antitijelima. Takva interferencijska antitijela nisu antitijela koja su „specifična“ za DmGPCR. Određivanje je li neko antitijelo specifično za DmGPCR ili je u interferenciji s drugim poznatim receptorom može se izvršiti pomoću nekoliko analiza, kao što su ‘Western blotting’ analize, što je dobro poznato u tehnici. Za identificiranje stanica s ekspresijom DmGPCR i također za moduliranje DmGPCR-ligand vezujuće aktivnosti, korisna su antitijela koja se specifično vežu za izvanstanični epitop DmGPCR-a.  The present invention defines antibodies that are specific for the DmGPCR of the present invention. Antibody specificity is described in detail below. However, it should be emphasized that antibodies that can arise from polypeptides previously described in the literature and that can similarly interfere with DmGPCR (e.g. due to the coincidental existence of a similar epitope in both polypeptides) are considered "interference" (cross-reactive) antibodies. . Such interfering antibodies are not antibodies that are "specific" for DmGPCR. Determining whether an antibody is specific for DmGPCR or interferes with another known receptor can be performed using several assays, such as Western blotting assays, which are well known in the art. To identify cells expressing DmGPCR and also to modulate DmGPCR-ligand binding activity, antibodies that specifically bind to the extracellular epitope of DmGPCR are useful. 
 
 
   U jednoj inačici, ovaj izum definira monoklonska antitijela. Hibridomi koji proizvode takva antitijela također se smatraju aspektima ovog izuma. U daljnjoj inačici, ovaj izum definira humanizirana antitijela. Humanizirana antitijela korisna su za in vivo terapijske indikacije za tretiranje bolesti ili stanja koja su izazvana ektoparazitima.  In one embodiment, the present invention defines monoclonal antibodies. Hybridomas producing such antibodies are also considered aspects of the present invention. In a further embodiment, the present invention defines humanized antibodies. Humanized antibodies are useful for in vivo therapeutic indications for treating diseases or conditions caused by ectoparasites. 
 
 
   U drugoj inačici, ovaj izum definira smjesu bez stanica (cell-free) koja sadrži poliklonska antitijela, pri čemu je bar jedno antitijelo antitijelo ovog izuma specifično za DmGPCR. Antiseurumi koji su izdvojeni iz životinje su primjer takve smjese, kao što je i smjesa koja sadrži frakciju antitijela antiseruma koja je resuspendirana u vodi ili u drugom otapalu, ekscipijentu ili nosaču.  In another version, the present invention defines a cell-free mixture containing polyclonal antibodies, wherein at least one antibody is an antibody of the present invention specific for DmGPCR. Antisera that have been isolated from an animal are an example of such a mixture, as is a mixture containing the antibody fraction of an antiserum that has been resuspended in water or another solvent, excipient, or carrier. 
 
 
   U sljedećoj srodnoj realizaciji, ovaj izum definira anti-idiotipska antitijela koja su specifična za antitijelo koje je specifično za DmGPCR.  In another related embodiment, the present invention defines anti-idiotypic antibodies that are specific for an antibody that is specific for a DmGPCR. 
 
 
   Dobro je poznato antitijela sadrže relativno malene antigen vezujuće domene koje se mogu izdvojiti kemijski ili rekombinantnim tehnikama. Takve domene korisne su za same DmGPCR vezujuće molekule i također mogu biti sjedinjene s toksinima ili drugim polipeptidima. Prema tome, u sljedećoj realizaciji, ovaj izum definira polipeptid koji sadrži DmGPCR-specifičnog antitijela, pri čemu se fragment i polipeptid vežu za DmGPCR. Kao primjer bez ograničenja, ovaj izum definira polipeptide koji su jednolančana antitijela, CDR-usađena antitijela i humanizirana antitijela.  It is well known that antibodies contain relatively small antigen-binding domains that can be separated by chemical or recombinant techniques. Such domains are useful for DmGPCR binding molecules themselves and can also be fused to toxins or other polypeptides. Accordingly, in a further embodiment, the present invention defines a polypeptide comprising a DmGPCR-specific antibody, wherein the fragment and the polypeptide bind to a DmGPCR. By way of example without limitation, the present invention defines polypeptides that are single-chain antibodies, CDR-grafted antibodies, and humanized antibodies. 
 
 
   Nehumana antitijela mogu biti humanizirana bilo kojom metodom koja je poznata u tehnici. U jednoj metodi, nehumani CDR-ovi ubacuju se u humano antitijelo ili koncenzusnu sekvenciju osnove antitijela. Nadalje u osnovu antitijela mogu se unijeti promjene da se modulira afinitet ili imunogenost.  Non-human antibodies can be humanized by any method known in the art. In one method, non-human CDRs are inserted into a human antibody or consensus antibody core sequence. Furthermore, changes can be made to the antibody backbone to modulate affinity or immunogenicity. 
 
 
   Antitijela ovog izuma korisna su npr. za terapijske potrebe (moduliranjem aktivnosti ektoparazitnog DmGPCR), dijagnostičke potrebe da se detektira ili kvantificira ektoparazitni DmGPCR i pročišćavanje DmGPCR-a. Pribori koji sadrže antitijelo ovog izuma za neku ovdje opisanu svrhu također su obuhvaćeni izumom. Općenito, pribor ovog izuma također sadrži kontrolni antigen na kojega je antitijelo imunospecifično.  Antibodies of the present invention are useful, for example, for therapeutic purposes (by modulating the activity of ectoparasitic DmGPCR), diagnostic purposes to detect or quantify ectoparasitic DmGPCR, and purification of DmGPCR. Kits containing an antibody of the present invention for a purpose described herein are also encompassed by the invention. In general, the kit of the present invention also contains a control antigen for which the antibody is immunospecific. 
 
 
   Izum također definira metode za korištenje antitijela ovog izuma. Primjerice, izumom su definirane metode za moduliranje ligandnog vezanja DmGPCR-a što uključuje stupanj dovođenja u dodir DmGPCR s antitijelom specifičnim za DmGPCR, u uvjetima gdje se antitijelo veže za receptor. Antitijela ovog izuma mogu se koristiti za kontroliranje populacije insekata primjenom anti-DmGPCR antitijela insektu da se modulira ligandno vezanje DmGPCR-a. Primjerice, insekti mogu biti odabrani između sljedećih: muha, voćna muha, krpelj, buha, uši, grinje i žohar.  The invention also defines methods for using the antibodies of the invention. For example, the invention defines methods for modulating ligand binding of DmGPCR, which includes the step of bringing the DmGPCR into contact with an antibody specific for DmGPCR, under conditions where the antibody binds to the receptor. The antibodies of the present invention can be used to control insect populations by administering an anti-DmGPCR antibody to the insect to modulate ligand binding of the DmGPCR. For example, insects can be selected from the following: fly, fruit fly, tick, flea, lice, mite and cockroach. 
 
 
   Manipuliranje genima  Gene manipulation 
 
 
   Manipuliranje genima korištenjem DmGPCR također je korisno u subjekata kao što su insekti. Manipuliranje genima uključuje obnavljanje aktivnosti DmGPCR-a aktivnost, preekspresiju DmGPCR i negativno reguliranje DmGPCR-a. Ovaj izum također obuhvaća manipuliranje genima da se obnovi DmGPCR aktivnost koja je izgubljena zbog gubitka funkcije mutiranja. Unošenje funkcionalnog DmGPCR gena u odgovarajuće stanice vrši se ex vivo, in situ ili in vivo korištenjem vektora i konkretnije virusnih vektora (npr. adenovirus, adeno-pridruženi virus ili retrovirus) ili ex vivo korištenjem metoda fizičkog DNA prijenosa (npr. liposomi ili kemijski tretmani). Vidi npr. Anderson, Nature, 1998, suppl. 392 (6679), 25-20. Za dodatni pregled tehnologije genske terapije vidi Friedmann, Science, 1989,244,1275-1281; Verma, Scientific American, 1990, 68-84; te Miller, Nature, 1992, 357, 455-460. Također se podrazumijeva da se manipuliranje genima, primjerice protivsmisleni tretman, može primijeniti za negativno reguliranje ekspresije DmGPCR-a. Kao neograničavajući primjer, manipuliranje genima može biti korisno za kontroliranje populacije insekata izbacivanjem (knocking-out) ili podreguliranjem jednog ili više DmGPCR gena ili njegovih fragmenata (vidi gore i dolje).  Gene manipulation using DmGPCR is also useful in subjects such as insects. Gene manipulation includes restoration of DmGPCR activity, overexpression of DmGPCR and negative regulation of DmGPCR. The present invention also encompasses manipulating genes to restore DmGPCR activity that has been lost due to loss of function mutations. The introduction of a functional DmGPCR gene into the corresponding cells is done ex vivo, in situ or in vivo using vectors and more specifically viral vectors (eg adenovirus, adeno-associated virus or retrovirus) or ex vivo using physical DNA transfer methods (eg liposomes or chemical treatments ). See, eg, Anderson, Nature, 1998, suppl. 392 (6679), 25-20. For an additional review of gene therapy technology, see Friedmann, Science, 1989,244,1275-1281; Verma, Scientific American, 1990, 68-84; and Miller, Nature, 1992, 357, 455-460. It is also understood that gene manipulation, for example antisense treatment, can be applied to negatively regulate DmGPCR expression. As a non-limiting example, gene manipulation may be useful for controlling insect populations by knocking-out or down-regulating one or more DmGPCR genes or fragments thereof (see above and below). 
 
 
   Smjese  Mixtures 
 
 
   Sljedeći aspekt ovog izuma odnosi se na smjese, uključujući insekticidne i farmaceutske smjese, koje sadrže bilo koju molekulu nukleinske kiseline ili rekombinantne ekspresijske vektore koji su prije opisani te prihvatljivi nosač i razrjeđivač. Nosač ili razrjeđivač može biti farmaceutski prihvatljiv. Pogodni nosači su opisani u najnovijem izdanju: Remington’s Pharmaceutical Sciences, A. Osol, što je standardni tekst u ovom području, što je ovdje uključeno kao referenca u cijelosti. Primjeri takvih nosača ili razrjeđivača uključuju, ali nisu ograničeni na vodu, slanu otopinu, Ringerovu otopinu, otopinu dekstroze i 5% humani serum albumin. Liposomi i nevodeni nosači kao što su čvrsta ulja mogu se također koristiti. Formulacije se steriliziraju uobičajenim tehnikama.  A further aspect of this invention relates to compositions, including insecticidal and pharmaceutical compositions, containing any of the nucleic acid molecules or recombinant expression vectors previously described and an acceptable carrier and diluent. The carrier or diluent may be pharmaceutically acceptable. Suitable carriers are described in the most recent edition: Remington's Pharmaceutical Sciences, A. Osol, which is a standard text in the field, which is incorporated herein by reference in its entirety. Examples of such carriers or diluents include, but are not limited to, water, saline, Ringer's solution, dextrose solution, and 5% human serum albumin. Liposomes and non-aqueous carriers such as solid oils may also be used. Formulations are sterilized using conventional techniques. 
 
 
   Također su unutar dosega ovog izuma smjese koje sadrže polipeptide, polinukleotide ili antitijela ovog izuma koji su formulirani s primjerice farmaceutski prihvatljivim nosačem.  Also within the scope of this invention are mixtures containing polypeptides, polynucleotides or antibodies of this invention which are formulated with, for example, a pharmaceutically acceptable carrier. 
 
 
   Ovaj izum definira insekticidne smjese koje sadrže DmGPCR polinukleotid, DmGPCR polipeptid, anti-DmGPCR antitijelo, njegove fragmente ili dijelove koji posjeduju DmGPCR-vezujuću aktivnost, DmGPCR vezujući partner ili DmGPCR modulator.  This invention defines insecticidal compositions containing a DmGPCR polynucleotide, a DmGPCR polypeptide, an anti-DmGPCR antibody, fragments or parts thereof possessing a DmGPCR-binding activity, a DmGPCR binding partner or a DmGPCR modulator. 
 
 
   Pribori i metode  Accessories and methods 
 
 
   Ovaj izum također je usmjeren prema priborima, uključujući farmaceutske i insekticidne pribore. Pribori mogu sadržavati bilo koju molekulu nukleinske kiseline koje su prije opisane, bilo koji od peptida koji su prije opisani i bilo koje antitijelo koje se veže za polipeptid ovog izuma kao što je prije opisano, kao i negativnu kontrolu. Pribor može sadržavati dodatne komponente, kao što su primjerice upute, čvrsta podloga, reagensi koji su korisni za kvantificiranje i slično.  This invention is also directed to accessories, including pharmaceutical and insecticidal accessories. Kits may contain any of the nucleic acid molecules described above, any of the peptides described above, and any antibody that binds to a polypeptide of the invention as described above, as well as a negative control. The kit may contain additional components, such as instructions, a solid substrate, reagents useful for quantification, and the like. 
 
 
   Može se načiniti pribor za detektiranje ekspresije polinukleotida ili kodiranih proteina. Primjerice, mogu se načiniti pribori za oligonukleotidno hibiridiziranje koji sadrže spremnik koji ima oligonukleotidnu sondu koja je specifična za DmGPCR-specifičan DNA i proizvoljno, spremnik s pozitivnim i negativnim kontrolama i/ili upute. Slično, mogu se načiniti PCR pribori koji sadrže spremnik s primerima koji su specifični za DmGPCR-specifične sekvencije, DNA i proizvoljno, spremnike s veličinskim obilježivačima, pozitivnim i negativnim kontrolama i/ili uputama.  A kit can be made to detect the expression of polynucleotides or encoded proteins. For example, oligonucleotide hybridization kits can be made that contain a container having an oligonucleotide probe that is specific for DmGPCR-specific DNA and optionally, a container with positive and negative controls and/or instructions. Similarly, PCR kits can be made that contain primers that are specific for DmGPCR-specific sequences, DNA, and optionally, size labelers, positive and negative controls, and/or instructions. 
 
 
   Uvjeti hibiridziranja moraju biti takvi da do hibridiziranja dolazi samo s genima u prisutnosti drugih molekula nukleinske kiseline. U strogim uvjetima hibridiziranja hibridiziraju samo jako komplementarne sekvencije nukleinske kiseline. Takvi uvjeti mogu spriječiti hibridiziranje nukleinske kiseline koja ima 1 ili 2 neslaganja na 20 kontinuiranih neukleotida. takvi uvjeti su definirani supra.  Hybridization conditions must be such that hybridization occurs only with genes in the presence of other nucleic acid molecules. Under stringent hybridization conditions, only highly complementary nucleic acid sequences hybridize. Such conditions may prevent nucleic acid having 1 or 2 mismatches per 20 contiguous nucleotides from hybridizing. such conditions are defined above. 
 
 
   Testni uzorci koji su pogodni za metode sondiranja nukleinske kiseline uključuju, primjerice, stanice ili ekstrakte stanica nukleinskih kisleina ili biološke tekućine. Uzorci koji se koriste u gore navedenim metodama će varirati ovisno o formatu analize, metodi detektiranja i prirodi tkiva, stanica ili ekstrakata koji se analiziraju. Metode priređivanja ekstrakata stanica nukleinskih kiselina dobro su poznate u tehnici i mogu se lako prilagoditi da se dobije uzorak koji je sukladan s korištenom metodom.  Test samples suitable for nucleic acid probing methods include, for example, cells or nucleic acid cell extracts or biological fluids. The samples used in the above methods will vary depending on the assay format, the detection method and the nature of the tissue, cells or extracts being analysed. Methods for preparing nucleic acid cell extracts are well known in the art and can be easily adapted to obtain a sample that is compatible with the method used. 
 
 
   U sljedećem aspektu, izumom su definirane metode za detektiranje polinukleotida u uzorku kao dijagnostičko pomagalo za bolesti i poremećaje koji su izazvani ektoparazitom, pri čemu metode uključuju sljedeće stupnjeve: (a) dovođenje u dodir uzorka sa sondom nukleinske kiseline koja hibridizira u uvjetima hibridizacijske analize prema ciljanom području nukleinske kiseline kodirajućeg peptida koji ima sekvenciju koja je odabrana iz skupa što ga sačinjavaju sekvencije s br. 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 i 24, a navedena sonda sastoji se od sekvencije nukleinske kiseline koja polipeptid, njenih fragmenata te komplemenata sekvencija i fragmenata; i (b) detektiranje prisutnosti ili količine hibrida sonda:ciljano područje kao indikacije bolesti.  In the next aspect, the invention defines methods for detecting polynucleotides in a sample as a diagnostic aid for diseases and disorders caused by an ectoparasite, wherein the methods include the following steps: (a) bringing the sample into contact with a nucleic acid probe that hybridizes under the conditions of a hybridization analysis according to to the target region of the nucleic acid encoding the peptide having a sequence selected from the group consisting of sequences with no. 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 and 24, and said probe consists of a nucleic acid sequence that is a polypeptide, its fragments, and complementary sequences and fragments; and (b) detecting the presence or amount of probe:target region hybrids as an indication of disease. 
 
 
   Alternativno, mogu se načiniti pribori za imunološke analize koji sadrže spremnike s antitijelima specifičnim za DmGPCR protein i proizvoljno, spremnike s pozitivnim i negativnim kontrolama i/ili uputama.  Alternatively, kits for immunoassays can be made that contain containers with antibodies specific for the DmGPCR protein and optionally, containers with positive and negative controls and/or instructions. 
 
 
   Pribori se koriste pod uvjetom da su korisni u identificiranju vezujućeg partnera DmGPCR-a, kao što su prirodni ligandi ili modulatori (agonisti ili antagonisti). Tvari koje su korisne za tretiranje poremećaja ili bolesti mogu dati pozitivne rezultate u jednoj ili više in vitro analiza na aktivnost koja odgovara tretmanu dotične bolesti ili poremećaja. Tvari koje moduliraju aktivnost polipeptida uključuju, ali bez ograničenja protivsmislene oligonukleotide, agoniste i antagoniste i antitijela.  Kits are used provided they are useful in identifying the binding partner of the DmGPCR, such as natural ligands or modulators (agonists or antagonists). Substances useful for the treatment of a disorder or disease may yield positive results in one or more in vitro assays for activity corresponding to the treatment of the disease or disorder in question. Agents that modulate polypeptide activity include, but are not limited to, antisense oligonucleotides, agonists and antagonists, and antibodies. 
 
 
   Izum također definira metode za moduliranje ligandnog vezanja DmGPCR-a što uključuje stupanj dovođenja u dodir DmGPCR s antitijelom specifičnim za DmGPCR, u uvjetima gdje se veže za receptor.  The invention also defines methods for modulating ligand binding of a DmGPCR which includes the step of contacting the DmGPCR with an antibody specific for the DmGPCR, under conditions where it binds to the receptor. 
 
 
   Metode izazivanja imunološkog odgovora  Methods of eliciting an immune response 
 
 
   Sljedeći aspekt ovog izuma odnosi se na metode izazivanja imunološkog odgovora u subjekta prema polipeptidu ovog izuma primjenom subjektu određene količine polipeptida koja je dovoljna da se izazove imunološki odgovor. Ta količina ovisi o vrsti subjekta, veličini subjekta i slično i može je odrediti osoba koja poznaje ovo područje tehnike.  Another aspect of the present invention relates to methods of inducing an immune response in a subject to a polypeptide of the present invention by administering to the subject an amount of the polypeptide sufficient to elicit an immune response. This amount depends on the type of subject, the size of the subject, and the like, and can be determined by a person skilled in the art. 
 
 
   Metode identificiranja liganda  Methods of identifying ligands 
 
 
   Sljedeći aspect ovog izuma odnosi se na metode identificiranja spojeva koji se vežu za DmGPCR ili molekula nukleinske kiseline koja kodira DmGPCR, što obuhvaća dovođenje u dodir DmGPCR ili molekule nukleinske kiseline koja kodira isto, sa spojem te određivanje veže li spoj DmGPCR ili molekulu nukleinske kiseline koja kodira isto. Vezanje se može odrediti pomoću analiza vezanja što je dobro poznato onima koji poznaju ovo područje, uključujući, ali bez ograničenja, gel-shift analize, ‘Western blots’, analizu radioobilježene kompeticije, fag-zasnovano ekspresijsko kloniranje, kofrakcioniranje pomoću kromatografije, koprecipitacija, unakrsno vezanje, interakcijska analiza zamka/dvohibrid, ‘southwestern’ analiza, ELISA i slično, što je primjerice opisano u: Current Protocols in Molecular Biology, John Wiley & Sons, NY, 1999, što je ovdje uključeno kao referenca u cijelosti. Spojevi koje treba provjeriti uključuju (što može uključivati spojeve koji su suspektni na vezanje DmGPCR ili molekule nukleinske kiseline koja ih kodira), ali nisu ograničeni na spojeve izvanstaničnog, unutarstaničnog, biološkog ili kemijskog podrijetla.  Another aspect of the present invention relates to methods of identifying compounds that bind to a DmGPCR or a nucleic acid molecule encoding a DmGPCR, which comprises contacting the DmGPCR or a nucleic acid molecule encoding the same with the compound and determining whether the compound binds the DmGPCR or nucleic acid molecule encoding the same. encodes the same. Binding can be determined using binding assays well known to those skilled in the art, including but not limited to gel-shift assays, Western blots, radiolabeled competition assays, phage-based expression cloning, chromatographic cofractionation, coprecipitation, cross- binding, trap/two-hybrid interaction assay, 'southwestern' assay, ELISA and the like, as described for example in: Current Protocols in Molecular Biology, John Wiley & Sons, NY, 1999, which is incorporated herein by reference in its entirety. Compounds to be screened include (which may include compounds suspected of binding DmGPCR or the nucleic acid molecule encoding them) but are not limited to compounds of extracellular, intracellular, biological or chemical origin. 
 
 
   Izum također definira analize za identificiranje spojevi koji vežu DmGPCR. Jedna takva analiza uključuje dovođenje u dodir DmGPCR sa spojem koji je suspektan na vezanje DmGPCR te mjerenje vezanja između spoja i DmGPCR. U nekim realizacijama, smjesa uključuje staničnu ekspresiju DmGPCR na njenoj površini. U sljedećoj inačici, koristi se izdvojen DmGPCR ili stanične membrane koje sadrže DmGPCR. Vezanje se može mjeriti izravno, npr. korištenjem obilježenog spoja ili se može izmjeriti posredno pomoću nekoliko tehnika, uključujući mjerenje unutarstaničnog signaliziranja DmGPCR-a koje je izazvano spojem (ili mjerenjem promjena razine signaliziranja DmGPCR-a).  The invention also defines assays for identifying compounds that bind DmGPCR. One such assay involves contacting the DmGPCR with a compound suspected of binding to the DmGPCR and measuring the binding between the compound and the DmGPCR. In some embodiments, the composition includes cellular expression of DmGPCR on its surface. In the following version, isolated DmGPCR or cell membranes containing DmGPCR are used. Binding can be measured directly, eg, using a labeled compound, or can be measured indirectly using several techniques, including measuring compound-induced intracellular DmGPCR signaling (or measuring changes in DmGPCR signaling levels). 
 
 
   Specifične vezujuće molekule, uključujući prirodne ligande i sintetske spojeve, mogu se identificirati ili razviti korištenjem izdvojenih ili rekombinantnih DmGPCR produkata, DmGPCR inačica ili stanica s ekspresijom takvih produkata. Vezujući partneri korisni su za pročišćavanje DmGPCR produkata te detektiranje ili kvantificiranje produkata DmGPCR-a u tekućim ili tkivnim uzorcima pomoću poznatih imunoloških postupaka. Vezujuće molekule su također korisne u moduliranju (tj. blokiranju, inhibiranju ili stimuliranju) bioloških aktivnosti DmGPCR-a, posebice aktivnosti koje su uključene u prijenos signala.  Specific binding molecules, including natural ligands and synthetic compounds, can be identified or developed using isolated or recombinant DmGPCR products, DmGPCR variants, or cells expressing such products. The binding partners are useful for purifying DmGPCR products and detecting or quantifying DmGPCR products in liquid or tissue samples using known immunological procedures. Binding molecules are also useful in modulating (ie, blocking, inhibiting, or stimulating) the biological activities of DmGPCRs, particularly activities involved in signal transduction. 
 
 
   Informacija o DNA i aminokiselinskoj sekvenciji koja se dobije ovim izumom također omogućuje identificiranje spojeva vezujućih partnera s kojima je u interakciji DmGPCR polipeptid ili polinukleotid. Metode za identificiranje spojeva vezujućeg partnera uključuju analize u otopini, in vitro analize gdje su DmGPCR polipeptidi imobilizirani i citološki zasnovane analize. Identificiranje spojeva vezujućih partnera DmGPCR polipeptida određuje kandidate za terapijsku ili profilaktičku intervenciju u patologijama koje su povezane s ektoparazitima s ekspresijom DmGPCR i kandidata za insekticide.  The information on DNA and amino acid sequence obtained by this invention also enables the identification of binding partner compounds with which the DmGPCR polypeptide or polynucleotide interacts. Methods for identifying binding partner compounds include assays in solution, in vitro assays where DmGPCR polypeptides are immobilized, and cytology-based assays. Identifying the binding partner compounds of DmGPCR polypeptides identifies candidates for therapeutic or prophylactic intervention in pathologies associated with DmGPCR-expressing ectoparasites and candidate insecticides. 
 
 
   Ovaj izum obuhvaća nekoliko sustava analiza za identificiranje DmGPCR vezujućih partnera. Ako se radi o analizi o otopini, metode ovog izuma uključuju sljedeće stupnjeve: (a) dovođenje u dodir DmGPCR polipeptida s jednim ili više spojeva kandidatskog vezujućeg partnera i (b) identificiranje spojeva koji se vežu za DmGPCR polipeptid. Identificiranje spojeva koji vežu DmGPCR polipeptid može se postići izdvajanjem kompleksa DmGPCR polipeptid/vezujući partner i izdvajanjem spoja vezujućeg partnera od DmGPCR polipeptida. U drugoj realizaciji ovog izuma obuhvaćen je dodatni stupanj karakteriziranja fizičkih, bioloških i/ili biokemijskih svojstava spoja vezujućeg partnera. U jednom aspektu, kompleks DmGPCR polipeptid/vezujući partner izdvaja se korištenjem antitijela koje je imunospecifično bilo za DmGPCR polipeptid ili spoj kandidatskog vezujućeg partnera.  The present invention encompasses several assay systems for identifying DmGPCR binding partners. In the case of a solution assay, the methods of the present invention include the following steps: (a) contacting the DmGPCR polypeptide with one or more candidate binding partner compounds and (b) identifying the compounds that bind to the DmGPCR polypeptide. Identification of compounds that bind the DmGPCR polypeptide can be achieved by isolating the DmGPCR polypeptide/binding partner complex and isolating the binding partner compound from the DmGPCR polypeptide. In another embodiment of this invention, an additional step of characterizing the physical, biological and/or biochemical properties of the binding partner compound is included. In one aspect, the DmGPCR polypeptide/binding partner complex is isolated using an antibody that is immunospecific for either the DmGPCR polypeptide or the candidate binding partner compound. 
 
 
   U drugim realizacijama, DmGPCR polipeptid ili spoj kandidatskog vezujućeg partnera sadrži oznaku ili tag što olakšava njegovo izdvajanje i metode ovog izuma da se identificiraju spojevi vezujućeg partnera uključuju stupanj izdvajanja kompleksa DmGPCR polipeptid/vezujući partner putem interakcije s oznakom ili tagom. Primjerni tag ovog tipa je poli-histidinska sekvencija, općenito oko šest histidinskih rezidua, koja omogućuje izdvajanje tako označenog spoja korištenjem keliranja niklom. Druge oznake i tagovi, kao što je FLAG® tag (Eastman Kodak, Rochester, NY), koji su dobro poznati i rutinski se koriste u tehnici, obuhvaćeni su ovim izumom. Oznake ovog izuma također uključuju ali nisu ograničene na radioaktivne oznake (npr. 125I, 35S, 32P, 33P, 3H), fluorescentne oznake, kemiluminscentne oznake, enzimske oznake i imunogene oznake.  In other embodiments, the DmGPCR polypeptide or candidate binding partner compound contains a label or tag that facilitates its isolation and the methods of the present invention to identify binding partner compounds include the step of isolating the DmGPCR polypeptide/binding partner complex via interaction with the label or tag. An exemplary tag of this type is a poly-histidine sequence, generally around six histidine residues, which allows isolation of the so-tagged compound using nickel chelation. Other labels and tags, such as the FLAG® tag (Eastman Kodak, Rochester, NY), which are well known and routinely used in the art, are encompassed by the present invention. Labels of the present invention also include but are not limited to radioactive labels (eg, 125I, 35S, 32P, 33P, 3H), fluorescent labels, chemiluminescent labels, enzymatic labels, and immunogenic labels. 
 
 
   U nekim realizacijama in vitro analiza, izumom su definirane metode koje uključuju sljedeće stupnjeve: (a) dovođenje u dodir imobiliziranog DmGPCR polipeptida sa spojem kandidatskog vezujućeg partnera i (b) detektiranje vezanja kandidatskog spoja za DmGPCR polipeptid. U alternativnoj realizaciji, spoj kandidatskog vezujućeg partnera je imobiliziran i detektirano je vezanje DmGPCR-a. Imobiliziranje se vrši bilo kojom metodom koja je poznata u tehnici, uključujući kovalentno vezanje za podlogu, nosač ili kromatografsku smolu, kao i nekovalentne, visoko afinitetne interakcije kao što je vezanje antitijelom ili korištenje vezanja streptavidin/biotin pri čemu imobilizirani spoj uključuje abiotin speciju. Detektiranje vezanja može se izvršiti (i) korištenjem radioaktivne oznake na spoju koji nije imobiliziran, (ii) korištenjem fluorescentne oznake na imobiliziranom spoju, (iii) korištenjem antitijela imunospecifičnog za neimobilizirani spoj, (iv) korištenjem oznake na imobiliziranom spoju koja ekscitira fluorescentnu podlogu na koju je dodan imobilizirani spoj, kao i druge tehnike koje su dobro poznate u rutinskom radu.  In some embodiments of in vitro assays, the invention defines methods that include the following steps: (a) contacting the immobilized DmGPCR polypeptide with a candidate binding partner compound and (b) detecting binding of the candidate compound to the DmGPCR polypeptide. In an alternative embodiment, the candidate binding partner compound is immobilized and DmGPCR binding is detected. Immobilization is performed by any method known in the art, including covalent binding to a substrate, support, or chromatographic resin, as well as non-covalent, high-affinity interactions such as antibody binding or using streptavidin/biotin binding wherein the immobilized compound includes an abiotin species. Detection of binding can be performed (i) using a radioactive label on the compound that is not immobilized, (ii) using a fluorescent label on the immobilized compound, (iii) using an antibody immunospecific for the non-immobilized compound, (iv) using a label on the immobilized compound that excites a fluorescent substrate on to which the immobilized compound has been added, as well as other techniques well known in routine work. 
 
 
   Izum također definira citološki zasnovane analize da se identificiraju spojevi vezujućeg partnera DmGPCR polipeptida. U jednoj realizaciji, izumom su definirane metode koje uključuju dovođenje u dodir DmGPCR polipeptida s ekspresijom na površini stanice s kandidatskim spojem vezujućeg partnera i detektiranje vezanja kandidatskog spoja vezujućeg partnera za DmGPCR polipeptid. U sljedećoj realizaciji, detektiranje uključuje detektiranje kalcijeva fluksa ili drugih fizioloških učinaka u stanici koji su izazvani vezanjem molekule.  The invention also defines cytology-based assays to identify binding partner compounds of DmGPCR polypeptides. In one embodiment, the invention defines methods that include contacting a cell surface-expressed DmGPCR polypeptide with a candidate binding partner compound and detecting binding of the candidate binding partner compound to the DmGPCR polypeptide. In another embodiment, detecting includes detecting calcium flux or other physiological effects in the cell that are induced by binding of the molecule. 
 
 
   U sljedećoj realizaciji ovog izuma, koristi se ‘high throughput’ screening za spojeve koji imaju odgovarajući vezujući afinitet za DmGPCR. Ukratko, sintetiziran je veliki broj različitih testnih spojeva koji su maleni peptidi na čvrstoj podlozi ili su slobodni spojevi otopljeni u odgovarajućem puferu. Testni peptidni spojevi su u dodiru s DmGPCR-om i ispiru se. Vezani DmGPCR se zatim detektira pomoću metoda koje su poznate u tehnici. Pročišćeni polipeptidi ovog izuma mogu se također postaviti izravno na ploče koje se rabe u prije navedenim vezujućim analizama. Nadalje, neneutralizirajuća antitijela mogu se koristiti za hvatanje proteina i imobiliziranje na čvrstoj podlozi.  In a further embodiment of the present invention, high throughput screening for compounds having appropriate binding affinity for DmGPCR is used. Briefly, a large number of different test compounds have been synthesized which are small peptides on a solid support or are free compounds dissolved in a suitable buffer. Test peptide compounds are in contact with DmGPCR and are washed away. Bound DmGPCR is then detected using methods known in the art. Purified polypeptides of the present invention can also be plated directly onto the plates used in the aforementioned binding assays. Furthermore, non-neutralizing antibodies can be used to capture proteins and immobilize them on a solid support. 
 
 
   Općenito, DmGPCR s ekspresijom može se koristiti za HTS vezujuće analize u sprezi s definiranim ligandom. Identificirani peptid se obilježava s odgovarajućim radioizotopom, uključujući, ali bez ograničenja, 125I, 3H, 35S ili 32P, pomoću metoda koje su dobro poznate onima koji poznaju ovo područje tehnike. Alternativno, peptidi mogu biti obilježeni pomoću dobro poznatih metoda s odgovarajućim fluorescentnim derivatom (Baindur et al., Drug Dev. Res., 1994, 33, 373-398; Rogers, Drug Discovery Today, 1997, 2, 156-160). Radioaktivni ligand koji je specifično vezan za receptor u membranskim pripravcima koji su načinjeni iz stanične linije koja vrši ekspresiju rekombinantnog proteina, može se detektirati u HTS analizama jednom od nekoliko standardnih načina, uključujući filtriranje kompleksa receptor-ligand da se odvoji vezani ligand od slobodnog liganda (Williams, Med. Res. Rev., 1991, 11, 147-184; Sweetnam et al., J. Natural Products, 1993, 56, 441-455). Alternativne metode uključuju analizu scintilacijske blizine (SPA) ili FlashPlate format kada takvo odvajanje nije neophodno (Nakayama, Curr. Opinion Drug Disc. Dev., 1998, 1, 85-91 Bosse et al., J. Biomolecular Screening, 1998, 3, 285-292). Vezanje fluorescentnih liganada može se detektirati na različite načine, uključujući fluorescentni prijenos energije (FRET), izravnu spektrofluorometrijsku analizu vezanog liganda ili fluorescentnu polarizaciju (Rogers, Drug Discovery Today, 1997, 2, 156-160; Hill, Curr. Opinion Drug Disc. Dev., 1998, 1, 92-97).  In general, an expressed DmGPCR can be used for HTS binding assays in conjunction with a defined ligand. The identified peptide is labeled with an appropriate radioisotope, including but not limited to 125 I, 3 H, 35 S or 32 P, using methods well known to those skilled in the art. Alternatively, peptides can be labeled using well-known methods with an appropriate fluorescent derivative (Baindur et al., Drug Dev. Res., 1994, 33, 373-398; Rogers, Drug Discovery Today, 1997, 2, 156-160). Radioactive ligand that is specifically bound to a receptor in membrane preparations made from a cell line expressing the recombinant protein can be detected in HTS assays by one of several standard methods, including filtering the receptor-ligand complex to separate bound ligand from free ligand ( Williams, Med. Res. Rev., 1991, 11, 147-184; Sweetnam et al., J. Natural Products, 1993, 56, 441-455). Alternative methods include scintillation proximity analysis (SPA) or FlashPlate format when such separation is not necessary (Nakayama, Curr. Opinion Drug Disc. Dev., 1998, 1, 85-91 Bosse et al., J. Biomolecular Screening, 1998, 3, 285-292). Binding of fluorescent ligands can be detected in a variety of ways, including fluorescence energy transfer (FRET), direct spectrofluorometric analysis of the bound ligand, or fluorescence polarization (Rogers, Drug Discovery Today, 1997, 2, 156-160; Hill, Curr. Opinion Drug Disc. Dev ., 1998, 1, 92-97). 
 
 
   Za identificiranje specifičnih liganada DmGPCR-a mogu se koristiti druge analize, uključujući analize za identificiranje liganada ciljanog proteina putem mjerenja izravnog vezanja testnih liganada za ciljani protein, kao i analize za identificiranje liganada ciljanih proteina putem afinitetnog ultrafiltriranja s ionskom sprej masenom spektroskopijom/HPLC metodama te drugim fizičkim i analitičkim metodama. Alternativno, takve vezujuće interakcije mogu se procijeniti posredno korištenjem kvaščeva dvohibridnog sustava koji je opisan u Fields et al. (Nature, 1989, 340, 245-246) te Fields et al. (Trends in Genetics, 1994, 10, 286-292), a obje te reference su ovdje uključene. Dvohibridni sustav je genetska analiza za detektiranje interakcija između dva proteina ili polipeptida. Može se koristiti za identificiranje proteina koji se vežu za poznati protein od interesa ili za domena ili rezidua koje su kritične za interakciju. Razvijene su inačice ove metodologije da se kloniraju geni koji kodiraju DNA vezujuće proteine, da se identificiraju peptidi koji se vežu za protein i za provjeru lijekova. Dvohibridni sustav koristi sposobnost para interakcijskih proteina da dovedu transkripcijsku aktivacijsku domenu vrlo blizu DNA vezujućoj domeni koja se veže za ‘uzvodnu’ aktivacijsku sekvenciju (UAS) reporterskog gena i općenito se provodi u kvascima. Analiza zahtijeva konstrukciju dviju hibridnih gena koji kodiraju (1) DNA-vezujuću domenu koja je sjedinjena s prvim proteinom i (2) aktivacijsku domenu koja je sjedinjena s drugim proteinom. DNA-vezujuća domena pogađa prvi hibridni protein UAS reporterskog gena. Međutim, budući da većini proteina nedostaje aktivacijska domena, ovaj DNA-vezujući hibridni protein ne aktivira transkripciju reporterskog gena. Drugi hibridni protein, koji sadrži aktivacijsku domenu, ne može sam aktivirati ekspresiju reporterskog gena budući da on ne veže UAS. Međutim, ako su prisutna oba hibridna proteina, nekovalentna interakcija prvog i drugog proteina sputava aktivacijsku domenu prema UAS, aktiviranjem transkripcije reporterskog gena. Primjerice, kada je prvi protein produkt DmGPCR gena ili njegov fragment, za kojega je poznato da je u interakciji s drugim proteinom ili nukleinskom kisleinom, ova analiza može se koristiti za detektiranje sredstava koja intereferiraju s vezujućom interakcijom. Prati se ekspresija reporterskog gena kako se dodaju u sustav različita sredstva koja se ispituju. Prisutnost inhibitorskog sredstva rezultira odsutnošću reporterskog signala.  Other assays can be used to identify specific DmGPCR ligands, including assays to identify target protein ligands by measuring direct binding of test ligands to the target protein, as well as assays to identify target protein ligands by affinity ultrafiltration with ion spray mass spectroscopy/HPLC methods, and other physical and analytical methods. Alternatively, such binding interactions can be assessed indirectly using the yeast two-hybrid system described in Fields et al. (Nature, 1989, 340, 245-246) and Fields et al. (Trends in Genetics, 1994, 10, 286-292), and both of these references are incorporated herein. The two-hybrid system is a genetic analysis for detecting interactions between two proteins or polypeptides. It can be used to identify proteins that bind to a known protein of interest or to domains or residues that are critical for the interaction. Versions of this methodology have been developed to clone genes encoding DNA-binding proteins, to identify protein-binding peptides, and for drug screening. The two-hybrid system uses the ability of a pair of interacting proteins to bring the transcriptional activation domain very close to the DNA binding domain that binds to the 'upstream' activation sequence (UAS) of the reporter gene and is generally carried out in yeast. The assay requires the construction of two hybrid genes encoding (1) a DNA-binding domain fused to the first protein and (2) an activation domain fused to the second protein. The DNA-binding domain hits the first hybrid protein of the UAS reporter gene. However, since most proteins lack an activation domain, this DNA-binding hybrid protein does not activate transcription of the reporter gene. The second hybrid protein, which contains the activation domain, cannot activate reporter gene expression by itself since it does not bind the UAS. However, if both hybrid proteins are present, the non-covalent interaction of the first and second proteins restrains the activation domain towards the UAS, activating transcription of the reporter gene. For example, when the first protein is a DmGPCR gene product or fragment thereof, which is known to interact with another protein or nucleic acid, this assay can be used to detect agents that interfere with the binding interaction. The expression of the reporter gene is monitored as the various test agents are added to the system. The presence of an inhibitory agent results in the absence of a reporter signal. 
 
 
   Kada je funkcija produkta DmGPCR gena nepoznata i nema poznatih liganada za vezanje s genskim produktom, može se također koristiti kvaščeva dvohibridna analiza da se identificiraju proteini koji se vežu za genski produkt. U analizi da se identificiraju proteini koji se vežu za DmGPCR receptor ili njegov fragment, može se koristiti fuzijski polinukleotid koji kodira i DmGPCR receptor (ili fragment) i UAS vezujuću domenu (tj. prvi protein). Nadalje, u analizi proizvodi se i provjerava veliki broj hibridnih gena od kojih svaki kodira različiti sekundarni protein koji je sjedinjen s aktivacijskom domenom. Tipično, drugi protein se kodira s jednim ili više članova fuzijske biblioteke ukupne cDNA ili genomske DNA., pri čemu je svako kodirajuće područje drugog gena sjedinjeno s aktivacijskom domenom. Ovaj sustav može se primijeniti za široki raspon proteina i nije čak nužno poznavati identičnost ili funkciju drugog vezujućeg proteina. Sustav je vrlo osjetljiv i može detektirati interakcije koje se ne mogu uočiti drugim metodama. Čak i prijelazne interakcije mogu pokrenuti transkripciju da se dobije postojana mRNA koja se može opetovano prevesti da se dobije reporterski protein.  When the function of the DmGPCR gene product is unknown and there are no known ligands to bind to the gene product, yeast two-hybrid analysis can also be used to identify proteins that bind to the gene product. In an assay to identify proteins that bind to a DmGPCR receptor or fragment thereof, a fusion polynucleotide encoding both the DmGPCR receptor (or fragment) and the UAS binding domain (ie, the first protein) can be used. Furthermore, a large number of hybrid genes, each encoding a different secondary protein fused to an activation domain, are produced and screened in the assay. Typically, the second protein is encoded by one or more members of a fusion library of total cDNA or genomic DNA, wherein each coding region of the second gene is fused to an activation domain. This system can be applied to a wide range of proteins and it is not even necessary to know the identity or function of the other binding protein. The system is very sensitive and can detect interactions that cannot be detected by other methods. Even transient interactions can initiate transcription to produce a stable mRNA that can be repeatedly translated to produce a reporter protein. 
 
 
   U potrazi za sredstvima koja se vežu za ciljani protein mogu se koristiti druge analize. Jedna takva screening metoda da se identificira izravno vezanje testnih liganada za ciljani protein opisana je u američkom patentu br. 5, 585, 277, koji je ovdje uključen kao referenca. Ova metoda temelji se na načelu da proteini općenito postoje kao smjesa savijenog i nesavijenog stanja i kontinuirano alterniraju između ovih dviju stanja. Kada se testni ligand veže za savijeni oblik ciljanog proteina (tj. kada je testni ligand ligand ciljanog proteina), molekula ciljanog proteina koja je vezana s ligandom ostaje u savijenom stanju. Dakle, savijeni ciljani protein nalazi se u većem dosegu u prisutnosti ciljanog spoja koji savija ciljani protein, nego u odsutnosti liganda. Vezanje liganda za ciljani protein može se odrediti nekom metodom kojom se mogu razlučiti savijeno i nesavijeno stanje ciljanog proteina. Funkcija ciljanog proteina ne mora biti poznata da bi se mogla izvršiti ova analiza. Ovom metodom se kao ispitivani ligand može ispitati bilo koje sredstvo, uključujući bez ograničenja metale, polipeptide, proteine, lipide, polisaharide, polinukleotide i malene organske molekule.  Other assays can be used to search for agents that bind to the target protein. One such screening method to identify direct binding of test ligands to a target protein is described in US Pat. 5, 585, 277, which is incorporated herein by reference. This method is based on the principle that proteins generally exist as a mixture of folded and unfolded states and continuously alternate between these two states. When the test ligand binds to the folded form of the target protein (ie, when the test ligand is a ligand of the target protein), the target protein molecule that is bound to the ligand remains in the folded state. Thus, the folded target protein is in greater reach in the presence of a targeting compound that folds the target protein, than in the absence of the ligand. Ligand binding to the target protein can be determined by a method that can distinguish between the folded and unfolded states of the target protein. The function of the target protein does not need to be known to perform this analysis. With this method, any agent can be tested as a test ligand, including but not limited to metals, polypeptides, proteins, lipids, polysaccharides, polynucleotides, and small organic molecules. 
 
 
   Druga metoda za identificiranje liganda ciljanog proteina opisana je u: Wieboldt et al. (Anal. Chem., 1997, 69, 1683-1691), što je ovdje uključeno kao referenca. Ova tehnika koristi kombinatorne biblioteke od 20-30 sredstava istovremeno u tekućoj fazi za vezanje za ciljani protein. Sredstva koja se vežu za ciljani protein odvajaju se od ostalih komponenti biblioteke pomoću jednostavne tehnike membranskog ispiranja. Specifično odabrane molekule koje su zadržane na filteru kasnije se oslobađaju od ciljanog proteina i analiziraju pomoću HPLC i plinski potpomognute elektrosprej (ion sprej) ionizacijske masene spektroskopije. Ovim postupkom odabiru se komponente biblioteke s visokim afinitetom za ciljani protein i posebno je koristan za biblioteke malenih molekula.  Another method for identifying a target protein ligand is described in: Wieboldt et al. (Anal. Chem., 1997, 69, 1683-1691), which is incorporated herein by reference. This technique uses combinatorial libraries of 20-30 agents simultaneously in the liquid phase to bind to the target protein. Agents that bind to the target protein are separated from other library components using a simple membrane washing technique. The specifically selected molecules retained on the filter are later released from the target protein and analyzed by HPLC and gas-assisted electrospray (ion spray) ionization mass spectroscopy. This procedure selects library components with high affinity for the target protein and is particularly useful for small molecule libraries. 
 
 
   Druge realizacije ovog izuma obuhvaćaju korištenje kompetitivnih screening analiza u kojima neutralizirajuća antitijela koja mogu vezati polipeptid ovog izuma specifično kompetiraju s ispitivanim spojem u vezanju za polipeptid. Na taj način, mogu se koristiti antitijela za detektiranje prisutnosti bilo kakvog peptida koji dijeli jednu ili više antigenih determinanti s DmGPCR. Istraživanja radioobilježenog kompetitivnog vezanja opisana su u A.H. Lin et al. (Antimicrobial Agents and Chemotherapy, 1997, 41(10), 2127-2131), a opis je ovdje uključen kao referenca u cijelosti.  Other embodiments of this invention include the use of competitive screening assays in which neutralizing antibodies capable of binding the polypeptide of this invention specifically compete with the test compound in binding to the polypeptide. In this way, antibodies can be used to detect the presence of any peptide that shares one or more antigenic determinants with the DmGPCR. Radiolabeled competitive binding studies are described in A.H. Lin et al. (Antimicrobial Agents and Chemotherapy, 1997, 41(10), 2127-2131), the disclosure of which is incorporated herein by reference in its entirety. 
 
 
   Metode identificiranja modulirajućih sredstava  Methods of identifying modulating agents 
 
 
   Ovim izumom su također definirane metode za identificiranje modulatora vezanja između DmGPCR i DmGPCR vezujućeg partnera, što uključuje sljedeće stupnjeve: (a) dovođenje u dodir DmGPCR vezujućeg partnera i smjese koja sadrži DmGPCR u prisutnosti i odsutnosti potencijalnog modulatorskog spoja; (b) detektiranje vezanja između vezujućeg partnera i DmGPCR; te (c) identificiranje potencijalnog modulatorskog spoja ili modulatorakog spoja u svjetlu smanjenog ili povećanog vezanja između vezujućeg partnera i DmGPCR u prisutnosti potencijalnog modulatora, u odnosu na vezanje u odsutnosti potencijalnog modulatora.  The present invention also defines methods for identifying binding modulators between a DmGPCR and a DmGPCR binding partner, comprising the following steps: (a) contacting the DmGPCR binding partner and a mixture containing the DmGPCR in the presence and absence of a potential modulatory compound; (b) detecting binding between the binding partner and the DmGPCR; and (c) identifying a potential modulatory compound or modulatory compound in light of decreased or increased binding between the binding partner and the DmGPCR in the presence of the potential modulator, relative to binding in the absence of the potential modulator. 
 
 
   DmGPCR vezujući partneri koji stimuliraju aktivnost DmGPCR korisni su kao agonisti u uvjetima koji su karakterizirani nedovoljnim DmGPCR signaliziranjem (npr. kao rezultat nedovoljne aktivnosti DmGPCR liganda). DmGPCR vezujući partneri koji blokiraju ligandom upravljano DmGPCR signaliziranje korisni su kao DmGPCR antagonisti u uvjetima kojima je svojstveno prekomjerno DmGPCR signaliziranje. Nadalje, DmGPCR modulatori općenito, kao i DmGPCR polinukleotidi i polipeptidi, korisni su za dijagnostičke analize bolesti izazvanih ektoparazitima ili stanjima u kojima je DmGPCR aktivnost povećana ili oštećena.  DmGPCR binding partners that stimulate DmGPCR activity are useful as agonists in conditions characterized by insufficient DmGPCR signaling (eg, as a result of insufficient DmGPCR ligand activity). DmGPCR binding partners that block ligand-gated DmGPCR signaling are useful as DmGPCR antagonists in conditions characterized by excessive DmGPCR signaling. Furthermore, DmGPCR modulators in general, as well as DmGPCR polynucleotides and polypeptides, are useful for diagnostic assays of diseases caused by ectoparasites or conditions in which DmGPCR activity is increased or impaired. 
 
 
   U sljedećem aspektu, izumom su definirane metode za tretiranje bolesti ili stanja primjenom subjektu kojemu je potreban takav tretman tvari koja modulira aktivnost ili ekspresiju polipeptida koji ima sekvenciju koja je odabrana između onih sa sekvencijskim vrojevima 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 i 24.  In a further aspect, the invention defines methods for treating a disease or condition by administering to a subject in need of such treatment a substance that modulates the activity or expression of a polypeptide having a sequence selected from those with sequence numbers 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 and 24. 
 
 
   U sljedećem aspektu, izumom su definirane metode za kontroliranje populacije insekata primjenom na populaciju insekata vezujućeg partnera ili modulatora koji modificira ekspresiju ili aktivnost DmGPCR.  In a further aspect, the invention defines methods for controlling an insect population by applying to the insect population a binding partner or modulator that modifies the expression or activity of DmGPCR. 
 
 
   Sredstva koja moduliraju (tj. povećavaju, smanjuju ili blokiraju) aktivnost ili ekspresiju DmGPCR mogu biti identificirana inkubiranjem potencijalnog modulatora sa stanicom koja sadrži DmGPCR polipeptid ili polinukleotid te određivanjem učinka potencijalnog modulatora na aktivnost ili ekspresiju DmGPCR. Selektivnost spoja koji modulira aktivnost DmGPCR može se procijeniti uspoređivanjem njegovih učinaka na DmGPCR prema njegovim učincima na druge GPCR spojeve. Selektivni modulatori mogu primjerice obuhvaćati antitijela i druge proteine, peptide i organske molekule koje se specifično vežu za DmGPCR polipeptid ili DmGPCR-kodirajuću nukleinsku kiselinu. Modulatori aktivnosti DmGPCR bit će terapijski korisni u tretiranju bolesti i fizioloških stanja u kojima je uključena normalna ili nenormalna aktivnost DmGPCR.  Agents that modulate (ie, increase, decrease, or block) DmGPCR activity or expression can be identified by incubating the potential modulator with a cell containing the DmGPCR polypeptide or polynucleotide and determining the effect of the potential modulator on DmGPCR activity or expression. The selectivity of a compound that modulates DmGPCR activity can be assessed by comparing its effects on DmGPCR to its effects on other GPCR compounds. Selective modulators can for example include antibodies and other proteins, peptides and organic molecules that specifically bind to the DmGPCR polypeptide or DmGPCR-encoding nucleic acid. Modulators of DmGPCR activity will be therapeutically useful in treating diseases and physiological conditions in which normal or abnormal DmGPCR activity is involved. 
 
 
   DmGPCR polinukleotidi i polipeptidi, kao i DmGPCR modulatori, mogu se također koristiti u dijagnostičkim analizama za bolesti izazvane ektoparazitima ili stanjima koja su karakterizirana povećanom ili oštećenom aktivnošću DmGPCR.  DmGPCR polynucleotides and polypeptides, as well as DmGPCR modulators, can also be used in diagnostic assays for diseases caused by ectoparasites or conditions characterized by increased or impaired DmGPCR activity. 
 
 
   Metode ovog izuma za identificranje modulatora obuhvaćaju varijacije bilo koje prije opisane metode da se identificiraju spojevi koji su vezujući partneri, a varijacije obuhvaćaju tehnike gdje je identificiran spoj-vezujući partner i vezujuća analiza se vrši u prisutnosti ili odsutnosti kandidatskog modulatora. Modulator se identificira u onim okolnostima kada se vezanje između DmGPCR polipeptida i vezujućeg partnera mijenja u prisutnosti kandidatskog modulatora u odnosu na vezanje u odsutnosti kandidatskog modulatorskog spoja. Modulator koji povećava vezanje između DmGPCR polipeptida i vezujućeg partnerskog spoja naziva se pojačivač ili aktivator dok se spoj koji smanjuje vezanje između DmGPCR polipeptida i vezujućeg partnerskog spoja naziva inhibitor.  The methods of the present invention for identifying modulators include variations of any previously described method to identify compounds that are binding partners, and variations include techniques where a compound-binding partner is identified and binding analysis is performed in the presence or absence of a candidate modulator. A modulator is identified in those circumstances where the binding between the DmGPCR polypeptide and the binding partner is altered in the presence of the candidate modulator relative to binding in the absence of the candidate modulator compound. A modulator that increases binding between a DmGPCR polypeptide and a binding partner compound is called an enhancer or activator, while a compound that decreases binding between a DmGPCR polypeptide and a binding partner compound is called an inhibitor. 
 
 
   Izumom su također obuhvaćene ‘high-throughput screening’ (HTS) analize s ciljem da se identificiraju spojevi koji su u interakciji s biološkom aktivnošću ili inhibiraju biološku aktivnost (tj. djeluju na enzimsku aktivnost, aktivnost vezanja itd.) DmGPCR polipeptida. HTS analize omogućuju screening velikog broja spojeva na djelotvoran način. Stanično zasnovani HTS sustavi namijenjeni su ispitivanju DmGPCR receptor-ligand interakcije. HTS analize oblikovane su da se identificiraju “pogoci” ili “vodeći spojevi” koji imaju željeno svojstvo, s kojima se mogu načiniti modifikacije da se pojača željeno svojstvo. Kemijsko modificiranje „pogotka“ ili „vodećeg spoja“ često se zasniva na odnosu identificirajuće strukture i aktivnosti između “pogotka” i DmGPCR polipeptida.  The invention also covers 'high-throughput screening' (HTS) analyzes with the aim of identifying compounds that interact with the biological activity or inhibit the biological activity (i.e. affect enzymatic activity, binding activity, etc.) of DmGPCR polypeptides. HTS analyzes enable the screening of a large number of compounds in an efficient manner. Cell-based HTS systems are intended for testing DmGPCR receptor-ligand interaction. HTS assays are designed to identify “hits” or “lead compounds” that have a desired property, with which modifications can be made to enhance the desired property. Chemical modification of the "hit" or "lead compound" is often based on the identifying structure-activity relationship between the "hit" and the DmGPCR polypeptide. 
 
 
   Modulatori koji spadaju unutar dosega ovog izuma obuhvaćaju, ali nisu ograničeni na nepeptidne molekule kao što su nepeptidni mimetici, nepeptidni alosterički efektori i peptidi. DmGPCR polipeptid ili polinukleotid koji se koristi u takvom ispitivanju može biti ili slobodan u otopini, vezan za čvrsti nosač, smješten na staničnoj površini ili unutar stanice ili vezan za dio stanice. Onaj tko poznaje ovo područje tehnike može primjerice mjeriti nastajanje kompleksa između DmGPCR i spoja koji se ispituje. Alternativno, onaj tko poznaje ovo područje tehnike može ispitati umanjenje nastajanja kompleksa između DmGPCR i njegova supstrata pomoću spoja koji se ispituje.  Modulators that fall within the scope of this invention include, but are not limited to non-peptide molecules such as non-peptide mimetics, non-peptide allosteric effectors and peptides. The dmGPCR polypeptide or polynucleotide used in such an assay can be either free in solution, attached to a solid support, located on the cell surface or inside the cell, or attached to a part of the cell. One skilled in the art can, for example, measure the formation of a complex between DmGPCR and the compound being tested. Alternatively, one of ordinary skill in the art can examine the reduction of complex formation between the DmGPCR and its substrate by the test compound. 
 
 
   Daljnji aspekt ovog izuma odnosi se na metode identificiranja spojeva koji moduliraju (tj. povećavaju ili smanjuju) aktivnost DmGPCR što obuhvaća dovođenje u dodir DmGPCR sa spojem i određivanje mijenja li spoj DmGPCR. Aktivnost u prisutnosti ispitivanog spoja uspoređuje se s aktivnošću u odsutnosti ciljanog spoja. Kada je aktivnost uzorka koji sadrži ispitivani spoj veća od aktivnosti uzorka bez ispitivanog spoja, spoje će imati povećanu aktivnost. Slično, ako je aktivnost uzorka koji sadrži ispitivani spoj manja od aktivnosti u uzorku u kojem nema ispitivanog spoja, spoj će imati inhibiranu aktivnost.  A further aspect of the present invention relates to methods of identifying compounds that modulate (ie, increase or decrease) DmGPCR activity comprising contacting the DmGPCR with the compound and determining whether the compound alters the DmGPCR. The activity in the presence of the test compound is compared to the activity in the absence of the target compound. When the activity of the sample containing the test compound is greater than the activity of the sample without the test compound, the compounds will have increased activity. Similarly, if the activity of a sample containing the test compound is less than the activity of a sample without the test compound, the compound will have inhibited activity. 
 
 
   Ovaj izum je osobito koristan za screening spojeva pomoću DmGPCR u cijelom nizu analiza aktivnosti. Spoj koji se podvrgava screening-u obuhvaća (što može uključivati spojeve za koje s eočekuje da moduliraju aktivnost DmGPCR), ali bez ograničenja, spojeve izvanstaničnog, unutarstaničnog, kemijskog ili biološkog porijekla. DmGPCR polipeptid koji se koristi u takvom testu može biti u bilo kojem obliku, kao što je slobodan u otopini, vezan za čvrsti nosač, smješten na površini stanice ili unutar stanice. Onaj tko poznaje ovo područje tehnike može primjerice mjeriti nastajanje kompleksa između DmGPCR i spoja koji se ispituje. Alternativno, onaj tko poznaje ovo područje tehnike može ispitati umanjenje nastajanja kompleksa između DmGPCR i njegova supstrata što je izazvano spojem koji se ispituje.  The present invention is particularly useful for screening compounds using DmGPCR across a range of activity assays. A compound to be screened includes (which may include compounds expected to modulate DmGPCR activity), but is not limited to compounds of extracellular, intracellular, chemical or biological origin. The dmGPCR polypeptide used in such an assay can be in any form, such as free in solution, attached to a solid support, located on the cell surface, or inside the cell. One skilled in the art can, for example, measure the formation of a complex between DmGPCR and the compound being tested. Alternatively, one skilled in the art can examine the reduction of complex formation between the DmGPCR and its substrate induced by the test compound. 
 
 
   Aktivnost DmGPCR polipeptida ovog izuma može se primjerice odrediti ispitivanjem sposobnosti da se veže ili aktivira pomoću kemijski sintetiziranih peptidnih liganada. Alternativno, aktivnost DmGPCR-ova može se analizirati ispitivanjem njihove sposobnosti da vežu kalcijeve ione, hormone, kemokine, neuropeptide, neurotransmitere, nukleotide, lipide, odorante i fotone. Alternativno, aktivnost DmGPCR-ova može se odrediti ispitvanjem aktivnosti efektorskih molekula što uključuje, ali nije ograničeno na adeniat ciklazu, fosfolipaze i ionske kanale. Dakle, modulatori aktivnosti DmGPCR mogu promijeniti funkciju DmGPCR receptora, kao što je svojstvo vezanja receptora ili aktivnost kao što je prijenos signala kojim upravlja G protein ili membranska lokalizacija. U različitim realizacijama ovog izuma, analiza može biti u obliku analize ionskog fluksa, analize nehidrolizirajućeg GTP analiza kao što je analiza [35S]GTPγ5, analiza cAMP, analiza inozitol trifosfata, analiza diacilglicerola, analiza ekvorina (Aequorin), analiza luciferase, analiza FLJPR za unutarstaničnu koncentraciju Ca2+, analiza mitogeneze, analiza aktivnosti MAP kinaze, analiza otpuštanja arahidonske kiseline (npr. pomoću [3H]-arahidonske kiseline) i analiza brzine izvanstaničnog zakiseljavanja, kao i ostale vezujuće ili funkcionalno zasnovane analize aktivnosti DmGPCR koje su općenito poznate u tehnici. U nekoliko ovih realizacija, izumom su obuhvaćena uključivanja bilo kojih G proteina koji su poznati u tehnici, kao što su G16, G15 ili kimerni Gqj5, Gqs5, Gqo5, Gqz5 i slično. Aktivnost DmGPCR može se odrediti metodologijama koje se rabe za analizu aktivnosti FaRP, što je dobro poznato onima koji poznaju ovo područje tehnike. Biološke aktivnosti DmGPCR receptora sukladno ovom izumu obuhvaćaju, ali bez ograničenja: vezanje prirodnih ili umjetnih liganada, kao i bilo koju od funkcionalnih aktivnosti GPCR-ova poznatih u tehnici. Neograničavajući primjeri GPCR aktivnosti obuhvaćaju transmembransko signaliziranje različitih oblika, što može uključivati povezivanje G proteina i/ili ispoljavanje utjecaja na vezanje G proteina različitih guanidilatnih nukleotida. Drugi primjer aktivnosti GPCR-ova je vezanje pomoćnih proteina ili polipeptida koji se razlikuju od poznatih G proteina.  The activity of a DmGPCR polypeptide of the present invention can be determined, for example, by testing its ability to bind or activate chemically synthesized peptide ligands. Alternatively, the activity of DmGPCRs can be analyzed by examining their ability to bind calcium ions, hormones, chemokines, neuropeptides, neurotransmitters, nucleotides, lipids, odorants, and photons. Alternatively, the activity of DmGPCRs can be determined by assaying the activity of effector molecules including but not limited to adenate cyclase, phospholipases, and ion channels. Thus, modulators of DmGPCR activity can alter DmGPCR receptor function, such as receptor binding property or activity such as G protein-directed signal transduction or membrane localization. In various embodiments of the present invention, the assay may be in the form of an ion flux assay, a non-hydrolyzable GTP assay such as [35S]GTPγ5 assay, cAMP assay, inositol triphosphate assay, diacylglycerol assay, Aequorin assay, luciferase assay, FLJPR assay for intracellular Ca2+ concentration, mitogenesis assay, MAP kinase activity assay, arachidonic acid release assay (eg, using [3H]-arachidonic acid) and extracellular acidification rate assay, as well as other binding or functional-based assays of DmGPCR activity generally known in the art. In several of these embodiments, the invention includes the inclusion of any G proteins known in the art, such as G16, G15 or chimeric Gqj5, Gqs5, Gqo5, Gqz5 and the like. DmGPCR activity can be determined by methodologies used to analyze FaRP activity, which are well known to those skilled in the art. Biological activities of DmGPCR receptors according to this invention include, but are not limited to: binding of natural or artificial ligands, as well as any of the functional activities of GPCRs known in the art. Non-limiting examples of GPCR activity include transmembrane signaling of various forms, which may include binding to G proteins and/or exerting an effect on G protein binding of various guanidylate nucleotides. Another example of the activity of GPCRs is the binding of accessory proteins or polypeptides that differ from known G proteins. 
 
 
   Modulatori ovog izuma su različitih kemijskih struktura, koje se mogu općenito grupirati u nepeptidne mimetike prirodnih DmGPCR receptorskih liganada, peptidne i ne-peptidne alosteričke efektore DmGPCR receptora te peptide koji mogu djelovati kao aktivatori ili inhibitori (kompetitivni, dekompetitivni i nekompetitivni) (npr. antitijela) DmGPCR receptora. Ovaj izum ne ograničuje izvore odgovarajućih modulatora, koji se mogu dobiti iz prirodnih izvora kao što su biljke, životinje i mineralni ekstrakti ili umjetni izvori kao što su biblioteke malenih molekula, uključujući produkte kombinatornih kemijskih pristupa izgradnji biblioteka i peptidnim bibliotekama. Primjeri peptidnih modulatora DmGPCR receptora pokazuju sljedeće primarne strukture: GLGPRPLRFamid (sekv. br. 49), GNSFLRFamid (sekv. br. 136), GGPQGPLRFamid (sekv. br. 102), GPSGPLRFamid (sekv. br. 103), PDVDHVFLRFamid (sekv. br. 150) i piro-EDVDHVFLRFamid (sekv. br. 167).  The modulators of this invention are of different chemical structures, which can generally be grouped into non-peptide mimetics of natural DmGPCR receptor ligands, peptide and non-peptide allosteric effectors of DmGPCR receptors, and peptides that can act as activators or inhibitors (competitive, decompetitive and non-competitive) (e.g. antibodies ) of DmGPCR receptors. The present invention does not limit the sources of suitable modulators, which may be obtained from natural sources such as plant, animal and mineral extracts or artificial sources such as small molecule libraries, including products of combinatorial chemical approaches to library construction and peptide libraries. Examples of DmGPCR receptor peptide modulators show the following primary structures: GLGPRPLRFamide (SEQ ID NO: 49), GNSFLRFamide (SEQ ID NO: 136), GGPQGPLRAFamide (SEQ ID NO: 102), GPSGPLRFamide (SEQ ID NO: 103), PDVDHVFLRFamide (SEQ ID NO: 103). no. 150) and pyro-EDVDHVFLRFamide (seq. no. 167). 
 
 
   Za ispitivanje enzimske aktivnosti mogu se koristiti druge analize što obuhvaća, ali bez ograničenja fotometrijske, radiometrijske, HPLC, elektrokemijske i slične, što je primjerice opisano u Enzyme Assays: Practical Approach, eds. R. Eisenthal and M. J. Danson, 1992, Oxford University Press, što je ovdje uključeno kao referenca u cijelosti.  Other assays may be used to test enzyme activity, including, but not limited to, photometric, radiometric, HPLC, electrochemical, and the like, as described for example in Enzyme Assays: Practical Approach, eds. R. Eisenthal and M. J. Danson, 1992, Oxford University Press , which is incorporated herein by reference in its entirety. 
 
 
   Korištenje cDNA koje kodiraju GPCR-ove u analizi aktivnosti dobro je poznato. Analize kojima se može ispitati tisuće nepoznatih spojeva dnevno u ‘high-throughput screens’ analizama (HTS-ovi) su detaljno dokumentirane. U literaturi se mogu naći primjeri upotrebe radioobilježenih liganada u HTS vezujućim analizama u otkrivanju lijeka (vidi Williams, Medicinal Research Reviews, 1991, 11, 147-184; Sweetnam, et al, J. Natural Products, 1993, 56, 441-455 za pregled). Rekombinantni receptori poželjni su za HTS vezujuću analizu jer omogućuju bolju specifičnost (veća relativna čistoća), čime se postiže sposobnost da se generiraju velike količine receptorskog materijala koji se može koristiti u cijelom nizu formata (vidi Hodgson, Bio/Technology, 1992,10, 973-980, uključeno ovdje kao referenca u cijelosti).  The use of cDNAs encoding GPCRs in activity analysis is well known. Analyzes capable of testing thousands of unknown compounds per day in high-throughput screens (HTSs) are documented in detail. Examples of the use of radiolabeled ligands in HTS binding assays in drug discovery can be found in the literature (see Williams, Medicinal Research Reviews, 1991, 11, 147-184; Sweetnam, et al, J. Natural Products, 1993, 56, 441-455 for review). Recombinant receptors are preferred for HTS binding assays because they allow for better specificity (higher relative purity), thereby enabling the ability to generate large quantities of receptor material that can be used in a variety of formats (see Hodgson, Bio/Technology, 1992, 10, 973 -980, incorporated herein by reference in its entirety). 
 
 
   Postoje brojni heterologni sustavi za funkcionalnu ekspresiju rekombinantnih receptora što je dobro poznato onima koji poznaju ovo područje. Takvi sustavi obuhvaćaju bakterije (Strosberg, et al, Trends in Pharmacological Sciences, 1992, 13, 95-98), kvasce (Pausch, Trends in Biotechnology, 1997, 15, 487-494), nekoliko vrsta insektnih stanica (Vanden Broeck, Int. Rev. Cytology, 1996,164, 189-268), amfibijske stanice (Jayawickreme et al, Curr. Opin. Biotechnol, 1997, 8, 629-634) i nekoliko staničnih linija sisavaca (CHO, HEK293, COS, itd., vidi Gerhardt, et al, Eur. J. Pharmacology, 1997, 334, 1-23). Ovi primjeri ne isključuju korištenje drugih mogućih sustava stanične ekspresije, uključujući stanične linije koje su dobivene iz nematoda (PCT prijava WO 98/37177).  Numerous heterologous systems exist for the functional expression of recombinant receptors as are well known to those skilled in the art. Such systems include bacteria (Strosberg, et al, Trends in Pharmacological Sciences, 1992, 13, 95-98), yeasts (Pausch, Trends in Biotechnology, 1997, 15, 487-494), several types of insect cells (Vanden Broeck, Int Rev. Cytology, 1996, 164, 189-268), amphibian cells (Jayawickreme et al, Curr. Opin. Biotechnol, 1997, 8, 629-634) and several mammalian cell lines (CHO, HEK293, COS, etc., see Gerhardt, et al, Eur. J. Pharmacology, 1997, 334, 1-23). These examples do not preclude the use of other possible cell expression systems, including cell lines derived from nematodes (PCT application WO 98/37177). 
 
 
   U nekim realizacijama ovog izuma, metode za screening spojeva koji moduliraju aktivnost DmGPCR uključuju dovođenje u međusoban dodir ispitivanih spojeva s DmGPCR te analizu na prisutnost kompleksa spoja i DmGPCR. U takvoj analizi, ligand je tipično obilježen. Nakon odgovarajućeg inkubiranja, slobodni ligand se odvaja od vezanoga te je količina slobodnog ili nekompleksiranoga mjera sposobnosti određenog spoja da se veže za DmGPCR.  In some embodiments of the present invention, methods for screening compounds that modulate DmGPCR activity include contacting the test compounds with DmGPCR and analyzing for the presence of a complex of the compound and DmGPCR. In such an analysis, the ligand is typically labeled. After appropriate incubation, the free ligand is separated from the bound one, and the amount of free or uncomplexed is a measure of the ability of a particular compound to bind to DmGPCR. 
 
 
   Poznato je da aktiviranje heterolognih receptora s ekspresijom u rekombinantnim sustavima rezultira cijelim nizom bioloških odgovora, koji su upravljani G proteinima s ekspresijom u stanicama domaćina. Zauzeće GPCR od strane agonista rezultira izmjenom vezanog GDP za GTP na mjestu vezanja G� podjedinice. Može se koristiti radioaktivni, nehidrolizirajući derivat GTP, [35S]GTPγ5, da bi se izmjerilo vezanje određenog agonista za receptor (Sim et al., Neuroreport, 1996, 7, 729-733). Ovo vezanje se može također koristiti da bi se izmjerila sposobnost antagonista da se veže za receptor smanjenjem vezanja [35S]GTP-γS u prisutnosti poznatog agonista. Može se dakle oblikovati HTS analiza zasnovana na vezanju [35S]GTPγS.  It is known that the activation of heterologous receptors with expression in recombinant systems results in a whole series of biological responses, which are directed by G proteins with expression in host cells. Occupancy of a GPCR by an agonist results in the exchange of bound GDP for GTP at the binding site of the G� subunit. A radioactive, non-hydrolyzable derivative of GTP, [35S]GTPγ5, can be used to measure the binding of a particular agonist to the receptor (Sim et al., Neuroreport, 1996, 7, 729-733). This binding can also be used to measure the ability of an antagonist to bind to a receptor by reducing the binding of [35S]GTP-γS in the presence of a known agonist. An HTS assay based on [35S]GTPγS binding can therefore be designed. 
 
 
   G proteini koji su nužni za funkcionalnu ekspresiju heterolognih GPCR-ova mogu biti nativni konstituenti stanice domaćina ili mogu biti uneseni dobro poznatom rekombinantnom tehnologijom. G proteini mogu biti intaktni ili kimerni. Često se rabi gotovo univerzalni kompetentni G protein (npr. G�i6) za vezanje bilo kojeg danog receptora za detektibilni put odgovora. Aktiviranje G proteina rezultira stimuliranjem ili inhibiranjem drugih nativnih proteina, efektima koji se mogu povezati za mjerljivi odgovor.  G proteins that are necessary for the functional expression of heterologous GPCRs can be native constituents of the host cell or can be introduced by well-known recombinant technology. G proteins can be intact or chimeric. An almost universally competent G protein (eg, G�i6) is often used to bind any given receptor to a detectable response pathway. Activation of G proteins results in stimulation or inhibition of other native proteins, effects that can be linked to a measurable response. 
 
 
   Primjeri takvih bioloških odgovora obuhvaćaju, ali nisu ograničeni na sljedeće: sposobnost preživljavanja u odsutnosti ograničavajućeg nutrienta u posebno inženjerski oblikovanih kvaščevih stanica (Pausch, Trends in Biotechnology, 1997, 15, 487-494); promjene unutarstanične koncentracije Ca2+ koja se mjeri pomoću fluorescentnih boja (Murphy, et al., Curr. Opm. Drug Disc. Dev., 1998, 1, 192-199). Promjene fluorescencije mogu se također koristiti za praćenje ligandom izazvanih promjena membranskog potencijala ili unutarstaničnog pH. U tu svrhu načinjen je i opisan automatiziran sustav za HTS (Schroeder, et al., J. Biomolecular Screening, 1996, 1, 75-80). Melanofori priređeni iz Xenopus laevis pokazuju promjene pigmentne organizacije kao odgovor na heterologno GPCR aktiviranje. Ovaj odgovor prilagodljiv je na HTS formate (Jayawickreme, et al., Curr. Opin. Biotechnol., 1997, 8, 629-634). Postoje također analize za mjerenje standardnih sekundarnih glasnika, uključujući cAMP, fosfoinozitide i arahidonsku kiselinu.  Examples of such biological responses include, but are not limited to: the ability to survive in the absence of a limiting nutrient in specially engineered yeast cells (Pausch, Trends in Biotechnology, 1997, 15, 487-494); changes in intracellular Ca2+ concentration measured using fluorescent dyes (Murphy, et al., Curr. Opm. Drug Disc. Dev., 1998, 1, 192-199). Fluorescence changes can also be used to monitor ligand-induced changes in membrane potential or intracellular pH. For this purpose, an automated system for HTS was developed and described (Schroeder, et al., J. Biomolecular Screening, 1996, 1, 75-80). Melanophores prepared from Xenopus laevis show changes in pigment organization in response to heterologous GPCR activation. This response is adaptable to HTS formats (Jayawickreme, et al., Curr. Opin. Biotechnol., 1997, 8, 629-634). There are also assays to measure standard second messengers, including cAMP, phosphoinositides, and arachidonic acid. 
 
 
   Metode HTS koje koriste ove receptore uključuju permanentno transficirane CHO stanice, u kojima se agonisti i antagonisti mogu identificirati pomoću sposobnosti da specifično mijenjaju vezanje [35S]GTPγS u membranama koje su priređene iz ovih stanica. U drugoj realizaciji ovog izuma, permanentno transficirane CHO stanice mogu se koristiti za priređivanje membrana koje sadrže značajne količine rekombinnantnih receptorskih proteina. Ovi membranski pripravci mogu se zatim koristiti u receptorskim vezujućim analizama, korištenjem radioobilježenog liganda koji je specifičan za konkretni receptor. Alternativno, funkcionalna analiza, kao što je fluorescentno praćenje ligandom izazvanih promjena unutrašnje Ca2+ koncentracije ili membranskog potencijala u permanentno transficiranim CHO stanicama koje sadrže svaki od ovih receptora pojedinačno ili u kombinaciji može biti korisna za HTS. Jednako koristan može biti alternativni tip stanice sisavaca, kao što su HEK293 ili COS stanice, u sličnim formatima. Permanentno transficirane linije insektnih stanica, kao što su Drosophila S2 stanice i rekombinantne kvaščeve stanice koje svrše ekspresiju Drosophila melanogaster receptora u HTS formatima dobro su poznate onima koji poznaju ovo područje tehnike (npr. Pausch, Trends in Biotechnology, 1997, 75, 487-494), što može također biti korisno u ovom izumu.  HTS methods using these receptors involve permanently transfected CHO cells, in which agonists and antagonists can be identified by their ability to specifically alter [35S]GTPγS binding in membranes prepared from these cells. In another embodiment of the present invention, permanently transfected CHO cells can be used to prepare membranes containing significant amounts of recombinant receptor proteins. These membrane preparations can then be used in receptor binding assays, using a radiolabeled ligand that is specific for that particular receptor. Alternatively, functional analysis such as fluorescent monitoring of ligand-induced changes in internal Ca2+ concentration or membrane potential in permanently transfected CHO cells containing each of these receptors individually or in combination may be useful for HTS. An alternative mammalian cell type, such as HEK293 or COS cells, in similar formats may be equally useful. Permanently transfected insect cell lines, such as Drosophila S2 cells and recombinant yeast cells expressing the Drosophila melanogaster receptor in HTS formats are well known to those skilled in the art (eg, Pausch, Trends in Biotechnology, 1997, 75, 487-494 ), which may also be useful in this invention. 
 
 
   Ovaj izum podrazumijeva više analiza za screening i identificiranje inhibitora ligandnog vezanja za DmGPCR receptore. U jednom primjeru, DmGPCR receptor je imobiliziran i interakcija s vezujućim partnerom vrši se u prisutnosti i odsutnosti kandidatskog modulatora kao što je inhibitorski spoj. U sljedećem primjeru, interakcija između DmGPCR receptora i njegova vezujućeg partnera vrši se u tekućoj analizi, u prisutnosti i odsutnosti kandidatskog inhibitorskog spoja. U bilo kojoj analizi, inhibitor se identificira kao spoj koji smanjuje vezanje između DmGPCR receptora i njegova vezujućeg partnera. Sljedeća analiza koja se podrazumijeva uključuje inačicu dvohibridne analize pri čemu se inhibitor protein/protein interakcija identificira detektiranjem pozitivnog signala u transformiranoj i transficiranoj stanici domaćina, kao što je opisano u PCT publikaciji br. WO 95/20652, publicirano 3. kolovoza 1995.  The present invention involves multiple assays for screening and identifying inhibitors of ligand binding to DmGPCR receptors. In one example, the DmGPCR receptor is immobilized and the interaction with the binding partner is performed in the presence and absence of a candidate modulator such as an inhibitory compound. In the following example, the interaction between a DmGPCR receptor and its binding partner is performed in a run-on assay, in the presence and absence of a candidate inhibitory compound. In any assay, an inhibitor is identified as a compound that reduces binding between a DmGPCR receptor and its binding partner. The next assay implied involves a version of the two-hybrid assay wherein the protein/protein interaction inhibitor is identified by detecting a positive signal in the transformed and transfected host cell, as described in PCT Publication No. WO 95/20652, published August 3, 1995. 
 
 
   Kandidatski modulatori koji se podrazumijevaju ovim izumom uključuju spojevi koji su odabrani iz biblioteka bilo potencijalnih aktivatora ili potencijalnih inhibitora. Postoji određen broj različitih biblioteka koje se rabe za identificiranje modulatora malenih molekula, uključujući: (1) kemijske biblioteke, (2) biblioteke prirodnih produkata i (3) kombinacijske biblioteke koje sadrže slučajne peptide, oligonukleotide ili organske molekule. Kemijske biblioteke sastoje se od slučajnih kemijskih struktura, a neke od njih su analozi poznatih spojeva ili analozi spojeva koji su identificirani kao “hitovi” ili “vodeći” u drugom screening-u otkrivanja lijekova, neki od njih su izvedeni iz prirodnih produkata dok se neki javljaju u neusmjerneoj sintetskoj organskoj kemiji. Biblioteke prirodnih produkata su zbirke mikroorganizama, životinja, bilja ili morskih organizama koji se koriste da se načine smjese za screening pomoću: (1) fermentiranja i ekstrakcije iz tla, biljaka ili morskih mikroorganizama ili (2) ekstrahiranja bilja i morskih organizama. Biblioteke prirodnih produkata uključuju poliketide, neribosomske peptide i njihove inačice (kojih nema u prirodi). Za pregled, vidi Science, 1998, 282, 63-68. Kombinacijske biblioteke sastavljene su od velikog broja peptida, oligonukleotida ili organskih spojeva kao smjese. Ove biblioteke je razmjerno lako načiniti metodama tradicionalne automatizirane sinteze, PCR, kloniranjem ili pogodnim sintetskim metodama. Od osobita značaja su nepeptidne kombinacijske biblioteke. Ostale biblioteke od interesa uključuju peptide, protein,e peptidomimetike, višeparalelnu sintetsku zbirku, rekombinatorne i polipeptidne biblioteke. Za prikaz kombinatorne kemije i biblioteka koje su načinjene iz njih vidi Myers, Curr. Opin. Biotechnol., 1997, 8, 701-707. Identificiranje modulatora putem upotrebe različitih biblioteka koje je ovdje opisano omogućuje modificiranje kandidatskih “hitova” (ili “vodiča”) da bi se optimizirao kapacitet “hita” da modulira aktivnost.  Candidate modulators contemplated by the present invention include compounds selected from libraries of either potential activators or potential inhibitors. There are a number of different libraries used to identify small molecule modulators, including: (1) chemical libraries, (2) natural product libraries, and (3) combinatorial libraries containing random peptides, oligonucleotides, or organic molecules. Chemical libraries consist of random chemical structures, and some of them are analogs of known compounds or analogs of compounds that have been identified as "hits" or "leads" in other drug discovery screenings, some of them are derived from natural products, while some occur in non-directional synthetic organic chemistry. Natural product libraries are collections of microorganisms, animals, plants, or marine organisms that are used to prepare mixtures for screening by: (1) fermentation and extraction from soil, plants, or marine microorganisms, or (2) extraction of plants and marine organisms. Natural product libraries include polyketides, non-ribosomal peptides and their variants (not found in nature). For review, see Science, 1998, 282, 63-68. Combinatorial libraries are composed of a large number of peptides, oligonucleotides or organic compounds as a mixture. These libraries are relatively easy to make using traditional automated synthesis methods, PCR, cloning, or convenient synthetic methods. Of particular importance are non-peptide combinatorial libraries. Other libraries of interest include peptide, protein, and peptidomimetics, multi-parallel synthetic library, recombinant and polypeptide libraries. For an overview of combinatorial chemistry and libraries made from it, see Myers, Curr. Opin. Biotechnol., 1997, 8, 701-707. Identifying modulators through the use of the various libraries described herein allows candidate “hits” (or “guides”) to be modified to optimize the capacity of the “hit” to modulate activity. 
 
 
   I drugi kandidatski inhibitori podrazumijevaju se ovim izumom i oni mogu biti oblikovani te uključuju topljive oblike vezujućih partnera, kao i takve vezujuće partnere kao kimerne ili sjedinjene proteine. Pojam „vezujući partner“ kako se ovdje rabi u širem smislu obuhvaća nepeptidne modulatore, kao i takve peptidne modulatore kao što su neuropeptidi koji nisu prirodni ligandi, antitijela, fragmenti antitijela i modificirani spojevi koji sadrže domene antitijela koje su imunospecifične za ekspresijski produkt identificiranog DmGPCR gen.  Other candidate inhibitors are contemplated by the present invention and may be designed to include soluble forms of binding partners, as well as such binding partners as chimeric or fusion proteins. The term "binding partner" as used herein broadly includes non-peptide modulators, as well as such peptide modulators as neuropeptides that are not natural ligands, antibodies, antibody fragments, and modified compounds containing antibody domains that are immunospecific for the expression product of the identified DmGPCR gene . 
 
 
   U drugim realizacijama ovog izuma, polipeptidi ovog izuma koriste se kao istraživačko pomagalo za identificiranje, karakteriziranje i pročišćavanje interakcijskih, regulacijskih proteina. Odgovarajuće oznake ugrađene su u polipeptide ovog izuma pomoću različitih metoda koje su poznate u tehnici i polipeptidi se koriste za hvatanje interakcijskih molekula. Primjerice, molekule se inkubiraju s obilježnim polipeptidima, ispiru da se uklone nevezani polipeptidi i kvantificira se polipeptidni kompleks. Podaci koji su dobiveni korištenjem različitih koncentracija polipeptida koriste se za izračunavanje vrijednosti za broj, afinitet i povezivanje polipeptida s proteinskim kompleksom.  In other embodiments of the present invention, the polypeptides of the present invention are used as a research tool to identify, characterize, and purify interacting, regulatory proteins. Appropriate tags are incorporated into the polypeptides of the present invention using various methods known in the art and the polypeptides are used to capture interacting molecules. For example, molecules are incubated with labeled polypeptides, washed to remove unbound polypeptides, and the polypeptide complex is quantified. Data obtained using different concentrations of polypeptides are used to calculate values for the number, affinity, and binding of polypeptides to the protein complex. 
 
 
   Obilježenoi polipeptidi su također korisni kao reagensi za pročišćenje molekula s kojima su polipeptidi u interakciji uključujući, ali bez ograničenja, inhibitore. U jednoj realizaciji afinitetnog pročišćavanja, polipeptid je kovalentno vezan za kromatografsku kolonu. Stanice i njihove membrane su ekstrahirani i različite stanične podkomponente su propuštene kroz kolonu. Molekule se vežu za kolonu sukladno njihovu afinitetu za polipeptid. Polipeptidni kompleks se skida s kolone, disocira i obnovljena kolona podvrgava se proteinskom sekvenciranju. Aminokiselinska sekvencija se zatim koristi za identificiranje uhvaćene molekule ili da se oblikuju degenerirani oligonukleotidi za kloniranje odgovarajućeg gena iz pripadne cDNA biblioteke.  Labeled polypeptides are also useful as reagents for the purification of molecules with which the polypeptides interact, including, but not limited to, inhibitors. In one embodiment of affinity purification, the polypeptide is covalently attached to a chromatographic column. The cells and their membranes were extracted and the various cellular subcomponents were passed through the column. Molecules bind to the column according to their affinity for the polypeptide. The polypeptide complex is removed from the column, dissociated and the recovered column is subjected to protein sequencing. The amino acid sequence is then used to identify the captured molecule or to design degenerate oligonucleotides to clone the corresponding gene from the corresponding cDNA library. 
 
 
   Alternativno, mogu biti identificirani spojevi koji pokazuju slična svojstva prema ligandu za DmGPCR ovog izuma, ali koji su manji i imaju dulje vrijeme poluživota nego endogeni ligand u čovječjem ili životinjskom tijelu. Kada je oblikovan organski spoj, molekula sukladno ovom izumu koristi se kao “vodeći” spoj. Oblikovanje mimetika za poznate farmaceutski aktivne spojeve dobro je poznati pristup u razvoju spojeva koji se temelje na ovim “vodećim” spojevima. Mimetičko oblikovanje, sinteza i ispitivanje općenito se koriste da se izbjegne slučajni screening velikog broja molekula na ciljno svojstvo. Štoviše, strukturni podaci koji su izvedeni iz analize izvedenih aminokiselinskih sekvencija koje su kodirane pomoću DNA ovog izuma korisni su za oblikovanje novih lijekova koji su specifičniji i koji prema tome imaju jaču farmakološku snagu.  Alternatively, compounds may be identified which exhibit similar properties to the DmGPCR ligand of the present invention, but which are smaller and have a longer half-life than the endogenous ligand in the human or animal body. When an organic compound is formed, a molecule according to the present invention is used as a "lead" compound. Designing mimetics for known pharmaceutically active compounds is a well-known approach in the development of compounds based on these "lead" compounds. Mimetic design, synthesis, and screening are generally used to avoid random screening of large numbers of molecules for a target property. Moreover, the structural data derived from analysis of the deduced amino acid sequences encoded by the DNA of the present invention is useful for designing new drugs that are more specific and thus have stronger pharmacological potency. 
 
 
   Uspoređivanje sekvencija proteina ovog izuma sa sekvencijama koje se nalaze u dostupnim bazama podataka pokazuju značajnu homologiju s transmembranskim dijelom G protein vezanih receptora. Prema tome, može se koristiti kompjutersko modeliranje da se razvije potencijalna tercijarna struktura proteina ovog izuma temeljem dostupnih informacija transmembranske domene drugih proteina. Dakle, mogu se oblikovati novi ligandi temeljem predviđene strukture DmGPCR.  Comparison of protein sequences of the present invention with sequences found in available databases show significant homology to the transmembrane portion of G protein-coupled receptors. Accordingly, computer modeling can be used to develop the potential tertiary structure of proteins of the present invention based on available transmembrane domain information of other proteins. Thus, new ligands can be designed based on the predicted structure of DmGPCR. 
 
 
   U konkretnoj realizaciji, nove molekule koje su identificirane pomoću screening metoda sukladno ovom izumu su niskomolekularne organske molekule, pri čemu se mogu prirediti smjese ili farmaceutske smjese za oralno unošenje, kao što su tablete. Smjese ili farmaceutske smjese, koje sadrže molekule organskih kiselina, vektore, polipeptide, antitijela i spojeve identificirane su pomoću screening metoda koje su ovdje opisane, koje su priređene za bilo koji način primjene uključujući, ali bez ograničenja, oralni, intravenski, kutani, supkutani, nazalni, intramuskularni ili intraperitonealni. Priroda nosača ili drugih sastojaka ovisi o specifičnom putu primjene i konkretnoj realizaciji izuma koja se primjenjuje. Primjeri tehnika i protokola koji se rabe u ovom kontekstu mogu se između ostalog naći u: Remington’s Pharmaceutical Sciences, Osol, (ed.), 1980, što je ovdje uključeno kao referenca u cijelosti.  In a specific embodiment, the new molecules identified using screening methods according to this invention are low molecular weight organic molecules, whereby mixtures or pharmaceutical mixtures for oral administration, such as tablets, can be prepared. Mixtures or pharmaceutical compositions, containing organic acid molecules, vectors, polypeptides, antibodies and compounds identified using the screening methods described herein, are prepared for any route of administration including, but not limited to, oral, intravenous, cutaneous, subcutaneous, nasal, intramuscular or intraperitoneal. The nature of the carrier or other ingredients depends on the specific route of administration and the particular embodiment of the invention being applied. Examples of techniques and protocols used in this context can be found, inter alia, in: Remington's Pharmaceutical Sciences, Osol, (ed.), 1980, which is incorporated herein by reference in its entirety. 
 
 
   Doziranje ovih niskomolekularnih spojeva ovisi o stanju bolesti ili stanju koje se tretira i drugim kliničkim čimbenicima, kao što je težina i stanje subjekta koji se tretira i putu primjene spoja. Za tretiranje životinja, primjenjuje se približno između 0,5 mg/kg tjelesne težine to 500 mg/kg tjelesne težine spoja. Terapija se tipično primjenjuje uz niže doze sve dok se ne uoči željeni terapijski učinak.  The dosage of these low molecular weight compounds depends on the disease state or condition being treated and other clinical factors, such as the weight and condition of the subject being treated and the route of administration of the compound. For the treatment of animals, approximately between 0.5 mg/kg body weight and 500 mg/kg body weight of the compound is applied. Therapy is typically administered at lower doses until the desired therapeutic effect is observed. 
 
 
   Metode za određivanje doziranja spojeva koji se primjenjuju subjektu i načina primjene spojeva nekom organizmu opisane su u američkoj patentnoj prijavi br. 08/702,282, podnesenoj 23. kolovoza 1996. i međunarodnoj patentnoj publikaciji br. WO 96/22976, tiskanoj 1. kolovoza 1996., a obje su ovdje uključene kao referenca u cijelosti, uključujući sve crteže, slike i tablice. Oni koji poznaju ovo područje tehnike znaku da se takvi opisi mogu primijeniti na ovaj izum i lako se mogu prilagoditi.  Methods for determining the dosage of compounds to be administered to a subject and the method of administration of compounds to an organism are described in US patent application no. 08/702,282, filed August 23, 1996, and International Patent Publication No. WO 96/22976, printed Aug. 1, 1996, both of which are incorporated herein by reference in their entirety, including all drawings, figures, and tables. Those skilled in the art will appreciate that such descriptions are applicable to the present invention and may be readily adapted. 
 
 
   Pravilno doziranje ovisi o različitim čimbenicima kao što je tip bolesti koja se tretira, konkretna smjesa koja se koristi te veličina i fiziološko stanje subjekta. Terapijski učinkovite doze spojeva ovog izuma mogu se početno procijeniti iz stanične kulture i životinjskih modela. Primjerice, doza se može formulirati u životinjskim modelima da se postigne cirkulirajući koncentracijski raspon koji početno uzima u obzir IC50 koji je određen u analizi stanične kulture.  The correct dosage depends on various factors such as the type of disease being treated, the specific mixture used, and the size and physiological state of the subject. Therapeutically effective doses of the compounds of this invention can be initially estimated from cell culture and animal models. For example, a dose can be formulated in animal models to achieve a circulating concentration range that initially accounts for the IC50 determined in a cell culture assay. 
 
 
   Vrijeme poluživota plazme i biološka raspodjela lijeka i metabolita u plazmi, tumorima i glavnim organima mogu se također odrediti da se olakša izbor lijeka koji najviše odgovara da se zaustavi poremećaj. Mogu se izvršiti potrebna mjerenja. Primjerice, HPLC analiza može se izvršiti s plazmom životinja koje su tretirane lijekom i smještaj radioobilježenih lijekova može se odrediti korištenjem metoda detekcije kao što su rentgensko zračenje, CAT skeniranje i MRI. Spojevi koji pokazuju jaku aktivnost inhibiranja u screening analizama, ali imaju slaba farmakokinetička svojstva mogu se optimizirati promjenom kemijske strukture i ponovnim ispitivanjem. U tom smislu, spojevi koji pokazuju dobra farmakokinetička svojstva mogu se rabiti kao model.  The plasma half-life and biodistribution of drug and metabolites in plasma, tumors, and major organs can also be determined to facilitate the selection of the most appropriate drug to arrest the disorder. The necessary measurements can be made. For example, HPLC analysis can be performed on plasma from drug-treated animals and the location of radiolabeled drugs can be determined using detection methods such as X-rays, CAT scans, and MRI. Compounds that show strong inhibitory activity in screening assays but have weak pharmacokinetic properties can be optimized by changing the chemical structure and retesting. In this sense, compounds that show good pharmacokinetic properties can be used as a model. 
 
 
   Ispitivanje toksičnosti može se također izvršiti mjerenjem sastava krvnih stanica. Primjerice, ispitivanje toksičnosti može se izvršiti na pogodnom životinjskom modelu na sljedeći način: 1) spoj se primijeni miševima (također se koristi netretirani kontrolni miš); 2) krvni uzorci se periodički dobiju iz repne vene jednog miša iz svake tretirane skupine; i 3) uzorci se analiziraju na broj crvenih i bijelih krvnih stanica, sastav krvnih stanica i postotak limfocita u odnosu na polimorfonuklearne stanice. Prikazana je usporedba rezultata za svaki režim doziranja s kontrolama koje pokazuju ako je uočena toksičnost.  Toxicity testing can also be done by measuring blood cell composition. For example, toxicity testing can be performed on a suitable animal model as follows: 1) the compound is administered to mice (an untreated control mouse is also used); 2) blood samples are periodically obtained from the tail vein of one mouse from each treated group; and 3) samples are analyzed for red and white blood cell counts, blood cell composition, and the percentage of lymphocytes in relation to polymorphonuclear cells. A comparison of the results for each dosing regimen with controls is shown to indicate if toxicity was observed. 
 
 
   Na završetku svakog istraživanja toksičnosti, mogu se izvršiti daljnja istraživanja žrtvovanjem životinja (poželjno u skladu s naputkom društva American Veterinary Medical Association u izvješću: Report of the American Veterinary Medical Assoc. Panel on Euthanasia, J. Amer. Vet. Med. Assoc, 1993, 202, 229-249). Reprezentativne životinje iz svake tretirane skupine mogu se ispitati pomoću opsežne nekropsije na pojavu metastaza, neobičnih bolesti ili toksičnost. Abnormnalnosti u tkivu se bilježe i tkivo se histološki ispituje.  At the conclusion of each toxicity study, further studies can be performed by sacrificing animals (preferably in accordance with the American Veterinary Medical Association's guideline in the report: Report of the American Veterinary Medical Assoc. Panel on Euthanasia, J. Amer. Vet. Med. Assoc, 1993 , 202, 229-249). Representative animals from each treatment group can be examined by extensive necropsy for metastases, unusual diseases or toxicity. Abnormalities in the tissue are noted and the tissue is examined histologically. 
 
 
   Ovi spojevi i metode, uključujući molekule nukleinske kiseline, polipeptide, antitijela, te spojevi identificirani screening metodama koje su ovdje opisane, nalaze brojne farmaceutske i agrikulturne primjene (npr. insekticidne) te se primjerice mogu koristiti za tretiranje ili sprječavanje stanja izazvanih ektoparazitima ili za kontrolu populacije insekata.  These compounds and methods, including nucleic acid molecules, polypeptides, antibodies, and compounds identified by the screening methods described herein, find numerous pharmaceutical and agricultural applications (e.g., insecticidal) and can, for example, be used to treat or prevent conditions caused by ectoparasites or to control insect populations. 
 
 
   Ovaj izum također obuhvaća metode za agoniziranje (stimuliranje) ili antagoniziranje aktivnosti koja je povezana s prirodnim DmGPCR vezujućim partnerom u subjekta što obuhvaća primjenu navedenom subjektu određenog agonista ili antagonista jedom od prije opisanih polipeptida u količini koja je dovoljna da se izazove navedeni agonizam ili antagonizam. Prema tome, jedna realizacija ovog izuma je metoda tretiranja bolesti ili stanja subjekta izazvanih ektoparazitom, pomoću agonista ili antagonista subjekta u količini koja je dovoljna da se agonizira ili antagonizira ektoparazitne DmGPCR-pridružene funkcije.  This invention also includes methods for agonizing (stimulating) or antagonizing the activity associated with a natural DmGPCR binding partner in a subject, which comprises administering to said subject a certain agonist or antagonist with one of the previously described polypeptides in an amount sufficient to cause said agonism or antagonism. Accordingly, one embodiment of the present invention is a method of treating a disease or condition of a subject caused by an ectoparasite, using an agonist or antagonist of the subject in an amount sufficient to agonize or antagonize ectoparasite DmGPCR-associated functions. 
 
 
   U sljedećoj tablici 4 navedene su sekvencije polinukleotida i polipeptida ovog izuma.  The following Table 4 lists the sequences of the polynucleotides and polypeptides of the present invention. 
 
 
   [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image]  [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] 
 
 
   Sukladno s Budimpeštanskim tretmanom, klonovi ovog izuma su pohranjeni u zbirci Agricultural Research Culture Collection (NRRL) International Depository Authority, 1815 N. University Street, Peoria, Illinois 61604, U.S.A. Pristupni brojevi i datumo pohranjivanja su navedeni u tablici 5.  Pursuant to Budapest treatment, clones of this invention are deposited in the Agricultural Research Culture Collection (NRRL) International Depository Authority, 1815 N. University Street, Peoria, Illinois 61604, U.S.A. Accession numbers and date of storage are listed in Table 5. 
 
 
   Tablica 5  Table 5 
 
 
   [image]  [image] 
 
 
   Ovaj izum je nadalje ilustriran putem primjera koji slijede koji su namijenjeni rasvjetljavanju ovog izuma. Ovi primjeri nemaju za cilj i ne treba ih smatrati ograničenjem dosega ovog izuma. Jasno je da se ovaj izum može ostvariti na drugi način osim onoga koji je ovdje prikazan. Brojne modifikacije i varijacije ovog izuma su moguće sukladno činjenicama koje su ovdje iznesene, pa su prema tome unutar dosega ovog izuma.  This invention is further illustrated by way of the following examples which are intended to elucidate this invention. These examples are not intended and should not be considered as limiting the scope of the present invention. It is clear that this invention can be practiced in other ways than that shown here. Numerous modifications and variations of this invention are possible in accordance with the facts presented herein, and are therefore within the scope of this invention. 
 
 
   Podrazumijeva se da je svaki patent, prijava i tiskana publikacija koja je spomenuta u ovom dokumentu uključena kao referenca u cijelosti.  It is understood that each patent, application and printed publication mentioned herein is incorporated by reference in its entirety. 
 
 
   Primjeri  Examples 
 
 
   Primjer 1: Identificiranje DmGPCR-ova  Example 1: Identifying DmGPCRs 
 
 
   Celera genomska D. melanogaster baza podataka prevedena je u bazu podatka predviđenih proteina i mRNA bazu podataka korištenjem cijelog niza softverskih pomagala za pronalaženje gena da se predvide mRNA koje mogu nastati („PnuFlyPep“ baza podataka). Postupci za analiziranje genomskih baza podataka korištenjem softverskih pomagala za pronalaženje gena poznato je onima koji se bave ovim područjem tehnike.  The Celera genomic D. melanogaster database was translated into a predicted protein database and an mRNA database using a suite of gene discovery software tools to predict putative mRNAs (the "PnuFlyPep" database). Procedures for analyzing genomic databases using gene finding software tools are known to those skilled in the art. 
 
 
   Nukleotidne sekvencije nekoliko C. elegans FaRP GPCR-ova korištene su kao sekvencije za traženje mRNA baze podataka koja je prije opisana. Ova baza podataka pretraživana je na područja sličnosti korištenjem cijelog niza pomoćnih alata, uključujući FASTA i Gapped BLAST (Altschul et al., Nuc. Acids Res., 1997, 25, 3389, što je ovdje uključeno kao referenca u cijelosti).  The nucleotide sequences of several C. elegans FaRP GPCRs were used as sequences to search the mRNA database described previously. This database was searched for regions of similarity using a variety of utility tools, including FASTA and Gapped BLAST (Altschul et al., Nuc. Acids Res., 1997, 25, 3389, which is incorporated herein by reference in its entirety). 
 
 
   Ukratko, BLAST algoritam, što označava Basic Local Alignment Search Tool pogodan je za određivanje sekvencije sličnosti (Altschul et al, J. Mol. Biol., 1990, 215, 403-410, što je ovdje uključeno kao referenca u cijelosti). Softver za izvršenje BLAST analiza javno je dostupan putem National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov/). Ovaj algoritam prvo obuhvaća identificiranje sekvencijskih parova s visokim rangom (HSP-ova) identificiranjem kratkih riječi duljine W u sekvenciji za pretraživanje koja bilo odgovara ili zadovoljava nekim graničnim T pozitivnim vrijednostima kada se uskladi s riječi identične duljine u sekvencijskoj bazi podataka. T smo označili kao granicu skora susjedne riječi (Altschul et al., supra). Ovaj početni pogodak susjedne riječi služi kao klica za započinjanje potrage da se nađu HSP-vi koji ih sadrže. Pogođene riječi proširuju se u oba smjera duž svake sekvencije sve dok se kumulativni indeks usklađenosti može povećati. Produžetak za pogotke riječi u svakom smjesu zaustavlja se kada: 1) kumulativni skor sukladnosti pada za iznos X od njegove maksimalne dosegnute vrijednosti; 2) kumulativni skor pada na nulu ili niže, zbog akumuliranja jednog ili više poklapanja rezidua s negativnim skorom; ili 3) dosegnut je završetak sekvencije. Parametri Blast algoritma W, T i X određuju osjetljivost i brzinu usklađivanja. Blast program koristi podrazumijevanje duljine riječi (W) od 11, BLOSUM62 matrice skora (vidi Henikoff et al, Proc. Natl Acad. Sci. USA, 1992, 89, 10915-10919, što je ovdje uključeno kao referenca u cijelosti) usklađivanja (B) od 50, očekivanja (E) od 10, M=5, N=4 i uspoređivanjem obiju zavojnica.  Briefly, the BLAST algorithm, which stands for Basic Local Alignment Search Tool is suitable for determining sequence similarity (Altschul et al, J. Mol. Biol., 1990, 215, 403-410, which is incorporated herein by reference in its entirety). Software for performing BLAST analyzes is publicly available through the National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov/). This algorithm first involves identifying high-ranking sequence pairs (HSPs) by identifying short words of length W in the search sequence that either match or satisfy some threshold T positive values when matched against words of identical length in the sequence database. We denoted T as the adjacent word score limit (Altschul et al., supra). This initial adjacent word hit serves as the seed to begin the search to find HSPs that contain them. Hit words are extended in both directions along each sequence as long as the cumulative match index can be increased. The extension for word hits in each mixture stops when: 1) the cumulative conformity score falls by an amount X from its maximum value reached; 2) the cumulative score drops to zero or lower, due to the accumulation of one or more matching residuals with a negative score; or 3) the end of the sequence is reached. The parameters of the Blast algorithm W, T and X determine the sensitivity and speed of matching. The Blast program uses a word length (W) implication of 11, BLOSUM62 score matrix (see Henikoff et al, Proc. Natl Acad. Sci. USA, 1992, 89, 10915-10919, incorporated herein by reference in its entirety) alignments (B ) of 50, expectations (E) of 10, M=5, N=4 and comparing both coils. 
 
 
   BLAST algoritam (Karlin et al, Proc. Natl Acad. Sci. USA, 1993, 90, 5873-5787, što je ovdje uključeno kao referenca u cijelosti) i Gapped BLAST vrše statističku analizu sličnosti između dviju sekvencija. Jedna mjera sličnosti koja se dobiva BLAST algoritmom je najmanja suma (P(N)), koja definira naznaku vjerojatnosti kojom se može slučajno postići podudarnost dviju nukleotida ili aminokselinskih sekvencija. Primjerice, nukleinske kiseline smatraju se sličnim prema DmGPCR genu ili cDNA ako je najmanja suma vjerojatnosti pri uspoređivanju testne nukleinske kiseline prema DmGPCR nukleinskoj kiselini manja od oko 1, poželjno manja od oko 0,1, poželjnije manja od oko 0,01 i najpoželjnije manja od oko 0,001.  The BLAST algorithm (Karlin et al, Proc. Natl Acad. Sci. USA, 1993, 90, 5873-5787, which is incorporated herein by reference in its entirety) and Gapped BLAST perform a statistical analysis of the similarity between two sequences. One measure of similarity obtained by the BLAST algorithm is the smallest sum (P(N)), which defines an indication of the probability that two nucleotide or amino acid sequences can match by chance. For example, nucleic acids are considered similar to a DmGPCR gene or cDNA if the lowest sum of probabilities when comparing a test nucleic acid to a DmGPCR nucleic acid is less than about 1, preferably less than about 0.1, more preferably less than about 0.01, and most preferably less than about 0.001. 
 
 
   mRNA koje odgovaraju predviđenim proteinima preuzete su iz baze podataka predviđenih mRNA da se priredi PnuFlyPep baza podataka. One su identificirane kao sljedeće nukleotidne sekvencije: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21 i 23, od kojih svaka ima statistički značajno preklapanje homologije sa sekvencijom za pretraživanje. Nukleotidne sekvencije sa sljedećim sekvencijom brojevima: 3, 5, 9, 11, 13 i 15 (što odgovara DmGPCR-ovima 2a, 2b, 5a, 5b, 6a i 6b) dobivene su PCR kloniranjem i sekvenciranjem druge identificicirane sekvencije (nije prikazano). Svaka od ovih sekvencija predstavlja splice inačicu gena DmGPCR-a.  mRNAs corresponding to predicted proteins were retrieved from the database of predicted mRNAs to prepare the PnuFlyPep database. These were identified as the following nucleotide sequences: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, and 23, each having a statistically significant homology overlap with the search sequence. Nucleotide sequences with the following sequence numbers: 3, 5, 9, 11, 13 and 15 (corresponding to DmGPCRs 2a, 2b, 5a, 5b, 6a and 6b) were obtained by PCR cloning and sequencing of the second identified sequence (not shown). Each of these sequences represents a spliced version of the DmGPCR gene. 
 
 
   Primjer 2: Kloniranje DmGPCR-ova  Example 2: Cloning of DmGPCRs 
 
 
   Priređivanje cDNA  Preparation of cDNA 
 
 
   cDNA priređena je bilo iz zrele Drosophila melanogaster poli A+ RNA (Clontech Laboratories, Palo Alto, CA) ili zrele Drosophila melanogaster ukupne RNA (dolje). Da se dobije ukupna RNA, matična zaliha Drosophila melanogaster (Biological Supply Company, Burlington, NC) anestezirana je hlađenjem i 5 do 6 odraslih jedinki dodano je u posudu koja sadrži 10 ml H2O, 10 ml medija 4-24 Instant Drosophila Medium i 6 do 10 grain-a s aktivnog suhog kvasca (Biological Supply Company). Poliuretanski pjenasti čep stavljen je na kraj svake posude i mušice su inkubirani na sobnoj temperaturi tijekom 4 do 6 tjedana. Nakon zrelosti, posude su ohlađene i anestezirane mušice su stavljene 50 ml polipropilensku epruvetu koja je držana u tekućem dušiku. Zamrznute mušice su pohranjene na -70 ºC dok nisu usitnjene u tarioniku uz tekući dušik. Praškasto tkivo zajedno s nešto tekućeg dušika dekantirano je u 50 ml polipropilenske epruvete na suhi led. Nakon uparavanja tekućeg dušika, praškasto tkivo pohranjeno je na -70 ºC.  cDNA was prepared from either mature Drosophila melanogaster poly A+ RNA (Clontech Laboratories, Palo Alto, CA) or mature Drosophila melanogaster total RNA (bottom). To obtain total RNA, Drosophila melanogaster mother stock (Biological Supply Company, Burlington, NC) was anesthetized by chilling, and 5 to 6 adults were added to a dish containing 10 ml H2O, 10 ml 4-24 Instant Drosophila Medium, and 6 to 10 grains of active dry yeast (Biological Supply Company). A polyurethane foam plug was placed at the end of each container and the flies were incubated at room temperature for 4 to 6 weeks. After maturity, the containers were cooled and the anesthetized flies were placed in a 50 ml polypropylene tube that was kept in liquid nitrogen. The frozen flies were stored at -70 ºC until they were crushed in a crucible under liquid nitrogen. The powdered tissue together with some liquid nitrogen was decanted into a 50 ml polypropylene test tube on dry ice. After evaporation of liquid nitrogen, the powdered tissue was stored at -70 ºC. 
 
 
   Da se priredi RNA, 300 mg praškastog tkiva stavljeno je u polipropilensku epruvetu na suhi led i dodano je 5 ml 6 M guanidin hidroklorida u 0,1 M NaOAc, pH 5,2. Sve otopine bile su tretirane s DEPC ili priređene s DEPC-tretiranom dH2O i sav stakleni pribor je pečen ili je korišten sasvim novi plastični pribort, da se smanje problemi s RNaza kontaminiranjem. Epruvete su miješane na vorteks-mješaču pa stavljene na led. Praškasto tkivo je homogenizirano uzastopnim propuštanjem kroz igle veličine 20, 21 i 22. Epruvete su centrifugirane (1000×g tijekom 10 min), zatim je 2,5 do 3 ml supernatanta stavljeno na vrh 8 ml 5,7 M cezijeva klorida u 0,1 M NaOAc sadržanom u 14×95 mm Ultra-Clear epruveti za centrifugiranje (Beckman Instruments, Inc., Palo Alto, CA). Uzorci su centrifugirani na 25000 rpm tijekom 18 h na 18°C u L8-70 ultracentrifugi (Beckman Instruments, Inc.,). Supernatant je odliven pa je epruveta okrenuta i ostavljena da se ocijedi. Talog RNA suspendiran je u 200 ml RNaza-slobodnoj dH2O (Qiagen Inc., Valencia, CA), zatim ispran dva puta sa 100 ml RNaza-slobodnom dH2O (ukupno, 400 ml). RNA je staložena dodatkom 44 ml 3M NaOAc, pH 5,2 i 1 ml hladnog 100% etanola. Nakon držanja preko noći na -70ºC, epruveta je centrifugirana na 14000 rpm tijekom 1 h (Eppendorf microfuge 5402), isprana s 75% etanolom (priređen s DEPC-tretiranom dH2O), zatim je talog otopljen u RNaza-slobodnoj dH2O. Apsorbancije izmjerene na 260 ili 280 nm određene u 10 mM Tris-HCl, pH 7,5 korištene su za procjenu koncentracije i čistoće RNA.  To prepare RNA, 300 mg of powdered tissue was placed in a polypropylene tube on dry ice and 5 ml of 6 M guanidine hydrochloride in 0.1 M NaOAc, pH 5.2, was added. All solutions were DEPC-treated or prepared with DEPC-treated dH2O and all glassware was baked or brand new plasticware was used, to reduce problems with RNase contamination. The test tubes were mixed on a vortex mixer and placed on ice. Pulverized tissue was homogenized by sequentially passing it through 20-, 21-, and 22-gauge needles. The tubes were centrifuged (1000×g for 10 min), then 2.5 to 3 ml of the supernatant was placed on top of 8 ml of 5.7 M cesium chloride in 0, 1 M NaOAc contained in a 14×95 mm Ultra-Clear centrifuge tube (Beckman Instruments, Inc., Palo Alto, CA). Samples were centrifuged at 25,000 rpm for 18 h at 18°C in an L8-70 ultracentrifuge (Beckman Instruments, Inc.). The supernatant was poured off and the test tube was inverted and left to drain. The RNA pellet was suspended in 200 ml RNase-free dH2O (Qiagen Inc., Valencia, CA), then washed twice with 100 ml RNase-free dH2O (total, 400 ml). RNA was precipitated by adding 44 ml of 3M NaOAc, pH 5.2 and 1 ml of cold 100% ethanol. After keeping overnight at -70ºC, the tube was centrifuged at 14000 rpm for 1 h (Eppendorf microfuge 5402), washed with 75% ethanol (prepared with DEPC-treated dH2O), then the pellet was dissolved in RNase-free dH2O. Absorbances measured at 260 or 280 nm determined in 10 mM Tris-HCl, pH 7.5 were used to estimate RNA concentration and purity. 
 
 
   Prva zavojnica cDNA priređena je sukladno postupku koji je dostavljen sa Superscript II enzimom (GIBCO BRL, Rockville, MD). Bilo 500 ng (2 ml) poli A+ RNA ili 3 mg (4 ml) ukupne RNA dodano je u microfuge epruvete koje sadrže RNaza-slobodnu dH2O i 250 ng (2,5 ml) slučajnih primera. Epruvete (12 ml) su inkubirane na 70 ºC tijekom 10 min, ohlađene na ledu, pa je dodano 4 ml 5 ́ pufera prve zavojnice, 2 ml 0,1 M DTT i 1 ml mM dNTP smjese. Nakon inkubiranja na 25ºC tijekom 10 min, pa na 42ºC tijekom 2 min, dodan je 1 m1 (200 jedinica) Superscript II i nastavljeno je inkubiranjem na at 42ºC tijekom 50 min. Enzim je deaktiviran inkubiranjem na 70ºC tijekom 15 min. Da se ukloni RNA koja je komplementarna s cDNA, dodano je 2 ml (2 jedinice) RNaze H (Boehringer Mannheim, Indianapolis, IN), pa je nastavljeno inkubiranjem na 37ºC tijekom 20 min. cDNA pohranjena je na -20ºC.  First strand cDNA was prepared according to the procedure provided with Superscript II enzyme (GIBCO BRL, Rockville, MD). Either 500 ng (2 ml) of poly A+ RNA or 3 mg (4 ml) of total RNA was added to microfuge tubes containing RNase-free dH2O and 250 ng (2.5 ml) of random primers. Test tubes (12 ml) were incubated at 70 ºC for 10 min, cooled on ice, then 4 ml of 5 ́ buffer of the first coil, 2 ml of 0.1 M DTT and 1 ml of mM dNTP mixture were added. After incubation at 25ºC for 10 min, then at 42ºC for 2 min, 1 m1 (200 units) of Superscript II was added and continued incubation at 42ºC for 50 min. The enzyme was deactivated by incubating at 70ºC for 15 min. To remove RNA complementary to the cDNA, 2 ml (2 units) of RNase H (Boehringer Mannheim, Indianapolis, IN) was added, followed by incubation at 37ºC for 20 min. cDNA was stored at -20ºC. 
 
 
   PCR reakcije  PCR reactions 
 
 
   Bilo standardna 50/100 ml PCR reakcija ili Hot Start PCR reakcija, korištenjem Ampliwax kuglica (Perlcin Elmer Cetus, Norwalk, CT) korištena je za pojačavanje Drosophila melanogaster G protein-vezanog receptora (DmGPCR-ovi). Destilirana H2O korištena je za otapanje primera (Genosys Biotechnologies, Inc., The Woodlands, TX): 5’- i 3’- primeri pri konventraciji 10 μM, interni primeri sa 1 mM. Svaka PCR reakcija sadržavala je 2 do 4 jedinice rTth XL DNA polimeraze, 1,2 do 1,5 mM Mg(OAc)2, 200 mM svakog dNTP i 200 ili 400 nM svakog primera. Za Hot Start PCR, 32 ili 36 ml ‘nižeg’ koktela (dH2O, 3,3 ́ XL-buffer, dNTP i Mg(OAc)2 dodani su na 2 ili 4 ml svakog primer-a (ukupni volumen, 40 ml). Dodana je Ampliwax kuglica (Perkin Elmer Cetus), epruvete su inkubirane na 75ºC tijekom 5 min, ohlađene na sobnu temperaturu (RT), zatim je dodano 60 ml ‘višeg’ koktela (dH2O, 3,3 ́ XL-buffer, rTth i šablona). PCR pojačavanja izvršena su u termičkom cikleru Perkin Elmer Series 9600. Tipični program za termički cikler uključuje: 1 min na 94ºC, zatim 30 ciklus apojačavanja (0,5 min na 94ºC, 0,5 min na 60ºC, 2 min na 72ºC), zatim 6 min na 60ºC. Da bi se dobili 3’ A-privjesci na PCR produktu (‘repovi’), 1 ml Taq polimeraze (Invitrogen, Carlsbad, CA) dodano je na kraju PCR pojačavanja i epruvete su inkubirane na 72ºC tijekom 10 min. Reakcijske smjese su analizirane na 1% agaroza gelu koji je priređen u TAE puferu (5). PCR produkti su tipično pročišćeni korištenjem QIAquick kolona (QIAGEN).  Either a standard 50/100 ml PCR reaction or a Hot Start PCR reaction, using Ampliwax beads (Perlcin Elmer Cetus, Norwalk, CT) was used to amplify Drosophila melanogaster G protein-coupled receptors (DmGPCRs). Distilled H2O was used to dissolve primers (Genosys Biotechnologies, Inc., The Woodlands, TX): 5'- and 3'- primers at a concentration of 10 μM, internal primers at 1 mM. Each PCR reaction contained 2 to 4 units of rTth XL DNA polymerase, 1.2 to 1.5 mM Mg(OAc) 2 , 200 mM of each dNTP, and 200 or 400 nM of each primer. For Hot Start PCR, 32 or 36 ml of 'lower' cocktail (dH2O, 3.3 ́ XL-buffer, dNTP and Mg(OAc)2) were added to 2 or 4 ml of each primer (total volume, 40 ml). An Ampliwax bead (Perkin Elmer Cetus) was added, the tubes were incubated at 75ºC for 5 min, cooled to room temperature (RT), then 60 ml of 'higher' cocktail (dH2O, 3.3 ́ XL-buffer, rTth and template) was added ).PCR amplifications were performed in a Perkin Elmer Series 9600 thermal cycler. A typical thermal cycler program includes: 1 min at 94ºC, then 30 cycles of amplification (0.5 min at 94ºC, 0.5 min at 60ºC, 2 min at 72ºC) , then 6 min at 60ºC.To obtain 3' A-hangs on the PCR product ('tails'), 1 ml of Taq polymerase (Invitrogen, Carlsbad, CA) was added at the end of the PCR amplification and the tubes were incubated at 72ºC for 10 min Reaction mixtures were analyzed on a 1% agarose gel prepared in TAE buffer (5).PCR products were typically purified using QIAquick columns (QIAGEN). 
 
 
   Ligacija i transformiranje  Ligation and transformation 
 
 
   Ligacija svih PCR produkata u PCR 3.1 vektor (Invitrogen) i transformiranje ligatnih produkata u One Shot™ TOPI10F competentnu stanicu (Invitrogen) načinjeno je sukladno uputama proizvođača. Tranformanti koje treba skenirati na inserte su propagirani u LB juhu koji sadrži 50 mg ampicilin/ml. Kolonije s umecima identificirane su pomoću mini-prep vrenje-lizis plazmid postupka (5) ili pomoću ‘kolonija PCR’ postupka koji izravno pojačava plazmid DNA iz transformirane bakterije (6).  Ligation of all PCR products into the PCR 3.1 vector (Invitrogen) and transformation of the ligated products into One Shot™ TOPI10F competent cells (Invitrogen) was performed in accordance with the manufacturer's instructions. Transformants to be scanned for inserts were propagated in LB broth containing 50 mg ampicillin/ml. Colonies with inserts were identified using the mini-prep boiling-lysis plasmid procedure (5) or using a 'colony PCR' procedure that directly amplifies plasmid DNA from transformed bacteria (6). 
 
 
   Sekvenciranje DNA  DNA sequencing 
 
 
   DNA za sekvenciranje priređena je korištenjem Qiagen anionsko-izmjenjivačkim plazmid priborima (QIAGEN-tip 20) da se izdvoji DNA iz 5 ml LB kultura koje su rasle na 37ºC preko noći sukladno naputku proizvođača. Četiri primera (T7, M13 reverzni, ‘smisleni’ i ‘protivsmisleni’) se tipično koriste za sekvenciranje svake DNA (tablica 6). Koristi se kemija boja-terminatorskog sekvenciranja, bilo s BigDye ™ Terminator reagensima (Applied Biosystems, Foster City, CA) ili DYEnamic™ ET terminator priborom (Amersham Pharmacia Biotech, Inc., Piscataway, NJ). Za priređivanje sekvencirajućih reakcija slijedili smo naputke proizvođača. Primeri i neugrađeni nukleotidi uklonjeni su korištenjem Centri-Sep kolona (Princeton Separations, Adelphia, NJ). Reakcije sekvenciranja analizirane su na Applied Biosystems 377 automatiziranom DNA sekvenceru. DNA sekvencije su sastavljene i analizirane korištenjem sekvencera (Gene Codes, Ann Arbor, MI), GCG skupine programa za analizu sekvencija (Wisconsin Package Version 10.1, Genetics Computer Group (GCG), Madison, WI) i funkcija koje su raspoložive putem Vektor NTI 5.5 paketa programa (Mormax, Bethesda, MD).  DNA for sequencing was prepared using Qiagen anion-exchange plasmid kits (QIAGEN-type 20) to extract DNA from 5 ml LB cultures grown at 37ºC overnight according to the manufacturer's instructions. Four primers (T7, M13 reverse, 'sense' and 'antisense') are typically used to sequence each DNA (Table 6). Dye-terminator sequencing chemistry is used, either with BigDye™ Terminator reagents (Applied Biosystems, Foster City, CA) or DYEnamic™ ET terminator kit (Amersham Pharmacia Biotech, Inc., Piscataway, NJ). To prepare the sequencing reactions, we followed the manufacturer's instructions. Primers and unincorporated nucleotides were removed using Centri-Sep columns (Princeton Separations, Adelphia, NJ). Sequencing reactions were analyzed on an Applied Biosystems 377 automated DNA sequencer. DNA sequences were assembled and analyzed using a sequencer (Gene Codes, Ann Arbor, MI), GCG Group sequence analysis program (Wisconsin Package Version 10.1, Genetics Computer Group (GCG), Madison, WI) and functions available through Vektor NTI 5.5 program package (Mormax, Bethesda, MD). 
 
 
   Tablica 6. DNA sekvencirajući primeri  Table 6. DNA sequencing primers 
 
 
   [image]  [image] 
 
 
   Rezultati kloniranja i sekvenciranja DmGPCR-ova ovog izuma su sljedeći:  The results of cloning and sequencing of the DmGPCRs of this invention are as follows: 
 
 
   DmGPCR1  DmGPCR1 
 
 
   PCR primeri oblikovani za cDNA koja odgovara PnuFlyPep34651 korišteni su za uspješno pojačavanje PCR produkta iz cDNA pripravka koji je priređen iz Drosophila polyA+ mRNA. Dobiveni produkt je kloniran i sekvenciran. Eksperimentalno dobivena sekvencija identična je predviđenoj sekvenciji. Intaktni klon je dobiven i označen ‘DmGPCR1’.  PCR primers designed for cDNA corresponding to PnuFlyPep34651 were used to successfully amplify the PCR product from a cDNA preparation prepared from Drosophila polyA+ mRNA. The obtained product was cloned and sequenced. The experimentally obtained sequence is identical to the predicted sequence. An intact clone was obtained and designated 'DmGPCR1'. 
 
 
   DmGPCR2  DmGPCR2 
 
 
   Početni pokušaji da se pojača PCR produkt korištenjem primera koji su oblikovani prema cDNA koja odgovara PnuFlyPep67585 nisu bili uspješni. Usklađenost previđene sekvencije prema postojećim C. elegans receptorima i prema drugim neuropeptidnim receptorima pokazuje da je 5’ kraj previđene sekvencije neuobičajeno dugačak što ukazuje da može postojati pogreška u predikciji gena na toj strani. Korištenje genomske sekvencije kao vodiča, oblikovan je i ispitan cijeli niz alternativnih 5’ PCR primera. Jedna od ovih primer kombinacija, korištenjem cDNA koja je priređena iz ukupne RNA, bila je uspješna u dobivanju produkta prave veličine. Sekvenciranje klonova koji su izvedeni iz PCR reakcije pokazalo je da pojačani product sadrži predviđene 5’ i 3’ krajeve i da je identičan predviđenoj sekvenciji s izuzetkom da je u pretpostavljenoj sekvenciji nedostajao maleni segment od 6 aminokiselina. Uspoređivanje klonova je također pokazalo da postoje dvije isprepletene izoforme, jedna koja je slična predviđenoj sekvenciji (označeno ‘DmGPCR2a’) i druga kojoj nedostaje segment od 23 aminokiseline koja je smještena upravo nakon TM VII u unutarstaničnom C-terminalu molekule (označeno DmGPCR2b’).  Initial attempts to amplify the PCR product using primers designed to the cDNA corresponding to PnuFlyPep67585 were unsuccessful. Alignment of the overlooked sequence to existing C. elegans receptors and to other neuropeptide receptors shows that the 5' end of the overlooked sequence is unusually long, indicating that there may be an error in gene prediction on that side. Using the genomic sequence as a guide, a series of alternative 5' PCR primers were designed and tested. One of these primer combinations, using cDNA prepared from total RNA, was successful in obtaining a product of the correct size. Sequencing of the clones derived from the PCR reaction showed that the amplified product contained the predicted 5' and 3' ends and was identical to the predicted sequence with the exception that a small segment of 6 amino acids was missing from the predicted sequence. Comparison of the clones also showed that there are two spliced isoforms, one that is similar to the predicted sequence (designated 'DmGPCR2a') and another that lacks a 23 amino acid segment located just after TM VII in the intracellular C-terminus of the molecule (designated DmGPCR2b'). 
 
 
   DmGPCR3  DmGPCR3 
 
 
   Gen koji odgovara DmGPCR3 predviđenom proteinu već je poznat iz literature. Ovaj gen (GenBank pristupni broj M77168) opisan je kao NKD, „razvojem reguliran tahikininski receptor“. Monnier D, et al, J. Biol. Chem. 1992, 267(2), 1298-302. Uspoređivanje M77168 i PnuFlyPep68505 sekvencija pokazalo je da se previđene sekvencije značajno razlikuju od cDNA. cDNA imala je dulji 5’ kraj, nedostajao je ekson koji kodira 51 aminokiseline i bila je značajno kraća na 3’ kraju. PCR primeri su oblikovani prema puliciranoj sekvenciji i PCR produkt je dobiven korištenjem cDNA koja je priređena iz ukupne RNA. Ovaj produkt bio je identične strukture s publiciranom NKD sekvencijom.  The gene corresponding to the DmGPCR3 predicted protein is already known from the literature. This gene (GenBank accession number M77168) is described as NKD, "developmentally regulated tachykinin receptor". Monnier D, et al, J. Biol. Chem. 1992, 267(2), 1298-302. Comparison of the M77168 and PnuFlyPep68505 sequences showed that the overlooked sequences were significantly different from the cDNA. The cDNA had a longer 5' end, lacked an exon encoding 51 amino acids, and was significantly shorter at the 3' end. PCR primers were designed according to the published sequence and the PCR product was obtained using cDNA prepared from total RNA. This product was identical in structure to the published NKD sequence. 
 
 
   DmGPCR4  DmGPCR4 
 
 
   cDNA koja odgovara PnuFlyPep 67393 korištena je za oblikovanje PCR primera za pojačanje DmGPCR4. Korištenjem cDNA biblioteke koja je priređena iz ukupne Drosophila mRNA, priređen je i kloniran PCR produkt. Uspoređivanje klonova sa sekvencijom koja je predviđena pomoću PnuFlyPep pokazalo je da su sekvencije identične s izuzetkom da jedan ekson koji je previđen pomoću HMMGene nije bio prisutan u bilo kojem od kloniranih PCR produkata. DmGPCR4 je nedavno kloniran: Lenz et al, Biochem. Biophys. Res. Comm., 2000, 273, 571-577 i klasificiran je ako drugi potencijalni alatostatinski receptor.  The cDNA corresponding to PnuFlyPep 67393 was used to design PCR primers to amplify DmGPCR4. Using a cDNA library prepared from total Drosophila mRNA, a cloned PCR product was prepared. Comparison of the clones with the sequence predicted by PnuFlyPep showed that the sequences were identical with the exception that one exon overlooked by HMMGene was not present in any of the cloned PCR products. DmGPCR4 was recently cloned: Lenz et al, Biochem. Biophys. Crisp. Comm., 2000, 273, 571-577 and is classified as another potential allatostatin receptor. 
 
 
   DmGPCR-ovi-ovi  DmGPCRs 
 
 
   DmGPCR5 (FlyPepCG7887) netočno sadrži frameshift mutaciju. PnuFlyPep inačica, PnuFlyPep67522, koja je opisana u literaturi kao ‘Drosophila receptor za tahikinin-srodne peptide’ (M77168) (Li XJ, et al, EMBO Journal, 1991, 10(11), 3221-3229), ispravlja tu pogrešku ali netočno predviđa neke unutrašnje sekvencije i C-terminal. Na prvi pogled, predviđena cDNA koja odgovara PnuFlyPep proteinu bila je identična publiciranoj sekvenciji. PCR primeri korišteni su za uspješno pojačavanje PCR produkta odgovarajuće veličine iz cDNA smjese koja je priređena iz Drosophila melanogaster poli A+ mRNA. Sekvenciranje kloniranih PCR produkata pokazalo je da, premda je ukupna splicing slika identična, postoje dvije pogreške sekvenciranja u PnuFlyPep sekvenciji. Ove pogreške rezultiraju frameshift mutacijom nakon koje slijedi kompenzatorska frameshift mutacija što daje razliku od 13 aminokiselina između eksperimentalno nađenih i objelodanjenih sekvencija, polazeći od aminokiseline na položaju 46. Ovaj kloniran gen je označen ‘DmGPCR5a.’  DmGPCR5 (FlyPepCG7887) incorrectly contains a frameshift mutation. A PnuFlyPep variant, PnuFlyPep67522, which is described in the literature as 'Drosophila receptor for tachykinin-related peptides' (M77168) (Li XJ, et al, EMBO Journal, 1991, 10(11), 3221-3229), corrects that error but incorrectly predicts some internal sequences and the C-terminal. At first glance, the predicted cDNA corresponding to the PnuFlyPep protein was identical to the published sequence. PCR primers were used to successfully amplify a PCR product of the appropriate size from a cDNA mixture prepared from Drosophila melanogaster poly A+ mRNA. Sequencing of the cloned PCR products showed that, although the overall splicing pattern was identical, there were two sequencing errors in the PnuFlyPep sequence. These errors result in a frameshift mutation followed by a compensatory frameshift mutation that gives a difference of 13 amino acids between the experimentally found and published sequences, starting at amino acid position 46. This cloned gene is designated 'DmGPCR5a.' 
 
 
   Nadalje, splicing izoforme nađene su za DmGPCR5. Ova inačica kodira ekstra tri aminokiseline u N-terminalnoj izvanstaničnoj domeni. Ova inačica je označena ‘DmGPCR5b’.  Furthermore, splicing isoforms were found for DmGPCR5. This variant encodes an extra three amino acids in the N-terminal extracellular domain. This version is designated 'DmGPCR5b'. 
 
 
   DmGPCR6  DmGPCR6 
 
 
   GPCR koji odgovara PnuFlyPep15731 već je opisan u literature kao ‘neuropeptidni Y’ receptor (M81490. Li XJ, et al., J. Biol. Chem., 1992, 267(1), 9-12). PnuFlyPep-predviđena sekvencija razlikuje se od M81490 na oba kraja molekule. PnuFlyPep15731 sadrži ekstra 15 aminokiselinu na N-terminu u usporedbi s M81490. 3’ kraj PnuFlyPep 15731 također se razlikuje od M81490, bio je krnji i nije sadržavao konzervirane TM VI i TM VII rezidue.  The GPCR corresponding to PnuFlyPep15731 has already been described in the literature as a 'neuropeptide Y' receptor (M81490. Li XJ, et al., J. Biol. Chem., 1992, 267(1), 9-12). The PnuFlyPep-predicted sequence differs from M81490 at both ends of the molecule. PnuFlyPep15731 contains an extra 15 amino acids at the N-terminus compared to M81490. The 3' end of PnuFlyPep 15731 also differs from M81490, being truncated and lacking the conserved TM VI and TM VII residues. 
 
 
   Početni PCR primeri su oblikovani korištenjem sekvencije M81490. Korištenjem ovih primera i šablone koja je izvedena iz ukupne mRNA, dobiven je PCR produkt. Ispitivanje kloniranog PCR produkta pokazalo je da on koristi identičnu sliku onoj M81490. Ovaj klon je označen ‘DmGPCR6a’.  Initial PCR primers were designed using sequence M81490. Using these primers and a template derived from total mRNA, a PCR product was obtained. Examination of the cloned PCR product showed that it uses an identical image to that of M81490. This clone was designated 'DmGPCR6a'. 
 
 
   Tijekom kloniranja DmGPCR-a6a otkrivena je dodatna splicing izoforma. Ova izoforma generirana je upotrebom alternativnog splice akceptorskog mjesta da se generira alternativni 3’ kraj molekule korištenjem gotovo identične sekvencijske ‘6a’ forme ali u različitom okviru za čitanje. Nadalje, otvoreni okvir za čitanje za ovaj klon proširio je prošli izvorni 3’ PCR primer. Ispitivanje genomske sekvencije na 3’ kraju pokazalo je određen broj sličnih kandidatskih eksona. PCR primeri koji odgovaraju broju mogućih eksona su ispitani sve dok nije nađen jedan koji bi mogao pojačati PCR produkt. Ovaj produkt je označen ‘6b’. Ispitivanje genomske sekvencije također je predvidjelo da je inicijator ATG koji je predviđen pomoću PnuFlyPep 15731 bio in-frame s M81490 inicijacijski kodonom koji sadrži ekstra 15 aminokiselina i da je vjerojatno da je PnuFlyPep 15731 početni kodon bio autentičan startni kodon. Oblikovan je novi 5’ PCR primer koji ima ugrađen PnuFlyPep 15731 startni kodon i korišten je u sprezi s dva 3’ PCR primera za pojačavanje i kloniranje ‘DmGPCR6aL’ i ‘DmGPCR6bL’ (‘dugačak’).   During the cloning of DmGPCR-a6a, an additional splicing isoform was discovered. This isoform was generated using an alternative splice acceptor site to generate an alternative 3' end of the molecule using an almost identical sequence '6a' form but in a different reading frame. Furthermore, the open reading frame for this clone extended past the original 3' PCR primer. Examination of the genomic sequence at the 3' end revealed a certain number of similar candidate exons. PCR primers corresponding to the number of possible exons were tested until one was found that could amplify the PCR product. This product is marked '6b'. Examination of the genomic sequence also predicted that the initiator ATG predicted by PnuFlyPep 15731 was in-frame with the M81490 initiation codon containing an extra 15 amino acids and that it was likely that the PnuFlyPep 15731 start codon was the authentic start codon. A new 5' PCR primer incorporating the PnuFlyPep 15731 start codon was designed and used in conjunction with two 3' PCR primers to amplify and clone 'DmGPCR6aL' and 'DmGPCR6bL' ('long'). 
 
 
   DmGPCR7  DmGPCR7 
 
 
   Početni pokušaji da se pojača DmGPCR7 genski product bili su neuspješni. Poklapanje predviđene sekvencije (PnuFlyPep67863) s drugim GPCR-ovima ukazalo je na to da je greška vjerojatno bila u predviđanju 3’ kraja molekule. Predviđena sekvencija imala je 3’ kraj koji je bio daleko dulji nego onaj od većine drugih GPCR-ova. Ispitivanje genomske sekvencije ukazalo je da je vjerojatna pogreška u predviđanju splicing događaja koji je uklonio in-frame stop kodon koji bi rezultirao molekulom odgovarajuće veličine. 3’ PCR primer oblikovan je unutar tog introna. Nadalje, oblikovan je novi 5’ PCR primer da se iskoristi in-frame ATG upravo uzvodno od predviđenog startnog kodona. PCR pojačavanje cDNA izvedene iz ukupne mRNA rezultiralo je produktom očekivane veličine.  Initial attempts to amplify the DmGPCR7 gene product were unsuccessful. The match of the predicted sequence (PnuFlyPep67863) with other GPCRs indicated that the error was probably in the prediction of the 3' end of the molecule. The predicted sequence had a 3' end that was much longer than that of most other GPCRs. Examination of the genomic sequence indicated a likely error in predicting a splicing event that removed an in-frame stop codon that would have resulted in a molecule of the appropriate size. The 3' PCR primer was designed within that intron. Furthermore, a new 5' PCR primer was designed to utilize the in-frame ATG just upstream of the predicted start codon. PCR amplification of cDNA derived from total mRNA resulted in a product of the expected size. 
 
 
   PnuFlyPep i WO 01/70980 inačice DmGPCR-a7 obje imaju manjak dviju aminokiselina na N-terminalu. Kao što je prije navedeno, PnuFlyPep i FlyPep CGI0626 inačice su također netočne na C-terminalu. Netočne inačice DmGPCR-a7 genskog produkta predviđene su da budu potencijalni Drosophila leukokininski receptori (npr. Hewes & Taghert, Genome Res., 2001,11, 1126-1142; Holmes et al, Insect. Mol. Biol., 2000,9, 457-465). Međutim, prije ovog izuma nije bilo eksperimentalnih dokaza da se potvrdi ovo očekivanje.  The PnuFlyPep and WO 01/70980 versions of DmGPCR7 both lack two amino acids at the N-terminal. As previously noted, the PnuFlyPep and FlyPep CGI0626 versions are also incorrect at the C-terminal. Missile versions of the DmGPCR-a7 gene product are predicted to be potential Drosophila leukokinin receptors (eg, Hewes & Taghert, Genome Res., 2001,11, 1126-1142; Holmes et al, Insect. Mol. Biol., 2000,9, 457 -465). However, prior to this invention there was no experimental evidence to confirm this expectation. 
 
 
   DmGPCR8  DmGPCR8 
 
 
   DmGPCR8 je uspješno pojačan korištenjem PCR primera koji su oblikovani prema PnuFlyPep predviđenoj sekvenciji. cDNA izvedena iz poli A+ RNA korištena je kao šablona za PCR reakciju. Svih šest sekvenciranih klonova bilo je identične strukture s PnuFlyPep-predviđenom sekvencijom. Polimorfizam je zabilježen u položaju #68 (DNA sekvencija), pri čemu polovina klonova ima „C“ u ovom položaju i druga polovina „A.“ Ova promjena ne rezultira aminokiselinskom promjenom, Asp, odnosno Glu. Celera sekvencija zabilježila je „A,“ tako da je „A“ klon (Glu) proizvoljno odabran za daljnje istraživanje. Nijedan „A“ klon nije dobiven u točnoj orijentaciji, pa je dakle stupanj subkloniranja, koji koristi Pme I da se ukloni umetak iz izvornog pCR3.1 klona i Pme I-razgrađeni pCR3.1 vektor, korišten da se obrne orijentacija.  DmGPCR8 was successfully amplified using PCR primers designed according to the PnuFlyPep predicted sequence. cDNA derived from poly A+ RNA was used as a template for the PCR reaction. All six sequenced clones were identical in structure to the PnuFlyPep-predicted sequence. The polymorphism was noted at position #68 (DNA sequence), with half of the clones having a "C" at this position and the other half having an "A." This change does not result in an amino acid change, Asp or Glu. The Celera sequence noted "A," so the "A" clone (Glu) was arbitrarily selected for further investigation. No "A" clone was obtained in the correct orientation, so a subcloning step, using Pme I to remove the insert from the original pCR3.1 clone and the Pme I-digested pCR3.1 vector, was used to reverse the orientation. 
 
 
   PnuFlyPep inačica je točna. WO 01/70980 inačici, međutim, nedostaje približno 17 N-terminalnih aminokiselina i približno 15 internih aminokiselina. Ovaj receptor je klasificiran kao potencijalni somatostatin-slični receptor (npr. Hewes & Taghert, Genome Res., 2001, 11, 1126-1142). Nijedan eksperimentalni dokaz prije ovog izuma nije potvrdio ovo predviđanje.  The PnuFlyPep version is correct. The WO 01/70980 version, however, lacks approximately 17 N-terminal amino acids and approximately 15 internal amino acids. This receptor has been classified as a potential somatostatin-like receptor (eg, Hewes & Taghert, Genome Res., 2001, 11, 1126-1142). No experimental evidence prior to this invention confirmed this prediction. 
 
 
   DmGPCR9  DmGPCR9 
 
 
   DmGPCR.9 je kloniran korištenjem PCR primera oblikovanih za PnuFlyPep predviđenu sekvenciju i cDNA šablone prep priređene iz poli A+ RNA. Genomske strukture su točno predviđene u PnuFlyPep.  DmGPCR.9 was cloned using PCR primers designed for the PnuFlyPep predicted sequence and a cDNA template prep prepared from poly A+ RNA. Genomic structures are accurately predicted in PnuFlyPep. 
 
 
   DmGPCRIO  DmGPCRIO 
 
 
   Početni pokušaji da se dobije PCR produkt s primerima koji su oblikovani za DmGPCRIO (PnuFlyPep70325) nisu bili uspješni. Ispitivanje predviđene cDNA pokazalo je da je predviđena sekvencija neobična i da ne sadrži vrlo sačuvani „WXP“ motiv u TM VI, niti „NPXXF“ motiv u TM VII, mada je prisutno nekoliko drugih sačuvanih rezidua. Ispitivanje genomskih sekvencija do 80 kb uzvodno od posljednjeg eksona nije dalo neke druge potencijalne eksone. Pokušaji da se dobije intaktni klon za DmGPCRIO nisu bili uspješni.  Initial attempts to obtain a PCR product with primers designed for DmGPCRIO (PnuFlyPep70325) were unsuccessful. Examination of the predicted cDNA showed that the predicted sequence is unusual and does not contain the highly conserved “WXP” motif in TM VI, nor the “NPXXF” motif in TM VII, although several other conserved residues are present. Examination of genomic sequences up to 80 kb upstream of the last exon did not yield any other potential exons. Attempts to obtain an intact clone for DmGPCRIO were unsuccessful. 
 
 
   DmGPCR1 1 (alatostatinu sličan peptidni receptor)  DmGPCR1 1 (allatostatin-like peptide receptor) 
 
 
   PCR primeri za alatostatin-slični peptidni receptor su oblikovani korištenjem publiciranih sekvencija. Birgul et at, EMBO Journal, 1999, 75(21), 5892- 5900. PCR produkt je dobiven korištenjem cDNA koja je izvedena iz ukupne mRNA prep te je klonirana i sekvencirana. Konačna cDNA kodirana za protein identična je onoj koja je opisana u publikaciji.  PCR primers for the allatostatin-like peptide receptor were designed using published sequences. Birgul et at, EMBO Journal, 1999, 75(21), 5892-5900. The PCR product was obtained using cDNA that was derived from total mRNA prep and was cloned and sequenced. The final cDNA encoding the protein is identical to that described in the publication. 
 
 
   Primjer 3: ‘Northern Blot’ analiza  Example 3: Northern Blot analysis 
 
 
   ‘Northern blots’ može se izvršiti da se istraži ekspresija mRNA. Oligonukleotidi smislene orijentacije i oligonukleotidi protivsmislene orijentacije, opisani prije, koriste se kao primeri da se pojača dio sekvencije GPCR cDNA iz nukleotidne sekvencije koja je odabrana iz skupa kojega sačinjavaju sekvencije s br. 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21 i 23.  Northern blots can be performed to investigate mRNA expression. The sense-orientation oligonucleotides and the antisense-orientation oligonucleotides described above are used as primers to amplify a portion of the GPCR cDNA sequence from a nucleotide sequence selected from the group consisting of sequences no. 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21 and 23. 
 
 
   Više humanih tkiva ‘northern blot’ od tvrtke Clontech (Human II # 7767-1) hibridizirano je sa sondom. Prehibridiziranje je izvršeno na 42ºC tijekom 4 sata u 5×SSC, 1x Denhardtov reagens, 0,1% SDS, 50% formamid, 250 mg/ml DNA sperme lososa. Hibridiziranje je izvršeno preko noći na 42ºC u istoj smjesi s dodatkom oko 1,5×106 cpm/ml obilježene sonde.  Multiple human tissue northern blots from Clontech (Human II # 7767-1) were hybridized with the probe. Prehybridization was performed at 42ºC for 4 hours in 5×SSC, 1x Denhardt's reagent, 0.1% SDS, 50% formamide, 250 mg/ml salmon sperm DNA. Hybridization was performed overnight at 42ºC in the same mixture with the addition of about 1.5×106 cpm/ml labeled probe. 
 
 
   Sonda je obilježena s �-32P-dCTP pomoću Rediprime DNA sustava za obilježavanje (Amersham Pharmacia), pročišćena na Nick koloni (Amersham Pharmacia) i dodana otopini za hibridiziranje. Filteri su isprani nekoliko puta na 42ºC u 0,2 ́SSC, 0,1% SDS. Filteri su postavljeni na Kodak XAR film (Eastman Kodak Company, Rochester, N.Y., USA) s intenzivirajućim zaslonom -80º.   The probe was labeled with �-32P-dCTP using the Rediprime DNA labeling system (Amersham Pharmacia), purified on a Nick column (Amersham Pharmacia), and added to the hybridization solution. Filters were washed several times at 42ºC in 0.2 ́SSC, 0.1% SDS. Filters were mounted on Kodak XAR film (Eastman Kodak Company, Rochester, N.Y., USA) with an intensifying screen -80º. 
 
 
   Primjer 4: Rekombinantna ekspresija DmGPCR u eukariotskim stanicama  Example 4: Recombinant expression of DmGPCR in eukaryotic cells 
 
 
   Ekspresija DmGPCR u stanicama sisavaca  Expression of DmGPCR in mammalian cells 
 
 
   Da se dobije DmGPCR protein, DmGPCR-kodirajući polinukleotid podvrgnut je ekspresiji u odgovarajućoj stanici domaćina korištenjem odgovarajućeg ekspresijskog vektora i standardnih tehnika genetskog inženjeringa. Primjerice, DmGPCR-kodirajuća sekvencija koja je opisana u primjeru 1 je subklonirana u komercijalni ekspresijski vektor pzeoSV2 (Invitrogen, San Diego, CA) i transficirana u stanicama jajnika kineskog zamorca (CHO) korištenjem transfekcijskog reagensa FuGENE 6 (Boehmger-Mannheim) i protokola transfekcije koji je priložen produktu. Druge linije eukariotskih stanica, uključujući bubreg čovječjeg zametka (HEK 293) i COS stanice, primjerice, također su odgovarajuće. Stanice s postojanom ekspresijom DmGPCR odabrane su rastom u prisutnosti 100 μg/ml zeocina (Stratagene, LaJolla, CA). Proizvoljno, DmGPCR može biti pročišćen iz stanica korištenjem standardnih kromatografskih tehnika. Da se olakša pročišćavanje, antiserum je povišen prema jednoj ili više sekvencija sintetskog peptida koje odgovaraju dijelovima DmGPCR-a aminokiselinske sekvencije i antiserum je korišten za afinitetno pročišćavanje DmGPCR. DmGPCR također može biti s ekspresijom in-frame s tag sekvencijom (npr. polihistidin, hemaglutinin, FLAG) da se olakša pročišćavanje. Štoviše, valja uočiti da mnoge upotrebe DmGPCR polipeptida, kao što su analize niže opisane, ne zahtijevaju pročišćavanje DmGPCR-a iz stanice domaćina.  To obtain the DmGPCR protein, the DmGPCR-encoding polynucleotide is subjected to expression in an appropriate host cell using an appropriate expression vector and standard genetic engineering techniques. For example, the DmGPCR-coding sequence described in Example 1 was subcloned into the commercial expression vector pzeoSV2 (Invitrogen, San Diego, CA) and transfected in Chinese guinea pig ovary (CHO) cells using the FuGENE 6 transfection reagent (Boehmger-Mannheim) and the transfection protocol which is attached to the product. Other eukaryotic cell lines, including human embryonic kidney (HEK 293) and COS cells, for example, are also suitable. Cells stably expressing DmGPCR were selected by growth in the presence of 100 μg/ml zeocin (Stratagene, LaJolla, CA). Optionally, DmGPCR can be purified from cells using standard chromatographic techniques. To facilitate purification, antiserum was raised against one or more synthetic peptide sequences corresponding to portions of the DmGPCR amino acid sequence and the antiserum was used to affinity purify the DmGPCR. The dmGPCR can also be expressed in-frame with a tag sequence (eg, polyhistidine, hemagglutinin, FLAG) to facilitate purification. Moreover, it should be noted that many uses of DmGPCR polypeptides, such as the assays described below, do not require purification of the DmGPCR from the host cell. 
 
 
   Ekspresija DmGPCR u 293 stanica  Expression of DmGPCR in 293 cells 
 
 
   Za ekspresiju DmGPCR-a u 293 stanicama, priređen je plazmid koji nosi relevantnu DmGPCR kodirajuću sekvenciju, korištenjem vektora pSecTag2A (Invitrogen). Vektor pSecTag2A sadrži mišju IgK vodeću sekvenciju lanca za sekreciju, c-myc epitop za detektiranje rekombinantnog proteina s anti-myc antitijelom, C-terminalni polihistidin za pročišćavanje s nikal kelatnom kromatografijom i Zeocin rezistentni gen za odabiranje postojanih transfektanata. Forward primer za pojačavanje ove GPCR cDNA određen je rutinskim postupcima i poželjno sadrži 5’ ekstenziju nukleotida za uvođenje HindIII klonirajućeg mjesta i nukleotida koji odgovaraju GPCR sekvenciji. Obrnuti primer je također određen rutinskim postupcima i poželjno sadrži 5’ ekstenziju nukleotida da se uvede XhoI restrikcijsko mjesto za kloniranje i nukleotidi koji odgovaraju obrnutom komplementu sekvencije DmGPCR-a. PCR uvjeti su 55ºC kao temperature pečenja. PCR produkt je pročišćen na gelu i kloniran u HindIII-XhoI mjestima vektora.  For DmGPCR expression in 293 cells, a plasmid carrying the relevant DmGPCR coding sequence was prepared using the pSecTag2A vector (Invitrogen). The pSecTag2A vector contains the mouse IgK leader sequence for secretion, c-myc epitope for detection of recombinant protein with anti-myc antibody, C-terminal polyhistidine for purification with nickel chelate chromatography and Zeocin resistance gene for selection of stable transfectants. The forward primer for amplifying this GPCR cDNA is determined by routine procedures and preferably contains a 5' extension of nucleotides for the introduction of the HindIII cloning site and nucleotides corresponding to the GPCR sequence. The reverse primer is also determined by routine procedures and preferably contains a 5' nucleotide extension to introduce an XhoI restriction site for cloning and nucleotides corresponding to the reverse complement of the DmGPCR sequence. PCR conditions are 55ºC as baking temperature. The PCR product was gel purified and cloned into the HindIII-XhoI sites of the vector. 
 
 
   DNA je pročišćena korištenjem Qiagen kromatografskih kolona i transficirana u 293 stanice korištenjem DOTAP transfekcijskog medija (Boehringer Mannheim, Indianapolis, IN). Prijelazno transficirane stanice ispitane su na nakon 24 sata transfekcije, korištenjem ‘western blots’ sondiranja s antiHis i anti-DmGPCR peptidnim antitijelima. Stalno transficirane stanice oidabrane su sa Zeocinom i propagirane. Proizvodnja rekombinantnog proteina detektirana je iz stanice i medija pomoću ‘western blots’ sondiranja s anti-His, anti-Myc ili anti-GPCR peptidnim antitijelima.  DNA was purified using Qiagen chromatography columns and transfected into 293 cells using DOTAP transfection medium (Boehringer Mannheim, Indianapolis, IN). Transiently transfected cells were examined 24 hours after transfection, using western blots probing with antiHis and anti-DmGPCR peptide antibodies. Permanently transfected cells were selected with Zeocin and propagated. Recombinant protein production was detected from cells and media using western blots probing with anti-His, anti-Myc or anti-GPCR peptide antibodies. 
 
 
   Ekspresija DmGPCR u COS stanicama  Expression of DmGPCR in COS cells 
 
 
   Za ekspresiju DmGPCR-a u COS7 stanicama, polinukleotidna molekula koja ima nukleotidnu sekvenciju koja je odabrana iz skupa kojega sačinjavaju sekvencije s br. 1, 3, 5,7, 9, 11, 13, 15, 17, 19, 21 ili 23 može biti klonirana u vektor p3-CI. Ovaj vektor je pUC18-izvedeni plasmid koji sadrži HCMV (humani citomegalovirus) promotor-intron koji je smješten uzvodno od bGH (volovski hormon rasta) poliadenilatcijske sekvencije i višestrukog klonirajućeg mjesta. Nadalje, plazmid sadrži dhfr (dihidrofolat reduktaza) gen koji definira odabiranje u prisutnosti lijeka metotreksana (MTX) za odabiranje postojanih transformanata.  For expression of DmGPCR in COS7 cells, a polynucleotide molecule having a nucleotide sequence selected from the group consisting of sequences with no. 1, 3, 5,7, 9, 11, 13, 15, 17, 19, 21 or 23 can be cloned into vector p3-CI. This vector is a pUC18-derived plasmid containing the HCMV (human cytomegalovirus) promoter-intron located upstream of the bGH (bovine growth hormone) polyadenylation sequence and a multiple cloning site. Furthermore, the plasmid contains a dhfr (dihydrofolate reductase) gene that defines selection in the presence of the drug methotrexan (MTX) to select stable transformants. 
 
 
   Forward primer određen je rutinskim postupcima i poželjno sadrži 5’ ekstenziju koja uvodi XbaI restrikcijsko mjesto za kloniranje, nakon čega slijede nukleotidi koji odgovaraju nukleotidnoj sekvenciji koja je odabrana iz skupa kojega sačinjavaju sekvencije s br. 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21 ili 23. Reverzni primer je također određen rutinskim postupcima i poželjno sadrži 5’- ekstenziju nukleotida koji uvode SaiI klonirajuće mjesto nakon čega slijede nukleotidi koji odgovaraju reverznom komplementu nukleotidne sekvencije koja je odabrana iz skupa sekvencija s br. 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21 ili 23.  The forward primer is determined by routine procedures and preferably contains a 5' extension that introduces an XbaI restriction site for cloning, followed by nucleotides corresponding to a nucleotide sequence selected from the set consisting of sequences with no. 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21 or 23. The reverse primer is also determined by routine procedures and preferably contains a 5'-extension of nucleotides introducing the SaiI cloning site followed by nucleotides corresponding to to the reverse complement of the nucleotide sequence which is selected from the set of sequences with no. 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21 or 23. 
 
 
   PCR se sastoji od početnog stupnja denaturiranja 5 min na 95ºC, 30 ciklusa od 30 sekundi denaturiranja na 95ºC, 30 sekundi pečenja na 58ºC i 30 sekundi ekstenzije na 72ºC, nakon čega slijedi 5 min ekstenzije na 72ºC. PCR produkt je pročišćen na gelu i ligiran u XbaI i SaiI mjesta vektora p3-CI. Ovaj konstrukt je transformiran u E. coli stanice za pojačavanje i DNA pročišćavanje. DNA je pročišćena pomoću Qiagen kromatografije na koloni i tranficirana u COS7 stanice korištenjem Lipofektamin reagensa tvrtke BRL, sukladno protokolima proizvođača. Četrdeset osam i 72 sata nakon transfekcije, mediji i stanice ispitani su na ekspresiju rekombinantnog proteina.  The PCR consists of an initial denaturation step of 5 min at 95ºC, 30 cycles of 30 seconds of denaturation at 95ºC, 30 seconds of annealing at 58ºC and 30 seconds of extension at 72ºC, followed by 5 min of extension at 72ºC. The PCR product was gel purified and ligated into the XbaI and SaiI sites of the p3-CI vector. This construct was transformed into E. coli cells for amplification and DNA purification. DNA was purified using Qiagen column chromatography and transfected into COS7 cells using Lipofectamine reagent from BRL, according to the manufacturer's protocols. Forty-eight and 72 hours after transfection, media and cells were assayed for recombinant protein expression. 
 
 
   DmGPCR s ekspresijom iz COS stanične kulture može se pročistiti koncentriranjem medija za stanični rast do oko 10 mg protein/ml i pročišćavanjem proteina pomoću, primjerice, kromatografije. Pročišćeni DmGPCR je koncentriran na 0,5 mg/ml u Amicon koncentratoru koji je opremljen s YM-10 membranom i pohranjen na -80ºC.  DmGPCR expressed from COS cell culture can be purified by concentrating the cell growth medium to about 10 mg protein/ml and purifying the protein using, for example, chromatography. Purified DmGPCR was concentrated to 0.5 mg/ml in an Amicon concentrator equipped with a YM-10 membrane and stored at -80ºC. 
 
 
   Ekspresija DmGPCR u insektnim stanicama  Expression of DmGPCR in insect cells 
 
 
   Za ekspresiju DmGPCR-a u akulovirusnom sustavu, polinukleotidna molekula koja ima nukleotidnu sekvenciju koja je odabrana iz skupa kojega sačinjavaju sekvencije s br. 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21 ili 23 može se pojačati pomoću PCR. Forward primer određen je rutinskim postupcima i poželjno sadrži 5’ ekstenziju koja dodaje NdeI klonirajuće mjesto, nakon čega slijede nukleotidi koji odgovaraju nukleotidnoj sekvenciji koja je odabrana iz skupa kojega sačinjavaju sekvencije s br. 1, 3, 5,1, 9, 11, 13, 15, 17, 19, 21 ili 23. Reverzni primer je također određen rutinskim postupcima i poželjno sadrži 5’ ekstenziju koja unosi KpnI klonirajuće mjesto, nakon čega slijede nukleotidi koji odgovaraju obrnutom komplementu nukleotidne sekvencije koja je odabrana iz skupa kojega sačinjavaju sekvencije s br. 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21 ili 23.  For the expression of DmGPCR in an aculovirus system, a polynucleotide molecule having a nucleotide sequence selected from the group consisting of sequences with no. 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21 or 23 can be amplified by PCR. The forward primer is determined by routine procedures and preferably contains a 5' extension that adds an NdeI cloning site, followed by nucleotides corresponding to a nucleotide sequence selected from the set consisting of sequences with no. 1, 3, 5, 1, 9, 11, 13, 15, 17, 19, 21 or 23. The reverse primer is also determined by routine procedures and preferably contains a 5' extension introducing a KpnI cloning site, followed by nucleotides corresponding to the reverse to the complement of the nucleotide sequence that is selected from the set consisting of sequences with no. 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21 or 23. 
 
 
   PCR produkt je pročišćen gelom, razgrađen s NdeI i KpnI i kloniran u odgovarajuća mjesta vektora pAcHTL-A (Pharmingen, San Diego, CA). pAcHTL ekspresijski vektor sadrži jaki polihedrinski promotor Autographa californica nuclear polyhedrosis virusa (AcMNPV) i 6XHis tag uzvodno od višestrukog klonirajućeg mjesta. Protein kinaza mjesto za fosforiliranje i trombinsko mjesto za eksciziju rekombinantnog proteina koje prethodi višestrukom klonirajućem mjestu također je uočeno. Naravno, mogu se koristiti drugi bakulovirusni vektori umjesto pAcHTL-A, kao što su pAc373, pVL941 i pAcIMl. Drugi odgovarajući vektori za ekspresiju GPCR polipeptida također se mogu koristiti, pod uvjetom da vektorski konstrukt sadrži odgovarajuće smještene signale za transkripciju, prevođenje i uvođenje, kao što su in-frame AUG i signalni peptid, po potrebi. Takvi vektori su opisani u Luckow et al., Virology 170:31-39, između ostalog.  The PCR product was gel purified, digested with NdeI and KpnI, and cloned into the appropriate sites of the vector pAcHTL-A (Pharmingen, San Diego, CA). The pAcHTL expression vector contains the strong polyhedrin promoter of Autographa californica nuclear polyhedrosis virus (AcMNPV) and a 6XHis tag upstream of the multiple cloning site. A protein kinase phosphorylation site and a thrombin excision site for the recombinant protein preceding the multiple cloning site were also observed. Of course, other baculovirus vectors can be used instead of pAcHTL-A, such as pAc373, pVL941 and pAcIM1. Other suitable vectors for expression of GPCR polypeptides may also be used, provided the vector construct contains appropriately positioned signals for transcription, translation and introduction, such as in-frame AUG and signal peptide, as appropriate. Such vectors are described in Luckow et al., Virology 170:31-39, among others. 
 
 
   Virus je uzgojen i izdvojen korištenjem standardnih metoda bukulovirusne ekspresije, kao što su one opisane u: Summers et al, (A Manual of Methods for Baculovirus Vektors and Insect Cell Culture Procedures, Texas Agricultural Experimental Station Bulletin No. 1555 (1987)).  Virus was grown and isolated using standard baculovirus expression methods, such as those described in: Summers et al, (A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures, Texas Agricultural Experimental Station Bulletin No. 1555 (1987)). 
 
 
   U jednoj realizaciji, pAcHLT-A koji sadrži DmGPCR gen uveden je u bakulovirus korištenjem „BaculoGold” transfekcijskog pribora (Pharmingen, San Diego, CA) korištenjem metoda koje je utvrdio proizvođač. Pojedini virusni izolati su analizirani na proizvodnju proteina radioobilježavanjem inficirane stanice s 35S-metioninom 24 sata nakon infekcije. Inficirane stanice su sakupljene 48 sati nakon infekcije i obilježeni proteini su vizualizirani s SDS-PAGE. Virusi koji pokazuju visoku razinu ekspresije mogu se izdvojiti i koristiti za uvećanu ekspresiju.  In one embodiment, pAcHLT-A containing the DmGPCR gene was introduced into baculovirus using the “BaculoGold” transfection kit (Pharmingen, San Diego, CA) using methods established by the manufacturer. Individual virus isolates were analyzed for protein production by radiolabeling the infected cell with 35S-methionine 24 hours after infection. Infected cells were harvested 48 hours post-infection and labeled proteins were visualized by SDS-PAGE. Viruses showing high levels of expression can be isolated and used for scale-up expression. 
 
 
   Za ekspresiju DmGPCR polipeptida u Sf9 stanicama, polinukleotidna molekula koja ima nukleotidnu sekvenciju koja je odabrana iz skupa kojega sačinjavaju sekvencije s br. 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21 ili 23, može se pojačati pomoću PCR korištenjem primera i metoda koje su opisane za bakulovirusnu ekspresiju. DmGPCR cDNA je klonirana u vektor pAcHLT-A (Pharmingen) za ekspresiju u Sf9 insektnim stanicama. Umetak je kloniran u NdeI i KpnI mjestima, nakon eliminiranja internog NdeI mjesta (korištenjem istih primera koji su prije opisani za ekspresiju u bakulovirusu). DNA je pročišćena s Qiagen kromatografijom na koloni i izvršena je ekspresija u Sf9 stanicama. Preliminarni ‘Western blot’ eksperimenti iz nepročišćenih plakova su testirani na prisutnost rekombinantniog proteina očekivane veličine koji reagira s GPCR-specifičnim antitijelom. Ovi rezultati su potvrđeni nakon daljnjeg pročišćavanja i ekspresijske optimizacije u HiG5 stanicama.  For the expression of DmGPCR polypeptide in Sf9 cells, a polynucleotide molecule having a nucleotide sequence selected from the group consisting of sequences with no. 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21 or 23, can be amplified by PCR using the primers and methods described for baculovirus expression. DmGPCR cDNA was cloned into pAcHLT-A vector (Pharmingen) for expression in Sf9 insect cells. The insert was cloned into the NdeI and KpnI sites, after eliminating the internal NdeI site (using the same primers previously described for baculovirus expression). DNA was purified by Qiagen column chromatography and expression was performed in Sf9 cells. Preliminary Western blot experiments from unpurified plaques were tested for the presence of recombinant protein of the expected size that reacts with a GPCR-specific antibody. These results were confirmed after further purification and expression optimization in HiG5 cells. 
 
 
   Primjer 5: Interakcija zamka/dvohibridni sustav  Example 5: Trap interaction/two-hybrid system 
 
 
   Da bi se izvršila analiza DmGPCR-interakcijskih proteina, korištena je screening metoda interakcije zamka/dvohibridna biblioteka. Ova analiza je prvi puta opisana u Fields, et al, Nature, 1989, 340, 245, što je ovdje uključeno kao referenca u cijelosti. Protokol je publiciran u: Current Protocols in Molecular Biology, John Wiley & Sons, NY, 1999 i Ausubel et al, Short Protocols in Molecular Biology, fourth edition, Greene i Wiley-interscience, NY, 1992, što je ovdje uključeno kao referenca u cijelosti. Pribori su nabavljeni od tvrtke Clontech, Palo Alto, CA (Matchmaker Two-Hybrid System 3).  In order to perform the analysis of DmGPCR-interacting proteins, an interaction trap/two-hybrid library screening method was used. This analysis was first described in Fields, et al, Nature, 1989, 340, 245, which is incorporated herein by reference in its entirety. The protocol is published in: Current Protocols in Molecular Biology, John Wiley & Sons, NY, 1999 and Ausubel et al, Short Protocols in Molecular Biology, fourth edition, Greene and Wiley-interscience, NY, 1992, which is incorporated herein by reference in in its entirety. Accessories were obtained from Clontech, Palo Alto, CA (Matchmaker Two-Hybrid System 3). 
 
 
   Sjedinjavanje nukleotidne sekvencije koja kodira ili sve ili samo dio DmGPCR i kvaščeva transkripcijskog faktora GAL4 DNA-vezujuće domene (DNA-BD) izvršeno je u odgovarajućem plazmidu (tj. pGBKT7) korištenjem standardnih tehnika subkloniranja. Slično, GAL4 aktivna domena (AD) fuzijske biblioteke načinjena je u drugom plazmidu (tj. pGADT7) iz cDNA potencijalnih GPCR-vezujućih proteina (za protokole stvaranja cDNA biblioteka, vidi Sambrook et al., Molecular cloning: laboratory manual, second edition, Cold Spring Harbor Press, Cold Spring Harbor, NY, 1989), što je ovdje uključeno kao referenca u cijelosti. DNA-BD/GPCR fuzijski konstrukt provjeren je pomoću sekvenciranja i ispitan je na autonomno aktiviranje reporterskog gena i staničnu toksičnost, što oboje sprječava uspješnu dvohibridnu analizu. Slične kontrole su izvršene s AD/biblioteka fuzijskog konstrukta da se osigura ekspresija u stanicama domaćina i nedostatak transkripcijske aktivnosti. Kvaščeve stanice su transformirane (ca. 105 transformanata/mg DNA) s GPCR i bibliotekom fuzijskih plazmida sukladno standardnom postupku (Ausubel et al, Short protocols in molecular biology, fourth edition, Greene i Wiley-interscience, NY, 1992, što je ovdje uključeno kao referenca u cijelosti). In vivo vezanje DNA-BD/GPCR s AD/biblioteka proteina rezultira transkripcijom specifičnih kvaščevih plazmid reporterskih gena (tj. lacZ, HIS3, ADE2, LEU2). Kvaščeve stanice su nanesene na ploču na medij koji je deficitaran hranom da se provjeri na ekspresiju reporterskih gena. Kolonije su dvojno analizirane na aktivnost β-galaktosidaza nakon rasta u XgaI (5-brom-4-klor-3-indolil-β-D-galaktozid) dopunskom mediju (filterska analiza na aktivnost β-galaktosidaze opisana je u Breeden et al, Cold Spring Harb. Symp. Quant. Biol., 1985, 50, 643, što je ovdje uključeno kao referenca u cijelosti). Pozitivni AD-biblioteka plazmidi su izvučeni iz transformanata i ponovo su uneseni u izvorni kvaščev soj kao i druge sojeve koji sadrže nesrodne DNA-BD fuzijske proteine da se potvrde specifične DmGPCR/biblioteka proteina interakcije. Ubačena DNA je sekvencirana da se provjeri prisutnost otvorenog okvira za čitanje fuzioniranog na GAL4 AD i da se odredi identičnost DmGPCR-vezujućeg proteina.  Fusion of the nucleotide sequence encoding either all or part of the DmGPCR and the yeast transcription factor GAL4 DNA-binding domain (DNA-BD) was performed in the appropriate plasmid (ie, pGBKT7) using standard subcloning techniques. Similarly, a GAL4 active domain (AD) fusion library was constructed in another plasmid (i.e., pGADT7) from cDNAs of potential GPCR-binding proteins (for cDNA library generation protocols, see Sambrook et al., Molecular cloning: laboratory manual, second edition, Cold Spring Harbor Press, Cold Spring Harbor, NY, 1989), which is incorporated herein by reference in its entirety. The DNA-BD/GPCR fusion construct was verified by sequencing and tested for autonomous activation of the reporter gene and cellular toxicity, both of which prevent successful two-hybrid analysis. Similar controls were performed with the AD/fusion construct library to ensure expression in host cells and lack of transcriptional activity. Yeast cells were transformed (ca. 105 transformants/mg DNA) with a GPCR and fusion plasmid library according to a standard procedure (Ausubel et al, Short protocols in molecular biology, fourth edition, Greene and Wiley-interscience, NY, 1992, which is incorporated herein as a reference in its entirety). In vivo binding of DNA-BD/GPCR to AD/protein library results in transcription of specific yeast plasmid reporter genes (ie lacZ, HIS3, ADE2, LEU2). Yeast cells were plated on nutrient-deficient medium to check for reporter gene expression. Colonies were assayed in duplicate for β-galactosidase activity after growth in XgaI (5-bromo-4-chloro-3-indolyl-β-D-galactoside) supplemented medium (filter assay for β-galactosidase activity is described in Breeden et al, Cold Spring Harb. Symp. Quant. Biol., 1985, 50, 643, which is hereby incorporated by reference in its entirety). Positive AD-library plasmids were recovered from transformants and reintroduced into the original yeast strain as well as other strains containing unrelated DNA-BD fusion proteins to confirm specific DmGPCR/library protein interactions. Inserted DNA was sequenced to verify the presence of the open reading frame fused to the GAL4 AD and to determine the identity of the DmGPCR-binding protein. 
 
 
   Primjer 6: Pomak mobilnosti DNA-vezujuće analize korištenjem gel elektroforeze  Example 6: Mobility shift DNA-binding analysis using gel electrophoresis 
 
 
   Gel elektroforetska analiza pomaka mobilnosti može brzo detektirati specifične protein-DNA interakcije. Protokoli su lako dostupni u priručnicima kao što su: Sambrook et al, Molecular cloning: laboratory manual, second edition, Cold Spring Harbor Press, Cold Spring Harbor, NY, 1989 i Ausubel et al, Short Protocols in Molecular Biology, fourth edition, Greene i Wiley-interscience, NY, 1992, a svaki od njih je ovdje uključen kao referenca u cijelosti.  Gel electrophoretic mobility shift analysis can rapidly detect specific protein-DNA interactions. Protocols are readily available in manuals such as: Sambrook et al, Molecular cloning: laboratory manual, second edition, Cold Spring Harbor Press, Cold Spring Harbor, NY, 1989 and Ausubel et al, Short Protocols in Molecular Biology, fourth edition, Greene and Wiley-interscience, NY, 1992, each of which is incorporated herein by reference in its entirety. 
 
 
   Sonda DNA (<300 bp) dobivena je iz sintetskih oligonukleotida, retrikcijskih fragmenata endonukleaze ili PCR fragmenata te krajnje obilježenih s 32P. Alikvot pročišćenog DmGPCR (ca. 15 μg) ili sirovog DmGPCR ekstrakta (ca. 15 ng) inkubiran je na konstantnoj temperaturi (u rasponu 22-37ºC) tijekom bar 30 minuta u 10-15 μl pufera (tj. TAE ili TBE, pH 8,0-8,5) koji sadrži radioobilježenu sondu DNA, nespecifični nosač DNA (ca. 1 μg), BSA (300 μg/ml) i 10% (v/v) glicerol. Reakcijska smjesa je zatim nanesena na poliakrilamidni gel i primijenjena je struja 30-35 mA sve dok nije postignuto dobro odvajanje slobodne sonde DNA od kompleksa protein-DNA. Gel je zatim osušen i vrpce koje odgovaraju slobodnoj DNA i protein-DNA kompleksima su detektirane autoradiografski.  The DNA probe (<300 bp) was obtained from synthetic oligonucleotides, endonuclease restriction fragments or PCR fragments and end-labeled with 32P. An aliquot of purified DmGPCR (ca. 15 μg) or crude DmGPCR extract (ca. 15 ng) was incubated at a constant temperature (in the range 22-37ºC) for at least 30 minutes in 10-15 μl buffer (i.e. TAE or TBE, pH 8 .0-8.5) containing radiolabeled DNA probe, non-specific DNA carrier (ca. 1 μg), BSA (300 μg/ml) and 10% (v/v) glycerol. The reaction mixture was then applied to a polyacrylamide gel and a current of 30-35 mA was applied until a good separation of the free DNA probe from the protein-DNA complex was achieved. The gel was then dried and bands corresponding to free DNA and protein-DNA complexes were detected autoradiographically. 
 
 
   Primjer 7: Antitijela za DmGPCR  Example 7: Antibodies for DmGPCR 
 
 
   Standard tehnike koriste se za generiranje polikoonskih ili monoklonskih antitijela za DmGPCR i da se generiraju korisni antigen-vezujući fragmenti ili inačice, uključujući „humanizirane“ inačice. Ti protokoli mogu se naći, primjerice, u: Sambrook et al. (1989), supra i Harlow et al. (Eds.), Antitijela: Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1988. U jednoj realizaciji, rekombinantni DmGPCR polipeptidi (ili stanice ili stanične membrane koje sadrže takve polipeptide) koriste se kao antigen za generiranje antitijela. U drugoj realizaciji, jedan ili više peptida koji imaju aminokiselinske sekvencije koje odgovaraju imunogenom dijelu DmGPCR-a (npr. 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 ili više aminokiselina) koristi se kao antigen. Peptidi koji odgovaraju izvanstaničnim dijelovima DmGPCR-a, posebice hidrofilni izvanstanični dijelovi, obuhvaćeni su ovim izumom. Antigen se može pomiješati s adjuvantom ili se može vezati za hapten da se poveća proizvodnja antitijela.  Standard techniques are used to generate polyclonal or monoclonal antibodies to DmGPCR and to generate useful antigen-binding fragments or variants, including “humanized” versions. These protocols can be found, for example, in: Sambrook et al. (1989), supra and Harlow et al. (Eds.), Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1988. In one embodiment, recombinant DmGPCR polypeptides (or cells or cell membranes containing such polypeptides) are used as an antigen to generate antibodies. In another embodiment, one or more peptides having amino acid sequences corresponding to the immunogenic portion of a DmGPCR (e.g., 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more amino acids) is used as an antigen. Peptides corresponding to extracellular portions of DmGPCR, particularly hydrophilic extracellular portions, are encompassed by the present invention. The antigen can be mixed with an adjuvant or can be attached to a hapten to increase antibody production. 
 
 
   Poliklonska ili monoklonska antitijela  Polyclonal or monoclonal antibodies 
 
 
   Kao jedan primjerni protokol, rekombinantni DmGPCR ili njegov sintetski fragment koristi se za imuniziranje miševa za generiranje monoklonskih antitijela (ili veći sisavci, kao što je kunić, za poliklonska antitijela). Da se poveća antigenost, peptidi su konjugirani za Keyhole Lympet Hemocyanin (Pierce), sukladno preporukama proizvođača. Za početnu injekciju, antigen je emulgiran s Freundovim cjelovitim adjuvantom, te potkožno injiciran. U intervalima od dva do tri tjedna, dodatni alikvoti DmGPCR antigena s emulgirani s Freundovim nepotpounim adjuvantom i injicirani potkožno. Prije konačne booster injekcije, uzet je uzorak seruma iz imuniziranog miša i analiziran je ‘western blot’ analizom da se potvrdi prisutnost antitijela koja su u imunoreakciji s DmGPCR-om. Serum imuniziranih životinja može se koristiti kao poliklonski antiserum ili se koristi za izdvajanje poliklonskih antitijela koja prepoznaju DmGPCR. Alternativno, miševi se mogu žrtvovati i njihova slezena uzeti za generiranje monoklonskih antitijela.  As one exemplary protocol, recombinant DmGPCR or a synthetic fragment thereof is used to immunize mice to generate monoclonal antibodies (or larger mammals, such as rabbit, for polyclonal antibodies). To increase antigenicity, peptides were conjugated to Keyhole Lympet Hemocyanin (Pierce), according to the manufacturer's recommendations. For the initial injection, the antigen was emulsified with complete Freund's adjuvant and injected subcutaneously. At two to three week intervals, additional aliquots of DmGPCR antigen were emulsified with Freund's incomplete adjuvant and injected subcutaneously. Before the final booster injection, a serum sample was taken from the immunized mouse and analyzed by western blot analysis to confirm the presence of antibodies immunoreacting with DmGPCR. Serum from immunized animals can be used as polyclonal antiserum or used to isolate polyclonal antibodies that recognize DmGPCR. Alternatively, mice can be sacrificed and their spleens harvested to generate monoclonal antibodies. 
 
 
   Da se dobiju monoklonska antitijela, slezena je stavljena u 10 ml serum-slobodnog RPMI1640 i načinjena je jednostančana suspenzija usitnjavanjem slezene u serum-slobodnom RPMI 1640, čemu je dodano 2 mM L-glutamina, 1 mM natrijeva piruvata, 100 jedinica/ml penicilina i 100 μg/ml streptomicina (RPMI) (Gibco, Canada). Stanične suspenzije su filtrirane i isprane centrifugiranjem te resuspendirane u serum-slobodnom RPMI. Timociti su uzeti iz tri nativna Balb/c miša i priređeni su na sličan način te korišteni kao hranjivi sloj. NS-1 stanice mijeloma, držane su u log fazi u RPMI s 10% seruma volovskog zametka (FBS) (Hyclone Laboratories, Inc., Logan, Utah) tijekom tri dana do fuzije te centrifugirane i isprane.  To obtain monoclonal antibodies, the spleen was placed in 10 ml of serum-free RPMI 1640 and a single cell suspension was made by mincing the spleen in serum-free RPMI 1640 supplemented with 2 mM L-glutamine, 1 mM sodium pyruvate, 100 units/ml penicillin and 100 μg/ml streptomycin (RPMI) (Gibco, Canada). Cell suspensions were filtered and washed by centrifugation and resuspended in serum-free RPMI. Thymocytes were taken from three native Balb/c mice and prepared in a similar manner and used as a nutrient layer. NS-1 myeloma cells were maintained in log phase in RPMI with 10% fetal bovine serum (FBS) (Hyclone Laboratories, Inc., Logan, Utah) for three days until confluent and centrifuged and washed. 
 
 
   Da se dobiju fuzije hibridoma, stanice slezene imuniziranih miševa su kombinirane s NS-1 stanicama i centrifugirane pa je supernatant usisan.Stanični talog je izbačen suženjem epruvete i 2 ml na 37ºC PEG 1500 (50% u 75 mM HEPES, pH 8,0) (Boehringer-Mannheim) je miješano s talogom, nakon čega je dodan serum-slobodni RPMI. Nakon toga, stanice su centrifugirane, resuspendirane u RPMI koji sadrži 15% FBS, 100 μM sodium hipoksantina, 0,4 μM aminopterina, 16 μM timidina (HAT) (Gibco), 25 jedinica/ml IL-6 (Boehringer-Mannheim) i 1,5×106 timociti/ml te nanesene na ploču 10 Corning kulture ploča s 96 jažica (Corning, Corning New York).  To obtain hybridoma fusions, spleen cells from immunized mice were combined with NS-1 cells and centrifuged, and the supernatant was aspirated. The cell pellet was removed by tapering the tube and 2 ml at 37ºC PEG 1500 (50% in 75 mM HEPES, pH 8.0) (Boehringer-Mannheim) was mixed with the precipitate, after which serum-free RPMI was added. After that, the cells were centrifuged, resuspended in RPMI containing 15% FBS, 100 μM sodium hypoxanthine, 0.4 μM aminopterin, 16 μM thymidine (HAT) (Gibco), 25 units/ml IL-6 (Boehringer-Mannheim) and 1.5×10 6 thymocytes/ml and plated on plate 10 Corning 96-well culture plates (Corning, Corning New York). 
 
 
   Na dane 2, 4 i 6 nakon sjedinjavanja, 100 μl medija je uklonjeno iz jažica na fuzijskim pločama i zamijenjeno svježim medijem. Na dan 8, ploče su provjerene ELISA analizom, ispitane na prisutnost mišjeg IgG koji se veže za DmGPCR. Odabrane fuzijske jažice su dalje klonirane razrjeđenjem sve dok nije dobivena monoklonska kultura koja daje anti-DmGPCR antitijela.  On days 2, 4, and 6 after fusion, 100 μl of medium was removed from the wells of the fusion plates and replaced with fresh medium. On day 8, the plates were checked by ELISA, tested for the presence of mouse IgG binding to DmGPCR. Selected fusion wells were further cloned by dilution until a monoclonal culture yielding anti-DmGPCR antibodies was obtained. 
 
 
   Humaniziranje anti-DmGPCR monoklonskih antitijela  Humanization of anti-DmGPCR monoclonal antibodies 
 
 
   Ekspresijska slika DmGPCR-a kao je ovdje navedena i potvrđeno bilježenje GPCR-ova kao ciljeva za terapijsku intervenciju ukazuju na terapijske indikacije za DmGPCR inhibitore (antagoniste). DmGPCR-neutralizirajuća antitijela koja sadrže jednu klasu terapeutika korisni su DmGPCR antagonisti. U nastavku slijede protokoli za humaniziranje monoklonskih antitijela ovog izuma.  The expression pattern of DmGPCRs as reported here and the confirmed recording of GPCRs as targets for therapeutic intervention indicate therapeutic indications for DmGPCR inhibitors (antagonists). DmGPCR-neutralizing antibodies comprising one class of therapeutics are useful DmGPCR antagonists. The following are protocols for humanizing the monoclonal antibodies of the present invention. 
 
 
   Načela humaniziranja su opisana u literaturi i humaniziranje je olakšano modularnim rasporedom proteina antitijela. Da se minimizira mogućnost vezanja komplementa, može se koristiti humanizirano antitijelo IgG4 izotipa.  Principles of humanization are described in the literature and humanization is facilitated by the modular arrangement of antibody proteins. To minimize the possibility of binding of complement, a humanized IgG4 isotype antibody can be used. 
 
 
   Primjerice, razina humaniziranja postiže se generiranjem kimernih antitijela koja sadrže promjenjive domene proteina nehumanih antitijela od interesa s nepromjenjivim domenama molekule humanog antitijela (vidi npr. Morrison et al, Adv. Immunol., 1989, 44, 65-92). Promjenjive domene neutralizirajućih anti-DmGPCR antitijela DmGPCR-a su klonirane iz genomske DNA B-stanica hibridoma ili iz cDNA koja je generirana iz mRNA izdvojene iz hibridoma od interesa. V područje fragmenata gena povezano je s eksonima koji kodiraju nepromjenjivu domenu humanog antitijela i rezultantni konstrukt ima ekspresiju u odgovarajućoj stanici domaćina sisavca (npr. mijelom ili CHO stanice).  For example, a level of humanization is achieved by generating chimeric antibodies that contain the variable domains of the nonhuman antibody protein of interest with the constant domains of the human antibody molecule (see, e.g., Morrison et al, Adv. Immunol., 1989, 44, 65-92). Variable domains of neutralizing anti-DmGPCR antibodies DmGPCRs are cloned from genomic DNA of hybridoma B-cells or from cDNA generated from mRNA isolated from the hybridoma of interest. The V region of the gene fragments is ligated to the exons encoding the constant domain of the human antibody and the resulting construct is expressed in the appropriate mammalian host cell (eg, myeloma or CHO cells). 
 
 
   Da se postigne još jača razina humanizacije, klonirani su samo oni dijelovi promjenjive domene fragmenata gena koji kodiraju antigen-vezujuća područja koja određuju komplementarnost („CDR“) nehumanog monoklonskog antitijela, u sekvencije humanog antitijela (vidi npr. Jones et al, Nature, 1986, 321, 522-525; Riechmann et al, Nature, 1988, 332, 323-327; Verhoeyen et al, Science, 1988, 239, 1534-36; i Tempest et al, Bio/Technology, 1991, 9, 266-71). Ako je potrebno, također je modificiran β-list kostura humanog antitijela koje okružuje CDR3 područja da još više odražava trodimenzionalnu strukturu antigen-vezujuće domene izvornog monoklonskog antitijela (vidi Kettleborough et al, Protein Engin., 1991, 4,773-783; i Foote et al, J. Mol. Biol., 1992, 224,487-499).  To achieve an even greater level of humanization, only those portions of the variable domain of the gene fragments encoding the antigen-binding complementarity-determining regions ("CDR") of the nonhuman monoclonal antibody were cloned into the human antibody sequences (see, e.g., Jones et al, Nature, 1986 , 321, 522-525; Riechmann et al, Nature, 1988, 332, 323-327; Verhoeyen et al, Science, 1988, 239, 1534-36; and Tempest et al, Bio/Technology, 1991, 9, 266- 71). If necessary, the β-sheet of the human antibody backbone surrounding the CDR3 region is also modified to more closely reflect the three-dimensional structure of the antigen-binding domain of the original monoclonal antibody (see Kettleborough et al, Protein Engin., 1991, 4,773-783; and Foote et al , J. Mol. Biol., 1992, 224, 487-499). 
 
 
   U alternativnom pristupu, površina nehumanog monoklonskog antitijela od interesa je humanizirana promjenom odabranih površinskih rezidua nehumanog antitijela, npr. pomoću mjesno-usmjerene mutageneze, uz zadržavanje svih unutrašnjih i kontaktnih rezidua nehumanog antitijela. Vidi Padlan, Molecular Immunol, 1991, 25(4/5), 489-98.  In an alternative approach, the surface of the nonhuman monoclonal antibody of interest is humanized by changing selected surface residues of the nonhuman antibody, eg, using site-directed mutagenesis, while retaining all internal and contact residues of the nonhuman antibody. See Padlan, Molecular Immunol, 1991, 25(4/5), 489-98. 
 
 
   Prije navedeni pristupi rabe se korištenjem DmGPCR-neutralizirajućeg anti-DmGPCR monoklonskog antitijela i hibridoma koji ih proizvode da se dobiju humanizirana DmGPCR-neutralizirajuća antitijela koja su korisna kao terapeutici da se tretira ili palijativno djeluje na stanja pri čemu je DmGPCR ekspresija ili ligand-upravljano signaliziranje DmGPCR štetno.  The foregoing approaches employ the use of a DmGPCR-neutralizing anti-DmGPCR monoclonal antibody and the hybridomas that produce them to obtain humanized DmGPCR-neutralizing antibodies that are useful as therapeutics to treat or palliate conditions in which DmGPCR expression or ligand-driven signaling is impaired. DmGPCR harmful. 
 
 
   Primjer 8: Analize za identificiranje modulatora aktivnosti DmGPCR  Example 8: Assays to identify modulators of DmGPCR activity 
 
 
   U nastavku je navedeno nekoliko neograničavajućih analiza za identificiranje modulatora (agonisti i antagonisti) aktivnosti DmGPCR-a. Među modulatorima koji se mogu identificirati pomoću analiza su prirodni ligandni spojevi receptora; sintetski analozi i derivati prirodnih liganada; antitijela, fragmenti antitijela, i/ili antitijelu slični spojevi koji su izvedeni iz prirodnih antitijela ili iz antitijelu sličnih kombinatornih biblioteka; i/ili sintetski spojevi koji su identificirani ‘high-throughput’ screening bibliotekama i slično. Svi modulatori koji vežu DmGPCR korisni su za identificiranje DmGPCR u uzorcima tkiva (npr. za dijagnostičke potrebe, patološke svrhe i slično). Modulatori agonista i antagonista korisni su za nadreguliranje i podreguliranje aktivnosti DmGPCR, odnosno, za tretiranje bolesnih stanja koja su karakterizirana nenormalnim razinama aktivnosti DmGPCR-a. Analize se mogu korištenjem samih potencijalnih modulatora i/ili se mogu izvršiti korištenjem poznatih agonista u kombinaciji s kandidatskim antagonistom (ili obrnuto).  Several non-limiting assays for identifying modulators (agonists and antagonists) of DmGPCR activity are listed below. Among the modulators that can be identified using the assays are naturally occurring ligand compounds of the receptor; synthetic analogues and derivatives of natural ligands; antibodies, antibody fragments, and/or antibody-like compounds derived from natural antibodies or from antibody-like combinatorial libraries; and/or synthetic compounds identified by high-throughput screening libraries and the like. All DmGPCR-binding modulators are useful for identifying DmGPCRs in tissue samples (eg, for diagnostic purposes, pathological purposes, and the like). Agonist and antagonist modulators are useful for upregulating and downregulating DmGPCR activity, respectively, for treating disease states characterized by abnormal levels of DmGPCR activity. Analyzes can be performed using potential modulators alone and/or can be performed using known agonists in combination with a candidate antagonist (or vice versa). 
 
 
   Analize cAMP  Analyzes of cAMP 
 
 
   U jednom tipu analize, razine cikličkog adenozin monofosfata (cAMP) mjere se u DmGPCR-transficiranim stanicama koje su izložene kandidatskim modulatorskim spojevima. Protokoli za cAMP analize opisani su u literaturi (vidi npr. Sutherland et al, Circulation, 1968, 37, 279; Frandsen et al, Life Sciences, 1976,18, 529-541; Dooley et al, J. Pharm. i Exper. Ther., 1997, 283(2), 735-41; i George et al, J. Biomolecular Screening, 1997, 2(4), 235-40). Primjerni protokol za takvu analizu, Adenylyl Cyclase Activation FlashPlate® analize iz NEN™ Life Science Products je niže naveden.  In one type of assay, levels of cyclic adenosine monophosphate (cAMP) are measured in DmGPCR-transfected cells exposed to candidate modulatory compounds. Protocols for cAMP assays are described in the literature (see, e.g., Sutherland et al, Circulation, 1968, 37, 279; Frandsen et al, Life Sciences, 1976, 18, 529-541; Dooley et al, J. Pharm. and Exper. Ther., 1997, 283(2), 735-41; and George et al, J. Biomolecular Screening, 1997, 2(4), 235-40). An exemplary protocol for such an assay, the Adenylyl Cyclase Activation FlashPlate® assay from NEN™ Life Science Products is listed below. 
 
 
   Ukratko, DmGPCR kodirajuća sekvencija (npr. cDNA ili bezintronska genomska DNA) je subklonirana u komercijalni ekspresijski vektor, kao što je pzeoSV2 (Invitrogen) i prijelazno je transficirana u stanice jajnika kineskog zamorca (CHO) korištenjem poznatih metoda, kao što je protokol transfekcije kojega daje such Boehringer-Mannheim kada se rabi FuGENE 6 reagens za transfekciju. Transficirane CHO stanice zasađene su u mikroploču s 96 jažica iz FlashPlate® pribora za analizu, koje su prevučene s čvrstim scintilantom na kojega se veže antiserum za cAMP. Kao kontrola, neke jažice su imale divlji tip (netransficirane) CHO stanica. Druge jažice na ploči primile su različite količine cAMP standardne otopine za dobivanje standardne krivulje.  Briefly, the DmGPCR coding sequence (eg, cDNA or intronless genomic DNA) was subcloned into a commercial expression vector, such as pzeoSV2 (Invitrogen) and transiently transfected into Chinese guinea pig ovary (CHO) cells using known methods, such as the transfection protocol of gives such Boehringer-Mannheim when FuGENE 6 transfection reagent is used. Transfected CHO cells were seeded in a 96-well microplate from the FlashPlate® assay kit, which was coated with a solid scintillant to which cAMP antiserum binds. As a control, some wells had wild-type (untransfected) CHO cells. Other wells of the plate received different amounts of cAMP standard solution to obtain a standard curve. 
 
 
   Jedan ili više testnih spojeva (tj. kandidatskih modulatora) dodano je stanicama u svaku jažicu, s vodom i/ili spoj-slobodnim medijem/razrjeđivačem koji služi kao kontrola ili kontrole. Nakon tretiranja, cAMP je ostavljen da se akumulira u stanicama točno 15 minuta na sobnoj temperaturi. Analiza je završena dodatkom liznog pufera koji sadrži [125I]-obilježeni cAMP i ploče su izbrojane korištenjem Packard Topcount™ microplate scintilacijskog brojača s 96 jažica. Neobilježeni cAMP iz lizirane stanice (ili standarda) i nepromjenjive količine [125I]-cAMP kompetiraju za antitijelo koje je vezano za ploču. Načinjena je standardna krivulja i cAMP vrijednosti za nepoznate uzorke su dobivene interpoliranjem. Promjene u razini unutarstaničnog cAMP kao odgovor na izloženost testnom spoju je indikacija modulirajuće aktivnosti DmGPCR-a. Modulatori koji djeluju kao agonisti receptora koji se vežu za Gs podtip G proteina će stimulirati proizvodnju cAMP, što dovodi do mjerljivog 3-10-strukog povećanja razine cAMP. Agonisti receptora koji se vežu za Gi/0 podtip G proteina će inhibirati forskolin-stimuliranu proizvodnju cAMP, što dovodi do mjerljivog smanjenja razine cAMP od 50-100%. Modulatori koji djeluju kao inverzni agonisti će obrnuti ove učinke na receptorima koji su ili konstitutivno aktivni ili su aktivirani pomoću poznatih agonista.  One or more test compounds (ie, candidate modulators) were added to the cells in each well, with water and/or compound-free medium/diluent serving as a control or controls. After treatment, cAMP was allowed to accumulate in the cells for exactly 15 minutes at room temperature. The assay was terminated by the addition of lysis buffer containing [125I]-labeled cAMP and plates were counted using a Packard Topcount™ 96-well microplate scintillation counter. Unlabeled cAMP from the lysed cell (or standard) and unaltered amounts of [125I]-cAMP compete for the antibody bound to the plate. A standard curve was constructed and cAMP values for unknown samples were obtained by interpolation. Changes in the level of intracellular cAMP in response to exposure to the test compound is an indication of the modulating activity of the DmGPCR. Modulators that act as receptor agonists that bind to the Gs subtype of G proteins will stimulate cAMP production, leading to a measurable 3-10-fold increase in cAMP levels. Receptor agonists that bind to the Gi/0 subtype of G protein will inhibit forskolin-stimulated cAMP production, leading to a measurable decrease in cAMP levels of 50-100%. Modulators that act as inverse agonists will reverse these effects at receptors that are either constitutively active or are activated by known agonists. 
 
 
   Analize ekvorina (aequorin)  Analyzes of aequorin 
 
 
   U sljedećoj analizi, stanice (npr. CHO stanice) prijelazno su kotransficirane s DmGPCR ekspresijskim konstruktom i konstruktom koji kodira fotoprotein apoakvorin. U prisutnosti kofaktora coelenterazina, apoakvorin će emitirati mjerljivu luminescenciju koja je razmjerna količini unutarstaničnog (citoplazmatskog) slobodnog kalcija (vidi općenito, Cobbold, et al, „Aequorin measurements of cytoplasmic free calcium,“ u: Cellular Calcium: Practical Approach, McCormack J.G. i Cobbold P.H., eds., Oxford: IRL Press, 1991; Stables et al., Anal. Biochem., 1997, 252,115-26; i Haugland, Handbook of Fluorescent Probes i Research Chemicals, sixth edition, Eugene, OR, Molecular Probes, 1996).  In the following analysis, cells (eg, CHO cells) were transiently cotransfected with a DmGPCR expression construct and a construct encoding the photoprotein apoaquorin. In the presence of the cofactor coelenterazine, apoaquorin will emit measurable luminescence that is proportional to the amount of intracellular (cytoplasmic) free calcium (see generally, Cobbold, et al, "Aequorin measurements of cytoplasmic free calcium," in: Cellular Calcium: A Practical Approach, McCormack J.G. and Cobbold P.H., eds., Oxford: IRL Press, 1991; Stables et al., Anal. Biochem., 1997, 252,115-26; and Haugland, Handbook of Fluorescent Probes and Research Chemicals, sixth edition, Eugene, OR, Molecular Probes, 1996 ). 
 
 
   U jednoj primjernoj analizi, DmGPCR je subkloniran u komercijalni ekspresijski vektor pzeoSV2 (Invitrogen) i prijelazno kotransficiran zajedno s konstruktom koji kodira fotoprotein apoakvorin (Molecular Probes, Eugene, OR) u CHO stanicama korištenjem transfekcijskog reagensa FuGENE 6 (Boehringer-Mannheim) i protokola za transfekciju koji je opisan uz produkt.  In one exemplary assay, the DmGPCR was subcloned into the commercial expression vector pzeoSV2 (Invitrogen) and transiently cotransfected together with a construct encoding the photoprotein apoaquorin (Molecular Probes, Eugene, OR) in CHO cells using the FuGENE 6 transfection reagent (Boehringer-Mannheim) and the protocol for transfection described with the product. 
 
 
   Stanice su uzgajane tijekom 24 sata na 37ºC u MEM (Gibco/BRL, Gaithersburg, MD) kojemu je dodan 10% serum volovskog zametka, 2 mM glutamin, 10 U/ml penicilin i 10 μg/ml streptomicin, nakon čega je medij zamijenjen sa serum-slobodnim MEM koji sadrži 5 μM koelenterazina (Molecular Probes, Eugene, OR). Uzgajanje je zatim nastavljeno daljnjih dva sata na 37ºC. Nakon toga, stanice su odvojene od ploče pomoću VERSEN (Gibco/BRL), isprane i resuspendirane sa 200000 stanica/ml u serum-slobodnom MEM.  Cells were grown for 24 hours at 37ºC in MEM (Gibco/BRL, Gaithersburg, MD) supplemented with 10% fetal bovine serum, 2 mM glutamine, 10 U/ml penicillin, and 10 μg/ml streptomycin, after which the medium was replaced with with serum-free MEM containing 5 μM coelenterazine (Molecular Probes, Eugene, OR). Cultivation was then continued for a further two hours at 37ºC. Subsequently, cells were detached from the plate using VERSEN (Gibco/BRL), washed and resuspended at 200,000 cells/ml in serum-free MEM. 
 
 
   Razrjeđenja kandidatskih DmGPCR modulatorskih spojeva priređena su u serum-slobodnom MEM i raspodijeljena su u jažice neprozirne ploče s 96 jažica sa 50 μl/jažica. Ploče su zatim stavljene na MLX luminometar mikrotitarske ploče (Dynex Technologies, Inc., Chantilly, VA). Instrument je programiran da dozira 50 μl stanične suspenzije u svaku jažicu, jažicu po jažicu i da neposredno očita luminescenciju 15 sekundi. Krivulje doza-odgovor za kandidatske modulatore načinjene su korištenjem površine pod krivuljom za svaki peak svjetlosnog signala. Podaci su analizirani s Slide Write, korištenjem jednadžbe za ligand na jednom mjestu i dobivene su vrijednosti EC50. Promjene luminescencije koje su izazvane spojevima smatraju se indikativnima za modulatorsku aktivnost. Modulatori koji djeluju kao agonisti na receptorima koji se vežu zao Gq podtip G proteina daju povećanje luminescencije do 100 puta. Modulatori koji djeluju kao inverzni agonisti će obrnuti ovaj efekt bilo da su konstitutivni aktivni ili su aktivirani poznatim agonistima.  Dilutions of candidate DmGPCR modulator compounds were prepared in serum-free MEM and dispensed into wells of an opaque 96-well plate at 50 μl/well. Plates were then loaded onto an MLX luminometer microtiter plate (Dynex Technologies, Inc., Chantilly, VA). The instrument is programmed to dispense 50 μl of cell suspension into each well, well by well, and to read the luminescence directly for 15 seconds. Dose-response curves for candidate modulators were constructed using the area under the curve for each light signal peak. Data were analyzed with Slide Write, using the single-site ligand equation, and EC50 values were obtained. Luminescence changes induced by compounds are considered indicative of modulatory activity. Modulators that act as agonists on receptors that bind to the evil Gq subtype of G protein give an increase in luminescence up to 100 times. Modulators that act as inverse agonists will reverse this effect whether they are constitutively active or are activated by known agonists. 
 
 
   Analiza luciferaza reporter gena  Analysis of luciferase reporter genes 
 
 
   Fotoprotein luciferaza definira drugo korisno pomagalo za analiziranje na modulatorsku aktivnost DmGPCR-a. Stanice (npr. CHO stanice ili COS7 stanice) su prijelazno kotransficirane s DmGPCR ekspresijskim konstruktom (npr. DmGPCR u pzeoSV2) i reporterskim konstruktom koji sadrži gen za ludiferaza protein nizvodno od vezujućeg mjesta transkripcijskog faktora, kao što je element cAMP-odgovora (CRE), AP-1 ili NF-kapa B. Agonist koji se veže za receptore koji su vezani za Gs podtip G proteina dovodi do povećanja cAMP, čime se aktivira CRE transkripcijski faktor i rezultat je ekspresija luciferaza gena. Agonističko vezanje za Gq podtip G proteina dovodi do proizvodnje diacilglicerola koji aktivira protein kinazu C, koja aktivira AP-1 ili NF-kapa B transkripcijske faktore, što opet rezultira ekspresijom luciferaza gena. Ekspresijske razine luciferaze odražavaju aktivacijski status signalnih događaja. Vidi općenito, George et al, J. Biomolecular Screening, 1997, 2(4), 235-240; i Stratowa et al, Curr. Opin. Biotechnol., 1995, 6, 574-581. Aktivnost luciferaze može se kvantitativno mjeriti korištenjem, npr. reagensa za luciferaza analizu koji se mogu komercijalno nabaviti od tvrtke Promega (Madison, WI).  Photoprotein luciferase defines another useful tool for assaying for DmGPCR modulatory activity. Cells (e.g., CHO cells or COS7 cells) are transiently cotransfected with a DmGPCR expression construct (e.g., DmGPCR in pzeoSV2) and a reporter construct containing a gene for a ludiferase protein downstream of a transcription factor binding site, such as a cAMP-response element (CRE). . Agonist binding to the Gq subtype of G protein leads to the production of diacylglycerol which activates protein kinase C, which activates AP-1 or NF-kappa B transcription factors, which in turn results in the expression of the luciferase gene. Luciferase expression levels reflect the activation status of signaling events. See generally, George et al, J. Biomolecular Screening, 1997, 2(4), 235-240; and Stratow et al., Curr. Opin. Biotechnol., 1995, 6, 574-581. Luciferase activity can be quantitatively measured using, for example, luciferase assay reagents commercially available from Promega (Madison, WI). 
 
 
   U jednoj primjernoj analizi, CHO stanice su nanesene na ploču s 24 jažice s gustoćom 100000 stanica/jažica jedan dan prije transfekcije i uzgajanje su na 37ºC u MEM (Gibco/BRL) kojemu je dodan 10% serum volovskog zametka, 2 mM glutamin, 10 U/ml penicilin i 10 μg/ml streptomicin. Stanice su prijelazno kotransficirane s DmGPCR ekspresijskim konstruktom i reporterskim konstruktom koji sadrži luciferaza gen. Reporterski plazmidi CRE-luciferaza, AP-1-luciferaza i NF-kapa B-luciferaza mogu se nabaviti od tvrtke Stratagene (LaJolla, CA). Transfekcije su izvršene korištenjem FuGENE 6 reagensa za transfekciju (Boehringer-Mannheim) sukladno naputku proizvođača. Stanice koje su transficirane samo s reporterskim genom korištene su kao kontrola. Dvadeset i četiri sata nakon transfekcije, stanice su isprane jednom s PBS koji je prethodno zagrijan na 37ºC. Serum-slobodni MEM zatim je dodan stanicama bilo sam (kontrola) ili s jednim ili više kandidatskih modulatora te su stanice inkubirane na 37ºC tijekom pet sati. Nakon toga, stanice su isprane jednom s ledenohladnim PBS i lizirane dodatkom 100 μl liznog pufera po jažici iz pribora za analizu luciferaze što proizvodi tvrtka Nakon inkubiranja 15 minuta na sobnoj temperaturi, 15 μl lizata pomiješano je s 50 μl otopine supstrata (Promega) na neprozirnoj bijeloj ploči s 96 jažica pa je luminescencija trenutačno očitana na Wallace model 1450 MicroBeta scintilacijskom i luminescencijskom brojaču (Wallace Instruments, Gaithersburg, MD).  In an exemplary assay, CHO cells were plated in a 24-well plate at a density of 100,000 cells/well one day before transfection and grown at 37ºC in MEM (Gibco/BRL) supplemented with 10% fetal bovine serum, 2 mM glutamine, 10 U/ml penicillin and 10 μg/ml streptomycin. Cells were transiently cotransfected with a DmGPCR expression construct and a reporter construct containing the luciferase gene. CRE-luciferase, AP-1-luciferase, and NF-kappa B-luciferase reporter plasmids are available from Stratagene (LaJolla, CA). Transfections were performed using FuGENE 6 transfection reagent (Boehringer-Mannheim) according to the manufacturer's instructions. Cells transfected with the reporter gene alone were used as a control. Twenty-four hours after transfection, cells were washed once with PBS prewarmed to 37ºC. Serum-free MEM was then added to the cells either alone (control) or with one or more of the candidate modulators, and the cells were incubated at 37ºC for five hours. After that, the cells were washed once with ice-cold PBS and lysed by adding 100 μl of lysis buffer per well from the luciferase assay kit produced by the company. After incubation for 15 minutes at room temperature, 15 μl of the lysate was mixed with 50 μl of substrate solution (Promega) on an opaque white 96-well plate and luminescence was instantaneously read on a Wallace model 1450 MicroBeta scintillation and luminescence counter (Wallace Instruments, Gaithersburg, MD). 
 
 
   Razlike u luminescenciji u prisutnosti i one u odsutnosti kandidatskog modulatorskog spoja su indicija modulatorske aktivnosti. Receptori koji su konstitutivno aktivni ili su aktivirani agonistima tipično daju 3-20-struko stimuliranje luminescencije u usporedbi sa stanicama koje su transficirane samo s reporterskim genom. Modulatori koji djeluju kao inverzni agonisti će obrnuti ovaj efekt.  Differences in luminescence in the presence and absence of a candidate modulatory compound are indicative of modulatory activity. Receptors that are constitutively active or activated by agonists typically provide a 3-20-fold stimulation of luminescence compared to cells transfected with the reporter gene alone. Modulators that act as inverse agonists will reverse this effect. 
 
 
   Mjerenje unutarstaničnog kalcija pomoću FLIPR  Measurement of intracellular calcium using FLIPR 
 
 
   Promjene u razini unutarstaničnog kalcija je drugi potvrđeni indikator aktivnosti G protein-vezanog receptora i takve analize mogu se izvršiti da se izvrši pretraživanje na modulatorsku aktivnost DmGPCR-a. Primjerice, CHO stanice postojano su transficirane s DmGPCR ekspresijskim vektorom i nanesene su na ploču 4×104 stanica/jažica (Packard crnih stijenki, 96 jažica po ploči) koja je posebno oblikovana da se diskriminiraju fluorescencijski signali koji dolaze iz različitih jažica na ploči. Stanice su inkubirane tijekom 60 minuta na 37ºC u modificiranom Dulbecco PBS (D-PBS) koji sadrži 36 mg/L piruvata i 1 g/L glukoze i jednu od četiri boje kao kalcijeva indikatora (Fluo-3™ AM, Fluo-4™ AM, Calcium Green™-1 AM ili Oregon Green™ 488 BAPTA-1 AM), svaka pri koncentraciji 4 μM. Ploče su isprane jednom s modificiranim D-PBS i inkubirane 10 minuta na 37ºC da se ukloni ostatna boja iz stanične membrane. Nadalje, izvršen je niz ispiranja s modificiranim D-PBS neposredno prije aktivacije kalcijeva odgovora.  Changes in the level of intracellular calcium is another validated indicator of G protein-coupled receptor activity, and such analyzes can be performed to search for modulatory activity of DmGPCRs. For example, CHO cells were stably transfected with a DmGPCR expression vector and plated on a 4x104 cells/well plate (Packard black wall, 96 wells per plate) specially designed to discriminate fluorescence signals coming from different wells of the plate. Cells were incubated for 60 minutes at 37ºC in modified Dulbecco's PBS (D-PBS) containing 36 mg/L pyruvate and 1 g/L glucose and one of four dyes as calcium indicators (Fluo-3™ AM, Fluo-4™ AM , Calcium Green™-1 AM or Oregon Green™ 488 BAPTA-1 AM), each at a concentration of 4 μM. Plates were washed once with modified D-PBS and incubated for 10 minutes at 37ºC to remove residual dye from the cell membrane. Furthermore, a series of washes with modified D-PBS was performed immediately before the activation of the calcium response. 
 
 
   Kalcijev odgovor je potaknut dodatkom jednog ili više kandidatskih receptorskih agonističkih spojeva, kalcijeva ionofora A23187 (10 μM; pozitivna kontrola) ili ATP (4 μM; pozitivna kontrola). Fluorescencija je mjerena pomoću Molecular Device’s FLIPR s argonskim laserom (ekscitacija na 488 nm) (vidi, npr. Kuntzweiler et at, Drug Dev. Res., 1998, 44(1), 14-20). F-stop (otvor blende) za detektorsku kameru postavljen je na 2,5 i dužina ekspozicije je bila 0,4 milisekunde. Osnovna fluorescencija stanica mjerena je tijekom 20 sekundi prije dodavanja kandidatskog agonista, ATP ili A23187 i razina osnovne fluorescencije oduzeta je od signala odgovora. Signal kalcija mjeren je približno 200 sekundi, uz očitanja svake 2 sekunde. Kalcij ionofor A23187 i ATP povećavaju signal kalcija 200% iznad osnovne razine. Općenito, aktivirani GPCR-ovi povećavaju signal kalcija približno 10-15% iznad osnovnog signala.  The calcium response was induced by the addition of one or more candidate receptor agonist compounds, the calcium ionophore A23187 (10 μM; positive control) or ATP (4 μM; positive control). Fluorescence was measured using Molecular Device's FLIPR with an argon laser (excitation at 488 nm) (see, e.g., Kuntzweiler et at, Drug Dev. Res., 1998, 44(1), 14-20). The f-stop (aperture) for the detector camera was set to 2.5 and the exposure length was 0.4 milliseconds. Baseline fluorescence of the cells was measured for 20 seconds before addition of the candidate agonist, ATP or A23187 and the baseline fluorescence level was subtracted from the response signal. The calcium signal was measured for approximately 200 seconds, with readings taken every 2 seconds. The calcium ionophore A23187 and ATP increase the calcium signal by 200% above baseline. In general, activated GPCRs increase the calcium signal approximately 10-15% above the baseline signal. 
 
 
   Analiza mitogeneze  Analysis of mitogenesis 
 
 
   U analizi mitogeneze, određuje se sposobnost kandidatskog modulatora da inducira ili inhibira DmGPCR-upravljano staničnu diobu (vidi, npr. Lajiness et al, J. Pharm. i Exper. r., 1993, 267(3), 1573-1581). Primjerice, CHO stanice s postojanom ekspresijom DmGPCR postavljene su u ploču s 96 jažica s gustoćom 5000 stanica/jažica i uzgajane su na 37ºC u MEM s 10% seruma goveđeg fetusa tijekom 48 sati. Nakon toga su stanice dva puta isprane sa serum-slobodnim MEM. Nakon ispiranja, dodano je 80 μl svježeg MEM ili MEM koji sadrži poznati mitogen, zajedno s 20 μl MEM koji sadrži promjenjive koncentracije jednog ili više kandidatskih modulatora ili testnih spojeva koji su razrijeđeni u serum-slobodnom mediju. Kao kontrole, neke jažice na svakoj ploči sadržavale su samo serum-slobodni medij i neke su imale medij koji sadrži 10% serum goveđeg fetusa. Netransficirane stanice ili stanice koje su transficirane samo s vektorom mogu služiti kao kontrole.  In a mitogenesis assay, the ability of a candidate modulator to induce or inhibit DmGPCR-driven cell division is determined (see, e.g., Lajiness et al, J. Pharm. and Exper. r., 1993, 267(3), 1573-1581). For example, CHO cells stably expressing DmGPCR were plated in a 96-well plate at a density of 5000 cells/well and grown at 37ºC in MEM with 10% fetal bovine serum for 48 hours. After that, the cells were washed twice with serum-free MEM. After washing, 80 μl of fresh MEM or MEM containing a known mitogen was added, along with 20 μl of MEM containing varying concentrations of one or more candidate modulators or test compounds diluted in serum-free medium. As controls, some wells on each plate contained only serum-free medium and some had medium containing 10% fetal bovine serum. Untransfected cells or cells transfected with vector alone can serve as controls. 
 
 
   Nakon uzgajanja tijekom 16-18 sati, dodan je u jažice 1 μCi [3H]-timidina (2 Ci/mmol) i stanice su inkubirane daljnjih 2 sata na 37ºC. Stanice su obrađene tripsinom i sakupljene na filteru sakupljačem stanica (Tomtec); pa su filteri izmjereni u Betaplate brojaču. Ugradnja [3H]-timidina u serum-slobodnim testnim jažicama uspoređena je s rezultatima koji su dobiveni u stanicama koje su stimulirane serumom (pozitivna kontrola). Upotreba više koncentracija testnih spojeva omogućuje dobivanje i analizu krivulja doza-odgovor korištenjem nelinearne jednadžbe za metodu najmanjih kvadrata: A = B × [C/ (D + C)] + G, gdje je A postotak stimuliranja seruma; B je maksimalni učinak minus osnovna razina; C je EC50; D je koncentracija spoja; i G je maksimalni učinak. Parametri B, C i G određuju se Simplex metodom optimiziranja.  After culturing for 16-18 hours, 1 μCi of [3H]-thymidine (2 Ci/mmol) was added to the wells and the cells were incubated for a further 2 hours at 37ºC. Cells were treated with trypsin and collected on the filter with a cell harvester (Tomtec); so the filters were measured in a Betaplate counter. Incorporation of [3H]-thymidine in serum-free test wells was compared with the results obtained in serum-stimulated cells (positive control). The use of multiple concentrations of test compounds allows dose-response curves to be obtained and analyzed using a nonlinear least-squares equation: A = B × [C/ (D + C)] + G, where A is the percent serum stimulation; B is the maximum effect minus the base level; C is the EC50; D is the concentration of the compound; and G is the maximum output. Parameters B, C and G are determined by the Simplex optimization method. 
 
 
   Agonisti koji se vežu za receptor očekuje se da povećavaju ugradnju [3H]-timidina u stanice, što daje do 80% odgovora seruma. Antagonisti koji se vežu za receptor će inhibirati stimuliranje koje je uočeno s poznatim agonistom sve do 100%.  Agonists that bind to the receptor are expected to increase [3H]-thymidine incorporation into cells, giving up to 80% of the serum response. Antagonists that bind to the receptor will inhibit the stimulation seen with a known agonist up to 100%. 
 
 
   Analiza vezanja [35S]GTPγS  Analysis of [35S]GTPγS binding 
 
 
   Budući da G protein-vezani receptori signaliziraju kroz unutarstanične G proteine čija aktivnost uključuje GTP vezanje i hidrolizu da se dobije vezani GDP, mjerenje vezanja nehidrolizirajućeg GTP analoga [35S]GTPγS u prisutnosti i odsutnosti kandidatskog modulatora definira drugu analizu za modulator aktivnosti. Vidi, npr. Kowal et al, Neuropharmacology, 1998, 37,179-187.  Because G protein-coupled receptors signal through intracellular G proteins whose activity involves GTP binding and hydrolysis to yield bound GDP, measurement of binding of the non-hydrolyzable GTP analog [35S]GTPγS in the presence and absence of a candidate modulator defines another assay for modulator activity. See, eg, Kowal et al, Neuropharmacology, 1998, 37,179-187. 
 
 
   U jednoj primjernoj analizi, stanice koje su postojano transficirane s DmGPCR-om ekspresijskim vektorom rastu u 10 cm posudama za kulture tkiva da se usklade, isperu jednom s 5 ml ledenohladnog Ca2+/Mg2+-slobodne fosfatno puferirane slane otopine i sastružu u 5 ml istog pufera. Stanice su prešle u talog centrifugiranjem (500×g, 5 minuta), resuspendirane u TEE puferu (25 mM Tris, pH 7,5, 5 mM EDTA, 5 mM EDTA) i zamrznute u tekućem dušiku. Nakon uzimanja, stanice su homogenizirane korištenjem Dounce homogenizatora (1 ml TEE po ploči stanica) i centrifugirane na 1,000×g tijekom 5 minuta da se uklone jezgre i neslomljene stanice.  In an exemplary assay, cells stably transfected with a DmGPCR expression vector are grown in 10 cm tissue culture dishes to confluence, washed once with 5 ml of ice-cold Ca2+/Mg2+-free phosphate-buffered saline, and scraped into 5 ml of the same buffer. . Cells were pelleted by centrifugation (500×g, 5 minutes), resuspended in TEE buffer (25 mM Tris, pH 7.5, 5 mM EDTA, 5 mM EDTA) and frozen in liquid nitrogen. After harvesting, cells were homogenized using a Dounce homogenizer (1 ml TEE per plate of cells) and centrifuged at 1,000×g for 5 min to remove nuclei and unbroken cells. 
 
 
   Homogenat supernatanta centrifugiran je na 20,000×g tijekom 20 minuta da se izdvoji membranska frakcija to i membranski talog je ispran jednom s TEE i resuspendiran u vezujućem puferu (20 mM HEPES, pH 7,5, 150 mM NaCl, 10 mM MgCl2, 1 mM EDTA). Resuspendirane membrane mogu se zamrznuti u tekućem dušiku i pohraniti na -70ºC do upotrebe.  The supernatant homogenate was centrifuged at 20,000×g for 20 min to isolate the membrane fraction and the membrane pellet was washed once with TEE and resuspended in binding buffer (20 mM HEPES, pH 7.5, 150 mM NaCl, 10 mM MgCl2, 1 mM EDTA). Resuspended membranes can be frozen in liquid nitrogen and stored at -70ºC until use. 
 
 
   Alikvoti staničnih membrane priređeni su kao što je prije opisano i pohranjeni na -70ºC pa uzeti, homogenizirani i razrijeđeni u puferu koji sadrži 20 mM HEPES, 10 mM MgCl2, 1 mM EDTA, 120 mM NaCl, 10 μM GDP i 0,2 mM askorbata, pri koncentraciji 10-50 μg/ml. U konačnom volumenu od 90 μl, homogenati su inkubirani s promjenjivom koncentracijom spojeva kandidatskog modulatora ili 100 μM GTP tijekom 30 minuta na 30ºC i zatim stavljeni na led. Svakom dodano je 10 μl guanozin 5’-O-(3[35S]tio) trifosfata (NEN, 1200 Ci/mmol; [35S]-GTPγS), do konačne koncentracije od 100-200 pM. Uzorci su inkubirani na 30ºC tijekom daljnjih 30 minuta, dodan je 1 ml 10 mM HEPES, pH 7,4, 10 mM MgCl2, na 4ºC, pa je reakcija zaustavljena filtriranjem.  Aliquots of cell membranes were prepared as previously described and stored at -70ºC, then harvested, homogenized, and diluted in a buffer containing 20 mM HEPES, 10 mM MgCl2, 1 mM EDTA, 120 mM NaCl, 10 μM GDP, and 0.2 mM ascorbate. , at a concentration of 10-50 μg/ml. In a final volume of 90 μl, homogenates were incubated with varying concentrations of candidate modulator compounds or 100 μM GTP for 30 min at 30ºC and then placed on ice. 10 μl of guanosine 5'-O-(3[35S]thio) triphosphate (NEN, 1200 Ci/mmol; [35S]-GTPγS) was added to each, to a final concentration of 100-200 pM. The samples were incubated at 30ºC for a further 30 minutes, 1 ml of 10 mM HEPES, pH 7.4, 10 mM MgCl2 was added at 4ºC, and the reaction was stopped by filtration. 
 
 
   Uzorci su filtrirani preko Whatman GF/B filtera i filteri su isprani s 20 ml ledenohladnog 10 mM HEPES, pH 7,4, 10 mM MgCl2. Filteri su Izmjereni LC spektroskopijom. Nespecifično vezanje [35S]-GTPγS izmjereno je u prisutnosti 100 μM GTP i oduzeto od totala. Odabrani su spojevi koji moduliraju količinu [35S]GTPγS vezanja u stanicama, u usporedbi s netransficiranim kontrolnim stanicama. Aktiviranje receptora pomoću agonista daje peterostruko povećanje [35S]GTPγS vezanja. Ovaj odgovor je blokiran pomoću antagonista.  Samples were filtered through Whatman GF/B filters and the filters were washed with 20 ml of ice-cold 10 mM HEPES, pH 7.4, 10 mM MgCl 2 . The filters were measured by LC spectroscopy. Nonspecific binding of [35S]-GTPγS was measured in the presence of 100 μM GTP and subtracted from the total. Compounds were selected that modulate the amount of [35S]GTPγS binding in the cells, compared to non-transfected control cells. Activation of the receptor by an agonist results in a fivefold increase in [35S]GTPγS binding. This response is blocked by antagonists. 
 
 
   Analiza aktivnosti MAP kinaze  Analysis of MAP kinase activity 
 
 
   Procjena MAP kinaza aktivnost u stanicama s ekspresijom GPCR definira drugu analizu da se identificiraju modulatori DmGPCR aktivnost. Vidi npr. Lajiness et al, J. Pharm. i Exper. r., 1993, 267(3), 1573-1581 te Boulton et al, Cell, 1991, 65, 663-675.  Assessment of MAP kinase activity in cells with GPCR expression defines another analysis to identify modulators of DmGPCR activity. See, eg, Lajiness et al, J. Pharm. and Exper. r., 1993, 267(3), 1573-1581 and Boulton et al, Cell, 1991, 65, 663-675. 
 
 
   U jednoj realizaciji, CHO stanice postojano transficirane s DmGPCR-om su zasađene na ploče sa 6 jažica s gustoćom 70000 stanica/jažica 48 sati prije analize. Tijekom ovog perioda od 48-sati, stanice su uzgojene na 37ºC u MEM mediju kojem je dodan 10% serum volovskog zametka, 2 mM glutamina, 10 U/ml penicilina i 10 μg/ml streptomicina. Stanice su serum izgladnjele tijekom 1-2 sata prije dodavanja stimulansa.  In one embodiment, CHO cells stably transfected with DmGPCR were seeded in 6-well plates at a density of 70,000 cells/well 48 hours prior to analysis. During this 48-hour period, cells were grown at 37ºC in MEM medium supplemented with 10% fetal bovine serum, 2 mM glutamine, 10 U/ml penicillin, and 10 μg/ml streptomycin. Cells were serum-starved for 1-2 hours before the addition of stimulants. 
 
 
   Za analizu, stanice su tretirane samo s medijem ili s medijem koji sadrži kandidatski agonist ili 200 nM Phorbol ester-miristoil acetata (tj. PMA, pozitivna kontrola) i stanice su inkubirane na 37ºC tijekom različitog vremena. Da se zaustavi reakcija, ploče su stavljene na led, medij je usisan i stanice su isprane s 1 ml ledenohaldnog PBS koji sadrži 1 mM EDTA. Nakon toga, stanicama je dodano 200 μl staničnog lizatnog pufera (12,5 mM MOPS, pH 7,3, 12,5 mM glicerofosfat, 7,5 mM MgCl2, 0,5 mM EDTA, 0,5 mM natrijeva vanadata, 1 mM benzamidina, 1 mM ditiotreitola, 10 μg/ml leupeptina, 10 μg/ml aprotinina, 2 μg/ml pepstatina i 1 μM okadaične kiseline). Stanice su sastrugane s ploča i homogenizirane s 10 prolaza kroz 23 3/4 G iglu i priređena je citosolna frakcija na 20000×g tijekom 15 minuta.  For analysis, cells were treated with medium alone or with medium containing the candidate agonist or 200 nM Phorbol ester-myristoyl acetate (ie, PMA, positive control) and cells were incubated at 37ºC for various times. To stop the reaction, the plates were placed on ice, the medium was aspirated, and the cells were washed with 1 ml of ice-cold PBS containing 1 mM EDTA. After that, 200 μl of cell lysate buffer (12.5 mM MOPS, pH 7.3, 12.5 mM glycerophosphate, 7.5 mM MgCl2, 0.5 mM EDTA, 0.5 mM sodium vanadate, 1 mM benzamidine, 1 mM dithiothreitol, 10 μg/ml leupeptin, 10 μg/ml aprotinin, 2 μg/ml pepstatin and 1 μM okadaic acid). Cells were scraped from the plates and homogenized with 10 passes through a 23 3/4 G needle, and the cytosolic fraction was prepared at 20,000×g for 15 minutes. 
 
 
   Alikvoti (5-10 μl koji sadrži 1-5 μg proteina) citosola pomiješani su s 1 mM MAPK supstratnog peptida (APRTPGGRR (sekv. br. 168), Upstate Biotechnology, Inc., N.Y.) i 50 μM [γ-32P]ATP (NEN, 3000 Ci/mmol), razrijeđeni na konačnu specifičnu aktivnost od ~2000 cpm/pmol, u ukupnom volumenu od 25 μl. Uzorci su inkubirani 5 minuta na 30ºC i reakcije su zaustavljene stavljanjem kapi od 20 μl na 2 cm2 kvadrat Whatman P81 fosfoceluloznog papira. Filterski kvadrati su isprani u 4 izmjene 1% H3PO4 i kvadrati su podvrgnuti LC spektroskopiji da se kvantificira vezani obilježeni dio. Ekvivalentni citosolni ekstrakti su inkubirani bez MAPK supstratnog peptida, te je vezani obilježeni dio iz obih uzoraka oduzet iz odgovarajućih uzoraka sa supstratnim peptidom. Citosolni ekstrakt iz svake jažice korišten je kao odvojena točka. Koncentracije proteina su određene pomoću proteinske analize vezanja boje (Bio-Rad Laboratories). Agonističko aktiviranje receptora očekuje se da rezultira do peterostrukog povećanja MAPK enzimske aktivnosti. Ovo povećanje je blokirano pomoću antagonista.  Aliquots (5–10 μl containing 1–5 μg protein) of cytosol were mixed with 1 mM MAPK substrate peptide (APRTPGGR (SEQ ID NO: 168), Upstate Biotechnology, Inc., N.Y.) and 50 μM [γ-32P]ATP (NEN, 3000 Ci/mmol), diluted to a final specific activity of ~2000 cpm/pmol, in a total volume of 25 μl. Samples were incubated for 5 minutes at 30ºC and reactions were stopped by placing a 20 μl drop on a 2 cm2 square of Whatman P81 phosphocellulose paper. The filter squares were washed with 4 changes of 1% H3PO4 and the squares were subjected to LC spectroscopy to quantify the bound labeled moiety. Equivalent cytosolic extracts were incubated without MAPK substrate peptide, and the bound labeled part from both samples was subtracted from the corresponding samples with substrate peptide. Cytosolic extract from each well was used as a separate spot. Protein concentrations were determined using a dye-binding protein assay (Bio-Rad Laboratories). Agonistic activation of the receptor is expected to result in up to a fivefold increase in MAPK enzymatic activity. This increase is blocked by antagonists. 
 
 
   Otpuštanje [3H]arahidonske kiseline  Release of [3H]arachidonic acid 
 
 
   Aktiviranje GPCR-ova također je uočeno da jača otpuštanje arahidonske kiseline u stanicama, što omogućuje još jednu korisnu analizu na modulatore GPCR aktivnosti. Vidi npr. Kanterman et al, Molecular Pharmacology, 1991, 39, 364-369. Primjerice, CHO stanice koje su postojano transficirane s DmGPCR ekspresijskim vektorom stavljene su na ploče s 24 jažice s gustoćom 15000 stanica/jažica i rasle su u MEM mediju kojem je dodan 10% serum volovskog zametka, 2 mM glutamin, 10 U/ml penicilin i 10 μg/ml streptomicin tijekom 48 sati na 37ºC prije upotrebe. Stanice svake jažice su obilježene inkubiranjem s [3H]-arahidonskom kiselinom (Amersham Corp., 210 Ci/mmol) na 0,5 piCi/ml u 1 ml MEM kojem je dodan 10 mM HEPES, pH 7,5 i 0,5% masna kiselina-slobodni volovski serum albumin tijekom 2 sata 37ºC. Stanice su zatim isprane dva puta s 1 ml istog pufera.  Activation of GPCRs has also been observed to enhance the release of arachidonic acid in cells, providing another useful assay for modulators of GPCR activity. See, eg, Kanterman et al, Molecular Pharmacology, 1991, 39, 364-369. For example, CHO cells stably transfected with a DmGPCR expression vector were plated in 24-well plates at a density of 15,000 cells/well and grown in MEM medium supplemented with 10% fetal bovine serum, 2 mM glutamine, 10 U/ml penicillin and 10 μg/ml streptomycin for 48 hours at 37ºC before use. Cells in each well were labeled by incubating with [3H]-arachidonic acid (Amersham Corp., 210 Ci/mmol) at 0.5 pCi/ml in 1 ml MEM supplemented with 10 mM HEPES, pH 7.5, and 0.5% fatty acid-free bovine serum albumin for 2 hours at 37ºC. The cells were then washed twice with 1 ml of the same buffer. 
 
 
   Kandidatski modulatorski spojevi dodani su u 1 ml istog pufera, bilo sami ili s 10 μM ATP i stanice su inkubirane na 37ºC tijekom 30 minuta. Sam puffer i mock-transfektirane stanice korištene su kao kontrole. Uzorci (0,5 ml) iz svake jažice izbrojani su LC spektroskopijom. Agonisti koji aktiviraju receptor vode do jačanja ATP-stimuliranog otpuštanja [3H]-arahidonske kiseline. Ovo jačanje je blokirano antagonistima.  Candidate modulatory compounds were added to 1 ml of the same buffer either alone or with 10 μM ATP and cells were incubated at 37ºC for 30 minutes. Puffer alone and mock-transfected cells were used as controls. Samples (0.5 ml) from each well were counted by LC spectroscopy. Agonists that activate the receptor lead to enhancement of ATP-stimulated release of [3H]-arachidonic acid. This strengthening is blocked by antagonists. 
 
 
   Brzina izvanstanične acidifikacije  The rate of extracellular acidification 
 
 
   U sljedećoj analizi, učinci kandidatske modulatorske aktivnosti DmGPCR analizirani su praćenjem izvanstaničnih promjena pH koje su izazvane testnim spojevima. Vidi npr. Dunlop et al., J. Pharmacological i Toxicological Methods, 1998, 40(1), 47-55. U jednoj realizaciji, CHO stanice transficirane s DmGPCR-om ekspresijskim vektorom su nasađene u 12 mm kapsulne čašice (Molecular Devices Corp.) na 4×105 stanica/čašica in MEM kojemu je dodan 10% serum volovskog zametka, 2 mM L-glutamin, 10 U/ml penicilin i 10 μg/ml streptomicin. Stanice su inkubirane u ovom mediju na 37ºC u 5% CO2 tijekom 24 sata.  In the following analysis, the effects of the candidate DmGPCR modulatory activity were analyzed by monitoring the extracellular pH changes induced by the test compounds. See, eg, Dunlop et al., J. Pharmacological and Toxicological Methods, 1998, 40(1), 47-55. In one embodiment, CHO cells transfected with a DmGPCR expression vector were seeded in 12 mm capsule dishes (Molecular Devices Corp.) at 4×10 5 cells/dish in MEM supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 10 U/ml penicillin and 10 μg/ml streptomycin. Cells were incubated in this medium at 37ºC in 5% CO2 for 24 hours. 
 
 
   Brzina izvanstaničnog zakiseljavanja mjerena je pomoću Cytosensor mikrofiziometra (Molecular Devices Corp.). Kapsulne čašice su unesene u komoru senzora mikrofiziometra i komore su perfudirane s tekućim puferom (bikarbonat-slobodan MEM obogaćen s 4 mM L-glutamin, 10 jedinica/ml penicilin, 10 μg/ml streptomicin, 26 mM NaCl) brzinom od 100 μl/minute. Kandidatski agonisti ili druga sredstva su razrijeđena u tekućem puferu i perfudirana kroz dugi fluidni put. Tijekom svakog 60-sekundnog ciklusa pumpanja, pumpa je radila 38 sekundi i bila je isključena preostale 22 sekunde. pH tekućeg pufera u komori senzora je bilježen tijekom ciklusa između 43-58 sekundi i pumpa je ponovo pokrenuta nakon 60 sekundi da se pokrene sljedeći ciklus. Brzina zakiseljavanja tekućeg pufera tijekom bilježenog vremena izračunata je pomoću Cytosoft programa. Promjene u brzini zakiseljavanja izračunate su oduzimanjem osnovne vrijednosti (prosjek od 4 mjerenja brzine neposredno prije dodavanja modulatorskog kandidata) od mjerenja najveće brzine koja je dobivena nakon dodavanja modulatorskog kandidata. Odabrani instrument detektira 61 mV/pH jedinica. Modulatori koji djeluju kao agonisti receptora rezultiraju povećanjem brzine izvanstaničnog zakiseljavanja u usporedbi s brzinom u odsutnosti agonista. Ovaj odgovor je blokiran pomoću modulatora koji djeluju kao antagonisti receptora.  The rate of extracellular acidification was measured using a Cytosensor microphysiometer (Molecular Devices Corp.). Capsule cups were inserted into the sensor chamber of the microphysiometer and the chambers were perfused with liquid buffer (bicarbonate-free MEM supplemented with 4 mM L-glutamine, 10 units/ml penicillin, 10 μg/ml streptomycin, 26 mM NaCl) at a rate of 100 μl/minute. . Candidate agonists or other agents are diluted in liquid buffer and perfused through a long fluid path. During each 60-second pumping cycle, the pump was on for 38 seconds and off for the remaining 22 seconds. The pH of the liquid buffer in the sensor chamber was recorded during the cycle between 43-58 seconds and the pump was restarted after 60 seconds to start the next cycle. The rate of acidification of the liquid buffer during the recorded time was calculated using the Cytosoft program. Changes in acidification rate were calculated by subtracting the baseline value (average of 4 rate measurements immediately before addition of the modulator candidate) from the peak rate measurement obtained after addition of the modulator candidate. The selected instrument detects 61 mV/pH units. Modulators that act as receptor agonists result in an increase in the rate of extracellular acidification compared to the rate in the absence of agonist. This response is blocked by modulators that act as receptor antagonists. 
 
 
   Primjer 9: Slaganje DmGPCR-ova s peptidnim ligandima  Example 9: Docking of DmGPCRs with Peptide Ligands 
 
 
   Stanične kulture i transfekcije  Cell cultures and transfections 
 
 
   Stanice divljeg tipa jajnika kineskog zamorca (CHO-K1) (iz: American Type Culture Collection, Rockville, MD) ili CHO-10001A stanice uzgajane su na 37ºC u vlažnoj atmosferi s 5% CO2 u zraku u DMEM mediju kojem je dodano 10% toplinski-neaktiviranog FBS, 10 μg/ml gentamicin, 0,1 mM neesencijalnih aminokiselina da se dobije cjeloviti DMEM medij. Stanice su transficirane s osamljenim GPCR DNAovima u pCR3.1 vektoru, korištenjem LipofectAMINE PLUS™, suštinski sukladno naputku proizvođača. Ukratko, CHO stanice stavljene su na ploču 10 cm sterilne posude tkivne kulture (Corning Glass Works, Corning, NY) i one su bile oko 50-60% konfluentne na dan transfekcije. U plastičnoj epruveti, PLUS (20 μl/plate) dodan je na cDNA plasmid (5 μg /ploča) koji je ranije razrijeđen u 0,75 ml OptiMEM, pomiješan i inkubiran na sobnoj temperature tijekom 15 min. Odvojeno, LipofectAMINE (30 μl/ploča) pomiješan je s 0,75 ml OptiMEM i dodan je pre-kompleksiranoj DNA/PLUS smjesi i inkubirano je na sobnoj temperaturi, tijekom 15 minuta. Medij na stanicama zamijenjen je sa serum-slobodnim transfekcijskim medijem (čisti DMEM, 5 ml/plate) i dodan je DNA-PLUS-LipofectAMINE kompleks (1,5 ml po ploči) te je nježno miješano u mediju uz 3 sata inkubiranje na 37ºC/5% CO2. Medij je zatim dopunjen s cjelovitim DMEM medijem koji sadrži 20% FBS (6,5 ml ml/ploča) i nastavljeno je inkubiranjem na 37ºC/5% CO2 tijekom 24 do 48 sati. Plazmid za zeleni fluorescentni protein (GFP, 4 μg/ploča) korišten je za prijelaznu GFP ekspresiju u CHO stanicama da se procijeni prinos transfekcije u identičnim uvjetima koji su također korišteni za GPCR-ove.  Wild-type Chinese guinea pig ovary cells (CHO-K1) (from: American Type Culture Collection, Rockville, MD) or CHO-10001A cells were grown at 37ºC in a humidified atmosphere with 5% CO2 in air in DMEM medium supplemented with 10% thermal -inactivated FBS, 10 μg/ml gentamicin, 0.1 mM non-essential amino acids to obtain complete DMEM medium. Cells were transfected with isolated GPCR DNAs in the pCR3.1 vector, using LipofectAMINE PLUS™, essentially according to the manufacturer's instructions. Briefly, CHO cells were plated on a 10 cm sterile tissue culture dish (Corning Glass Works, Corning, NY) and were approximately 50–60% confluent on the day of transfection. In a plastic tube, PLUS (20 μl/plate) was added to the cDNA plasmid (5 μg/plate) previously diluted in 0.75 ml OptiMEM, mixed and incubated at room temperature for 15 min. Separately, LipofectAMINE (30 μl/plate) was mixed with 0.75 ml of OptiMEM and added to the pre-complexed DNA/PLUS mixture and incubated at room temperature for 15 minutes. The medium on the cells was replaced with serum-free transfection medium (pure DMEM, 5 ml/plate) and the DNA-PLUS-LipofectAMINE complex (1.5 ml per plate) was added and gently mixed in the medium with 3 hours incubation at 37ºC/ 5% CO2. The medium was then supplemented with complete DMEM medium containing 20% FBS (6.5 ml ml/plate) and continued incubation at 37ºC/5% CO2 for 24 to 48 hours. A plasmid for green fluorescent protein (GFP, 4 μg/plate) was used for transient GFP expression in CHO cells to assess transfection yield under identical conditions also used for GPCRs. 
 
 
   Priređivanje membrane  Preparing the membrane 
 
 
   Transficirane stanice isprane su jednom s ledenohladnom Dulbecco fosfatno puferiranom slanom otopinom (PBS), 5 ml po ploči 10 cm i sastrugane u 5 ml istog pufera. Stanične suspenzije iz više ploča su kombinirane i centrifugirane na 500×g tijekom 10 min na 4ºC. Stanični talog je rekonstituiran na ledenohladnom TEE (25 mM TRIS, 5 mM EGTA, 5 mM EDTA). Pogodni alikvoti su naglo zamrznuti u tekućem dušiku i pohranjeni na -70ºC. Nakon uzimanja, stanice su homogenizirane i centrifugirane na 4ºC, 500×g tijekom 5 minuta da se stalože jezgre i neslomljene stanice. Supernatant je centrifugiran na 47000×g tijekom 30 minuta na 4ºC. Membranski talog je ispran jednom s TEE, resuspendiran u 20 mM HEPES, pH 7,4, 100 mM NaCl, 10 mM MgCl2, 1 mM EDTA (pufer analize), podijeljen u alikvote i zamrznut u tekućem dušiku. Membranski alikvoti su pohranjeni na -70ºC. Koncentracija membranskog proteina određena je korištenjem BCA reagensa za proteinsku analizu od tvrtke Pierce (Rockford, Illinois) i BSA kao standarda.  Transfected cells were washed once with ice-cold Dulbecco's phosphate-buffered saline (PBS), 5 ml per 10 cm plate, and scraped into 5 ml of the same buffer. Cell suspensions from multiple plates were combined and centrifuged at 500×g for 10 min at 4ºC. The cell pellet was reconstituted on ice-cold TEE (25 mM TRIS, 5 mM EGTA, 5 mM EDTA). Suitable aliquots were snap frozen in liquid nitrogen and stored at -70ºC. After collection, cells were homogenized and centrifuged at 4ºC, 500×g for 5 minutes to pellet nuclei and unbroken cells. The supernatant was centrifuged at 47000×g for 30 minutes at 4ºC. The membrane pellet was washed once with TEE, resuspended in 20 mM HEPES, pH 7.4, 100 mM NaCl, 10 mM MgCl2, 1 mM EDTA (assay buffer), aliquoted, and frozen in liquid nitrogen. Membrane aliquots were stored at -70ºC. Membrane protein concentration was determined using BCA protein assay reagent from Pierce (Rockford, Illinois) and BSA as a standard. 
 
 
   Analiza [35S]GTPγS vezanja  Analysis of [35S]GTPγS binding 
 
 
   Uzeti su alikvoti staničnih mebrana, homogenizirani su i razrijeđeni u puferu koji sadrži 20 mM HEPES, pH 7,4, 100 mM NaCl, 10 mM MgCl2, 1 mM EDTA (pufer analize). Na početku, priređene su reakcijske smjese na polipropilenskim pločama s 96 jažica (Nunc). U svaku jažicu, pomiješani su vodena otopina peptida (20 μl, 10 ×) ili vodena kontrola (20 μl), 18,2 μM GDP u puferu analize (0,11 ml, 10 μM final) i membrane koje su suspendirane u puferu analize (50 μl, 10 μg membranskog proteina) te stavljeni na led. Smjese ligand-GDP-membrana inkubirane su tijekom 20 min na sobnoj temperaturi na platformi za mućkanje i zatim stavljene na led. Svakom uzorku dodano je 20 μl guanozin-5’-O-(3-[35S]tio)-trifosfata ([35S]GTPγS) (600-1200 Ci/mmol iz New England Nuclear, Boston, MA) na ~ 40,000 cpm/0,2 ml ili konačne koncentracije 0,1 nM. Ploče s inkubacijskim smjesama (ukupno 0,2 ml/jažica) inkubirane su na sobnoj temperaturi tijekom 45 minuta. Alikvoti reakcijske smjese, 0,175 ml svaki, preneseni su u puferom za ispiranje pretretirane (100 μl/jažica) 96-jažica FB MultiScreen filterske ploče (Millipore) i vakuumski filtrirani korištenjem MultiScreen Vacuum pumpe (Millipore). Membrane su zatim isprane 3 puta s 0,25 ml ledenohladnbog pufera za ispiranje/jažica (10 mM HEPES, 10 mM MgCl2, pH 7,4) i vakuumski filtrirane. Nakon zadnjeg ispiranja, dodana je Supermix Opti-phase scintilacijska tekućina (25 μl /jažica, Wallac) i ploče su zatvorene te izmjerene u Trilux 1450 Microbeta brojaču (Wallac) tijekom 1 minuta/jažica. Kao pozitivne kontrole, membrane iz CHO stanica sa postojanom ekspresijom dopamin tip 2 (rD2) receptora tretirane su s 1 mM dopaminom u 0,025% askorbinskoj kiselini (100 μM konačna koncentracija dopamina) ili nosaču (0,0025% konačna koncentracija askorbinske kiseline). Nespecifično vezanje izmjereno je u prisutnosti 100 μM hladnog GTPγS i oduzeto od totala. Svako tretiranje izvršeno je u triplikatu.  Aliquots of cell membranes were taken, homogenized and diluted in a buffer containing 20 mM HEPES, pH 7.4, 100 mM NaCl, 10 mM MgCl2, 1 mM EDTA (analysis buffer). Initially, reaction mixtures were prepared in 96-well polypropylene plates (Nunc). Into each well, aqueous peptide solution (20 μl, 10×) or aqueous control (20 μl), 18.2 μM GDP in assay buffer (0.11 ml, 10 μM final) and membranes suspended in assay buffer were mixed. (50 μl, 10 μg membrane protein) and placed on ice. Ligand-GDP-membrane mixtures were incubated for 20 min at room temperature on a shaking platform and then placed on ice. To each sample, 20 μl of guanosine-5'-O-(3-[35S]thio)-triphosphate ([35S]GTPγS) (600-1200 Ci/mmol from New England Nuclear, Boston, MA) was added at ~ 40,000 cpm/ 0.2 ml or a final concentration of 0.1 nM. Plates with incubation mixtures (total 0.2 ml/well) were incubated at room temperature for 45 minutes. Aliquots of the reaction mixture, 0.175 ml each, were transferred to wash buffer-pretreated (100 μl/well) 96-well FB MultiScreen filter plates (Millipore) and vacuum filtered using a MultiScreen Vacuum pump (Millipore). Membranes were then washed 3 times with 0.25 ml of ice-cold wash buffer/well (10 mM HEPES, 10 mM MgCl2, pH 7.4) and vacuum filtered. After the last wash, Supermix Opti-phase scintillation fluid (25 μl/well, Wallac) was added and the plates were sealed and counted in a Trilux 1450 Microbeta counter (Wallac) for 1 minute/well. As positive controls, membranes from CHO cells stably expressing dopamine type 2 (rD2) receptors were treated with 1 mM dopamine in 0.025% ascorbic acid (100 μM final concentration of dopamine) or vehicle (0.0025% final concentration of ascorbic acid). Nonspecific binding was measured in the presence of 100 μM cold GTPγS and subtracted from the total. Each treatment was performed in triplicate. 
 
 
   Analiza podataka  Data analysis 
 
 
   Ligand-izazvano stimuliranje [35S]GTPγS vezanja izraženo je kao povećanje u odnosu na osnovnu aktivnost kada nije dodan ligand. Svaki tretman izvršen je u triplikatu ili, povremeno, u duplikatu i vezanje (cpm) je izračunato kao prosjek +/- standardna devijacija. Krivulje doza-odgovor za sustave receptor/ligand analizirane su korištenjem nelinearnog SAS modela metode najmanjih kvadrata, y= BmaxX/(Kd + X). Druge krivulje doza-odgovor analizirane su korištenjem Prism programa (GraphPad Software, Inc. San Diego, CA) i sukladno jednadžbi y = dno + (vrh - dno)/ (1 + 10logEC50-X).  Ligand-induced stimulation of [35S]GTPγS binding was expressed as an increase over baseline activity when no ligand was added. Each treatment was performed in triplicate or, occasionally, in duplicate and binding (cpm) was calculated as the mean +/- standard deviation. Dose-response curves for receptor/ligand systems were analyzed using a non-linear least-squares SAS model, y= BmaxX/(Kd + X). Other dose-response curves were analyzed using the Prism program (GraphPad Software, Inc. San Diego, CA) and according to the equation y = bottom + (peak - bottom)/ (1 + 10logEC50-X). 
 
 
   Rezultati  the results 
 
 
   Izvorno, odabrali smo GTPγS analizu kao funkcionalnu analizu jer agonist-pokrenuto stimuliranje GTPγS odražava rane događaje u DmGPCR aktivacijskoj kaskadi, bez obzira na dalje aktivacijske putove različitih nizvodnih signalizirajućih događaja. Ovo se čini osobito korisnim za procjenu mogućeg aktiviranja usamljenih DmGPCR-ova s nepoznatim funkcijama i nepoznatim putovima signaliziranja. GTPγS analiza provedena je s membranama koje su priređene iz CHO stanica koje su prijelazno transficirane s DNA koja kodira Drosophila GPCR-ove korištenjem filterskih ploča s 96 jažica MultiScreen G/FB i MultiScreen vacuumske pumpe (Millipore) za filtriranje. Budući da je poznato da GTPγS analiza slabo prepoznaje GPCR-ove koji su vezani za Gq klasu G-proteina, analiza Ca+2 mobilizacije koja se temelji na FLIPR očitanju korištena je također za procjenu Gq-vezanih usamljenih GPCR-ova u CHO stanicama koje su prijelazno transficirane s DNA koja kodira Drosophila GPCR-ove.  Originally, we chose the GTPγS assay as a functional assay because agonist-triggered stimulation of GTPγS reflects early events in the DmGPCR activation cascade, regardless of further activation pathways of various downstream signaling events. This seems particularly useful for assessing the possible activation of single DmGPCRs with unknown functions and unknown signaling pathways. GTPγS analysis was performed with membranes prepared from CHO cells transiently transfected with DNA encoding Drosophila GPCRs using MultiScreen G/FB 96-well filter plates and a MultiScreen vacuum pump (Millipore) for filtration. Since the GTPγS assay is known to poorly recognize GPCRs that are coupled to the Gq class of G-proteins, a Ca+2 mobilization assay based on FLIPR readout was also used to assess Gq-coupled single GPCRs in CHO cells that were transiently transfected with DNA encoding Drosophila GPCRs. 
 
 
   Korištenjem GTPγS analize, DmGPCR1 (PnuFlyPep34651) nađeno je da je aktiviran pomoću dva Drosophila NPF-slična peptida, AQRSPSLRLRF-NH2 (sekv. br. 186) i PIRSPSLRLRF-NH2 (sekv. br. 187 ) što se odrazilo nađenim EC50 vrijednostima od oko 2,5 nM. Aktiviranje s DPKQDFMRF-NH2 (sekv. br. 26) i PDNFMRF-NH2 (sekv. br. 27) rezultiralo je GTPγS odgovorima s EC50 u rasponu od 370 nM do 500 nM. Kao što je izvijestio Nambu et al. (Neuron, 1988,1, 55-61), ova dva peptida su kodirana na istom prekursorskom genu zajedno s devet drugih FaRPova. Daljnji FaRPovi i drugi neuropeptidi koji stimuliraju GTPγS vezanje, premda su manje učinkoviti (EC50 u rasponu 5 do 10 μM), uključuju sljedeće peptide: TDVDHVFLRF-NH2 (sekv. br. 25), TPAEDFMRF-NH2 (sekv. br. 28), SLKQDFMHF-NH2 (sekv. br. 29), SVKQDFMHF-NH2 (sekv. br. 30), AAMDRY-NH2 (sekv. br. 31) i SVQDNFMHF-NH2 (sekv. br. 32). Nadalje, FLIPR analiza identificirala je peptid Colorado krumpirove zlatice, ARGPQLRLRF-NH2 (sekv. br. 33), što odgovara DmGPCR1 receptoru s EC50 od 100-200 nM. Naši podaci pokazuju da bi Dmgpcrl trebao biti klasificiran kao kratki neuropeptidni F receptor jer je jako aktiviran s dva kratka NPF peptida, sekv. br. 186 i sekv. br. 187.  Using the GTPγS assay, DmGPCR1 (PnuFlyPep34651) was found to be activated by two Drosophila NPF-like peptides, AQRSPSLRRLRF-NH2 (SEQ ID NO: 186) and PIRSPSLRLRF-NH2 (SEQ ID NO: 187), as reflected by EC50 values of approx. 2.5 nM. Activation with DPKQDFMRF-NH2 (SEQ ID NO: 26) and PDNFMRF-NH2 (SEQ ID NO: 27) resulted in GTPγS responses with EC50s ranging from 370 nM to 500 nM. As reported by Nambu et al. (Neuron, 1988,1, 55-61), these two peptides are encoded on the same precursor gene along with nine other FaRPs. Further FaRPs and other neuropeptides that stimulate GTPγS binding, albeit less efficiently (EC50 in the 5 to 10 μM range), include the following peptides: TDVDHVFLRF-NH2 (SEQ ID NO: 25), TPAEDFMRF-NH2 (SEQ ID NO: 28), SLKQDFMHF-NH2 (SEQ ID NO: 29), SVKQDFMHF-NH2 (SEQ ID NO: 30), AAMDRY-NH2 (SEQ ID NO: 31) and SVQDNFMHF-NH2 (SEQ ID NO: 32). Furthermore, FLIPR analysis identified a Colorado potato beetle peptide, ARGPQLRLRF-NH2 (SEQ ID NO: 33), corresponding to the DmGPCR1 receptor with an EC50 of 100-200 nM. Our data indicate that Dmgpcrl should be classified as a short neuropeptide F receptor because it is strongly activated by two short NPF peptides, seq. no. 186 et seq. no. 187. 
 
 
   Kao što su pokazali GTPγS odgovori, DmGPCR4 (PnuFlyPep 67393) je aktiviran pomoću Drosophila melanogaster alatostatina, drostatina-3 (SRPYSFGL-NH2 (sekv. br. 165)) s EC50 u niskom nanomolarnom rasponu, kao i pomoću različitih Diplotera punctata (žohar) alatostatina, dotično: GDGRLYAFGL-NH2 (sekv. br. 34), DRLYSFGL-NH2 (sekv. br. 35), APSGAQRLYGFGL-NH2 (sekv. br. 36) i GGSLYSFGL-NH2 (sekv. br. 37) (EC50 u rasponu ca. 20-280 nM). Isti peptidi izazvali su vrlo jak kalcijev signal kada su ispitani na 10 μM pomoću FLIPR. DmGPCR4 bio je nedavno kloniran od strane Lenza i suradnika, supra i klasificiran je kao drugi potencijalni alatostatinski receptor (DARII). Međutim, do danas nema farmakoloških podataka o receptorskom aktiviranju. Sukladno našem znanju, ovo je prvi eksperimentalni dokaz da različiti alatostatini aktiviraju ovaj receptor.  As shown by GTPγS responses, DmGPCR4 (PnuFlyPep 67393) was activated by the Drosophila melanogaster allatostatin, drostatin-3 (SRPYSFGL-NH2 (SEQ ID NO: 165)) with an EC50 in the low nanomolar range, as well as by various Diplotera punctata (cockroach) allatostatin, respectively: GDGRLYAFGL-NH2 (SEQ ID NO: 34), DRLYSFGL-NH2 (SEQ ID NO: 35), APSGAQRLYGFGL-NH2 (SEQ ID NO: 36) and GGSLYSFGL-NH2 (SEQ ID NO: 37) (EC50 in range approx. 20-280 nM). The same peptides elicited a very strong calcium signal when probed at 10 μM by FLIPR. DmGPCR4 was recently cloned by Lenz et al., supra and classified as a second potential allatostatin receptor (DARII). However, to date there is no pharmacological data on receptor activation. To our knowledge, this is the first experimental evidence that different allatostatins activate this receptor. 
 
 
   Kao što su pokazali GTP75 odgovori, DmGPCR5 (GenBank pristupni br. AX128628) kada prijelazno imaju ekspresiju u CHO-10001A stanicama, aktivirani su pomoću drotahikinina (DTKs), dotično DTK-1 (APTSSFIGMR-NH2) (sekv. br. 169), Met8-DTK-2 (APLAFYGMR-NH2) (sekv. br. 170), DTK-2 (APLAPYGLR-NH2) (sekv. br. 171, DTK-3 (APTGFTGMR-NH2) (sekv. br. 172), DTK-4 (APVNSFVGMR-NH2) (sekv. br. 173) i DTK-5 (APNGFLGMR-NH2) (sekv. br. 174). U eksperimentima doza-odgovor, DTK-1, Met8-DTK-2, DTK-3 i DTK-5 stimulirano GTP-γS vezanje je s EC50 u 250-500 nM rasponu i maksimalno stimuliranje je cca 1,5-puta iznad osnovne razine. DTK-2 i DTK-4 su slabije snage sudeći prema njihovu EC50 koji je u niskom mikromolarnom rasponu. U analizi kalcijeve mobilizacije (FLIPR), DmGPCR5 pokazao je Ca+2 odgovore na iste DTKove s EC50 u rasponu 1-20 nM. Nadalje, DTK-5, DTK-2 i Met8-DTK-2 ispitani su u cAMP (reporter-gen-zasnovanoj) analizi te je stimulirano cAMP otpuštanje na način doza-odgovor s EC50 vrijednostima od 197 nM, 1,06 μM, odnosno 583 nM. Ovi podaci pokazuju da se DmGPCR5 veže za oba Gs (cAMP) i Gq (Ca+2)-upravljana signalna puta što je analogno signalnim putovima koji su navedeni za tahikinin receptore kralježnjaka.  As shown by GTP75 responses, DmGPCR5 (GenBank accession no. AX128628) when transiently expressed in CHO-10001A cells, was activated by drotachikinins (DTKs), namely DTK-1 (APTSSFIGMR-NH2) (SEQ ID NO: 169), Met8-DTK-2 (APLAFYGMR-NH2) (SEQ ID NO: 170), DTK-2 (APLAPYGLR-NH2) (SEQ ID NO: 171, DTK-3 (APTGFTGMR-NH2) (SEQ ID NO: 172), DTK -4 (APVNSFVGMR-NH2) (SEQ ID NO: 173) and DTK-5 (APNGFLGMR-NH2) (SEQ ID NO: 174). In dose-response experiments, DTK-1, Met8-DTK-2, DTK-3 and DTK-5 stimulated GTP-γS binding with an EC50 in the 250-500 nM range and maximal stimulation was approximately 1.5-fold above baseline DTK-2 and DTK-4 are less potent judging by their EC50 which is in the low micromolar range. In a calcium mobilization assay (FLIPR), DmGPCR5 showed Ca+2 responses to the same DTKs with EC50 in the range 1-20 nM. Furthermore, DTK-5, DTK-2 and Met8-DTK-2 were tested in cAMP ( reporter-gene-based) analysis and cAMP release was stimulated in a dose-response manner with EC50 values of 197 nM, 1.06 μM, or 583 nM. These data indicate that DmGPCR5 binds to both Gs (cAMP) and Gq (Ca+2)-operated signaling pathways analogous to the signaling pathways reported for vertebrate tachykinin receptors. 
 
 
   DmGPCR6a (M811490) objelodanjen je kao PYY receptor: Li et al. (J. Biol. Chem., 1992,267, 9-12). Korištenjem GTPγS analize, peptidi koji su navedeni u tablici 7 ispitani su pri 5 μM, stimuliranim GTPγS vezanjem (1,7 do 4 puta povećanje prema osnovnoj razini) za membrane iz CHO stanica koje su transficirane s DNA koja kodira DmGPCR6a. Valja naglasiti da, uz bateriju insektnih i C. elegans peptida koji aktiviraju ovaj receptor, također je nađeno da je humani NPFF (FLFQPQRF-NH2 (sekv. br. 59)) ligand za DmGPCR6 (4-struko povećanje GTPγS vezanja za 5 μM NPFF).  DmGPCR6a (M811490) is disclosed as a PYY receptor: Li et al. (J. Biol. Chem., 1992, 267, 9-12). Using the GTPγS assay, the peptides listed in Table 7 were tested at 5 μM, stimulated GTPγS binding (1.7- to 4-fold increase over baseline) to membranes from CHO cells transfected with DNA encoding DmGPCR6a. It should be noted that, in addition to a battery of insect and C. elegans peptides that activate this receptor, human NPFF (FLFQPQRF-NH2 (SEQ ID NO: 59)) was also found to be a ligand for DmGPCR6 (4-fold increase in GTPγS binding by 5 μM NPFF ). 
 
 
   Dmgpcr6aL i Dmgpcr6bL su dvije splice inačice DmGPCR-a6a (M811490). Ovaj drugi naveden je kao PYY receptor od strane Li et al. (J. Biol. Chem., 1992, 267, 9-12). Mi smo nazvali i DmGPCR6aL i DmGPCR6bL, RF-amidnim receptorima jer oni prepoznaju samo peptide koji imaju Arg-Phe-NH2 (RFa) sekvenciju na C-terminalu. Peptidi koji ne “vide” ove DmGPCR-ove imaju drukčije od RFa sekvencija na C-kraju (npr. SFa, QFa, YFa, RLa, DWa, RPa, HFa, LQa, SNa itd.). U analizi kalcijeve mobilizacije (FLIPR), Dmgpcr6aL i Dmgpcr6bL pokazali su vrlo jake Ca+2 odgovore na bateriju FaRPova koji su testirani na 10 μM. Sekvencije koje su prikazane niže u tablici 7 predstavljaju sve identificirane aktivne FaRPove koji pripadaju različitim specijama uključujući Drosophila, C. elegans, A. suum, Mollusca, P. redivivus, Trematoda, jastog, čovjek i pijavica. Jedini izuzetak za C-kraj „RFamid pravila“ bio je peptid pGluDRDYRPLQF-NH2 (sekv. br. 120), čiji C-terminal završava sekvencijom Gln-Phe-NH2 (QFa). Zanimljivo, i Dmgpcr6aL i Dmgpcr6bL također prepoznaju NPFF (FLFQPQRF-NH2 (sekv. br. 152)), peptid sisavaca s RFamid sekvencijom na C-terminalu (pozornost: u gore navedenim rezultatima p-Glu ili pQ odnose se na piroglutaminsku kiselinu).  Dmgpcr6aL and Dmgpcr6bL are two splice variants of DmGPCR-a6a (M811490). The latter was listed as a PYY receptor by Li et al. (J. Biol. Chem., 1992, 267, 9-12). We named both DmGPCR6aL and DmGPCR6bL RF-amide receptors because they only recognize peptides that have an Arg-Phe-NH2 (RFa) sequence at the C-terminal. Peptides that do not "see" these DmGPCRs have different than RFa sequences at the C-end (eg SFa, QFa, YFa, RLa, DWa, RPa, HFa, LQa, SNa, etc.). In a calcium mobilization assay (FLIPR), Dmgpcr6aL and Dmgpcr6bL showed very strong Ca+2 responses to a battery of FaRPs tested at 10 μM. The sequences shown below in Table 7 represent all identified active FaRPs belonging to different species including Drosophila, C. elegans, A. suum, Mollusca, P. redivivus, Trematoda, lobster, human and leech. The only exception to the C-terminus of the "RFamide rule" was the peptide pGluDRDYRPLQF-NH2 (SEQ ID NO: 120), whose C-terminus ends with the sequence Gln-Phe-NH2 (QFa). Interestingly, both Dmgpcr6aL and Dmgpcr6bL also recognize NPFF (FLFQPQRF-NH2 (SEQ ID NO: 152)), a mammalian peptide with a C-terminal RFamide sequence (caution: in the above results p-Glu or pQ refer to pyroglutamic acid). 
 
 
   Kao što se pokazalo pomoću FLIPR analize, DmGPCR7 (GenBank pristupni br. AX128636) s prijelaznom ekspresijom u CHO-10001A stanicama, aktiviran je pomoću leukokinina (LK-ovi) i srodnih peptida, dotično LK-I (DPAFNSWGa) (sekv. br. 175), LK-V (GSGFSSWGa) (sekv. br. 176), LK-VI (pGlu-SSFHSWGa) (sekv. br. 177), LK-VHI (GSAFYSWGa) (sekv. br. 178), kulekinin (NPFHSWGa) (sekv. br. 179), mekušac limnokinin (PSFHSWSa) (sekv. br. NO: 180) i Drosophila leukokinin-slični peptidi DLK-1 (NSVVLGKKQRFHSWGa) (sekv. br. 181), DLK-2 (pGlu-RFHSWGa) (sekv. br. 182) i DLK-2A (QRFHSWGa) (sekv. br. 183). DmGPCR7 bio je najbolje aktiviran pomoću LK peptida koji imaju zajedničku C-terminalnu tetrapeptidnu sekvenciju, HSWGa. Tretmani s ovom skupinom peptida, koji obuhvaćaju DLK-1, DLK-2, DLK-2a, LK-VI i kulekinin, rezultiraju vrlo snažnim unutarstaničnim otpuštanjem kalcija (EC50 je u rasponu od pikomolarnog do subnanomolarnog). Nasuprot tome, lokust LK-ovi s C-terminanim S/NSWGa (LK-I, LK-V) kao što je Lymnaea LK (sekv. br. 180), pokazali su se manje snažnim (EC50 15-30 nM) i LK-VIII sa svojom YSWGa C-terminalnom sekvencijom bio je najmanje snažan u nizu (EC50 u rasponu 100-200 nM). Nisu uočeni nikakvi GTPγS odgovori u membranama koje su priređene iz DmGPCR7/CHO stanica, što je indikacija Gqm-vezanog receptora. Prema tome, DmGPCR7 identificiran je kao kalcij-signalizirajući leukokininski receptor (najvjerojatnije Gq/n -vezan) i u paru je s drolukokininima kao njihov poznat ligand.  As shown by FLIPR analysis, DmGPCR7 (GenBank accession no. AX128636) transiently expressed in CHO-10001A cells was activated by leukokinins (LKs) and related peptides, namely LK-I (DPAFNSWGa) (SEQ ID NO. 175), LK-V (GSGFSSWGa) (SEQ ID NO: 176), LK-VI (pGlu-SSFHSWGa) (SEQ ID NO: 177), LK-VHI (GSAFYSWGa) (SEQ ID NO: 178), Kulekinin (NPFHSWGa ) (SEQ ID NO: 179), mollusc limnokinin (PSFHSWSa) (SEQ ID NO: 180) and Drosophila leucokinin-like peptides DLK-1 (NSVVLGKKQRFHSWGa) (SEQ ID NO: 181), DLK-2 (pGlu-RFHSWGa ) (SEQ ID NO: 182) and DLK-2A (QRFHSWGa) (SEQ ID NO: 183). DmGPCR7 was best activated by LK peptides sharing a common C-terminal tetrapeptide sequence, HSWGa. Treatments with this group of peptides, which include DLK-1, DLK-2, DLK-2a, LK-VI, and culekinin, result in very strong intracellular calcium release (EC50 ranges from picomolar to subnanomolar). In contrast, locust LKs with C-terminal S/NSWGa (LK-I, LK-V) such as Lymnaea LK (SEQ ID NO: 180), were shown to be less potent (EC50 15-30 nM) and LK -VIII with its YSWGa C-terminal sequence was the least potent of the series (EC50 in the range 100-200 nM). No GTPγS responses were observed in membranes prepared from DmGPCR7/CHO cells, indicating a Gqm-coupled receptor. Therefore, DmGPCR7 has been identified as a calcium-signaling leucokinin receptor (most likely Gq/n -coupled) and is paired with droleukokinins as their known ligand. 
 
 
   Kao što su pokazali GTPγS odgovori, DmGPCR8 (GenBank pristupni br. AX128638) s prijelaznom ekspresijom u CHO-10001A stanicama je aktiviran pomoću Manduca sexta alatostatina-C (AST-C ili Manse-AC), (pGlu-VRFRQCYFNPISCF-OH) (sekv. br. 184) ili drostatina-C (DST-C), koji je također nazvan flatline peptid (FLT) (pGlu-VRYRQCYFNPISCF-OH) (sekv. br. 185). U eksperimentima s doznim odgovorom GTP-γS-vezanja, uočeni su vrlo jaki AST-C i DST-C odgovori (EC50 je u donjem nanomolarnom području). Ove aktivnosti su u potpunosti uklonjene prethodnim tretiranjem stanica s pertussin toksinom što ukazuje na uključenost Gi/Go u receptorskom aktiviranju. U analizi izravne kalcijeve mobilizacije (FLIPR), DmGPCR8 nije pokazao nikakvu aktivnost kada je izazvan s AST-C ili DST-C. Međutim, jaka aktivnost otpuštanja kalcija prema DST-C uočena je u CHO-10001A stanicama koje su kotransficirane s DmGPCR-8 i kimernim G-proteinima Gqi5 ili Gqo5 (EC50 oko 30 nM). S druge strane, vezanje za Gqz5 bilo je manje učinkovito (EC50 244 nM) i nikakva mobilizacija kalcija nije uočena u stanicama koje su kotransficirane s DmGPCR-8 i Gqs5. Ovi rezultati pokazuju da je DmGPCR8 inhibitorski receptor u CHO stanicama koji se poželjno veže za Gi/Go tipa G-proteina. Ovi rezultati nesumnjivo identificiraju DmGPCR8 kao DST-C/FLT receptor.  As shown by GTPγS responses, DmGPCR8 (GenBank accession no. AX128638) transiently expressed in CHO-10001A cells was activated by Manduca sexta alatostatin-C (AST-C or Manse-AC), (pGlu-VRFRQCYFNPISCF-OH) (seq .No. 184) or drostatin-C (DST-C), which is also called flatline peptide (FLT) (pGlu-VRYRQCYFNPISCF-OH) (SEQ ID NO: 185). In GTP-γS-binding dose-response experiments, very strong AST-C and DST-C responses were observed (EC50 is in the lower nanomolar range). These activities were completely removed by pretreatment of cells with pertussin toxin, indicating the involvement of Gi/Go in receptor activation. In the direct calcium mobilization (FLIPR) assay, DmGPCR8 showed no activity when challenged with AST-C or DST-C. However, strong calcium-releasing activity towards DST-C was observed in CHO-10001A cells co-transfected with DmGPCR-8 and chimeric G-proteins Gqi5 or Gqo5 (EC50 about 30 nM). On the other hand, binding to Gqz5 was less efficient (EC50 244 nM) and no calcium mobilization was observed in cells cotransfected with DmGPCR-8 and Gqs5. These results indicate that DmGPCR8 is an inhibitory receptor in CHO cells that preferentially binds to G-protein-type Gi/Go. These results unequivocally identify DmGPCR8 as a DST-C/FLT receptor. 
 
 
   DmGPCR9 sparen je sa FDDY(SO3H)GHLRF-NH2 (sekv. br. 157), temeljem njegova vrlo jakog signala u analizi mobilizacije kalcija (EC50 u nižem nanomolarnom rasponu). Činjenica da nikakvi GTPγS odgovori na ovaj peptid nisu uočeni s membranama koje su priređene iz CHO stanica koje su transficirane s DNA koja kodira DmGPCR9, pokazuje da je DmGPCR9 najvjerojatnije vezan sa Gq signalne putove. FDDY(SO3H)GHLRF-NH2 (sekv. br. 157) predstavlja Met7→Leu7 analog prirodnog drosulfakinina-1 (DSK-1), FDDY(SO3H)GHMRF-NH2 (sekv. br. 159). Prema tome mi smo odredili DmGPCR9 receptor kao sulfakininski receptor. Ovo sparivanje je vrlo specifično jer je čak FDDYGHLRF-NH2 (sekv. br. 158), što je nesulfatirana protuteža FDDY(SO3H)GHLRF-NH2 (sekv. br. 157), pokazao samo vrlo slab signal kalcija kada je ispitan s 10 mM ili nijedan od drugih 117 testiranih FaRP-ova i srodnih peptida nije pokazao nekakvu aktivnost bilo u FLIPR ili u GTPγS analiza na DmGPCR9 receptoru.  DmGPCR9 was paired with FDDY(SO3H)GHLRF-NH2 (SEQ ID NO: 157), based on its very strong signal in the calcium mobilization assay (EC50 in the lower nanomolar range). The fact that no GTPγS responses to this peptide were observed with membranes prepared from CHO cells transfected with DNA encoding DmGPCR9 indicates that DmGPCR9 is most likely linked to Gq signaling pathways. FDDY(SO3H)GHLRF-NH2 (SEQ ID NO: 157) represents the Met7→Leu7 analog of native drosulfakinin-1 (DSK-1), FDDY(SO3H)GHMRF-NH2 (SEQ ID NO: 159). Accordingly, we designated the DmGPCR9 receptor as a sulfakinin receptor. This pairing is highly specific because even FDDYGHLRF-NH2 (SEQ ID NO: 158), which is the non-sulfated counterpart of FDDY(SO3H)GHLRF-NH2 (SEQ ID NO: 157), showed only a very weak calcium signal when probed with 10 mM or none of the other 117 FaRPs and related peptides tested showed any activity in either the FLIPR or the GTPγS assay at the DmGPCR9 receptor. 
 
 
   Podudarni ligandi i njihovi odgovarajući receptori navedeni su niže u tablici 7.  Matched ligands and their corresponding receptors are listed below in Table 7. 
 
 
   Tablica 7  Table 7 
 
 
   [image] [image]  [image] [image] 
 
 
   [image]  [image] 
 
 
   Primjer 10: Kompeticijska analiza  Example 10: Competitive analysis 
 
 
   Priređivanje monojodiranog peptide  Preparation of monoiodinated peptide 
 
 
   Peptid je jodiran tipičnim kloramin-T postupkom. U staklenu epruvetu od 2 ml dodano je 10 μl 1 mM vodene otopine peptida, 10 μl 0,1M (pH 7,99) natrij-fosfatnog pufera, 1,0 mCi [125I] natrijeva jodida i 5 ml 2 mg/ml otopine kloramina-T (u fosfatnom puferu). Smjesa je miješana 60 sekundi i reakcija je zaustavljena dodatkom 25 ml 5 mg/ml otopine natrijeva metabisulfita u fosfatnom puferu. Smjesa je zatim podvrgnuta HPLC analizi injiciranjem na Vydac C18 (0,45×15 cm) kolonu i gradijentnim odvajanjem. Korišteni gradijent je 70% i 30% B u vremenu nula do 20% i 80% B u vremenu 25 minuta (A = 0,1M NH4 acetat u vodi. B = 0,1M NH4 acetat u vodi 40%: CH3CN 60%, v:v.). Brzina protoka je 1,0 ml/minuta. Uzorci su sakupljeni u 0,25 ml pufera (0,1M natrij-fosfatni puffer s 0,5% albumina volovskog seruma, 0,1% Triton X100 i 0,05% Tween 20) u intervalima 30 sekundi od t=8 do t=20 minuta. Monojodirani peptid tipično eluira u vremenu t=11 minuta i prinos je približno 100 mCi u 0,75 ml.  The peptide was iodinated by a typical chloramine-T procedure. 10 μl of 1 mM aqueous peptide solution, 10 μl of 0.1 M (pH 7.99) sodium phosphate buffer, 1.0 mCi [125I] sodium iodide and 5 ml of 2 mg/ml chloramine solution were added to a 2 ml glass tube. -T (in phosphate buffer). The mixture was stirred for 60 seconds and the reaction was stopped by the addition of 25 ml of a 5 mg/ml solution of sodium metabisulfite in phosphate buffer. The mixture was then subjected to HPLC analysis by injection onto a Vydac C18 (0.45×15 cm) column and gradient separation. The gradient used is 70% and 30% B in time zero to 20% and 80% B in time 25 minutes (A = 0.1M NH4 acetate in water. B = 0.1M NH4 acetate in water 40%: CH3CN 60%, v: v.). The flow rate is 1.0 ml/minute. Samples were collected in 0.25 ml of buffer (0.1 M sodium phosphate buffer with 0.5% bovine serum albumin, 0.1% Triton X100 and 0.05% Tween 20) at 30 second intervals from t=8 to t = 20 minutes. The monoiodinated peptide typically elutes at time t=11 minutes and the yield is approximately 100 mCi in 0.75 ml. 
 
 
   Analiza vezanja  Binding analysis 
 
 
   Ploča s 96 jažica korištena za analizu bila je Millipore Multiscreen® filtracijska ploča (FB neprozirna 1,0 μM stakleno vlakno tipa B, kat. br. MAFBNOB50). Millipore Multiscreen® višestruko otporno otapalo (kat. br. MAVMO960R ) korišteno je u sprezi s pločama za filtriranje analize na završetku. Svaki replikat je jedna jažica i ima volumen od 100 μl koji sadrži 5 μg proteina (priređivanje prije opisano). Svaka ispitivana skupina sadrži dva replikata. Za svaki ispitivani spoj, jedna skupina je izvršena samo s [125I]peptidom (za ukupno vezanje) i jedna s 1 μM (ili kako je predviđeno) koncentracijom ispitivanog spoja i [125I]peptidom (za nespecifično vezanje). Redoslijed dodavanja reagensa za svaki replikat je: pufer analize (20 mM HEPES, 10 mM MgCl2, 1% albumin volovskog seruma, pH 7,4) testni spoj (načinjen u puferu analize), [125I]peptid (u puferu analize) i membranska suspenzija (u puferu analize). Dodatak membranske suspenzije potiče reakciju vezanja koja se vrši tijekom 30 minuta na sobnoj temperature (22º C). Nakon 30 minuta inkubiranja svaka ploča je stavljena na filtracijsku pumpu i primijenjen je vakuum, propuštanjem tekućine kroz filter (bačeno) i hvatanjem proteina na filterima u svaku jažicu. Za ispiranje, otpušten je vakuum i dodano je 200 μl pufera analize u svaku jažicu nakon čega je ponovo primijenjen vakuum. Ovo ispiranje je ponovljeno još dva puta (ukupno 3× ispiranje za svaki replikat). Nakon ispiranja, uklonjen je plastični pokrov na donjoj strani svake ploče i ploča je stavljena na dno zatvorene Microbeta® brojačke scintilacijske kasete (kat br. 1450-105). U svaku jažicu dodano je 25 μl scintilanta i ploča je postavljena na rotacijsku mućkalicu pri brzini 80 rpm tijekom 1 sat i zatim u mirovanju preko noći. Sljedećeg dana ploča je izmjerena na Microbeta® scintilacijskom brojaču. Prosječno nespecifično vezanje oduzeto je od prosječnog ukupnog vezanja da se dobije specifično vezanje za standard (peptidamid) i uzorke.  The 96-well plate used for the assay was a Millipore Multiscreen® filtration plate (FB opaque 1.0 μM glass fiber type B, cat. no. MAFBNOB50). A Millipore Multiscreen® Multi-Resistance Solvent (Cat. No. MAVMO960R ) was used in conjunction with filter plates for analysis at the end. Each replicate is a single well and has a volume of 100 μl containing 5 μg of protein (preparation described previously). Each tested group contains two replicates. For each test compound, one group was performed with [125I]peptide alone (for total binding) and one with 1 μM (or as predicted) concentration of test compound and [125I]peptide (for nonspecific binding). The order of addition of reagents for each replicate is: assay buffer (20 mM HEPES, 10 mM MgCl2, 1% bovine serum albumin, pH 7.4) test compound (made in assay buffer), [125I]peptide (in assay buffer) and membrane suspension (in assay buffer). The addition of the membrane suspension promotes the binding reaction, which takes place during 30 minutes at room temperature (22º C). After 30 minutes of incubation, each plate was placed on a filtration pump and a vacuum was applied, passing the liquid through the filter (discarded) and trapping the proteins on the filters in each well. For washing, the vacuum was released and 200 μl of assay buffer was added to each well, after which the vacuum was applied again. This wash was repeated two more times (a total of 3× washes for each replicate). After washing, the plastic cover on the underside of each plate was removed and the plate was placed on the bottom of a sealed Microbeta® counting scintillation cassette (cat. no. 1450-105). 25 μl of scintillant was added to each well and the plate was placed on a rotary shaker at 80 rpm for 1 hour and then left overnight. The next day, the plate was measured on a Microbeta® scintillation counter. The average non-specific binding was subtracted from the average total binding to obtain the specific binding for the standard (peptidamide) and samples. 
 
 
   Kao što je poznato onima koji poznaju ovo područje, moguće su brojne izmjene i modifikacije realizacija ovog izuma pri čemu se ne udaljavamo od duha ovog izuma. Smatra se da sve takve inačice spadaju u doseg ovog izuma.  As is known to those skilled in the art, numerous changes and modifications are possible to the embodiments of this invention without departing from the spirit of this invention. All such variations are considered to be within the scope of the present invention. 
 
 
   Cjelokupni sadržaj svake citirane publikacije je u cijelosti obuhvaćen kao referenca.  The entire content of each cited publication is incorporated by reference in its entirety. 
 
 
 
 
 
 
 
 
 
 
